 |
3-4-diaminopyridine |
  |
ATC : N07XX05 |
|
4-aminopyridine |
|
ATC : N07XX07 |
|
5 aminosalicylic acid |
  |
ATC : A07EC02 |
|
8-methoxypsoralen |
 |
ATC : D05AD02 |
|
Acetazolamide |
  |
ATC : S01EC01 |
|
Acetazolamide |
 |
ATC : S01EC01 |
|
Acetylsalicylic Acid |
 |
ATC : B01AC06 |
|
Acetylsalicylic acid lysinate |
|
ATC : N02BA01 |
|
Aciclovir sodium |
 |
ATC : J05AB01 |
|
Adalimumab |
 |
ATC : L04AB04 |
|
Adapalene |
|
ATC : D10AD03 |
|
Adenosin |
 |
ATC : C01EB10 |
|
Aflibercept |
 |
ATC : L01XX44 |
|
Aldesleukin |
|
ATC : L03AC01 |
|
Alemtuzumab |
|
ATC : L04AA34 |
|
Alfentanil hydrochloride |
|
ATC : N01AH02 |
|
Alizapride hydrochloride |
 |
ATC : A03FA05 |
|
Allopurinol |
 |
ATC : M04AA01 |
|
Allopurinol sodium |
|
ATC : M04AA01 |
|
Alpha-tocopherol acetate |
 |
ATC : A11HA03 |
|
Alprazolam |
 |
ATC : N05BA12 |
|
Alprostadil |
|
ATC : G04BE01 |
|
Alteplase |
 |
ATC : B01AD02 |
|
Ambrisentan |
|
ATC : C02KX02 |
|
Amifostine |
 |
ATC : V03AF05 |
|
Amikacin sulfate |
 |
ATC : J01GB06 |
|
Aminophylline |
|
ATC : R03DA05 |
|
Amiodarone hydrochloride |
 |
ATC : C01BD01 |
|
Amiodarone hydrochloride |
|
ATC : C01BD01 |
|
Amiodarone hydrochloride |
|
ATC : C01BD01 |
|
Amitriptyline hydrochloride |
 |
ATC : N06AA09 |
|
Amitriptyline hydrochloride |
|
ATC : N06AA09 |
|
Amitriptyline hydrochloride |
|
ATC : N06AA09 |
|
Amlodipine besylate |
 |
ATC : C08CA01 |
|
Amobarbital sodium |
 |
ATC : N05CA02 |
|
Amoxicillin sodium |
|
ATC : J01CA04 |
|
Amoxicillin sodium / clavulanic acid |
|
ATC : J01CR02 |
|
Amoxicillin sodium / clavulanic acid |
|
ATC : J01CR02 |
|
Amoxicilline |
|
ATC : J01CA04 |
|
Amoxicilline |
|
ATC : J01CA04 |
|
Amphotericin B |
 |
ATC : J02AA01 |
|
Amphotericin B |
 |
ATC : J02AA01 |
|
Amphotericin B |
 |
ATC : J02AA01 |
|
Amphotericin B |
 |
ATC : J02AA01 |
|
Amphotericin B |
|
ATC : J02AA01 |
|
Amphotericin B cholesteryl sulfate complex |
|
ATC : J02AA01 |
|
Amphotericin B lipid complex |
|
ATC : J02AA01 |
|
Amphotericin B liposomale |
|
ATC : J02AA01 |
|
Amphotericin B liposomale |
|
ATC : J02AA01 |
|
Ampicillin sodium |
|
ATC : J01CA01 |
|
Ampicillin sodium |
|
ATC : J01CA01 |
|
Ampicillin sodium - sulbactam sodium |
|
ATC : J01CR01 |
|
Amsacrine |
|
ATC : L01XX01 |
|
Angiotensin II |
|
ATC : C01CX09 |
|
Anidulafungin |
|
ATC : J02AX06 |
|
Antithymocyte globulin (rabbit) |
|
ATC : L04AA04 |
|
Apixaban |
 |
ATC : B01AF02 |
|
Aprepitant |
|
ATC : A04AD12 |
|
Arformoterol |
 |
|
|
Argatroban |
|
ATC : B01AE03 |
|
Arnica tincture |
|
|
|
Arsenic trioxyde |
|
ATC : L01XX27 |
|
Artesunate |
 |
ATC : P01BE03 |
|
Artesunate |
|
ATC : P01BE03 |
|
Ascorbic acid |
|
ATC : A11GA01 |
|
Asparaginase |
|
ATC : L01XX02 |
|
Atenolol |
 |
ATC : C07AB03 |
|
Atenolol |
|
ATC : C07AB03 |
|
Atenolol |
|
ATC : C07AB03 |
|
Atezolizumab |
|
ATC : L01FF05 |
|
Atorvastatine |
 |
ATC : C10AA05 |
|
Atosiban |
|
ATC : G02CX01 |
|
Atracurium besylate |
 |
ATC : M03AC04 |
|
Atropine sulfate |
 |
ATC : A03BA01 |
|
Atropine sulfate |
|
ATC : A03BA01 |
|
Atropine sulfate |
|
ATC : A03BA01 |
|
Atropine sulfate |
|
ATC : S01FA01 |
|
Avelumab |
|
ATC : L01FF04 |
|
Azacitidine |
|
ATC : L01BC07 |
|
Azasetron |
|
|
|
Azathioprine |
|
ATC : L04AX01 |
|
Azathioprine sodium |
|
ATC : L04AX01 |
|
Azelaique acide |
|
ATC : D10AX03 |
|
Azithromycine |
|
ATC : J01FA10 |
|
Azithromycine |
|
ATC : S01AA26 |
|
Aztreonam |
|
ATC : J01DF01 |
|
Aztreonam / Avibactam |
|
ATC : J01DF51 |
|
Baclofen |
|
ATC : M03BX01 |
|
Baclofen |
|
ATC : M03BX01 |
|
Baclofen |
|
ATC : M03BX01 |
|
Belatacept |
|
ATC : L04AA28 |
|
Belimumab |
|
ATC : L04AA26 |
|
Belinostat |
|
ATC : L01XX49 |
|
Bendamustine hydrochloride |
|
ATC : L01AA09 |
|
Benzoate sodium |
|
ATC : V04CG30 |
|
Benzoyl peroxyde |
|
ATC : D10AE01 |
|
Benztropine mesylate |
|
ATC : N04AC01 |
|
Betamethasone sodium phosphate |
|
ATC : A07EA04 |
|
Betamethasone sodium phosphate |
|
ATC : D07AC01 |
|
Betaxolol |
|
ATC : C07AB05 |
|
Bethanechol chloride |
|
ATC : N07AB02 |
|
Bevacizumab |
|
ATC : L01FG01 |
|
Bevacizumab |
|
ATC : L01FG01 |
|
Bivalirudin |
|
ATC : B01AE06 |
|
Bleomycin sulfate |
|
ATC : L01DC01 |
|
Blinatumomab |
|
ATC : L01FX07 |
|
Bortezomib |
|
ATC : L01XG01 |
|
Bosentan monohydrate |
|
ATC : C02KX01 |
|
Brentuximab vedotin |
|
ATC : L01FX05 |
|
Brompheniramine maleate |
 |
ATC : R06AB01 |
|
Budesonide |
|
ATC : A07EA06 |
|
Budesonide |
|
ATC : A07EA06 |
|
Bumetanide |
|
ATC : C03CA02 |
|
Bupivacaine hydrochloride |
 |
ATC : N01BB01 |
|
Buprenorphine |
|
ATC : N07BC01 |
|
Buprenorphine hydrochloride |
|
ATC : N02AE01 |
|
Busulfan |
|
ATC : L01AB01 |
|
Cabazitaxel |
|
ATC : L01CD04 |
|
Cafeine |
 |
ATC : N06BC01 |
|
Cafeine |
|
ATC : N06BC01 |
|
Caffeine citrate |
|
ATC : N06BC01 |
|
Caffeine citrate |
|
ATC : N06BC01 |
|
Calcitriol |
|
ATC : A11CC04 |
|
Calcium chloride |
 |
ATC : A12AA07 |
|
Calcium gluconate |
|
ATC : A12AA20 |
|
Calcium gluconate |
|
ATC : A12AA03 |
|
Captopril |
|
ATC : C09AA01 |
|
Captopril |
 |
ATC : C09AA01 |
|
Carbamazepine |
 |
ATC : N03AF01 |
|
Carbidopa |
|
ATC : N04BA02 |
|
Carbimazole |
|
ATC : H03BD01 |
|
Carboplatin |
|
ATC : L01XA02 |
|
Carfilzomib |
|
ATC : L01XG02 |
|
Carmustine |
|
ATC : L01AD01 |
|
Carvedilol |
|
ATC : C07AG02 |
|
Caspofungin acetate |
|
ATC : J02AX04 |
|
Caspofungin acetate |
|
ATC : J02AX04 |
|
Cefadroxil |
|
ATC : J01DB05 |
|
Cefamandole nafate |
|
ATC : J01DC03 |
|
Cefazolin sodium |
|
ATC : J01DB04 |
|
Cefazolin sodium |
|
ATC : J01DB04 |
|
Cefepime dihydrochloride |
|
ATC : J01DE01 |
|
Cefepime dihydrochloride |
|
ATC : J01DE01 |
|
Cefiderocol sulfate tosylate |
|
ATC : J01DI04 |
|
Cefotaxime sodium |
|
ATC : J01DD01 |
|
Cefoxitin sodium |
|
ATC : J01DC01 |
|
Ceftaroline fosamil |
|
ATC : J01DI02 |
|
Ceftazidime |
|
ATC : J01DD02 |
|
Ceftazidime |
|
ATC : J01DD02 |
|
Ceftazidime Avibactam |
|
ATC : J01DD52 |
|
Ceftobiprole medocaril sodium |
|
ATC : J01DI01 |
|
Ceftolozane / tazobactam |
|
ATC : J01DI54 |
|
Ceftriaxone disodium |
|
ATC : J01DD04 |
|
Ceftriaxone disodium |
|
ATC : J01DD04 |
|
Cefuroxime axetil |
|
ATC : J01DC02 |
|
Cefuroxime sodium |
|
ATC : J01DC02 |
|
Cefuroxime sodium |
|
ATC : J01DC02 |
|
Celecoxib |
|
ATC : L01XX33 |
|
Cemiplimab |
|
ATC : L01XC33 |
|
Cetuximab |
|
ATC : L01FE01 |
|
Chloral hydrate |
|
|
|
Chloramphenicol sodium succinate |
|
ATC : J01BA01 |
|
Chlormethine hydrochloride |
|
ATC : L01AA05 |
|
Chloroquine phosphate |
|
ATC : P01BA01 |
|
Chlorothiazide sodium |
|
ATC : C03AA04 |
|
Chlorpromazine hydrochloride |
|
ATC : N05AA01 |
|
Chlorpromazine hydrochloride |
 |
ATC : N05AA01 |
|
Cholecalciferol |
|
ATC : A11CC05 |
|
Cholecalciferol |
|
ATC : A11CC05 |
|
Cholic acid |
|
ATC : A05AA03 |
|
Ciclosporin |
|
ATC : L04AD01 |
|
Ciclosporin |
|
ATC : L04AD01 |
|
Ciclosporin |
|
ATC : L04AD01 |
|
Ciclosporin |
|
ATC : S01XA18 |
|
Cidofovir |
|
ATC : J05AB12 |
|
Cilazapril |
|
ATC : C09AA08 |
|
Cimetidine hydrochloride |
 |
ATC : A02BA01 |
|
Cipepofol |
|
|
|
Ciprofloxacin hydrochloride |
|
ATC : J01MA02 |
|
Ciprofloxacin lactate |
|
ATC : J01MA02 |
|
Cisatracurium besylate |
|
ATC : M03AC11 |
|
Cisplatin |
|
ATC : L01XA01 |
|
Citalopram |
|
ATC : N06AB04 |
|
Citric acid |
|
ATC : A09AB04 |
|
Cladribine |
|
ATC : L01BB04 |
|
Clarithromycin |
|
ATC : J01FA09 |
|
Clindamycin phosphate |
|
ATC : J01FF01 |
|
Clindamycine hydrochloride |
|
ATC : J01FF01 |
|
Clobazam |
|
ATC : N05BA09 |
|
Clobetasol propiomate |
|
ATC : D07AD01 |
|
Clofarabine |
|
ATC : L01BB06 |
|
Clofazimine |
|
ATC : J04BA01 |
|
Clomipramine |
|
ATC : N06AA04 |
|
Clomipramine hydrochloride |
|
ATC : N06AA04 |
|
Clonazepam |
|
ATC : N03AE01 |
|
Clonazepam |
|
ATC : N03AE01 |
|
Clonidine hydrochloride |
|
ATC : C02AC01 |
|
Clonidine hydrochloride |
|
ATC : C02AC01 |
|
Clonidine hydrochloride |
|
ATC : C02AC01 |
|
Clonidine hydrochloride |
|
ATC : C02AC01 |
|
Clopidogrel bisulfate |
|
ATC : B01AC04 |
|
Clorazepate di potassium |
|
ATC : N05BA05 |
|
Clotrimazole |
 |
ATC : A01AB18 |
|
Cloxacillin sodium |
|
ATC : J01CF02 |
|
Cloxacilline |
|
ATC : J01CF02 |
|
Clozapine |
|
ATC : N05AH02 |
|
Co-trimoxazole |
|
ATC : J01EE01 |
|
Co-trimoxazole |
|
ATC : J01EE01 |
|
Cocaine hydrochloride |
|
ATC : S01HA01 |
|
Codeine phosphate |
|
ATC : R05DA04 |
|
Colistin mesilate sodium |
|
ATC : J01XB01 |
|
Colistin mesilate sodium |
|
ATC : J01XB01 |
|
Colistin sulfate |
|
ATC : A07AA10 |
|
Conivaptan |
|
ATC : C03XA02 |
|
Crisantaspase |
|
ATC : L01XX02 |
|
Cromoglycate sodium |
|
ATC : A07EB01 |
|
Cyamemazin |
|
ATC : N05AA06 |
|
Cyanocobalamine |
|
ATC : B03BA01 |
|
Cyclizine lactate |
|
ATC : R06AE03 |
|
Cyclopentolate |
|
ATC : S01FA04 |
|
Cyclophosphamide |
|
ATC : L01AA01 |
|
Cyclophosphamide |
|
ATC : L01AA01 |
|
Cyclophosphamide |
|
ATC : L01AA01 |
|
Cytarabine |
|
ATC : L01BC01 |
|
Dacarbazine |
|
ATC : L01AX04 |
|
Dactinomycin |
|
ATC : L01DA01 |
|
Dalbavancin |
|
ATC : J01XA04 |
|
Dalteparin sodium |
|
ATC : B01AB04 |
|
Dantrolene sodium |
|
ATC : M03CA01 |
|
Dapsone |
|
ATC : J04BA02 |
|
Dapsone |
|
ATC : J04BA02 |
|
Daptomycin |
|
ATC : J01XX09 |
|
Daratumumab |
|
ATC : L01FC01 |
|
Daunorubicin hydrochloride |
|
ATC : L01DB02 |
|
Daunorubicin hydrochloride liposome |
|
ATC : L01DB02 |
|
Daunorubicin/cytarabine liposomale |
|
ATC : L01XY01 |
|
Decitabine |
|
ATC : L01BC08 |
|
Deferoxamine mesylate |
 |
ATC : V03AC01 |
|
Defibrotide |
|
ATC : B01AX01 |
|
Desmopressine acetate |
  |
ATC : H01BA02 |
|
Desonide |
|
ATC : S01BA11 |
|
Desoximetasone |
|
ATC : D07AC03 |
|
Dexamethasone |
|
ATC : A01AC02 |
|
Dexamethasone acetate |
|
ATC : A01AC02 |
|
Dexamethasone sodium phosphate |
|
ATC : H02AB02 |
|
Dexamethasone sodium phosphate |
|
ATC : A01AC02 |
|
Dexketoprofen |
|
ATC : M01AE17 |
|
Dexmedetomidine |
 |
ATC : N05CM18 |
|
Dexrazoxane hydrochloride |
|
ATC : V03AF02 |
|
Dextrose |
|
|
|
Dezocine |
|
ATC : N02AX03 |
|
Diamorphine hydrochloride |
|
ATC : N02AA09 |
|
Diatrizoate meglumine |
 |
ATC : V08AA01 |
|
Diazepam |
|
ATC : N05BA01 |
|
Diazepam |
|
ATC : N05BA01 |
|
Diazepam |
|
ATC : N05BA01 |
|
Diazoxide |
|
ATC : V03AH01 |
|
Dichloroacetate sodium |
|
|
|
Diclofenac |
|
ATC : M01AB05 |
|
Diclofenac |
|
ATC : D11AX18 |
|
Diclofenac |
|
ATC : D11AX18 |
|
Diclofenac |
|
ATC : M02AA15 |
|
Digoxin |
 |
ATC : C01AA05 |
|
Dihydralazine mesilate |
|
ATC : C02DB01 |
|
Diltiazem hydrochloride |
|
ATC : C08DB01 |
|
Diltiazem hydrochloride |
|
ATC : C08DB01 |
|
Diltiazem hydrochloride |
|
ATC : C08DB01 |
|
Dimenhydrinate |
|
ATC : R06AA52 |
|
Diphenhydramine hydrochloride |
|
ATC : D04AA32 |
|
Dipyridamol |
|
ATC : B01AC07 |
|
Dipyridamol |
|
ATC : B01AC07 |
|
Disodium glucose-1-phosphate tetrahydrate |
|
ATC : B05XA09 |
|
Disopyramide phosphate |
|
ATC : C01BA03 |
|
Disulfiram |
|
ATC : N07BB01 |
|
Dithranol |
|
ATC : D05AC01 |
|
Dobutamine hydrochloride |
|
ATC : C01CA07 |
|
Docetaxel |
|
ATC : L01CD02 |
|
Domperidone |
|
ATC : A03FA03 |
|
Dopamine hydrochloride |
|
ATC : C01CA04 |
|
Dornase alfa |
|
ATC : R05CB13 |
|
Dostarlimab |
|
ATC : L01FF07 |
|
Doxapram hydrochloride |
|
ATC : R07AB01 |
|
Doxepine |
|
ATC : N06AA12 |
|
Doxorubicin hydrochloride |
|
ATC : L01DB01 |
|
Doxorubicin hydrochloride liposome |
|
ATC : L01DB01 |
|
Doxorubicin hydrochloride liposome peg |
|
ATC : L01DB01 |
|
Doxycycline |
|
ATC : J0AA02 |
|
Doxycycline hyclate |
|
ATC : J01AA02 |
|
Droperidol |
|
ATC : N05AD08 |
|
Durvalumab |
|
ATC : L01FF03 |
|
Dutasteride |
|
ATC : G04CB02 |
|
Eculizumab |
|
ATC : L04AA25 |
|
Elranatamab |
|
ATC : L01FX32 |
|
Enalapril maleate |
|
ATC : C09AA02 |
|
Enalaprilate |
|
ATC : C09AA02 |
|
Enoxaparin sodium |
|
ATC : B01AB05 |
|
Enoxolone |
|
ATC : R02AD |
|
Ephedrine hydrochloride |
|
ATC : C01CA26 |
|
Ephedrine sulfate |
|
ATC : C01CA26 |
|
Epigallocatechin gallate |
|
|
|
Epinephrine hydrochloride |
|
ATC : C01CA24 |
|
Epinephrine hydrochloride |
|
ATC : A01AD01 |
|
Epirubicin hydrochloride |
|
ATC : L01DB03 |
|
Epoetin alfa |
|
ATC : B03XA01 |
|
Eptifibatide |
|
ATC : B01AC16 |
|
Eravacycline |
|
ATC : J01AA13 |
|
Eribulin mesylate |
|
ATC : L01XX41 |
|
Erlotinib |
|
ATC : L01XE03 |
|
Ertapenem |
|
ATC : J01DH03 |
|
Erythromycin lactobionate |
|
ATC : J01FA01 |
|
Erythromycine |
|
ATC : J01FA01 |
|
Esketamine |
|
ATC : N01AX14 |
|
Eslicarbazepine acetate |
|
ATC : N03AF04 |
|
Esmolol hydrochloride |
|
ATC : C07AB09 |
|
Esomeprazole magnesium trihydrate |
 |
ATC : A02BC05 |
|
Esomeprazole sodium |
|
ATC : A02BC05 |
|
Estradiol |
|
ATC : G03CA01 |
|
Estriol |
|
ATC : G03CC06 |
|
Estrone |
|
ATC : G03CA07 |
|
Ethacrynate sodium |
|
ATC : C03CC01 |
|
Ethambutol hydrochloride |
|
ATC : J04AK02 |
|
Ethanol |
|
ATC : V03AB16 |
|
Etomidate |
|
ATC : N01AX07 |
|
Etoposide |
|
ATC : L01CB01 |
|
Etoposide |
|
ATC : L01CB01 |
|
Etoposide phosphate |
|
ATC : L01CB01 |
|
Famotidine |
|
ATC : A02BA03 |
|
Famotidine |
|
ATC : A02BA03 |
|
Faricimab |
|
ATC : S01LA09 |
|
Fenoterol |
|
ATC : R03AC04 |
|
Fentanyl citrate |
|
ATC : N01AH01 |
|
Ferric carboxymaltose |
|
ATC : B03AC01 |
|
Filgrastim |
|
ATC : L03AA02 |
|
Finasteride |
|
ATC : G04CB01 |
|
Finasteride |
|
ATC : D11AX10 |
|
Flecainide acetate |
|
ATC : C01BC04 |
|
Flecainide acetate |
|
ATC : C01BC04 |
|
Floxuridine |
|
ATC : L01BC09 |
|
Flucinonide |
|
ATC : C05AA11 |
|
Flucloxacillin sodium |
|
ATC : J01CF05 |
|
Fluconazole |
|
ATC : J02AC01 |
|
Fluconazole |
|
ATC : D01AC15 |
|
Flucytosine |
|
ATC : D01AE21 |
|
Fludarabine phosphate |
|
ATC : L01BB05 |
|
Fludrocortisone |
|
ATC : H02AA02 |
|
Fludrocortisone acetate |
|
ATC : H02AA02 |
|
Flumazenil |
 |
ATC : V03AB25 |
|
Fluocinolone |
|
ATC : D07AC04 |
|
Fluorouracil |
|
ATC : L01BC02 |
|
Fluoxetine |
|
ATC : N06AB03 |
|
Fluphenazine |
|
ATC : N05AB02 |
|
Fluticasone |
|
ATC : D07AC17 |
|
Folic acid |
|
ATC : B03BB01 |
|
Folinate calcium |
|
ATC : V03AF03 |
|
Folinate sodium |
|
ATC : V03AF03 |
|
Formoterol fumarate |
|
ATC : R03AC13 |
|
Fosaprepitant dimeglumine |
|
ATC : A04AD12 |
|
Foscarnet sodium |
|
ATC : J05AD01 |
|
Fosfomycin |
|
ATC : J01XX01 |
|
Fosphenytoin sodium |
|
ATC : N03AB05 |
|
Fotemustine |
|
ATC : L01AD05 |
|
Fumagillin |
|
ATC : P01AX10 |
|
Furosemide |
|
ATC : C03CA01 |
|
Furosemide |
|
ATC : C03CA01 |
|
Fusidate sodium |
|
ATC : J01XC01 |
|
Gabapentine |
|
ATC : N03AX12 |
|
Gabapentine |
|
ATC : N03AX12 |
|
Gadoterate meglumine |
|
ATC : V08CA02 |
|
Gallium nitrate |
 |
|
|
Ganciclovir |
|
ATC : S01AD09 |
|
Ganciclovir sodium |
|
ATC : J05AB06 |
|
Gelatin |
|
ATC : B05AA06 |
|
Gemcitabine hydrochloride |
|
ATC : L01BC05 |
|
Gemtuzumab ozogamicin |
|
ATC : L01FX02 |
|
Gentamicin sulfate |
|
ATC : J01GB03 |
|
Gentamicin sulfate |
|
ATC : D06AX07 |
|
Gestrinone |
|
ATC : G03XA02 |
|
Glibenclamide |
 |
ATC : A10BB01 |
|
Glofitamab |
|
ATC : L01FX28 |
|
Glutamine |
|
ATC : B05XB02 |
|
Glycerophosphate disodium |
|
ATC : B05XA14 |
|
Glycopyrronium bromide |
|
ATC : A03AB02 |
|
Glycopyrronium bromide |
|
ATC : A03AB02 |
|
Granisetron hydrochloride |
|
ATC : A04AA02 |
|
Granisetron hydrochloride |
|
ATC : A04AA02 |
|
Griseofulvine |
|
ATC : D01BA01 |
|
Haloperidol |
|
ATC : N05AD01 |
|
Haloperidol lactate |
|
ATC : N05AD01 |
|
Heparin sodium |
|
ATC : B01AB01 |
|
Histamine |
|
ATC : L03AX14 |
|
Human albumin |
|
ATC : B05AA01 |
|
Hyaluronidase |
|
ATC : B06AA03 |
|
Hydralazine hydrochloride |
|
ATC : C02DB02 |
|
Hydralazine hydrochloride |
|
ATC : C02DB02 |
|
Hydrochlorothiazide |
|
ATC : C03AA03 |
|
Hydrocortisone |
|
ATC : D07BA04 |
|
Hydrocortisone |
|
ATC : D07BA04 |
|
Hydrocortisone |
|
ATC : D07BA04 |
|
Hydrocortisone 17 valerate |
|
ATC : A01AC03 |
|
Hydrocortisone acetate |
|
ATC : D07AA02 |
|
Hydrocortisone sodium phosphate |
|
ATC : A01AC03 |
|
Hydrocortisone sodium succinate |
|
ATC : H02AB09 |
|
Hydrocortisone sodium succinate |
|
ATC : H02AB09 |
|
Hydromorphone hydrochloride |
|
ATC : N02AA03 |
|
Hydroquinone |
|
ATC : D11AX11 |
|
Hydroxocobalamin |
|
ATC : V03AB33 |
|
Hydroxychloroquine sulfate |
|
ATC : P01BA02 |
|
Hydroxyurea |
|
ATC : L01XX05 |
|
Ibuprofen arginine |
|
ATC : C01EB16 |
|
Ibuprofen lysinate |
|
ATC : C01EB16 |
|
Idarubicin hydrochloride |
|
ATC : L01DB06 |
|
Idebenone |
|
ATC : N06BX13 |
|
Ifosfamide |
|
ATC : L01AA06 |
|
Iloprost |
|
ATC : B01AC11 |
|
Imatinib |
|
ATC : L01XE01 |
|
Imiglucerase |
|
ATC : A16AB02 |
|
Imipenem - cilastatin sodium |
|
ATC : J01DH51 |
|
Imipenem-Cilastatin / Relebactam |
|
ATC : J01DH56 |
|
Imipramine hydrochloride |
|
ATC : N06AA02 |
|
Indocyanine green |
|
ATC : V04CX01 |
|
Infliximab |
|
ATC : L04AB02 |
|
Infliximab |
|
ATC : L04AB02 |
|
Insulin |
|
ATC : A10AB01 |
|
Insulin aspart |
|
ATC : A10AB05 |
|
Insulin glulisine |
|
ATC : A10AB06 |
|
Insulin lyspro |
|
ATC : A10AB04 |
|
Interferon alfa 2b |
|
ATC : L03AB05 |
|
Iobitridol |
|
ATC : V08AB11 |
|
Iodixanol |
|
ATC : V08AB09 |
|
Iohexol |
|
ATC : V08AB02 |
|
Iomeprol |
|
ATC : V08AB10 |
|
Iopromide |
|
ATC : V08AB05 |
|
Ioversol |
|
ATC : V08AB07 |
|
Ioxaglate |
|
ATC : V08AB03 |
|
Ioxitalamate sodium |
|
ATC : V08AA05 |
|
Ipilimumab |
|
ATC : L01FX04 |
|
Ipratropium bromide |
|
ATC : R01AX03 |
|
Irinotecan |
|
ATC : L01CE02 |
|
Iron (polymaltose) |
|
ATC : B03AC01 |
|
Iron dextran |
|
ATC : QB03AB90 |
|
Isatuximab |
|
ATC : L01FC02 |
|
Isavuconazonium sulfate |
|
ATC : J02AC05 |
|
Isoniazid |
|
ATC : J04AC01 |
|
Isoniazid |
|
ATC : J04AC01 |
|
Isoprenaline hydrochloride |
|
ATC : C01CA02 |
|
Isosorbide dinitrate |
|
ATC : C01DA08 |
|
Isradipine |
|
ATC : C08CA03 |
|
Itraconazole |
|
ATC : J02AC02 |
|
Ixabepilone |
|
ATC : L01DC04 |
|
Ketamine hydrochloride |
|
ATC : N01AX03 |
|
Ketamine hydrochloride |
|
ATC : N01AX03 |
|
Ketoconazole |
|
ATC : J02AB02 |
|
Ketoprofene |
|
ATC : M01AE03 |
|
Ketoprofene |
|
ATC : M01AE03 |
|
Ketoprofene |
|
ATC : M01AE03 |
|
Ketoprofene |
|
ATC : M02AA10 |
|
Ketorolac tromethamine |
|
ATC : M01AB15 |
|
L-carnitine |
|
ATC : A16AA01 |
|
L-Methionine |
|
ATC : V03AB26 |
|
Labetalol hydrochloride |
|
ATC : C07AG01 |
|
Labetalol hydrochloride |
|
ATC : C07AG01 |
|
Lamotrigine |
|
ATC : N03AX09 |
|
Lansoprazole |
|
ATC : A02BC03 |
|
Lenograstim |
|
ATC : L03AA10 |
|
Levalbuterol |
|
ATC : R03AC02 |
|
Levamisol |
|
ATC : P02CE01 |
|
Levetiracetam |
|
ATC : N03AX14 |
|
Levetiracetam |
|
ATC : N03AX14 |
|
Levobupivacaine hydrochloride |
|
ATC : N01BB10 |
|
Levodopa/Carbidopa |
|
ATC : N04BA02 |
|
Levodopa/Carbidopa |
|
ATC : N04BA02 |
|
Levofloxacine |
|
ATC : J01MA12 |
|
Levofloxacine |
|
ATC : S01AX19 |
|
Levofolinate calcium |
|
ATC : V03AF04 |
|
Levomepromazine |
|
ATC : N05AA02 |
|
Levosimendan |
|
ATC : C01CX08 |
|
Levothyroxine |
|
ATC : H03AA01 |
|
Levothyroxine |
|
ATC : H03AA01 |
|
Lidocaine hydrochloride |
|
ATC : N01BB02 |
|
Lidocaine hydrochloride |
|
ATC : N01BB02 |
|
Lidocaine hydrochloride |
|
ATC : N01BB02 |
|
Lincomycin |
|
ATC : J01FF02 |
|
Linezolid |
|
ATC : J01XX08 |
|
Lisinopril |
|
ATC : C09AA03 |
|
Lithium citrate |
|
ATC : N05AN01 |
|
Loperamide |
|
ATC : A07DA03 |
|
Lorazepam |
|
ATC : N05BA06 |
|
Lorazepam |
|
ATC : N05BA06 |
|
Lormetazepam |
|
ATC : N05CD06 |
|
Lornoxicam |
|
ATC : M01AC05 |
|
Loxapine |
|
ATC : N05AH01 |
|
Loxapine |
|
ATC : N05AH01 |
|
Lurasidone |
|
ATC : N05AE05 |
|
Lurbinectedin |
|
ATC : L01XX69 |
|
Magnesium chloride |
|
ATC : B05XA11 |
|
Magnesium sulfate |
|
ATC : B05XA05 |
|
Mannitol |
|
ATC : B05BC01 |
|
Marigold tincture |
|
|
|
Mebeverine hydrochloride |
 |
ATC : A03AA04 |
|
Melatonine |
|
ATC : N05CH01 |
|
Melatonine |
|
ATC : N05CH01 |
|
Melatonine |
|
ATC : N05CH01 |
|
Melatonine |
|
ATC : N05CH01 |
|
Melphalan |
|
ATC : L01AA03 |
|
Melphalan captisol |
|
ATC : L01AA03 |
|
Memantine |
 |
ATC : N06DX01 |
|
Menadione |
|
ATC : B02BA02 |
|
Meptazinol |
|
ATC : N02AX05 |
|
Mercaptopurine |
|
ATC : L01BB02 |
|
Meropenem |
|
ATC : J01DH02 |
|
Meropenem Vaborbactam |
|
ATC : J01DH52 |
|
Mesna |
|
ATC : V03AF01 |
|
Metamizol sodium |
|
ATC : N02BB02 |
|
Metaraminol |
|
ATC : C01CA09 |
|
Methacholine chloride |
|
ATC : V04CL01 |
|
Methadone hydrochloride |
|
ATC : N07BC02 |
|
Methadone hydrochloride |
|
ATC : N07BC02 |
|
Methohexital sodium |
|
ATC : N01AF01 |
|
Methotrexate |
|
ATC : L04AX03 |
|
Methotrexate sodium |
|
ATC : L01BA01 |
|
Methylprednisolone acetate |
|
ATC : H02AB04 |
|
Methylprednisolone sodium succinate |
|
ATC : H02AB04 |
|
Methylprednisolone sodium succinate |
|
ATC : H02AB04 |
|
Metoclopramide hydrochloride |
|
ATC : A03FA01 |
|
Metolazone |
|
ATC : C03BA08 |
|
Metoprolol tartrate |
|
ATC : C07AB02 |
|
Metoprolol tartrate |
|
ATC : C07AB02 |
|
Metronidazole |
|
ATC : J01XD01 |
|
Metronidazole |
|
ATC : J01XD01 |
|
Metronidazole |
|
ATC : D06BX01 |
|
Metronidazole benzoate |
|
ATC : J01XD01 |
|
Mexiletine |
|
ATC : C01BB02 |
|
Micafungin |
|
ATC : J02AX05 |
|
Midazolam hydrochloride |
|
ATC : N05CD08 |
|
Midazolam hydrochloride |
|
ATC : N05CD08 |
|
Midazolam hydrochloride |
|
ATC : N05CD08 |
|
Milrinone lactate |
|
ATC : C01CE02 |
|
Minocycline hydrochloride |
|
ATC : J01AA08 |
|
Minocycline hydrochloride |
|
ATC : J01AA08 |
|
Minoxidil |
|
ATC : C02DC01 |
|
Minoxidil |
|
ATC : C02DC01 |
|
Misoprostol |
|
ATC : A02BB01 |
|
Mitomycin |
|
ATC : L01DC03 |
|
Mitoxantrone dihydrochloride |
|
ATC : L01DB07 |
|
Mivacurium chloride |
|
ATC : M03AC10 |
|
Molindone |
|
ATC : N05AE02 |
|
Mometasone furoate |
|
ATC : D07AC13 |
|
Morphine hydrochloride |
|
ATC : N02AA01 |
|
Morphine hydrochloride |
|
ATC : N02AA01 |
|
Morphine sulfate |
|
ATC : N02AA01 |
|
Morphine sulfate |
|
ATC : N02AA01 |
|
Morphine sulfate |
|
ATC : N02AA01 |
|
Morphine tartrate |
|
ATC : N02AA01 |
|
Moxifloxacin |
|
ATC : J01MA14 |
|
Moxifloxacin |
|
ATC : J01MA14 |
|
Mycophenolate mofetil |
|
ATC : L04AA06 |
|
Mycophenolate mofetil |
|
ATC : L04AA06 |
|
N-acetylcysteine |
|
ATC : V03AB23 |
|
N-acetylcysteine |
|
ATC : R05CB01 |
|
N-acetylcysteine |
|
ATC : R05CB01 |
|
N-acetylcysteine |
|
ATC : R05CB01 |
|
Nadifloxacin |
|
ATC : D10AF05 |
|
Nadolol |
|
ATC : C07AA12 |
|
Nadroparin |
|
ATC : B01AB06 |
|
Nafamostat |
|
|
|
Nalbuphine hydrochloride |
|
ATC : N02AF02 |
|
Nalidixic acid |
|
ATC : J01MB02 |
|
Naloxone hydrochloride |
|
ATC : V03AB15 |
|
Naltrexone |
|
ATC : N07BB04 |
|
Naltrexone |
|
ATC : N07BB04 |
|
Naproxen |
|
ATC : M01AE02 |
|
Naratriptan Hydrochloride |
|
ATC : N02CC02 |
|
Natalizumab |
|
ATC : L04AA23 |
|
Nefopam |
|
ATC : N02BG06 |
|
Nelarabine |
|
ATC : L01BB07 |
|
Neostigmine methylsulfate |
|
ATC : N07AA01 |
|
Nesiritide |
|
ATC : C01DX19 |
|
Netilmicin sulfate |
|
ATC : J01GB07 |
|
Netilmicin sulfate |
|
ATC : J01GB07 |
|
Nicardipine hydrochloride |
|
ATC : C08CA04 |
|
Nicardipine hydrochloride |
|
ATC : C08CA04 |
|
Nicotinamide |
|
ATC : A11AH01 |
|
Nifedipine |
|
ATC : C08CA05 |
|
Nifedipine |
|
ATC : C08CA05 |
|
Nifedipine |
|
ATC : C08CA05 |
|
Nimesulide |
|
ATC : M01AX17 |
|
Nimodipine |
|
ATC : C08CA06 |
|
Nimodipine |
|
ATC : C08CA06 |
|
Nitrendipine |
|
ATC : C08CA08 |
|
Nitrofurantoin |
|
ATC : J01XE01 |
|
Nitroglycerin |
|
ATC : C01DA02 |
|
Nitroglycerin |
|
ATC : C01DA02 |
|
Nitroprusside sodium |
|
ATC : C02DD01 |
|
Nivolumab |
|
ATC : L01FF01 |
|
Nizatidine |
|
ATC : A02BA04 |
|
Norepinephrine bitartrate |
|
ATC : C01CA03 |
|
Norfloxacine |
|
ATC : J01MA06 |
|
Nystatin |
|
ATC : A07AA02 |
|
Obinutuzumab |
|
ATC : L01FA03 |
|
Octreotide acetate |
|
ATC : H01CB02 |
|
Ofloxacin |
|
ATC : J01MA01 |
|
Olmesartan medoxomil |
|
ATC : C09CA08 |
|
Omacetaxine mepesuccinate |
|
ATC : L01XX40 |
|
Omadacycline |
|
ATC : J01AA15 |
|
Omeprazole sodium |
|
ATC : A02BC01 |
|
Omeprazole sodium |
|
ATC : A02BC01 |
|
Ondansetron hydrochloride |
|
ATC : A04AA01 |
|
Ondansetron hydrochloride |
|
ATC : A04AA01 |
|
Orciprenaline sulfate |
|
ATC : R03AB03 |
|
Oritavancin |
|
ATC : J01XA05 |
|
Ornidazole |
|
ATC : J01XD03 |
|
Oseltamivir |
|
ATC : J05AH02 |
|
Oxacillin sodium |
|
ATC : J01CF04 |
|
Oxaliplatin |
|
ATC : L01XA03 |
|
Oxandrolone |
|
ATC : A14AA08 |
|
Oxybutynin |
|
ATC : G04BD04 |
|
Oxybutynin |
 |
ATC : G04BD04 |
|
Oxycodone hydrochloride |
|
ATC : N02AA05 |
|
Oxycodone hydrochloride |
|
ATC : N02AA05 |
|
Oxytocin |
|
ATC : H01BB02 |
|
Paclitaxel |
|
ATC : L01CD01 |
|
Paclitaxel albumin |
|
ATC : L01CD01 |
|
Palonosetron hydrochloride |
|
ATC : A04AA05 |
|
Pamidronate disodium |
|
ATC : M05BA03 |
|
Pancuronium bromide |
|
ATC : M03AC01 |
|
Panitumumab |
|
ATC : L01FE02 |
|
Pantoprazole sodium |
|
ATC : A02BC02 |
|
Pantoprazole sodium |
|
ATC : A02BC02 |
|
Papaverine hydrochloride |
|
ATC : A03AD01 |
|
Paracetamol |
|
ATC : N02BE01 |
|
Paracetamol |
|
ATC : N02BE01 |
|
Paracetamol |
|
ATC : N02BE01 |
|
Parecoxib sodium |
|
ATC : M01AH04 |
|
Pefloxacine |
|
ATC : J01MA03 |
|
Pegaspargase |
|
ATC : L01XX24 |
|
Pembrolizumab |
|
ATC : L01FF02 |
|
Pemetrexed diarginine |
|
ATC : L01BA04 |
|
Pemetrexed disodium |
|
ATC : L01BA04 |
|
Pemetrexed disodium hemipentahydrate |
|
ATC : L01BA04 |
|
Penicillamine-D |
|
ATC : M01CC01 |
|
Penicillin G potassium |
|
ATC : J01CE01 |
|
Penicillin G sodium |
|
ATC : J01CE01 |
|
Pentamidine isetionate |
|
ATC : P01CX01 |
|
Pentobarbital |
|
ATC : N05CA01 |
|
Pentobarbital sodium |
|
ATC : N05CA01 |
|
Pentobarbital sodium |
|
ATC : N05CA01 |
|
Pentostatin |
|
ATC : L01XX08 |
|
Pentoxifyllin |
|
ATC : C04AD03 |
|
Pentoxifyllin |
|
ATC : C04AD03 |
|
Pentoxifyllin |
|
ATC : C04AD03 |
|
Perphenazine |
|
ATC : N05AB03 |
|
Pertuzumab |
|
ATC : L01FD02 |
|
Pethidine hydrochloride |
|
ATC : N02AB02 |
|
Pevonedistat |
|
ATC : L01XX86 |
|
Phenobarbital |
|
ATC : N05CA24 |
|
Phenobarbital sodium |
|
ATC : N03AA02 |
|
Phenoxybenzamine |
|
ATC : C04AX02 |
|
Phentolamine mesylate |
|
ATC : C04AB01 |
|
Phenylbutyrate sodium |
|
ATC : A16AX03 |
|
Phenylephrine hydrochloride |
|
ATC : C01CA06 |
|
Phenylephrine hydrochloride |
|
ATC : C01CA06 |
|
Phenytoin |
|
ATC : N03AB02 |
|
Phenytoin sodium |
|
ATC : N03AB02 |
|
Phloroglucinol |
|
ATC : A03AX12 |
|
Phytomenadione |
|
ATC : B02BA01 |
|
Phytomenadione |
|
ATC : B02BA01 |
|
Pimavanserin |
|
ATC : N05AX17 |
|
Piperacillin sodium |
|
ATC : J01CA12 |
|
Piperacillin sodium / tazobactam |
|
ATC : J01CR05 |
|
Piritramide |
|
ATC : N02AC03 |
|
Piroxicam |
|
ATC : M01AC02 |
|
Piroxicam |
|
ATC : M01AC02 |
|
Pixantrone dimaleate |
|
ATC : L01DB11 |
|
Plazomicin sulfate |
|
ATC : J01GB14 |
|
Plerixafor |
|
ATC : L03AX16 |
|
Polyhexamethylene biguanide |
|
ATC : D08AC05 |
|
Polyhexamethylene biguanide |
|
ATC : D08AC05 |
|
Polymyxine B |
|
ATC : J01XB02 |
|
Posaconazole |
|
ATC : J02AC03 |
|
Potassium chloride |
|
ATC : B05XA01 |
|
Potassium phosphate |
|
ATC : B05XA06 |
|
Povidone iodine |
|
ATC : DO8AG02 |
|
Pravastatine |
|
ATC : C10AA03 |
|
Prednisolone |
|
ATC : A07EA01 |
|
Prednisone |
|
ATC : H02AB |
|
Pregabaline |
|
ATC : N03AX16 |
|
Procainamide hydrochloride |
|
ATC : C01BA02 |
|
Procainamide hydrochloride |
|
ATC : C01BA02 |
|
Procaine hydrochloride |
|
ATC : N01BA02 |
|
Prochlorperazine edysilate |
|
ATC : N05AB04 |
|
Prochlorperazine edysilate |
|
ATC : N05AB04 |
|
Proflavine |
|
ATC : D08AA02 |
|
Progestérone |
|
ATC : G03DA04 |
|
Promethazine hydrochloride |
|
ATC : R06AD02 |
|
Propafenone hydrochloride |
|
ATC : C01BC03 |
|
Propafenone Hydrochloride |
|
ATC : C01BC03 |
|
Propofol |
|
ATC : N01AX10 |
|
Propranolol hydrochloride |
|
ATC : C07AA05 |
|
Propranolol hydrochloride |
|
ATC : C07AA05 |
|
Propylthiouracil |
|
ATC : H03BA02 |
|
Protamine hydrochloride |
|
ATC : V03B14 |
|
Protamine sulfate |
|
ATC : V03AB14 |
|
Pyrazinamide |
|
ATC : J04AK01 |
|
Pyridoxine hydrochloride |
|
ATC : A11HA02 |
|
Pyridoxine hydrochloride |
|
ATC : A11HA02 |
|
Pyridoxine hydrochloride |
|
ATC : A11HA02 |
|
Pyrimethamine |
|
ATC : P01BD01 |
|
Quetiapine fumarate |
|
ATC : N04AH04 |
|
Quinapril |
|
ATC : C09AA06 |
|
Quinidine gluconate |
|
ATC : C01BA01 |
|
Quinidine sulfate |
|
ATC : C01BA01 |
|
Quinine dihydrochloride |
|
ATC : P01BC01 |
|
Quinupristine/dalfopristine |
|
ATC : J01FG02 |
|
Raltitrexed |
|
ATC : L01BA03 |
|
Ramipril |
|
ATC : C09AA05 |
|
Ramosetron hydrochloride |
|
|
|
Ramucirumab |
|
ATC : L01FG02 |
|
Ranibizumab |
|
ATC : S01LA04 |
|
Ranitidine hydrochloride |
|
ATC : A02BA02 |
|
Rasburicase |
|
ATC : V03AF07 |
|
Remdesivir |
|
ATC : J05AB16 |
|
Remifentanil hydrochloride |
|
ATC : N01AH06 |
|
Remimazolam besylate |
|
ATC : N05CD14 |
|
Resorcinol |
|
ATC : D10AX02 |
|
Reteplase |
|
ATC : B01AD07 |
|
Retinoic acid |
|
ATC : D10AD01 |
|
Retinol |
|
ATC : A11CA01 |
|
Ribavirine |
|
ATC : J05AB04 |
|
Ribavirine |
|
ATC : J05AB04 |
|
Riboflavine |
|
ATC : A11HA04 |
|
Rifabutin |
|
ATC : J04AB04 |
|
Rifampicin |
|
ATC : J04AB02 |
|
Rifampicin |
|
ATC : J04AB02 |
|
Rifaximin |
|
ATC : A07AA11 |
|
Rituximab |
|
ATC : L01FA01 |
|
Rocuronium bromide |
|
ATC : M03AC09 |
|
Rolapitant |
|
ATC : A04AD14 |
|
Romidepsin |
|
ATC : L01XX39 |
|
Ropivacain hydrochloride |
|
ATC : N01BB09 |
|
Rosuvastatin |
|
ATC : C10AA07 |
|
Rufinamide |
|
ATC : N03AF03 |
|
Ruxolitinib |
|
ATC : L01EJ01 |
|
Salbutamol sulfate |
|
ATC : R03CC02 |
|
Salbutamol sulfate |
|
ATC : R03AC02 |
|
Saquinavir |
|
ATC : J05AE01 |
|
Sargramostim |
|
ATC : L03AA09 |
|
Scopolamine hydrobromide |
|
ATC : A04AD01 |
|
Scopolamine hydrobromide |
|
ATC : N05CM05 |
|
Scopolamine N-butyl bromide |
|
ATC : A03BB01 |
|
Sertraline hydrochloride |
|
ATC : N06AB06 |
|
Sildenafil citrate |
|
ATC : G04BE03 |
|
Sildenafil citrate |
|
ATC : G04BE03 |
|
Siltuximab |
|
ATC : L04AC11 |
|
Simvastatin |
|
ATC : C10AA01 |
|
Sirolimus |
|
ATC : L04AA10 |
|
Sirolimus |
|
ATC : L04AA10 |
|
Sitagliptine phosphate |
|
ATC : A10BH01 |
|
Sodium bicarbonate |
|
ATC : B05XA02 |
|
Sodium bicarbonate |
|
ATC : B05XA02 |
|
Sodium citrate |
|
ATC : B05CB02 |
|
Sodium oxybate |
|
ATC : N07XX04 |
|
Sodium Phosphate |
|
ATC : A06AG01 |
|
Sodium thiosulfate |
|
ATC : V03AB06 |
|
Sotalol hydrochloride |
|
ATC : C07AA07 |
|
Spiramycine adipate |
|
ATC : J01FA02 |
|
Spironolactone |
|
ATC : C03DA01 |
|
Spironolactone |
|
ATC : C03DA01 |
|
Streptokinase |
|
ATC : B01AD01 |
|
Streptomycin sulfate |
|
ATC : A07AA04 |
|
Streptozocin |
|
ATC : L01AD04 |
|
Sufentanil citrate |
|
ATC : N01AH03 |
|
Sugammadex |
|
ATC : V03AB35 |
|
Sulfadiazine |
|
ATC : J01EC02 |
|
Sulfasalazine |
|
ATC : A07EC01 |
|
Sumatriptan succinate |
|
ATC : N02CC01 |
|
Sumatriptan succinate |
|
ATC : N02CC01 |
|
Sunitinib |
|
ATC : L01XE04 |
|
Suxamethonium chloride |
|
ATC : M03AB01 |
|
Tacrolimus |
|
ATC : D11AX14 |
|
Tacrolimus |
|
ATC : D11AX14 |
|
Tacrolimus |
|
ATC : L04AD02 |
|
Tadalafil |
|
ATC : G04BE08 |
|
Tafasitamab |
|
ATC : L01FX12 |
|
Teclistamab |
|
ATC : L01FX24 |
|
Tedizolid phosphate |
|
ATC : J01XX11 |
|
Teduglutide |
|
ATC : A16AX08 |
|
Teicoplanine |
|
ATC : J01XA02 |
|
Telavancin hydrochloride |
|
ATC : J01XA03 |
|
Temocilline |
|
ATC : J01CA17 |
|
Temozolomide |
|
ATC : L01AX03 |
|
Temozolomide |
|
ATC : L01AX03 |
|
Temsirolimus |
|
ATC : L01EG01 |
|
Tenecteplase |
|
ATC : B01AD11 |
|
Teniposide |
|
ATC : L01CB02 |
|
Terbinafine |
|
ATC : D01AE15 |
|
Terbutaline sulfate |
|
ATC : R03CC03 |
|
Terbutaline sulfate |
|
ATC : R03AC03 |
|
Testostérone |
|
ATC : G03BA03 |
|
Tetracain hydrochloride |
|
ATC : N01BA03 |
|
Tetracain hydrochloride |
|
ATC : N01BA03 |
|
Tetracaine |
|
ATC : N01BA03 |
|
Tetracycline hydrochloride |
|
ATC : A01AB13 |
|
Thalidomide |
|
ATC : L04AX02 |
|
Theophylline |
|
ATC : R03DA04 |
|
Theophylline |
|
ATC : R03DA04 |
|
Thiamazole |
|
ATC : H03BB02 |
|
Thiamine hydrochloride |
|
ATC : A11DA01 |
|
Thiamine hydrochloride |
|
ATC : A11DA01 |
|
Thiocolchicoside |
|
ATC : M03BX05 |
|
Thioguanine |
|
ATC : L01BB03 |
|
Thiopental sodium |
|
ATC : N01AF03 |
|
Thioridazine |
|
ATC : N05AC02 |
|
Thiotepa |
|
ATC : L01AC01 |
|
Thiothixene |
|
ATC : N05AF04 |
|
Tiagabine |
|
ATC : N03AG06 |
|
Tiapride |
|
ATC : N05AL03 |
|
Ticarcillin sodium |
|
ATC : J01CA13 |
|
Tigecycline |
|
ATC : J01AA12 |
|
Timolol maleate |
|
ATC : C07AA06 |
|
Tirofiban |
|
ATC : B01AC17 |
|
Tizanidine hydrochloride |
|
ATC : M03BX02 |
|
Tobramycin sulfate |
|
ATC : J01GB01 |
|
Tobramycin sulfate |
|
ATC : J01GB01 |
|
Tobramycin sulfate |
|
ATC : J01GB01 |
|
Tobramycin sulfate |
|
ATC : J01GB01 |
|
Tocilizumab |
|
ATC : L04AC07 |
|
Topiramate |
|
ATC : N03AX11 |
|
Topotecan |
|
ATC : L01XX17 |
|
Torsemide |
|
ATC : C03CA04 |
|
Trabectedine |
|
ATC : L01CX01 |
|
Tramadol hydrochloride |
|
ATC : N02AX02 |
|
Tramadol hydrochloride |
|
ATC : N02AX02 |
|
Tranexamic acid |
 |
ATC : B02AA02 |
|
Tranexamic acid |
|
ATC : B02AA02 |
|
Trastuzumab |
|
ATC : L01FD01 |
|
Trastuzumab deruxtecan |
|
ATC : L01FD04 |
|
Trastuzumab emtansine |
|
ATC : L01FD03 |
|
Tremelimumab |
|
ATC : L01FX20 |
|
Treosulfan |
|
ATC : L01AB02 |
|
Treprostinil |
|
ATC : B01AC21 |
|
Tretinoin |
|
ATC : D10AD01 |
|
Triamcinolone |
|
ATC : A01AC01 |
|
Triamcinolone acetonide |
|
ATC : D07XB02 |
|
Trifluoperazine |
|
ATC : N05AB06 |
|
Trihexyphenidyl |
|
ATC : N04AA01 |
|
Trimebutine |
|
ATC : A03AA05 |
|
Trimethoprim |
|
ATC : J01EA01 |
|
Trisodium citrate |
|
ATC : B05CB02 |
|
Tropicamide |
|
ATC : S01FA06 |
|
Tropisetron hydrochloride |
|
ATC : A04AA03 |
|
Turoctocog alfa |
|
ATC : B02BD02 |
|
Urapidil |
|
ATC : C02CA06 |
|
Urokinase |
|
ATC : B01AD04 |
|
Ursodesoxycholique acid |
|
ATC : A05AA02 |
|
Valacyclovir chlorhydrate |
|
ATC : J05AB11 |
|
Valganciclovir |
|
ATC : J05AB14 |
|
Valproic acid |
|
ATC : N03AG01 |
|
Valsartan |
|
ATC : C09CA03 |
|
Vancomycin hydrochloride |
|
ATC : J01XA01 |
|
Vancomycin hydrochloride |
|
ATC : A07AA09 |
|
Vancomycin hydrochloride |
|
ATC : A07AA09 |
|
Vasopressin |
|
ATC : H01BA01 |
|
Vecuronium bromide |
|
ATC : M03AC03 |
|
Vedolizumab |
|
ATC : L04AA33 |
|
Venlafaxine |
|
ATC : N06AX16 |
|
Verapamil hydrochloride |
|
ATC : C08DA01 |
|
Verapamil hydrochloride |
|
ATC : C08DA01 |
|
Verteporfine |
|
ATC : S01LA01 |
|
Vinblastine sulfate |
|
ATC : L01CA01 |
|
Vincristine sulfate |
|
ATC : L01CA02 |
|
Vincristine sulfate liposome |
|
ATC : L01CA02 |
|
Vindesine sulfate |
|
ATC : L01CA03 |
|
Vinflunine |
|
ATC : L01CA05 |
|
Vinorelbine |
|
ATC : L01CA04 |
|
Vinorelbine tartrate |
|
ATC : L01CA04 |
|
Voriconazole |
|
ATC : J02AC03 |
|
Voriconazole |
|
ATC : J02AC03 |
|
Voriconazole |
|
ATC : J02AC03 |
|
Warfarin sodium |
|
ATC : B01AA03 |
|
Warfarin sodium clathrate |
|
ATC : B01AA03 |
|
Ziconotide acetate |
|
ATC : N02BG08 |
|
Zidovudine |
|
ATC : J05AF01 |
|
Zidovudine |
|
ATC : J05AF01 |
|
Zoledronic acid |
|
ATC : M05BA08 |
|
Zonisamide |
|
ATC : N03AX15 |
 |
1 |
Am J Health-Syst Pharm |
Stability of cidofovir in 0.9% sodium chloride and in 5% dextrose injection. |
|
2 |
Am J Hosp Pharm |
Stability of foscarnet in 0.9% sodium chloride injection. |
|
3 |
Am J Health-Syst Pharm |
Compatibility of amifostine with selected drugs during simulated Y-site administration. |
|
4 |
Act Pharm Biol Clin |
Reconstitution centralisée du ganciclovir : méthode de contrôle et étude de stabilité. |
|
5 |
Am J Health-Syst Pharm |
Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes. |
|
6 |
Am J Hosp Pharm |
Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C. |
|
8 |
Am J Hosp Pharm |
Compatibility of esmolol hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site administration. |
|
9 |
Can J Hosp Pharm |
Compatibility and stability of hyaluronidase and hydromorphone. |
|
10 |
Am J Health-Syst Pharm |
Stability of meropenem in intravenous solutions. |
|
11 |
Am J Health-Syst Pharm |
Stability of ceftriaxone sodium and metronidazole hydrochloride. |
|
12 |
Am J Health-Syst Pharm |
Stability of amphotericin B 0.05 and 0.5 mg/ml in 20% fat emulsion. |
|
13 |
Am J Health-Syst Pharm |
Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs. |
|
14 |
Am J Health-Syst Pharm |
Compatibility of ciprofloxacin lactate with sodium bicarbonate during simulated Y-site administration. |
|
16 |
Am J Health-Syst Pharm |
Compatibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration. |
|
18 |
Am J Hosp Pharm |
Stability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazole during simulated Y-site administration. |
|
19 |
Am J Hosp Pharm |
Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin. |
|
20 |
Am J Hosp Pharm |
Stability of erythromycin in intravenous admixtures. |
|
21 |
Am J Hosp Pharm |
Compatibility of imipenem-cilastatin sodium with commonly used intravenous solutions. |
|
22 |
Int J Pharm |
The chemical and physical stability of three intravenous infusions subjected to frozen storage and microwave thawing. |
|
23 |
Am J Health-Syst Pharm |
Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride and in 5% dextrose injection. |
|
24 |
Am J Hosp Pharm |
Stability of dexamethasone sodium phosphate, diphenhydramine hydrochloride, lorazepam, and metoclopramide hydrochloride in portable infusion-pump reservoirs. |
|
25 |
Am J Hosp Pharm |
Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions. |
|
26 |
Am J Health-Syst Pharm |
Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. |
|
27 |
Am J Health-Syst Pharm |
Stability of granisetron hydrochloride with dexamethasone sodium phosphate for 14 days. |
|
28 |
PDA J Pharm Sci Technol |
Dexamethasone phosphate stability and contamination of solutions stored in syringes. |
|
29 |
J Pharm Sci |
Compatibility and stability of granisetron, dexamethasone, and methylprednisolone in injectable solutions. |
|
30 |
Am J Health-Syst Pharm |
Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days. |
|
31 |
Hosp Pharm |
Physical and chemical stability of methotrexate sodium, cytarabine, and hydrocortisone sodium succinate in Elliott’s B solution. |
|
32 |
Am J Health-Syst Pharm |
Stability of doxorubicin and vincristine sulfate in two portable infusion-pump reservoirs. |
|
33 |
Am J Health-Syst Pharm |
Stability of fluorouracil in polypropylene syringes and ethylene vinyl acetate infusion-pump reservoirs. |
|
35 |
Am J Health-Syst Pharm |
Long term stability of interferon alfa-2b diluted to 2 million units/mL. |
|
36 |
Am J Health-Syst Pharm |
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. |
|
38 |
Int J Pharm |
The extraction of diethylhexylphtalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection. |
|
39 |
J Pharm Clin |
Influence of intravenous admixtures on the stability of the new solution of 5-fluorouracil. |
|
40 |
Pharm Sci Communications |
Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags. |
|
41 |
Am J Health-Syst Pharm |
Stability of midazolam hydrochloride in syringes and IV fluids. |
|
42 |
Am J Health-Syst Pharm |
Stability of bumetanide in 5% dextrose injection. |
|
43 |
Am J Health-Syst Pharm |
Stability of caffeine citrate injection in polypropylene syringes at room temperature. |
|
44 |
Am J Health-Syst Pharm |
Stability of nicardipine hydrochloride in intravenous solutions. |
|
45 |
Am J Hosp Pharm |
Stability of succinylcholine chloride injection. |
|
46 |
Am J Health-Syst Pharm |
Stability of ranitidine hydrochloride in water for injection in glass vials and plastic syringes. |
|
47 |
Am J Hosp Pharm |
Stability of paclitaxel with ondansetron or ranitidine hydrochloride during simulated Y site administration. |
|
48 |
Am J Health-Syst Pharm |
Stability of granisetron hydrochloride in polypropylene syringes. |
|
49 |
Am J Health-Syst Pharm |
Compatibility of granisetron hydrochloride with selected alkaline drugs. |
|
50 |
Am J Health-Syst Pharm |
Stability of ondansetron hydrochloride and cyclophosphamide in injectable solutions. |
|
51 |
Am J Health-Syst Pharm |
Stability of granisetron hydrochloride in a disposable elastomeric infusion device. |
|
52 |
Am J Health-Syst Pharm |
Stability of ondansetron hydrochloride in a total parenteral nutrient admixture. |
|
53 |
Am J Health-Syst Pharm |
Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. |
|
54 |
J Pharm Clin |
Compatibility PVC-psychotropic drugs during an infusion. |
|
55 |
J Clin Hosp Pharm |
The compatibility of diazepam with infusion fluids and their containers. |
|
57 |
Am J Health-Syst Pharm |
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. |
|
58 |
Can J Hosp Pharm |
Physical compatibility of ranitidine HCl with preoperative injectable medications. |
|
59 |
Am J Health-Syst Pharm |
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. |
|
60 |
Am J Hosp Pharm |
Stability of fentanyl citrate and bupivacaine hydrochloride in portable pump reservoirs. |
|
62 |
Am J Hosp Pharm |
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. |
|
63 |
Am J Hosp Pharm |
Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. |
|
64 |
Am J Hosp Pharm |
Additional data on visual compatibility of foscarnet sodium with morphine sulfate. |
|
65 |
Am J Hosp Pharm |
Stability of morphine sulfate in infusion devices and containers for intravenous administration. |
|
66 |
Can J Hosp Pharm |
Stability and compatibility of reconstituted hydromorphone with potassium chloride or heparin. |
|
67 |
Am J Hosp Pharm |
Visual compatibility of ganciclovir sodium and parenteral nutrient solution during simulated Y-site injection. |
|
68 |
J Clin Pharm Ther |
Stability of acyclovir sodium in dextrose and sodium chloride injections. |
|
69 |
Am J Hosp Pharm |
Stability of ganciclovir sodium (DHPG sodium) in 5% dextrose or 0.9% sodium chloride injections. |
|
70 |
Am J Hosp Pharm |
Stability and compatibility of ganciclovir sodium in 5% dextrose injection over 35 days. |
|
71 |
Am J Health-Syst Pharm |
Stability of cidofovir in 0.9% sodium chloride injection for five days. |
|
72 |
Am J Hosp Pharm |
Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions. |
|
73 |
Am J Hosp Pharm |
Visual compatibility of foscarnet with other injectable drugs. |
|
74 |
Am J Hosp Pharm |
Stability of ganciclovir sodium in an infusion-pump syringe. |
|
75 |
J Clin Pharm Ther |
Stability of foscarnet sodium in 5% dextrose and 0.9% sodium chloride injections. |
|
76 |
Am J Hosp Pharm |
Stability of ganciclovir sodium in 5% dextrose injection and in 0.9% sodium chloride injection over 35 days. |
|
77 |
Am J Hosp Pharm |
Stability of famotidine frozen in polypropylene syringes. |
|
78 |
Am J Hosp Pharm |
Stability of ranitidine in intravenous admixtures stored frozen, refrigerated, and at room temperature. |
|
79 |
Am J Hosp Pharm |
Compatibility of cefoperazone sodium and cimetidine hydrochloride in 5% dextrose injection. |
|
80 |
Am J Hosp Pharm |
Stability of cimetidine hydrochloride and of clindamycin phosphate in water for injection stored in glass vials at two temperatures. |
|
81 |
Am J Hosp Pharm |
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. |
|
84 |
Am J Hosp Pharm |
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. |
|
85 |
Am J Hosp Pharm |
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. |
|
86 |
Am J Hosp Pharm |
Stability of midazolam hydrochloride and morphine sulfate during simulated intravenous coadministration. |
|
87 |
Am J Hosp Pharm |
Compatibility of cefoperazone sodium and furosemide in 5% dextrose injection. |
|
88 |
J Acquired Immune Defic Syndr |
Extended stability of ganciclovir for outpatient parenteral therapy for cytomegalovirus retinitis. |
|
89 |
Am J Hosp Pharm |
Incompatibility of labetalol hydrochloride and furosemide. |
|
90 |
Am J Hosp Pharm |
Stability of nitroglycerin concentrate for injection stored in plastic syringes. |
|
91 |
Am J Hosp Pharm |
Visual compatibility of gallium nitrate with selected drugs during Y-site injection. |
|
92 |
Am J Hosp Pharm |
Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. |
|
93 |
Am J Health-Syst Pharm |
Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. |
|
94 |
Am J Hosp Pharm |
Aztreonam-vancomycin incompatibility. |
|
95 |
Am J Hosp Pharm |
Incompatibility of ceftriaxone with vancomycin. |
|
96 |
Am J Hosp Pharm |
Stability of cefuroxime sodium and aminophylline or theophylline. |
|
99 |
Am J Health-Syst Pharm |
Compatibility of aztreonam with selected drugs during simulated Y-site administration. |
|
100 |
Am J Health-Syst Pharm |
Stability of ceftriaxone sodium in polypropylene syringes at -20, 4, and 20°C. |
|
103 |
Am J Health-Syst Pharm |
Incompatibility of cefotetan disodium and promethazine hydrochloride. |
|
104 |
Am J Health-Syst Pharm |
Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. |
|
106 |
Am J Hosp Pharm |
Incompatibility of cefoperazone and promethazine. |
|
107 |
J Pharm Biomed Anal |
Stability of stored methacholine solutions: study of hydrolysis kinetic by IP-LC. |
|
108 |
Am J Health-Syst Pharm |
Stability of levofloxacin in intravenous solutions in polyvinyl chloride bags. |
|
110 |
Int J Pharm |
Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers. |
|
111 |
Am J Health-Syst Pharm |
Stability of cefazolin sodium and meperidine hydrochloride. |
|
113 |
Am J Hosp Pharm |
Stability of ondansetron hydrochloride stored in a disposable, elastomeric infusion device at 4°C. |
|
115 |
Am J Hosp Pharm |
Stability of morphine sulfate in bacteriostatic 0.9% sodium chloride injection stored in glass vials at two temperatures. |
|
116 |
Am J Hosp Pharm |
Stability of morphine sulfate in portable pump reservoirs during storage and simulated administration. |
|
117 |
Can J Hosp Pharm |
The stability of morphine intravenous infusion solutions. |
|
119 |
J Clin Pharm Ther |
Shelf-lives and factors affecting the stability of morphine sulphate and meperidine (pethidine) hydrochloride in plastic syringes for use in patient-controlled analgesic devices. |
|
120 |
Can J Hosp Pharm |
Hydromorphone and morphine stability in portable infusion pump cassettes and minibags. |
|
121 |
Can J Hosp Pharm |
Stability of sulfite free high potency morphine sulfate solutions in portable infusion pump cassettes. |
|
122 |
Int J Pharm Pract |
Factors affecting the physical and chemical stability of morphine sulphate solutions stored in syringes. |
|
124 |
Int Pharm J |
An in vitro interaction between promethazine hydrochloride and chloroquine phosphate. |
|
125 |
Am J Health-Syst Pharm |
Stability of thiopental sodium and propofol in polypropylene syringes at 23 and 4°C. |
|
126 |
Am J Health-Syst Pharm |
Physicochemical compatibility of propofol with thiopental sodium. |
|
127 |
Am J Health-Syst Pharm |
Stability of octreotide acetate in polypropylene syringes at 5 and -20°C. |
|
129 |
Am J Hosp Pharm |
Visual compatibility of insulin with secondary intravenous drugs in admixtures. |
|
132 |
Am J Health-Syst Pharm |
Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. |
|
138 |
Am J Health-Syst Pharm |
Precipitation of fluorouracil in elastomeric infusers with a polyisoprene reservoir and in polypropylene syringes with an elastomeric joint. |
|
140 |
Am J Hosp Pharm |
Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. |
|
141 |
Hosp Pharm |
Stability of gallium nitrate and mitoguazone dihydrochloride in commonly used intravenous fluids. |
|
142 |
Am J Hosp Pharm |
Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs. |
|
144 |
Int J Pharm |
Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags. |
|
145 |
J Pharm Clin |
Photosensibility of 5-fluorouracile and methotrexate in translucent or opaque perfusers. |
|
146 |
Clin Ther |
Effects of temperature, solution composition, and type of container on the stability and absorption of carmustine. |
|
147 |
Pharm World Sci |
Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container’s material. |
|
148 |
Pharm Weekbl [Sci] |
Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. |
|
149 |
J Clin Pharm Ther |
Stability of cisplatin in ethylene vinylacetate portable infusion-pump reservoirs. |
|
150 |
J Pharm Clin |
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. |
|
151 |
Am J Hosp Pharm |
Stability of paclitaxel and fluconazole during simulated Y-site administration. |
|
152 |
Pharm Acta Helv |
Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion. |
|
153 |
Am J Health-Syst Pharm |
Stability of fluorouracil-metoclopramide hydrochloride admixture. |
|
154 |
Pharm Res |
Chemical stability of pentostatin (NSC-218321), a cytotoxic and immunosuppressant agent. |
|
155 |
Am J Health-Syst Pharm |
Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium. |
|
156 |
Anticancer Drugs |
Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions. |
|
157 |
Am J Hosp Pharm |
Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32°C. |
|
158 |
Am J Hosp Pharm |
Compatibility of paclitaxel injection vehicle with intravenous administration and extension sets. |
|
160 |
Am J Hosp Pharm |
Effect of sodium chloride concentration and temperature on melphalan stability during storage and use. |
|
161 |
Am J Hosp Pharm |
Stability and compatibility of etoposide in 0.9% sodium chloride injection in three containers. |
|
162 |
Int J Pharm |
Compatibility study of methotrexate with PVC bags after repackaging into two types of infusion admixtures. |
|
163 |
J Clin Pharm Ther |
Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens. |
|
164 |
J Clin Pharm Ther |
Stability and compatibility of cisplatin and carboplatin with PVC infusion bags. |
|
165 |
Int J Pharm |
Leaching of diethylhexyl phthlate from PVC bags into intravenous teniposide solution. |
|
166 |
Int J Pharm |
Stability and compatibility study of carboplatin with three portable infusion pump reservoirs. |
|
167 |
Int J Pharm |
Adsorption of vincristine, vinblastine, doxorubicin and mitoxantrone to in-line intravenous filters. |
|
168 |
J Pharm Pharmacol |
The long term stability of mechlorethamine hydrochloride (Nitrogen Mustard) ointment measured by HPLC. |
|
169 |
Am J Hosp Pharm |
Physical compatibility of melphalan with selected drugs during simulated Y-site administration. |
|
170 |
Am J Hosp Pharm |
Effect of briefly heating cyclophosphamide solutions. |
|
172 |
J Parenter Sci Technol |
Chemical stability of two sterile, parenteral formulations of cyclophosphamide (Endoxan) after reconstitution and dilution in commonly used infusion fluids. |
|
173 |
J Infus Chemother |
Precipitation of paclitaxel from continuous infusion fluids. |
|
174 |
Am J Hosp Pharm |
Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride. |
|
175 |
Am J Hosp Pharm |
Storage of lorazepam in three injectable solutions in polyvinyl chloride and polyolefin bags. |
|
176 |
Am J Health-Syst Pharm |
Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. |
|
177 |
Am J Health-Syst Pharm |
Avaibility of lorazepam after simulated administration from glass and polyvinyl chloride containers. |
|
179 |
Am J Hosp Pharm |
Stability of ondansetron hydrochloride in portable infusion-pump reservoirs. |
|
180 |
Am J Health-Syst Pharm |
Stability of metoclopramide hydrochloride in plastic syringes. |
|
181 |
Med Sci Monit |
Butorphanol and Ketamine Combined in Infusion Solutions for Patient-Controlled Analgesia Administration: A Long-Term Stability Study. |
|
182 |
Am J Health-Syst Pharm |
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. |
|
183 |
Am J Hosp Pharm |
Stability of ondansetron hydrochloride in injectable solutions at -20, 5, and 25°C. |
|
184 |
Am J Health-Syst Pharm |
Stability of ondansetron hydrochloride and five antineoplasic medications. |
|
185 |
Am J Health-Syst Pharm |
Stability of midazolam hydrochloride in polyvinyl chloride bags under fluorescent light. |
|
186 |
Am J Health-Syst Pharm |
Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. |
|
187 |
Am J Hosp Pharm |
Stability of flumazenil with selected drugs in 5% dextrose injection. |
|
188 |
Am J Hosp Pharm |
Visual compatibility of neuroleptics with anticholinergics or antihistamines in polyethylene syringes. |
|
190 |
Am J Hosp Pharm |
Sorption of four drugs to polyvinyl chloride and polybutadiene intravenous administration sets. |
|
191 |
Am J Hosp Pharm |
Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection. |
|
192 |
Am J Health-Syst Pharm |
Stability of high-concentration dopamine hydrochloride, norepinephrine bitartrate, epinephrine hydrochloride, and nitroglycerin in 5% dextrose injection. |
|
193 |
Am J Health-Syst Pharm |
Stability of propafenone hydrochloride in IV solutions. |
|
194 |
Am J Hosp Pharm |
Effect of vehicle ionic strength on sorption of nitroglycerin to a polyvinyl chloride administration set. |
|
196 |
J Clin Pharm Ther |
Stabilities of dobutamine, dopamine, nitroglycerin and sodium nitroprusside in disposable plastic syringes. |
|
197 |
J Clin Pharm Ther |
The stability of four catecholamines in 5% glucose infusions. |
|
198 |
Am J Health-Syst Pharm |
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. |
|
199 |
Am J Hosp Pharm |
Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection. |
|
200 |
Am J Health-Syst Pharm |
Incompatibility of amiodarone hydrochloride and sodium bicarbonate injections. |
|
201 |
Am J Hosp Pharm |
Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection. |
|
204 |
Am J Hosp Pharm |
Stability of esmolol hydrochloride in intravenous solutions. |
|
205 |
Am J Health-Syst Pharm |
Incompatibility of amiodarone hydrochloride and evacuated glass bottles. |
|
206 |
Am J Health-Syst Pharm |
Stability of dopamine hydrochloride and of dobutamine hydrochloride in plastic syringes and administration sets. |
|
207 |
Am J Health-Syst Pharm |
Compatibility of tacrolimus injection with cimetidine hydrochloride injection in 0.9% sodium chloride injection. |
|
208 |
Am J Health-Syst Pharm |
Stability of ranitidine hydrochloride and human insulin in 0.9% sodium chloride injection. |
|
209 |
Am J Hosp Pharm |
In vitro evaluation of the stability of raniditine hydrochloride in total parenteral nutrient mixtures. |
|
210 |
Am J Hosp Pharm |
Stability of ranitidine hydrochloride and seven medications. |
|
211 |
Am J Hosp Pharm |
Stability and compatibility of methylprednisolone sodium succinate and cimetidine hydrochloride in 5% dextrose injection. |
|
212 |
Am J Hosp Pharm |
Stability of diluted methylprednisolone sodium succinate injection at two temperatures. |
|
213 |
Am J Hosp Pharm |
Stability of ranitidine hydrochloride at dilute concentration in intravenous infusion fluids at room temperature. |
|
214 |
Am J Hosp Pharm |
Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. |
|
215 |
Ann Pharmacotherapy |
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. |
|
216 |
Am J Hosp Pharm |
Compatibility of hydromorphone hydrochloride with haloperidol lactate and ketorolac tromethamine. |
|
217 |
Am J Hosp Pharm |
Stability of bupivacaine hydrochloride, epinephrine hydrochloride, and fentanyl citrate in portable infusion-pump reservoirs. |
|
218 |
Am J Hosp Pharm |
Compatibility of magnesium sulfate and morphine sulfate in 0.9% sodium chloride injection. |
|
219 |
J Clin Pharm Ther |
Study protocol : stability of morphine injected without preservative, delivered with a disposable infusion device. |
|
220 |
Am J Health-Syst Pharm |
Compatibility of bupivacaine hydrochloride and morphine sulfate. |
|
221 |
Am J Hosp Pharm |
Compatibility of bupivacaine hydrochloride with hydromorphone hydrochloride or morphine sulfate. |
|
222 |
Am J Hosp Pharm |
Stability of fentanyl citrate in 0.9% sodium chloride solution in portable infusion pumps. |
|
223 |
Am J Hosp Pharm |
Stability of fentanyl citrate in glass and plastic containers and in a patient-controlled delivery system. |
|
224 |
Am J Hosp Pharm |
Stability of methadone hydrochloride in 0.9% sodium chloride injection in single-dose plastic containers. |
|
225 |
Am J Health-Syst Pharm |
Stability of fentanyl citrate and midazolam hydrochloride during simulated intravenous coadministration. |
|
226 |
Can J Hosp Pharm |
Stability and compatibility of combinations of hydromorphone and a second drug. |
|
227 |
Am J Hosp Pharm |
Compatibility of cyclizine lactate and haloperidol lactate. |
|
228 |
Am J Hosp Pharm |
Incompatibility of ketorolac tromethamine with haloperidol lactate and triethylperazine maleate. |
|
229 |
Am J Hosp Pharm |
Compatibility of haloperidol lactate with benztropine mesylate. |
|
230 |
Am J Hosp Pharm |
Visual compatibility of haloperidol lactate with injectable solutions. |
|
231 |
Am J Hosp Pharm |
Stability of midazolam hydrochloride in 5% dextrose injection or 0.9% sodium chloride injection over 30 days. |
|
232 |
Am J Hosp Pharm |
Stability of midazolam hydrochloride in parenteral nutrient solutions. |
|
233 |
Am J Health-Syst Pharm |
Precipitation of lorazepam during infusion by volumetric pump. |
|
234 |
J Clin Pharm Ther |
Stability of refrigerated and frozen solutions of tropisetron in either polyvinylchloride or polyolefin infusion bags. |
|
235 |
Am J Hosp Pharm |
Stability of piperacillin sodium-tazobactam sodium and ranitidine hydrochloride in 0.9% sodium chloride injection during simulated Y-site administration. |
|
237 |
Am J Health-Syst Pharm |
Stability of cefmetazole and famotidine. |
|
238 |
Am J Hosp Pharm |
Stability of metoprolol tartrate in 5% dextrose injection or 0.9% sodium chloride injection. |
|
239 |
Am J Health-Syst Pharm |
Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. |
|
240 |
Am J Health-Syst Pharm |
Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. |
|
241 |
Am J Health-Syst Pharm |
Incompatibility between ceftriaxone sodium and labetolol hydrochloride. |
|
242 |
Am J Hosp Pharm |
Stability of amiodarone hydrochloride in admixtures with other injectable drugs. |
|
244 |
Am J Hosp Pharm |
Compatibility of filgrastim with selected drugs during simulated Y-site administration. |
|
245 |
J Pharm Belg |
Stability of ganciclovir sodium (Cymevan*) after dilution in PVC infusions and polypropylene syringes. |
|
246 |
Aust J Hosp Pharm |
The stability of foscarnet in the presence of potassium. |
|
248 |
Am J Hosp Pharm |
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. |
|
249 |
Am J Health-Syst Pharm |
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. |
|
250 |
Am J Health-Syst Pharm |
Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. |
|
251 |
Am J Health-Syst Pharm |
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. |
|
252 |
Am J Hosp Pharm |
Stability of bleomycin sulfate reconstituted in 5% dextrose injection or 0.9% sodium chloride injection stored in glass vials or polyvinyl chloride containers. |
|
253 |
Am J Hosp Pharm |
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. |
|
255 |
Am J Hosp Pharm |
Visual compatibility of fluconazole with drugs given by continuous infusion. |
|
256 |
Am J Hosp Pharm |
Stability of fluconazole in commonly used intravenous antibiotic solutions. |
|
257 |
Am J Hosp Pharm |
Stability of fluconazole in injectable solutions. |
|
258 |
Am J Hosp Pharm |
Stability of aztreonam and ampicillin sodium-sulbactam sodium in 0.9% sodium chloride injection. |
|
259 |
Am J Hosp Pharm |
Stability of ceftriaxone sodium in infusion-pump syringes. |
|
260 |
Am J Hosp Pharm |
Incompatibility of cefotaxime sodium and vancomycin sulfate during Y-site administration. |
|
261 |
Am J Hosp Pharm |
Visual compatibility of ciprofloxacin with selected components of total parenteral nutrient solutions during simulated Y-site injection. |
|
262 |
Am J Hosp Pharm |
Stability and compatibility of fluconazole and aminophylline in intravenous admixtures. |
|
263 |
Am J Hosp Pharm |
Stability and compatibility of minocycline hydrochloride and rifampicin in intravenous solutions at various temperatures. |
|
264 |
Pharm Hosp Fr |
Incompatibilité physico-chimique entre l’oméprazole et la vancomycine. |
|
265 |
Am J Health-Syst Pharm |
Amphotericin B does not mix with fat emulsion. |
|
266 |
Am J Health-Syst Pharm |
Compatibility of meropenem with commonly used injectable drugs. |
|
267 |
Am J Health-Syst Pharm |
Stability of metronidazole and ceftizoxime sodium in ready-to-use metronidazole bags stored at 4 and 25°C. |
|
268 |
Am J Health-Syst Pharm |
Ciprofloxacin and sodium phosphate not compatible during actual Y-site injection. |
|
269 |
Am J Health-Syst Pharm |
Concentration-dependent precipitation of sodium bicarbonate with ciprofloxacin lactate. |
|
270 |
Am J Health-Syst Pharm |
Precipitation of amphotericin B from IV fat emulsion. |
|
273 |
Am J Health-Syst Pharm |
Ceftazidime degradation rates for predicting stability in a portable infusion-pump reservoir. |
|
274 |
Am J Health-Syst Pharm |
Stability of piperacillin sodium-tazobactam sodium in polypropylene syringes and polyvinyl chloride minibags. |
|
275 |
Am J Health-Syst Pharm |
Cephalosporin-pentamidine isethionate incompatibilities. |
|
276 |
Am J Hosp Pharm |
Stability of ceftriaxone sodium and aminophylline or theophylline in intravenous admixtures. |
|
278 |
Am J Health-Syst Pharm |
Stability of nafcillin sodium in the presence of lidocaine hydrochloride. |
|
279 |
Am J Hosp Pharm |
Stability of ceftriaxone sodium in injectable solutions stored frozen in syringes. |
|
280 |
Am J Health-Syst Pharm |
Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. |
|
281 |
Am J Health-Syst Pharm |
Stability of cefotaxime sodium and metronidazole in 0.9% sodium chloride injection or in ready-to-use metronidazole bags. |
|
282 |
Am J Health-Syst Pharm |
Stability of ceftizoxime sodium, ceftriaxone sodium, and ceftazidime with metronidazole in ready-to-use metronidazole bags. |
|
283 |
Am J Hosp Pharm |
Stability of amphotericin B in 5% dextrose injection stored at 4 or 25°C for 120 hours. |
|
284 |
Am J Health-Syst Pharm |
Compatibility and stability of aztreonam and vancomycin hydrochloride. |
|
285 |
Clin Ther |
Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. |
|
286 |
Am J Hosp Pharm |
Stability of fluconazole and amino acids in parenteral nutrient solutions. |
|
287 |
Am J Health-Syst Pharm |
Stability of ceftazidime (with arginine) in an elastomeric infusion device. |
|
288 |
Hosp Pharm |
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. |
|
289 |
Ann Pharmacotherapy |
Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. |
|
291 |
Am J Hosp Pharm |
Stability of cyclosporine with magnesium sulfate in 5% dextrose injection. |
|
293 |
Am J Hosp Pharm |
Stability of bupivacaine hydrochloride in polypropylene syringes. |
|
294 |
Am J Hosp Pharm |
Stability of octreotide acetate in polypropylene syringes. |
|
295 |
Am J Health-Syst Pharm |
Compatibility of selected critical care drugs during Y-site administration. |
|
298 |
Am J Health-Syst Pharm |
Compatibility of mannitol and sodium bicarbonate in injectable fluids. |
|
299 |
Am J Health-Syst Pharm |
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. |
|
300 |
Am J Health-Syst Pharm |
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. |
|
301 |
Am J Health-Syst Pharm |
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. |
|
302 |
Am J Health-Syst Pharm |
Stability of thiotepa (lyophilized) in 0.9% sodium chloride injection. |
|
303 |
Am J Health-Syst Pharm |
Stability of reconstituted indomethacin sodium trihydrate in original vials and polypropylene syringes. |
|
304 |
Am J Hosp Pharm |
Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacterostatic diluent. |
|
305 |
Am J Hosp Pharm |
Stability and sorption of calcitriol in plastic tuberculin syringes. |
|
306 |
Am J Health-Syst Pharm |
Stability of bupivacaine hydrochloride and hydromorphone hydrochloride during simulated epidural coadministration. |
|
307 |
Am J Hosp Pharm |
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. |
|
309 |
Am J Health-Syst Pharm |
Stability of propofol with parenteral nutrient solutions during simulated Y-site injection. |
|
310 |
Am J Hosp Pharm |
Compatibility and pH variability of four injectable phenytoin sodium products. |
|
311 |
Am J Health-Syst Pharm |
Compatibility and activity of enoxaparin sodium in 0.9% sodium chloride injection for 48 hours. |
|
312 |
Am J Health-Syst Pharm |
Compatibility of iron dextran with neonatal parenteral nutrient solutions. |
|
313 |
Am J Hosp Pharm |
Compatibility of iron dextran with total nutrient admixtures. |
|
314 |
Am J Health-Syst Pharm |
Visual compatibility of injectable drugs used in the intensive care unit. |
|
315 |
Am J Health-Syst Pharm |
Visual compatibility of warfarin sodium injection with selected medications and solutions. |
|
316 |
Am J Health-Syst Pharm |
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. |
|
317 |
Am J Hosp Pharm |
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. |
|
318 |
Am J Hosp Pharm |
Stability of citrated caffeine injectable solution in glass vials. |
|
319 |
Am J Health-Syst Pharm |
Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. |
|
321 |
Am J Health-Syst Pharm |
Compatibility of ketamine hydrochloride and meperidine hydrochloride. |
|
322 |
Am J Health-Syst Pharm |
More on compatibility of mannitol and sodium bicarbonate in injectable fluids. |
|
331 |
Am J Hosp Pharm |
Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents. |
|
332 |
Ann Pharmacotherapy |
Compatibility of ondansetron hydrochloride with meperidine hydrochloride for combined administration. |
|
333 |
Ann Pharmacotherapy |
Stability of ondansetron in large-volume parenteral solutions. |
|
334 |
Am J Hosp Pharm |
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. |
|
335 |
Am J Hosp Pharm |
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. |
|
336 |
Am J Hosp Pharm |
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. |
|
337 |
Am J Hosp Pharm |
Visual compatibility of zidovudine with other drugs during simulated Y-site administration. |
|
338 |
Am J Hosp Pharm |
Stability of zidovudine in 5% dextrose injection and 0.9% sodium chloride injection. |
|
339 |
Am J Hosp Pharm |
Stability of heroin hydrochloride in infusion devices and containers for intravenous administration. |
|
340 |
Am J Hosp Pharm |
Stability of morphine sulfate and meperidine hydrochloride in a parenteral nutrient formulation. |
|
341 |
Am J Hosp Pharm |
Compatibility of heparin sodium and morphine sulfate. |
|
342 |
Am J Hosp Pharm |
Stability of an analgesic-sedative combination in glass and plastic single-dose syringes. |
|
345 |
Can J Hosp Pharm |
Stability and compatibility of reconstituted sterile hydromorphone with midazolam. |
|
346 |
J Pain Symptom Manage |
The stability of mixtures of morphine hydrochloride, bupivacaine hydrochloride, and clonidine hydrochloride in portable pump reservoirs for the management of chronic pain syndromes. |
|
347 |
Am J Hosp Pharm |
Effect of syringe filter and IV administration set on delivery of propofol emulsion. |
|
348 |
Am J Hosp Pharm |
Effect of a polyethylene-lined administration set on the avaibility of diazepam injection. |
|
349 |
Am J Hosp Pharm |
Stability of phenobarbital sodium diluted in 0.9% sodium chloride injection. |
|
350 |
Am J Hosp Pharm |
Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. |
|
351 |
Am J Hosp Pharm |
Effect of flow rate and type of IV container on adsorption of diazepam to IV administration systems. |
|
352 |
Am J Hosp Pharm |
Effect of tubing length on adsorption of diazepam to polyvinyl chloride administration sets. |
|
353 |
Am J Hosp Pharm |
Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid. |
|
354 |
Am J Hosp Pharm |
Stability of famotidine 20 and 40 mg/L in total nutrient admixtures. |
|
355 |
Am J Hosp Pharm |
Stability of famotidine 20 and 50 mg/L in total nutrient admixtures. |
|
356 |
Am J Hosp Pharm |
Stability of famotidine 20 and 40 mg/L and amino acids in total parenteral nutrient solutions. |
|
357 |
Am J Hosp Pharm |
Stability of ranitidine hydrochloride in total nutrient admixtures. |
|
358 |
Am J Hosp Pharm |
Stability of ranitidine admixtures frozen and refrigerated in minibags. |
|
359 |
Am J Hosp Pharm |
Stability of ranitidine hydrochloride and amino acids in parenteral nutrient solutions. |
|
360 |
Am J Hosp Pharm |
Stability of ranitidine hydrochloride with aztreonam, ceftazidime, or piperacillin sodium during simulated Y-site administration. |
|
361 |
Am J Hosp Pharm |
Stability of nizatidine in total nutrient admixtures. |
|
362 |
Am J Hosp Pharm |
Stability of cimetidine hydrochloride in a total nutrient admixture. |
|
363 |
Am J Hosp Pharm |
Stability of esmolol hydrochloride and sodium nitroprussiate in intravenous admixtures. |
|
364 |
Am J Hosp Pharm |
Compatibility of aminophylline and verapamil in intravenous admixtures. |
|
365 |
Med Sci Monit |
Long-Term Stability of Tramadol and Ketamine Solutions for Patient-Controlled Analgesia Delivery. |
|
366 |
Am J Hosp Pharm |
Stability of milrinone in 0.45% sodium chloride, 0.9% sodium chloride, or 5% dextrose injections. |
|
367 |
Am J Hosp Pharm |
Compatibility of furosemide with aminoglycoside admixtures. |
|
370 |
Am J Hosp Pharm |
Stability of procainamide hydrochloride in neutralized 5% dextrose injection. |
|
371 |
Am J Hosp Pharm |
Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection. |
|
372 |
Am J Hosp Pharm |
Compatibility of premixed theophylline and verapamil intravenous admixtures. |
|
375 |
Am J Hosp Pharm |
Activity of urokinase diluted in 0.9% sodium chloride injection or 5% dextrose injection and stored in glass or plastic syringes. |
|
377 |
Am J Hosp Pharm |
Interaction of heparin sodium and dopamine hydrochloride in admixtures studied by microcalorimetry. |
|
379 |
Am J Hosp Pharm |
Sorption of amiodarone to polyvinyl chloride infusion bags and administration sets. |
|
380 |
Crit Care Med |
Chemical compatibility of inotropic and vasoactive agents delivered via a multiple line infusion system. |
|
381 |
J Parenter Sci Technol |
Chemical stability of the cardioprotective agent ICRF-187 in infusion fluids. |
|
384 |
Am J Hosp Pharm |
Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. |
|
385 |
Am J Hosp Pharm |
Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. |
|
386 |
Am J Hosp Pharm |
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. |
|
388 |
Am J Hosp Pharm |
Stability of nizatidine in commonly used intravenous fluids and containers. |
|
389 |
Am J Hosp Pharm |
Compatibility of dexamethasone sodium phosphate with hydromorphone hydrochloride or diphenhydramine hydrochloride. |
|
390 |
Am J Hosp Pharm |
Compatibility of aminophylline and methylprednisolone sodium succinate intravenous admixtures. |
|
391 |
Am J Hosp Pharm |
Compatibility of premixed theophylline and methylprednisolone sodium succinate intravenous admixtures. |
|
394 |
Am J Hosp Pharm |
Long-term stability of famotidine 20 mg/L in a total parenteral nutrient solution. |
|
396 |
Am J Hosp Pharm |
Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications. |
|
397 |
Am J Hosp Pharm |
Visual compatibility of intravenous famotidine with selected drugs. |
|
398 |
Am J Hosp Pharm |
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. |
|
399 |
Aust J Hosp Pharm |
Stability of midazolam in sodium chloride infusion packs. |
|
401 |
Aust J Hosp Pharm |
A preliminary study of the stability of midazolam in polypropylene syringes. |
|
402 |
Am J Hosp Pharm |
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. |
|
403 |
Am J Hosp Pharm |
Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. |
|
404 |
Am J Hosp Pharm |
Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. |
|
405 |
Am J Hosp Pharm |
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. |
|
406 |
Am J Hosp Pharm |
Visual compatibility of narcotic analgesics with selected intravenous admixtures. |
|
407 |
Am J Hosp Pharm |
Stability of mitomycin admixtures. |
|
408 |
Am J Hosp Pharm |
Stability of intravenous admixtures of doxorubicin and vincristine. |
|
409 |
Am J Hosp Pharm |
Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. |
|
410 |
Am J Hosp Pharm |
Characterization of cisplatin degradation as affected by pH and light. |
|
411 |
Am J Hosp Pharm |
Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration. |
|
412 |
Am J Hosp Pharm |
Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. |
|
413 |
Am J Hosp Pharm |
Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection. |
|
414 |
Am J Hosp Pharm |
Stability of azacitidine in lactated Ringer’s injection frozen in polypropylene syringes. |
|
415 |
Am J Hosp Pharm |
Stability of fluorouracil administered through four portable infusion pumps. |
|
417 |
Am J Hosp Pharm |
Stability of cisplatin and etoposide in intravenous admixtures. |
|
418 |
Am J Hosp Pharm |
Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitine sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions. |
|
419 |
Am J Hosp Pharm |
Stability of intravenous admixtures of aztreonam and clindamycin phosphate. |
|
420 |
Am J Hosp Pharm |
Stability of cefonicid sodium in infusion fluids. |
|
421 |
Am J Hosp Pharm |
Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures. |
|
422 |
Am J Hosp Pharm |
Stability of intravenous admixtures of aztreonam and ampicillin. |
|
423 |
Am J Hosp Pharm |
Stability and cost analysis of clindamycin-gentamicin admixtures given every eight hours. |
|
424 |
Am J Hosp Pharm |
Stability of pentamidine isethionate in 5% dextrose and 0.9% sodium chloride injections. |
|
426 |
Am J Hosp Pharm |
Stability of intravenous admixtures containing aztreonam and cefazolin. |
|
427 |
Am J Hosp Pharm |
Stability of aqueous solutions of amoxicillin sodium in the frozen and liquid states. |
|
428 |
Am J Hosp Pharm |
Stability of vancomycin hydrochloride in various concentrations of dextrose injection. |
|
430 |
Am J Hosp Pharm |
Stability of vancomycin hydrochloride in 5% dextrose and 0.9% sodium chloride injections. |
|
431 |
Am J Hosp Pharm |
Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures. |
|
432 |
Am J Hosp Pharm |
Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions. |
|
433 |
Am J Hosp Pharm |
Interaction of aztreonam with nafcillin in intravenous admixtures. |
|
434 |
Am J Hosp Pharm |
Compatibility of ciprofloxacin injection with selected drugs and solutions. |
|
435 |
Am J Hosp Pharm |
Stability of amphotericin B in four concentrations of dextrose injection. |
|
436 |
Am J Hosp Pharm |
Chemical and visual stability of amphotericin B in 5% dextrose injection stored at 4°C for 35 days. |
|
439 |
Am J Hosp Pharm |
Stability of amphotericin B in 5% dextrose injection at concentrations used for administration through a central venous line. |
|
440 |
Am J Hosp Pharm |
Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs. |
|
442 |
Am J Hosp Pharm |
Stability of a concentrated trimethoprim-sulfamethoxazole admixtures. |
|
443 |
Am J Hosp Pharm |
Stability of ceftazidime (with arginine) and of cefuroxime sodium in infusion-pump reservoirs. |
|
444 |
Am J Hosp Pharm |
Stability of an ofloxacin injection in various infusion fluids. |
|
445 |
Am J Hosp Pharm |
Stability of ceftazidime in plastic syringes and glass vials under various storage conditions. |
|
446 |
Am J Hosp Pharm |
Stability of undiluted trimethoprim-sulfamethoxazole for injection in plastic syringes. |
|
448 |
Am J Hosp Pharm |
Stability of terbutaline sulfate admixtures stored in polyvinyl chloride bags. |
|
449 |
Am J Hosp Pharm |
Stability of terbutaline sulfate repackaged in disposable plastic syringes. |
|
451 |
Int J Pharm Compound |
Stability of ketorolac tromethamine in 5% dextrose injection and 0.9% sodium chloride injections. |
|
453 |
Am J Hosp Pharm |
Stability and availability of cyclosporine stored in plastic syringes. |
|
454 |
Am J Hosp Pharm |
Stability and availability of cyclosporine in 5% dextrose injection or 0.9% sodium chloride injection. |
|
455 |
Am J Hosp Pharm |
Leaching of diethylhexyl phtalate from polyvinyl chloride bags into intravenous cyclosporine solution. |
|
456 |
Am J Hosp Pharm |
Stability of papaverine hydrochloride and phentolamine mesylate in injectable mixtures. |
|
460 |
Am J Hosp Pharm |
Stability of acetazolamide sodium in 5% dextrose and 0.9% sodium chloride injection. |
|
464 |
Am J Hosp Pharm |
Effect of pretreatment with 0.9% sodium chloride or insulin solutions on the delivery of insuline from an infusion system. |
|
465 |
Am J Hosp Pharm |
More information on the visual compatibility of hetastarch with injectable critical-care drugs. |
|
466 |
Am J Hosp Pharm |
Activity of octreotide acetate in a total nutrient admixture. |
|
467 |
Am J Hosp Pharm |
Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion. |
|
468 |
Am J Hosp Pharm |
Stability and sterility of biosynthetic human insulin stored in plastic insulin syringes for 28 days. |
|
469 |
Am J Hosp Pharm |
Compatibility of ketorolac tromethamine injection with common infusion fluids and administration sets. |
|
471 |
Am J Hosp Pharm |
Stability of cyclosporine in 5% dextrose injection. |
|
472 |
Am J Hosp Pharm |
Visual compatibility of hetastarch with injectable critical-care drugs. |
|
475 |
Am J Hosp Pharm |
Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. |
|
476 |
Am J Hosp Pharm |
Incompatibility of ketorolac tromethamine with selected postoperative drugs. |
|
477 |
Am J Hosp Pharm |
Stability of ceftazidime (with arginine) stored in plastic syringes at three temperatures. |
|
478 |
Am J Hosp Pharm |
Stability of aminophylline in bacteriostatic water for injection stored in plastic syringes at two temperatures. |
|
479 |
Am J Hosp Pharm |
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. |
|
481 |
J Parenter Sci Technol |
Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids. |
|
482 |
J Parenter Sci Technol |
Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids. |
|
484 |
J Clin Pharm Ther |
The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged “in use” conditions. |
|
485 |
J Oncol Pharm Practice |
Stability of mitomycin C in different infusion fluids: compatibility with heparin and glucocorticosteroids. |
|
486 |
Am J Health-Syst Pharm |
Stability of carboplatin in polyvinyl chloride bags. |
|
489 |
Am J Hosp Pharm |
Stability of ifosfamide in 0.9% sodium chloride solution or water for injection in a portable IV pump cassette. |
|
491 |
Am J Hosp Pharm |
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. |
|
492 |
Am J Hosp Pharm |
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. |
|
494 |
Am J Hosp Pharm |
Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate. |
|
496 |
Am J Hosp Pharm |
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. |
|
497 |
Am J Hosp Pharm |
Stability of amphotericin B in 5% dextrose injection at 25°C. |
|
499 |
Hosp Pharm |
Intramuscular antibiotic preparation and administration using a 1% lidocaine diluent: policies for the pediatric patient. |
|
500 |
Am J Hosp Pharm |
Visual compatibility of ciprofloxacin lactate with five broad-spectrum antimicrobial agents during simulated Y-site injection. |
|
501 |
Am J Hosp Pharm |
Crystal formation after reconstituting cefazolin sodium with 0.9% sodium chloride injection. |
|
503 |
Am J Hosp Pharm |
Stability of tobramycin sulfate in admixtures with calcium gluconate. |
|
504 |
Sci Tech Pharm |
Etude de la stabilité dans des solutions diluées destinées à la perfusion de deux antimitotiques dérivés de la podophyllotoxine : l’étoposide (VP 16), le téniposide (VM 26). |
|
506 |
J Pharm Pharmacol |
Diamorphine stability in aqueous solution for subcutaneous infusion. |
|
507 |
Br J Anaesth |
Stability of fentanyl, bupivacaine and adrenaline solutions for extradural infusion. |
|
509 |
Pharm World Sci |
Effect of pH absorption of sufentanil citrate in a portable pump reservoir during storage and administration under simulated epidural conditions. |
|
510 |
Pharm World Sci |
Effect of glucose 5% solution and bupivacaine hydrochloride on absorption of sufentanil citrate in a portable pump reservoir during storage and simulated infusion by an epidural catheter. |
|
512 |
Pharm World Sci |
Stability of bupivacaine hydrochloride with diamorphine hydrochloride in an epidural infusion. |
|
513 |
Ann Pharmacotherapy |
Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride. |
|
514 |
Ann Pharmacotherapy |
Rapid loss of fentanyl citrate admixed with fluorouracil in polyvinyl chloride containers. |
|
515 |
J Pharm Clin |
Stability of morphine hydrochloride solutions in portable single-use PCA systems. Additives leaching into the morphine solutions. |
|
517 |
Am J Hosp Pharm |
Visual compatibility of magnesium sulfate with narcotic analgesics. |
|
518 |
Am J Hosp Pharm |
Visual compatibility of nalbuphine hydrochloride and promethazine hydrochloride. |
|
519 |
Aust J Hosp Pharm |
Compatibility of morphine tartrate admixtures in polypropylene syringes. |
|
522 |
Can J Hosp Pharm |
Famotidine stability in total parenteral nutrient solutions. |
|
523 |
Am J Hosp Pharm |
Visual compatibility of esmolol hydrochloride and furosemide in 5% dextrose or 0.9% sodium chloride injections. |
|
524 |
Am J Hosp Pharm |
Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. |
|
525 |
Int J Pharm |
A study on the stability of three antineoplastic drugs and on their sorption by IV delivery systems and end-line filters. |
|
527 |
J Clin Pharm Ther |
Chemical stability of thiopental sodium injection in disposable plastic syringes. |
|
529 |
Pharm Weekbl [Sci] |
Compatibility of bupivacaine and iohexol in two mixtures for paediatric regional anaesthesia. |
|
531 |
J Oral Maxillofac Surg |
Stability of reconstituted methohexital sodium. |
|
532 |
Ann Pharmacotherapy |
Lorazepam stability in parenteral solutions for continuous intravenous administration. |
|
533 |
Am J Health-Syst Pharm |
Stability of cisatracurium besylate in vials, syringes and infusion admixtures. |
|
539 |
Drug Intell Clin Pharm |
Stability and compatibility of cimetidine hydrochloride and aminophylline in dextrose 5% in water injection. |
|
546 |
Ann Pharmacotherapy |
Stability of diluted dexamethasone sodium phosphate injection at two temperatures. |
|
549 |
Int J Pharm Compound |
Compatibility of common respiratory therapy drug combinations. |
|
550 |
Int J Pharm Compound |
Stability of aminocaproic acid injection admixtures in 5% dextrose injection and 0.9% sodium chloride injection. |
|
552 |
Int J Pharm Compound |
Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions. |
|
553 |
Ann Pharmacotherapy |
Stability of famotidine in minibags refrigerated and/or frozen. |
|
554 |
J Parenter Sci Technol |
A study of the interaction of selected drugs and plastic syringes. |
|
558 |
Br J Parent Ther |
Stability of reconstituted mustine injection BP during storage. |
|
561 |
Current Ther Res |
Physical compatibility and chemical stability of amikacin sulfate in large-volume parenteral solutions. Part II. |
|
563 |
Am J Hosp Pharm |
Stability of frozen solutions of doxycycline hyclate for injection. |
|
565 |
Drug Intell Clin Pharm |
Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions. |
|
566 |
Am J Hosp Pharm |
Compatibility and stability of clindamycin phosphate with intravenous fluids. |
|
567 |
Can J Hosp Pharm |
Stability of clindamycin phophate in dextrose and saline solutions. |
|
573 |
Drug Intell Clin Pharm |
Stability of antibiotic admixtures frozen in minibags. |
|
574 |
Am J Hosp Pharm |
Stability of antibiotics frozen and stored in disposable hypodermic syringes. |
|
575 |
Am J Hosp Pharm |
Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags. |
|
576 |
Drug Intell Clin Pharm |
Activity of antibiotic admixtures subjected to different freeze-thaw treatments. |
|
580 |
Am J Hosp Pharm |
Stability of frozen solutions of sodium cephalothin and cephaloridine. |
|
581 |
Am J Hosp Pharm |
Stability of frozen solutions of cefazolin sodium. |
|
582 |
Am J Hosp Pharm |
Stability of cefazolin sodium admixtures in plastic bags after thawing by microwave radiation. |
|
585 |
J Clin Pharm Ther |
Chemical stabilities of cefaperazone sodium and ceftazidime in 5% dextrose and 0.9% sodium chloride injections. |
|
587 |
Am J Hosp Pharm |
Effect of storage temperature and time stability of cefmenoxime, ceftriaxone, and cefotetan in 5% dextrose injection. |
|
589 |
J Pharm Sci |
Stability of parenteral ceftriaxone disodium solutions in frozen and liquid states: effect of freezing and microwave thawing. |
|
591 |
Can J Hosp Pharm |
Stability of ceftizoxime in 5 percent dextrose and 0.9 percent sodium chloride. |
|
592 |
J Pharm Clin |
Effects of storage temperature and pH on the stability of cefotaxime in PVC bags. |
|
593 |
J Pharm Sci |
Stability of cefotaxime sodium as determined by High-Performance Liquid Chromatography. |
|
598 |
J Clin Pharm Ther |
The stability of amoxycillin sodium in normal saline and glucose (5%) solutions in the liquid and frozen states. |
|
600 |
Am J IV Ther Clin Nut |
Stability of piperacillin sodium in dextrose 5% and sodium chloride 0.9% injections. |
|
604 |
Baxter |
Stabilité des médicaments dans l'Intermate® SV50, 100, 200 |
|
605 |
Am J Hosp Pharm |
Stability of haloperidol in 5% dextrose injection. |
|
612 |
Am J Hosp Pharm |
Stability of cefamandole nafate injection with parenteral solutions and additives. |
|
616 |
Am J Hosp Pharm |
Compatibility of nalbuphine hydrochloride with other preoperative medications. |
|
617 |
Am J Hosp Pharm |
Compatibility of haloperidol lactate and heparin sodium. |
|
618 |
Am J Hosp Pharm |
Stability of digoxin in common large-volume injections. |
|
619 |
Am J Hosp Pharm |
Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives. |
|
621 |
Am J Hosp Pharm |
Sorptive loss of diazepam and nitroglycerin from solutions to three types of containers. |
|
626 |
Am J Hosp Pharm |
Moxalactam disodium compatibility with intramuscular and intravenous diluents. |
|
628 |
Am J Hosp Pharm |
Stability of dobutamine hydrochloride in selected large-volume parenterals. |
|
630 |
J Clin Hosp Pharm |
Stability of metronidazole and ten antibiotics when mixed with magnesium sulphate solutions. |
|
631 |
J Parenter Sci Technol |
Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion. |
|
632 |
J Parenter Sci Technol |
Stability of anthracycline antitumour agents in infusion fluids. |
|
633 |
J Clin Hosp Pharm |
The stability of sodium nitroprusside infusion during administration by motorized syringe-pump. |
|
636 |
J Clin Hosp Pharm |
Stability of cefuroxime sodium in some aqueous buffered solutions and intravenous admixtures. |
|
639 |
Drug Intell Clin Pharm |
Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes. |
|
640 |
Can J Hosp Pharm |
Stability of reconstituted ceftriaxone in dextrose and saline solutions. |
|
642 |
Hosp Pharm |
Norepinephrine stability in saline solutions. |
|
643 |
Cancer Treat Rep |
In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. |
|
644 |
Drug Intell Clin Pharm |
Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles. |
|
645 |
J Clin Pharm Ther |
The stability of carboplatin in ambulatory continuous infusion regimes. |
|
646 |
J Clin Pharm Ther |
Stability of methacholine chloride in isotonic sodium chloride using a capillary electrophoresis assay. |
|
647 |
Int J Pharm Compound |
Chemical stability of amiodarone hydrochloride in intravenous fluids. |
|
648 |
Int J Pharm Compound |
Stability of mitomycin aqueous solution when stored in tuberculin syringes. |
|
649 |
Int J Pharm Compound |
Stability of ceftriaxone sodium when mixed with metronidazole injection. |
|
650 |
Int J Pharm Compound |
Development of clonidine hydrochloride injections for epidural and intrathecal administration. |
|
652 |
Int J Pharm Compound |
Stability of cefmetazole sodium in 5% dextrose injection and 0.9% sodium chloride injection. |
|
653 |
Int J Pharm Compound |
Quantification of metoprolol tartrate and propranolol hydrochloride in pharmaceutical dosage forms : stability of metoprolol in aqueous mixture. |
|
654 |
Int J Pharm Compound |
Stability of vancomycin hydrochloride in Medication Cassette* reservoirs. |
|
656 |
J Clin Pharm Ther |
Long-term stability of cefuroxime and cefazolin sodium in intravenous infusions. |
|
657 |
J Clin Pharm Ther |
Chemical stability and adsorption of atracurium besylate injections in disposable plastic syringes. |
|
658 |
J Oncol Pharm Practice |
Stability of busulfan injection admixtures in 5% dextrose injection and 0.9% sodium chloride injection. |
|
659 |
Can J Hosp Pharm |
Epinephrine stability in plastic syringes and glass vials. |
|
660 |
Ann Pharmacotherapy |
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. |
|
665 |
Int J Pharm Compound |
Stability of Nebulizer Admixtures. |
|
666 |
J Clin Pharm Ther |
Stability of ciprofloxacin in 5% dextrose and normal saline injections. |
|
667 |
J Clin Pharm Ther |
Chemical stability and adsorption of succinylcholine chloride injections in disposable plastic syringes. |
|
668 |
Medicine |
Stability of Butorphanol–Tropisetron Mixtures in 0.9% Sodium Chloride Injection for Patient-Controlled Analgesia Use. |
|
669 |
Ann Pharmacotherapy |
Paclitaxel stability and compatibility in polyolefin containers. |
|
671 |
J Parenter Sci Technol |
Stability of cefazolin sodium and metronidazole at 8°C for use as an IV admixture. |
|
673 |
JPEN |
The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures. |
|
674 |
Can J Hosp Pharm |
Cephalotin stability in normal saline, five percent dextrose in water, and Dianeal* solutions. |
|
675 |
Pharm Weekbl [Sci] |
Stability of sufentanil citrate in a portable pump reservoir, a glass container and a polyethylene container. |
|
677 |
Can J Hosp Pharm |
Stability of Extemporaneously Compounded Levetiracetam in Glass and Plastic Bottles and Plastic Syringes. |
|
679 |
Pharm Weekbl [Sci] |
Stability of morphine hydrochloride in a portable pump reservoir. |
|
681 |
Can J Hosp Pharm |
Doxorubicin stability in syringes and glass vials and evaluation of chemical contamination. |
|
682 |
Ann Pharmacotherapy |
Physical compatibility and chemical stability of amphotericin B in combination with magnesium sulfate in 5% dextrose injection. |
|
683 |
Can J Hosp Pharm |
Epirubicin stability in syringes and glass vials and evaluation of chemical contamination. |
|
684 |
Ann Pharmacotherapy |
Chemical stability of suramin in commonly used infusion fluids. |
|
686 |
J Clin Pharm Ther |
Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. |
|
687 |
Ann Pharmacotherapy |
Stability of famotidine in a 3-in-1 total nutrient admixture. |
|
689 |
Can J Hosp Pharm |
Stability of ranitidine hydrochloride admixtures refrigerated in polyvinyl chloride minibags. |
|
690 |
Ann Pharmacotherapy |
Stability of intravenous famotidine stored in polyvinyl chloride syringes. |
|
691 |
J Clin Pharm Ther |
Stability of caffeine citrate injection in intravenous admixtures and parenteral nutrition solutions. |
|
693 |
J Clin Pharm Ther |
Chemical stabilities of famotidine and ranitidine hydrochloride in intravenous admixtures. |
|
694 |
Can J Hosp Pharm |
Stability of intravenous vancomycin. |
|
695 |
Drug Intell Clin Pharm |
Compatibility and stability of cefazolin sodium, clindamycin phosphate, and gentamicin sulfate in two intravenous solutions. |
|
697 |
Can J Hosp Pharm |
Ceftazidime stability in normal saline and dextrose in water. |
|
698 |
Ann Pharmacotherapy |
Stability of caffeine injection in intravenous admixtures and parenteral nutrition solutions. |
|
702 |
J Pharm Clin |
Stability of vancomycin in polyolefine or PVC bags and glass vials. |
|
703 |
Am J Hosp Pharm |
Effect of inline filtration on the potency of low-dose drugs. |
|
705 |
Am J Hosp Pharm |
Bretylium tosylate admixture compatibility. II : Dopamine, lidocaine, procainamide, and nitroglycerin. |
|
706 |
Am J Hosp Pharm |
Compatibility of verapamil hydrochloride with other additives. |
|
707 |
Am J Hosp Pharm |
Solubility and stability of phenytoin sodium when mixed with intravenous solutions. |
|
708 |
Am J Hosp Pharm |
Nitroglycerin compatibility with intravenous fluid filters containers, and administration sets. |
|
709 |
Am J Hosp Pharm |
Stability of tobramycin sulfate in plastic syringes. |
|
711 |
Am J Hosp Pharm |
Avaibility of diazepam from plastic containers. |
|
712 |
Am J Hosp Pharm |
Compatibility of diazepam with intravenous fluid containers and administration sets. |
|
715 |
Am J Hosp Pharm |
Stability of carmustine in the presence of sodium bicarbonate. |
|
729 |
Am J Hosp Pharm |
Effect of inline filtration on the potency of drugs administered intravenously. |
|
730 |
Am J Hosp Pharm |
Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. |
|
731 |
Am J Hosp Pharm |
Compatibility and stability of diazepam injection following dilution with intravenous fluids. |
|
732 |
Am J Hosp Pharm |
Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 1: Stability with common intravenous fluids. |
|
738 |
Am J Hosp Pharm |
Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. |
|
739 |
Am J Hosp Pharm |
Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. |
|
740 |
Am J Hosp Pharm |
Stability of refrigerated and frozen solutions of doxorubicin hydrochloride. |
|
742 |
Am J Hosp Pharm |
Stability of cisplatin in aqueous solution. |
|
743 |
Am J Hosp Pharm |
Bretylium tosylate intravenous admixture compatibility. I: Stability in common large-volume parenteral solutions. |
|
747 |
Am J Hosp Pharm |
Cimetidine hydrochloride compatibility. I: Chemical aspects and room temperature stability in intravenous infusion fluids. |
|
753 |
Medac |
Topotecan (Topotecan Medac®) - Summary of Product Characteristics |
|
754 |
Merck Sharp & Dohme |
Infliximab (Remicade®) – Summary of Product Characteristics |
|
755 |
MSD France |
Pancuronium (Pavulon®) - Résumé des caractéristiques du produit |
|
761 |
EJHP |
Physicochemical and microbiological stability studies of a melatonin oral suspension in a commercially available vehicle for paediatric use. |
|
763 |
Cancer Treat Rep |
Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. |
|
765 |
Am J Health-Syst Pharm |
Stability of lorazepam 1 and 2 mg/ml in glass bottles and polypropylene syringes. |
|
767 |
Ann Pharmacotherapy |
Compatibility of hydromorphone and prochlorperazine, and irritation due to subcutaneous prochlorperazine infusion. |
|
779 |
J Pharm Pharmacol |
Stability of diamorphine hydrochloride with haloperidol in prefilled syringes for continuous subcutaneous administration. |
|
780 |
Ann Pharmacotherapy |
Precipitation of lorazepam infusion. |
|
788 |
Lancet |
Subcutaneous drug compatibility in palliative care. |
|
789 |
Am J Hosp Pharm |
Compatibility of drugs separated by a fluid barrier in a retrograde intravenous infusion system. |
|
791 |
JPEN |
Stability of heparin anticoagulant activity over time in parenteral nutrition solutions. |
|
793 |
J Antimicrob Chemother |
Amphotericin B intralipid formulation: stability and particule size. |
|
794 |
Anaesthesia |
The effect of the addition of lignocaine on propofol emulsion stability. |
|
795 |
Am J Health-Syst Pharm |
21-day compatibility of hydromorphone hydrochloride and promethazine hydrochloride in a cassette. |
|
796 |
PDA J Pharm Sci Technol |
Photodegradation of furosemide solutions. |
|
798 |
Ann Pharmacotherapy |
Epoetin alfa loss with NaCl 0.9% dilution. |
|
800 |
Ann Pharmacotherapy |
Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes. |
|
803 |
Diabetes Care |
Stability of insulin lispro in insulin infusion systems. |
|
805 |
Hosp Pharm |
An automated process for determining the physical compatibility of drugs. |
|
811 |
Am J Health-Syst Pharm |
Activity of enoxaparin sodium in tuberculin syringes for 10 days. |
|
813 |
Am J Health-Syst Pharm |
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. |
|
814 |
Am J Health-Syst Pharm |
Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration. |
|
815 |
Am J Health-Syst Pharm |
Stability of ondansetron hydrochloride and 12 medications in plastic syringes. |
|
816 |
Am J Health-Syst Pharm |
Stability of undiluted and diluted adenosine at three temperatures in syringes and bags. |
|
817 |
Am J Health-Syst Pharm |
Drug stability and pyridine generation in ceftazidime injection stored in an elastomeric infusion device. |
|
818 |
Am J Health-Syst Pharm |
Stability of torsemide in 5% dextrose injection. |
|
820 |
Am J Health-Syst Pharm |
Stability of adenosine 6 microg/ml in 0.9% sodium chloride solution. |
|
821 |
Am J Health-Syst Pharm |
Visual compatibility of fentanyl citrate with parenteral nutrient solutions. |
|
822 |
Am J Health-Syst Pharm |
Stability of acyclovir sodium 1, 7, and 10 mg/ml in 5% dextrose injection and in 0.9% sodium chloride injection. |
|
823 |
Am J Health-Syst Pharm |
Microbial inhibitory properties and stability of topotecan hydrochloride injection. |
|
824 |
Am J Health-Syst Pharm |
Stability of albumin-free interferon alfa-2b for 42 days. |
|
827 |
Drug Intell Clin Pharm |
Stability of vinblastine sulfate when exposed to light. |
|
828 |
J Pharm Clin |
Stability of mitoxantrone (Novantrone*) after dilution in PVC infusions. |
|
829 |
Int J Pharm |
Examination of sorption and photodegradation of amsacrine during storage in intravenous burette administration sets. |
|
835 |
Int J Pharm |
Determination of the stability of mitomycin C by high performance liquid chromatography. |
|
837 |
Acta Pharm Suec |
Stability of carmustine - kinetics and compatibility during administration. |
|
840 |
Can J Hosp Pharm |
Stability of 5-fluorouracil and flucytosine in parenteral solutions. |
|
842 |
J Pharm Clin |
Stability of 5-fluorouracil to heat and light. |
|
844 |
J Pharm Clin |
Stability of fluorouracil and cytarabine in ethylvinylacetate containers. |
|
847 |
J Pharm Pharmacol |
Photolytic degradation of adriamycin. |
|
850 |
Drug Intell Clin Pharm |
Cytosine arabinose stability in intravenous admixtures with sodium bicarbonate and in plastic syringes. |
|
854 |
J Pharm Pharmacol |
The stability of melphalan in the presence of chloride ion. |
|
855 |
Cancer Chemother Pharmacol |
Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump. |
|
857 |
Am J Hosp Pharm |
Binding of selected drugs to a “treated” inline filter. |
|
859 |
Nor Pharm Acta |
Stability of cytotoxic intravenous solutions subjected to freeze-thaw treatment. |
|
860 |
Am J Hosp Pharm |
Visual incompatibility of dacarbazine and heparin. |
|
865 |
Int J Pharm Compound |
Physical compatibility and chemical stability of atracurium besylate and midazolam hydrochloride during intravenous coinfusion. |
|
871 |
Anesth Analg |
The chemical stability and sterility of sodium thiopental after preparation. |
|
872 |
Ann Pharmacotherapy |
Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. |
|
873 |
Int J Pharm Compound |
Stability of cefepime hydrochloride dextrose in 5% dextrose injection and 0.9% sodium chloride injection. |
|
874 |
Int J Pharm Compound |
Stability of two concentrations of heparin sodium prefilled in CADD-Micro pump syringes. |
|
887 |
Ann Pharmacotherapy |
Stability study of epirubicin in NaCl 0.9% injection. |
|
889 |
Pharm Weekbl [Sci] |
Ofloxacin intravenous. Compatibility with other antibacterial agents. |
|
891 |
Hosp Pharm |
Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents. |
|
892 |
Am J Hosp Pharm |
Practical guidelines for preparing and administering amphotericin B. |
|
895 |
JPEN |
Vancomycin stability in heparin and total parenteral nutrition solutions: novel approach to therapy of central venous catheter-related infections. |
|
896 |
J Clin Pharm Ther |
Sorption studies of dipotassium clorazepate salt (Tranxene®) and midazolam hydrochloride (Hypnovel®) in polyvinyl chloride and glass infusion containers. |
|
898 |
JPEN |
Stability of imipenem and cilastatin sodium in total parenteral nutrient solution. |
|
900 |
Ann Pharmacotherapy |
Compatibility of ceftazidime and aminophylline admixtures for different methods of intravenous infusion. |
|
903 |
J Parenter Sci Technol |
Chemical compatibility of cefmetazole sodium with ranitidine hydrochloride during simulated Y-site administration. |
|
905 |
Hosp Pharm |
Screening teniposide for Y-site physical incompatibilities. |
|
907 |
J Pharm Technol |
Stability of tacrolimus injection in total parenteral nutrition solution. |
|
909 |
J Informed Pharmacother |
Stability of hydrocortisone in extemporaneously compounded suspensions. |
|
913 |
J Clin Pharm Ther |
Stability of vancomycin in plastic syringes measured by high-performance liquid chromatography. |
|
915 |
Ann Pharmacotherapy |
Stability of ondansetron stored in polypropylene syringes. |
|
916 |
J Clin Pharm Ther |
Stability of quinine dihydrochloride in commonly used intravenous solutions. |
|
917 |
EJHP |
Stability of refrigerated and frozen solutions of ondansetron hydrochloride. |
|
918 |
EJHP |
Stability of ornidazole in PVC bags under various storage conditions. |
|
919 |
Anesth Analg |
Propofol and thiopental in a 1:1 volume mixture is chemically stable. |
|
920 |
Aust J Hosp Pharm |
Stability of two concentrations of morphine tartrate in 10 mL polypropylene syringes. |
|
921 |
Hosp Pharm |
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. |
|
922 |
Int J Pharm Compound |
Stability of milrinone lactate 200 microg /mL in 5% dextrose injection and 0.9% sodium chloride injection. |
|
923 |
Int J Pharm Compound |
Stability of indomethacin in 0.9% sodium chloride injection. |
|
924 |
J Pharm Pharmacol |
Compatibility of tropisetron with glass and plastics. Stability under different storage conditions. |
|
925 |
Can J Hosp Pharm |
Compatibility and stability of propafenone hydrochloride with five critical-care medications. |
|
928 |
Int J Pharm Compound |
Stability of milrinone lactate in 5% dextrose injection and 0.9% sodium chloride injection at concentrations of 400, 600 and 800 microg/mL. |
|
929 |
J Pain Symptom Manage |
Stability of midazolam and fentanyl in infusion solutions. |
|
930 |
J Clin Pharm Ther |
Stability of admixtures of pethidine and metoclopramide in aqueous solution, 5% dextrose and 0.9% sodium chloride. |
|
931 |
J Clin Pharm Ther |
Long-term stability of vancomycin hydrochloride in intravenous infusions. |
|
932 |
J Clin Pharm Ther |
Stability of morphine sulphate in saline under simulated patient administration conditions. |
|
934 |
Int J Pharm Compound |
Compatibility and stability of ranitidine hydrochloride with six cephalosporins during simulated Y-site administration. |
|
935 |
Int J Pharm Compound |
Stability of lorazepam in 5% dextrose injection. |
|
939 |
Aust J Hosp Pharm |
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. |
|
948 |
J Pharm Sci |
Photodegradation of some quinolones used as antimicrobial therapeutics. |
|
951 |
PDA J Pharm Sci Technol |
Influence of DL methionine and sodium metasulphite on the photostability of vitamin K1. |
|
957 |
J Parenter Sci Technol |
Stability studies of hydralazine in aqueous solutions. |
|
958 |
Ann Pharmacotherapy |
Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion. |
|
960 |
Can J Hosp Pharm |
Stability of aqueous solutions of deferoxamine. |
|
961 |
J Clin Pharm Ther |
Chemical stabilities of cefuroxime sodium and metronidazole in an admixture for intravenous infusion. |
|
963 |
J Clin Pharm Ther |
Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside. |
|
966 |
JPEN |
In vitro assessment of vancomycin HCl compatibility after coinfusion with a specialized amino acid formulation. |
|
969 |
N Engl J Med |
Precipitation of ondansetron in alkaline solutions. |
|
978 |
Can J Hosp Pharm |
Methotrexate and cytarabine for intrathecal administration. |
|
979 |
Int Pharm J |
In vitro compatibility of granisetron with selected alkaline drugs. |
|
980 |
Aust J Hosp Pharm |
Compatibility of morphine and ketamine for subcutaneous infusion. |
|
982 |
Ann Pharmacotherapy |
Compatibility of haloperidol and diphenhydramine in a hypodermic syringes. |
|
984 |
Ann Pharmacotherapy |
Amphotericin B is incompatible with lipid emulsions. |
|
985 |
Ann Pharmacotherapy |
Haloperidol and diphenhydramine compatibility. |
|
990 |
Ann Pharmacotherapy |
Stability of caffeine injection stored in plastic and glass syringes. |
|
992 |
Ann Pharmacotherapy |
Visual compatibility of ondansetron and dexamethasone. |
|
999 |
JPEN |
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. |
|
1009 |
J Pharm Sci |
Studies on the stability of vinblastine sulfate in aqueous solution. |
|
1014 |
Clin Pharmacol Ther |
Lack of photodegradation but significant adsorption of nifedipine in administration systems. |
|
1020 |
Am J Hosp Pharm |
Compatibility of morphine sulfate injection and prochlorperazine injection. |
|
1021 |
J Clin Hosp Pharm |
Methotrexate in solutions - A stability test for the hospital pharmacy. |
|
1022 |
Drug Intell Clin Pharm |
Heparin and aminoglycosides instability. |
|
1026 |
Am J Health-Syst Pharm |
Stability and compatibility of topotecan hydrochloride with selected drugs. |
|
1027 |
Am J Hosp Pharm |
Stability of nitroglycerin solutions in polyolefin and glass containers. |
|
1028 |
Am J Hosp Pharm |
Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures. |
|
1029 |
Am J Health-Syst Pharm |
Stability of sumatriptan succinate in polypropylene syringes. |
|
1033 |
Am J Health-Syst Pharm |
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. |
|
1035 |
J Parenter Sci Technol |
Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. |
|
1036 |
Am J Hosp Pharm |
Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. |
|
1037 |
J Pharm Sci |
In vitro stability of sodium nitroprusside solutions for intravenous administration. |
|
1039 |
Am J Hosp Pharm |
Stability of azacitidine in infusion fluids. |
|
1040 |
Am J Hosp Pharm |
Stability of fluorouracil in plastic containers used for continuous infusion at home. |
|
1041 |
Am J Hosp Pharm |
Visual compatibility of dobutamine hydrochloride with other injectable drugs. |
|
1045 |
Am J Hosp Pharm |
Stability of dobutamine hydrochloride and verapamil hydrochloride in 0.9% sodium chloride and 5 % dextrose injections. |
|
1046 |
Am J Health-Syst Pharm |
Stability of cefepime hydrochloride in polypropylene syringes. |
|
1047 |
Am J Hosp Pharm |
Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. |
|
1049 |
Am J Hosp Pharm |
Stability of nitroglycerin in intravenous admixtures. |
|
1050 |
Am J Hosp Pharm |
Shelf life of unrefrigerated succinylcholine chloride injection. |
|
1055 |
Can J Hosp Pharm |
Compatibility of antibiotics and other drugs in total parenteral nutrition solutions. |
|
1057 |
Am J Hosp Pharm |
Compatibility of verapamil hydrochloride injection with commonly used additives. |
|
1058 |
Am J Hosp Pharm |
Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. |
|
1061 |
Am J Health-Syst Pharm |
Urokinase after freezing : Implications for thrombolysis in intraventricular hemorrhage. |
|
1062 |
Int J Pharm |
The stability of morphine and the stability of concentrated morphine solutions in glass, polypropylene syringes and PVC containers. |
|
1064 |
Pharm World Sci |
Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatement (HIVAT). |
|
1067 |
EJHP |
Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. |
|
1068 |
Am J Health-Syst Pharm |
Stability of cefepime hydrochloride in polypropylene syringes at -20°C, 4°C and 22-24°C. |
|
1069 |
Am J Health-Syst Pharm |
Stability and compatibility of promethazine hydrochloride and dihydroergotamine mesylate in combination. |
|
1070 |
Am J Health-Syst Pharm |
Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium. |
|
1071 |
Am J Health-Syst Pharm |
Stability of tirofiban hydrochloride in three commonly used IV solutions and polyvinyl chloride administration sets. |
|
1072 |
Am J Health-Syst Pharm |
Compatibility of levofloxacin with 34 medications during simulated Y-site administration. |
|
1075 |
J Pharm Biomed Anal |
Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers. |
|
1079 |
Am J Hosp Pharm |
Incompatibility of morphine sulfate and prochlorperazine edisylate in syringes. |
|
1080 |
Am J Hosp Pharm |
Stability of cisplatin admixtures in polyvinyl chloride bags. |
|
1084 |
Lancet |
Incompatibility between fat emulsion and calcium plus heparin in parenteral nutrition of premature babies. |
|
1085 |
Radiology |
Incompatibility of contrast agents with intravascular medications. |
|
1088 |
JAMA |
Drug trapping in intravenous infusion side arms. |
|
1091 |
Anesthesiology |
Insulin adsorption by glass infusion bottles, polyvinylchloride infusion containers, and intravenous tubing. |
|
1093 |
Anesthesiology |
Stability of atracurium administered by infusion. |
|
1098 |
Ann Intern Med |
Verapamil precipitation. |
|
1099 |
Ann Intern Med |
Precipitation of verapamil in an intravenous line. |
|
1100 |
Ann Intern Med |
Precipitation of verapamil. |
|
1102 |
Eur J Clin Pharmacol |
Availability of isosorbide dinitrate, diazepam and chlormethiazole, from i.v. delivery systems. |
|
1103 |
J Pediatr |
Antibiotic stability in a pediatric parenteral alimentation solution. |
|
1108 |
Crit Care Med |
Loss of nitroglycerin to cardiopulmonay bypass apparatus. |
|
1109 |
Crit Care Med |
Intravenous infusions of nitroprusside, dobutamine, and nitroglycerin are compatible. |
|
1113 |
Am J Hosp Pharm |
Nitroglycerin delivery through a polyethylene-lined intravenous administration set. |
|
1115 |
Am J Hosp Pharm |
Stability of procainamide hydrochloride in dextrose solutions. |
|
1116 |
Am J Hosp Pharm |
Stability of thiamine hydrochloride repackaged in disposable syringes. |
|
1120 |
Am J Hosp Pharm |
Interactions between drugs and plastic intravenous fluid bags. Part I: Sorption studies on 17 drugs. |
|
1121 |
Am J Hosp Pharm |
Stability of prostaglandins. |
|
1126 |
Am J Hosp Pharm |
Lidocaine stability in cardioplegic solution stored in glass bottles and polyvinyl chloride bags. |
|
1135 |
Am J Hosp Pharm |
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. |
|
1137 |
Am J Hosp Pharm |
Incompatibility of iron dextran and a total nutrient admixture. |
|
1147 |
J Pharm Pharmacol |
Influence of intravenous administration set composition on the sorption of isosorbide dinitrate. |
|
1148 |
J Pharm Pharmacol |
The sorption of isosorbide dinitrate to intravenous delivery systems. |
|
1151 |
J Chromatogr |
High-performance liquid chromatographic determination of sodium nitroprusside. |
|
1153 |
Int J Pharm |
The influence of buffering on the stability of erythromycin injection in small-volume infusions. |
|
1154 |
Int J Pharm |
The stability of erythromycin injection in small-volume infusions. |
|
1155 |
Int J Pharm |
Stability of methotrexate injection in prefilled plastic disposable syringes. |
|
1157 |
Int J Pharm |
Degradation kinetics of vinblastine sulphate in aqueous solutions. |
|
1158 |
Int J Pharm |
Stability of methotrexate and vinblastine in burette administration sets. |
|
1160 |
Int J Pharm |
Aspects of the degradation kinetics of doxorubicin in aqueous solution. |
|
1161 |
Int J Pharm |
Sorption of parenteral nitrates during administration with a syringe pump and extension set. |
|
1165 |
Int J Pharm |
Compatibility of the cephalosporin, cefamandole nafate with injections. |
|
1166 |
Int J Pharm |
Rapid adsorptive loss of nitroglycerin from aqueous solution to plastic. |
|
1167 |
Antimicrob Agents Chemother |
Instability of vancomycin in infusaid drug pump model 100. |
|
1168 |
Antimicrob Agents Chemother |
Tobramycin inactivation by carbenicillin, ticarcillin and piperacillin. |
|
1169 |
Am J Hosp Pharm |
Phenytoin sodium solubility in three intravenous solutions. |
|
1172 |
Am J Hosp Pharm |
Compatibility of amphotericin B with certain large-volume parenterals. |
|
1173 |
Am J Hosp Pharm |
Interactions between drugs and polyvinyl chloride infusion bags. |
|
1175 |
Am J Hosp Pharm |
Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets. |
|
1178 |
Am J Hosp Pharm |
Stability and compatibility of antitumor agents in glass and plastic containers. |
|
1182 |
Am J Hosp Pharm |
Factors affecting diazepam infusion: solubility, administration-set composition, and flow rate. |
|
1183 |
Am J Hosp Pharm |
Stability of diluted heparin sodium stored in plastic syringes. |
|
1188 |
Am J Hosp Pharm |
Stability of aminophylline injection in three parenteral nutrient solutions. |
|
1189 |
Am J Hosp Pharm |
Uptake of clonazepam by plastic intravenous infusion bags and administration sets. |
|
1193 |
Am J Hosp Pharm |
Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives. |
|
1194 |
Am J Hosp Pharm |
Compatibility and stability of labetolol hydrochloride in commonly used intravenous solutions. |
|
1197 |
Am J Hosp Pharm |
Stability of trimethoprim-sulfamethoxazole injection in five infusion fluids. |
|
1198 |
Am J Hosp Pharm |
Compatibility of propranolol hydrochloride injection with intravenous infusion fluids in plastic containers. |
|
1199 |
Am J Hosp Pharm |
Stability of diazepam injection repackaged in glass unit-dose syringes. |
|
1200 |
Am J Hosp Pharm |
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. |
|
1201 |
Am J Hosp Pharm |
Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. |
|
1202 |
Am J Hosp Pharm |
Stability of lidocaine hydrochloride in 5% dextrose injection in plastic bags. |
|
1203 |
Am J Hosp Pharm |
Cimetidine hydrochloride compatibility with preoperative medications. |
|
1206 |
Am J Hosp Pharm |
Cefoperazone-aminoglycoside incompatibility. |
|
1221 |
Am J Hosp Pharm |
Visual compatibility of dobutamine with seven parenteral drug products. |
|
1223 |
Am J Hosp Pharm |
Plastic IV container for nitroglycerin. |
|
1228 |
Am J Hosp Pharm |
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. |
|
1229 |
Br J Pharm Pract |
Chemical stability of cytarabine and vinblastine injections. |
|
1230 |
Br J Pharm Pract |
Anti-emetic / diamorphine mixture compatibility in infusion pumps. |
|
1232 |
Br J Pharm Pract |
A physical compatibility study of furosemide & flucloxacillin injections. |
|
1233 |
Br J Pharm Pract |
The stability of reconstituted aztreonam. |
|
1234 |
Br J Pharm Pract |
Stability of low-dosage heparin in pre-filled syringes. |
|
1235 |
Br J Pharm Pract |
Pentamidine infusion stability. |
|
1236 |
Am J Hosp Pharm |
Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline. |
|
1237 |
Pharm Weekbl [Sci] |
Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation. |
|
1239 |
Pharm Weekbl [Sci] |
Stability after freezing and thawing of solutions of mitomycin C in plastic minibags for intravesical use. |
|
1241 |
Can J Hosp Pharm |
The stability of penicillin G sodium in 5% dextrose in water minibags after freezing. |
|
1242 |
Pharm Weekbl [Sci] |
Adsorption of human and porcin insulins to intravenous administration sets. |
|
1243 |
Can J Hosp Pharm |
The use of stability-indicating assays to determine the in vitro compatibility and stability of metronidazole / gentamicin admixtures. |
|
1245 |
JPEN |
Insulin adsorption to three-liter ethylen vinyl acetate bags during 24-hour infusion. |
|
1246 |
Pharm Weekbl [Sci] |
Comparison of clonazepam sorption to polyvinyl chloride-coated and polyethylene-coated tubings. |
|
1248 |
Am J Hosp Pharm |
Stability of ranitidine hydrochloride in total parenteral nutrient solution. |
|
1249 |
Am J Hosp Pharm |
Stability of dopamine hydrochloride exposed to blue-light phototherapy. |
|
1258 |
Am J Hosp Pharm |
Effect of gentamicin on heparin activity. |
|
1259 |
Am J Hosp Pharm |
Compatibility of aminophylline with hydrocortisone sodium succinate or dexamethasone sodium phosphate in 5% dextrose injection. |
|
1260 |
Am J Hosp Pharm |
Compatibility of azathioprime sodium with intravenous fluids. |
|
1263 |
Int J Pharm Pract |
The effect of buffering on the stability of reconstituted benzylpenicillin injection. |
|
1264 |
Ann Pharm Fr |
Study of Lavoisier morphine chlorhydrate in different active perfusion systems after reconstitution in different solvents. |
|
1265 |
J Clin Pharm Ther |
Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. |
|
1269 |
J Clin Pharm Ther |
Binding of drugs to end-line filters: a study of four commonly administered drugs in intensive care units. |
|
1270 |
J Pharm Belg |
IV infusion of glyceryl trinitrate. Study of the sorption on various plastic containers. |
|
1271 |
J Pharm Belg |
Reliable continuous IV perfusion system for diazepam. |
|
1274 |
TAP Pharmazeutische Zeitung |
Pharmazeutische aspekte von topotecan-infusionen. |
|
1275 |
Can J Hosp Pharm |
Stability of meropenem in saline and dextrose solutions and compatibility with potassium chloride. |
|
1276 |
Can J Hosp Pharm |
Stability and compatibility of morphine with bupivacaine. |
|
1277 |
Can J Hosp Pharm |
Chemical stability of diphenhydramine hydrochloride in minibags and polypropylene syringes. |
|
1278 |
Can J Hosp Pharm |
Concentration and solution dependent stability of cloxacillin intravenous solutions. |
|
1284 |
Photochem Photobiol |
Photoinactivation of anthracyclines. |
|
1286 |
Ann Pharmacotherapy |
Compatibility and stability of paclitaxel combined with doxorubicin hydrochloride in infusion solutions. |
|
1287 |
Pharm Ind |
Stability study of reconstituted and diluted solutions of calcium folinate. |
|
1288 |
Int J Pharm Pract |
Stability of injections containing diamorphine and midazolam in plastic syringes. |
|
1289 |
Pharmakon |
Etude de stabilité visuelle du chlorhydrate de chlorpromazine, du chlorure de potassium, de la furosémide et de l’héparine sodique en perfusion continue. |
|
1290 |
Ann Pharmacotherapy |
Stability of cefepime in peritoneal dialysis solution. |
|
1291 |
Int J Pharm Pract |
Long term stability of heparin in dextrose-saline intravenous fluids. |
|
1292 |
Int J Pharm Pract |
Stability of epidural opiate solutions in 0.9 per cent sodium chloride infusion bags. |
|
1300 |
Hosp Pharm Pract |
The stability of drugs in pre-filled syringes: flucloxacillin, ampicillin, cefuroxime, cefotaxime and ceftazidime. |
|
1301 |
Hosp Pharm Pract |
The stability of reconstituted diethanolamine fusidate in a 5% dextrose infusion. |
|
1302 |
Drug Intell Clin Pharm |
Cyclosporine binding to components in medication administration sets. |
|
1315 |
Int J Pharm Clin Pharmacol Ther Tox |
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. |
|
1316 |
Pharm J |
Sodium nitroprusside stability in light-protective administration sets. |
|
1317 |
Pharm J |
Pharmaceutical aspects of home infusion therapy for cancer patients. |
|
1318 |
Pharm J |
Stability and administration of intravenous Augmentin. |
|
1322 |
JPEN |
In vitro study of inline filtration of medications commonly administered to pediatric cancer patients. |
|
1325 |
JPEN |
Compatibility of 5-fluorouracil and total nutrition solutions. |
|
1326 |
Am J Roentgenol |
Incompatibility of Hexabrix and papaverine. |
|
1329 |
Br J Parent Ther |
Freeze-thaw stability of antibiotics used in an IV additive service. |
|
1331 |
J Clin Hosp Pharm |
Chemical stabilities of lignocaine hydrochloride and phenylephrine hydrochloride in aqueous solution. |
|
1332 |
J Clin Hosp Pharm |
Absorption of isosorbide dinitrate by PVC infusion bags and administration sets. |
|
1333 |
J Clin Hosp Pharm |
The stability of amoxycillin sodium in intravenous infusion fluids. |
|
1338 |
Am J Hosp Pharm |
Compatibility of total nutrient admixtures and secondary cardiovascular medications. |
|
1341 |
Pharm J |
Stability of an intrathecal morphine injection formulation. |
|
1346 |
Am J Hosp Pharm |
Stability and sterility of cimetidine admixtures frozen in minibags. |
|
1349 |
Aust J Hosp Pharm |
Effects of freezing, long term storage and microwave thawing on the stability of three antibiotics reconstituted in minibags. |
|
1351 |
Am J Hosp Pharm |
Precipitation of verapamil with nafcillin. |
|
1352 |
Am J Hosp Pharm |
Dobutamine-heparin mixture inadvisable. |
|
1353 |
Am J Hosp Pharm |
Effects of presaturation on nitroglycerin delivery by polyvinyl chloride infusion sets. |
|
1357 |
Ann Pharmacotherapy |
Quinolones and penicillins incompatibility. |
|
1359 |
Am J Hosp Pharm |
Interaction between vancomycin and ticarcillin. |
|
1366 |
Am J Hosp Pharm |
Nafcillin sodium incompatibility with acidic solutions. |
|
1371 |
Am J Hosp Pharm |
Crystal formation after reconstituting cefazolin sodium with 0.9% sodium chloride injection. |
|
1372 |
Int J Pharm Compound |
Chemical Stability of Desonide in Ear Drops. |
|
1379 |
Aust J Hosp Pharm |
Stability and light sensitivity of sodium nitroprusside infusions. |
|
1380 |
Am J Hosp Pharm |
Identification of labetolol precipitate. |
|
1383 |
J Pharm Pharmacol |
Photodegradation of solutions of the antitumour drug DTIC. |
|
1385 |
Pharm J |
Diamorphine injection BP incompatibility. |
|
1386 |
Pharm J |
Antibiotic interactions. |
|
1388 |
Pharm J |
Diamorphine hydrochloride compatibility with saline. |
|
1391 |
Can J Hosp Pharm |
Is heparin always compatible with TPN and fat emulsion admixtures? |
|
1392 |
Can J Hosp Pharm |
Ampicillin and ciprofloxacin incompatibility. |
|
1393 |
Pharm J |
Ciprofloxacin lactate infusion. |
|
1394 |
Thromb Haemost |
Urokinase therapy: dose reduction by administration in plastic material. |
|
1395 |
Thromb Haemost |
Glass adsorption of highly purified urokinase. |
|
1396 |
J Clin Oncol |
Ondansetron compatible with sodium acetate. |
|
1397 |
Pharm J |
Dopamine dilutions. |
|
1399 |
Pharm J |
Incompatibility of ceftazidime and vancomycin. |
|
1405 |
J Clin Pharm Ther |
Compatibility and stability of fentanyl admixtures in polypropylene syringes. |
|
1407 |
Hosp Pharm |
Stability of amphotericin B cholesteryl sulfate complex after reconstitution and admixture. |
|
1408 |
J Oncol Pharm Practice |
Stability of three cytotoxic drugs infusions in the Graseby 9000 ambulatory infusion pump. |
|
1410 |
J Am Pharm Assoc |
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. |
|
1411 |
J Am Pharm Assoc |
Physical and chemical stability of etoposide phosphate solutions. |
|
1412 |
Int J Pharm Compound |
Y-site stability of fosphenytoin and sodium phenobarbital. |
|
1413 |
Int J Pharm Compound |
Five-day stability of vinorelbine in 5% dextrose injection and in 0.9% sodium chloride injection at room temperature. |
|
1414 |
J Pharm Technol |
Stability of low-dose vancomycin hydrochloride in heparin sodium 100 UI / ml. |
|
1415 |
JPEN |
Compatibility of medications with 3-in-1 parenteral nutrition admixtures. |
|
1416 |
Am J Health-Syst Pharm |
Stability of high-dose vancomycin and ceftazidime in peritoneal dialysis solutions. |
|
1419 |
Int J Pharm Compound |
Fosphenytoin Y-site stability studies with lorazepam and midazolam hydrochloride. |
|
1420 |
J Clin Pharm Ther |
Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. |
|
1421 |
J Am Pharm Assoc |
Stability and compatibility of tacrolimus and fluconazole in 0.9% sodium chloride. |
|
1422 |
J Am Pharm Assoc |
Physical and chemical stability of gemcitabine hydrochloride solutions. |
|
1423 |
J Am Pharm Assoc |
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. |
|
1424 |
Am J Emerg Med |
Prehospital stability of diazepam and lorazepam. |
|
1425 |
J Oncol Pharm Practice |
Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices. |
|
1438 |
Am J Hosp Pharm |
Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications. |
|
1452 |
Eur Hosp Pharm |
Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*. |
|
1454 |
Am J Health-Syst Pharm |
Stability of meropenem in a portable infusion device in a cold pouch. |
|
1455 |
J Pharm Clin |
Etude de la stabilité de deux benzamides antiémétiques en poches PVC de chlorure de sodium 0.9% et de glucose 5% sur une période de 5 mois. |
|
1461 |
J Pharm Pharmacol |
Chemical incompatibility between procainamide hydrochloride and glucose following intravenous admixture. |
|
1462 |
J Pharm Pharmacol |
The availability of diltiazem: a study on the sorption by intravenous delivery systems and on the stability of the drug. |
|
1467 |
Int J Pharm |
Stability and compatibility of baclofen and morphine admixtures for use in an implantable infusion pump. |
|
1468 |
Int J Pharm |
Compatibility with medical plastics and stability of continuously and simultaneously infused isosorbide dinitrate and heparin. |
|
1469 |
Int J Pharm |
Stability and compatibility of 2.5 mg/ml methotrexate solution in plastic syringes over 7 days. |
|
1472 |
Int J Pharm |
Sorptive loss of diazepam, nitroglycerin and warfarin sodium to polypropylene-lined infusion bags (Softbags). |
|
1475 |
J Pharm Biomed Anal |
Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs. |
|
1477 |
J Pharm Biomed Anal |
Stability of revex, nalmefene hydrochloride injection, in injectable solutions. |
|
1479 |
Krankenhauspharmazie |
Cefamandolnafat und metronidazol. Chemische stabilität in einer mischung zur intravenösen infusion. |
|
1481 |
Krankenhauspharmazie |
Kompatibilität von ofloxacin mit ampicillin. |
|
1482 |
Krankenhauspharmazie |
Pharmazeutische kompatibilität der kombination cefotiam und ampicillin. |
|
1486 |
Hosp Pharm |
Stability of gentamicin diluted in 0.9% sodium chloride injection in glass syringes. |
|
1490 |
Int J Pharm Clin Pharmacol Ther Tox |
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. |
|
1491 |
Eur Hosp Pharm |
Stability of sufentanil citrate and sufentanil citrate/bupivacaine mixture in portable infusion pump reservoirs. |
|
1492 |
Can J Hosp Pharm |
Compatibility of morphine and midazolam or haloperidol in parenteral admixtures. |
|
1494 |
Hosp Pharm Pract |
When is flucloxacillin stable ? |
|
1495 |
Pharm J |
The stability of morphine sulphate and metoclopramide hydrochloride in various delivery presentations. |
|
1496 |
Hosp Pharm |
Screening cladribine for Y-site physical compatibility with selected drugs. |
|
1497 |
Can J Hosp Pharm |
Stability and compatibility of combinations of hydromorphone and dimenhydrinate lorazepam or prochlorperazine. |
|
1498 |
Ann Pharmacotherapy |
Amphotericin B formulated in a lipid emulsion. |
|
1500 |
Ann Pharmacotherapy |
Ciprofloxacin-ampicillin sulbactam incompatibility. |
|
1501 |
Int J Pharm |
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. |
|
1503 |
Am J Hosp Pharm |
Stability of cimetidine hydrochloride in admixtures after microwave thawing |
|
1505 |
Eur Hosp Pharm |
Stability of cladribine in either polyethylene containers or polyvinylchloride bags. |
|
1506 |
EJHP |
Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. |
|
1508 |
EJHP |
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. |
|
1509 |
Norgine |
Dantrolene sodium (Dantrium®) - Summary of Product Characteristics |
|
1510 |
AHFS Formulary service |
|
|
1512 |
Beacon Pharmaceuticals Ltd |
Tirofiban (Aggrastat®) - Summary of Product Characteristics |
|
1513 |
Monarch Pharmaceuticals Ireland |
Quinupristine / dalfopristine (Synercid®) - Résumé des caractéristiques du produit |
|
1514 |
Novartis Pharmaceuticals UK Ltd |
Verteporfin (Visudyne®) – Summary of Product Characteristics |
|
1516 |
Mercury Pharmaceuticals Limited |
Ropivacaine (Naropeine®) - Summary of Product Characteristics |
|
1517 |
Sanofi-Aventis |
Rasburicase (Fasturtec®) - Summary of Product Characteristics |
|
1518 |
Hospira UK Ltd |
Raltitrexed (Tomudex®) - Summary of Product Characteristics |
|
1519 |
Merck Sharp Dohme |
Caspofungine (Cancidas®) - Summary of Product Characteristics |
|
1520 |
B Braun |
Etude de stabilité des médicaments en Ecoflac® |
|
1522 |
Maco Pharma |
Macoflex N® |
|
1600 |
Am J Health-Syst Pharm |
Stability of tirofiban hydrochloride in 0.9% sodium chloride injection for 30 days. |
|
1601 |
Hosp Pharm |
Stability of a baclofen and clonidine hydrochloride admixture for intrathecal administration. |
|
1602 |
Hosp Pharm |
The stablity of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. |
|
1603 |
Am J Health-Syst Pharm |
Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. |
|
1604 |
Eur Hosp Pharm |
Stability of citalopram hydrochloride in polyvinyl chloride bag for I.V. solutions and compatibility in the presence of dipotassium clorazepate. |
|
1605 |
Hosp Pharm |
Stability of cefepime hydrochloride injection and metronidazole in polyvinyl chloride bags at 4°C and 22-24°C. |
|
1606 |
Am J Health-Syst Pharm |
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection. |
|
1607 |
Hosp Pharm |
Incompatibility of erythromycin lactobionate and sulfamethoxazole/trimethoprim with linezolid injection. |
|
1608 |
Int J Pharm Compound |
Assessment of the stability of teicoplanin in intravenous infusions. |
|
1611 |
Am J Health-Syst Pharm |
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. |
|
1613 |
Can J Hosp Pharm |
Stability and compatibility of etoposide in normal saline. |
|
1614 |
Hosp Pharm |
Stability of ciprofloxacin and vancomycin hydrochloride in autodose infusion system bags. |
|
1617 |
Am J Health-Syst Pharm |
Stability of irinotecan hydrochloride in aqueous solutions. |
|
1618 |
Am J Health-Syst Pharm |
Stability of fenoldopam in two infusion solutions. |
|
1620 |
Am J Health-Syst Pharm |
Stability and compatibility of methylprednisolone acetate and ropivacaine hydrochloride in polypropylene syringes for epidural administration. |
|
1622 |
Am J Health-Syst Pharm |
Stability of carmustine in polyvinyl chloride bags and polyethylene-lined trilayer plastic containers. |
|
1624 |
Am J Health-Syst Pharm |
Activity of dalteparin sodium in polypropylene syringes. |
|
1625 |
Int J Pharm Compound |
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. |
|
1626 |
Int J Pharm Compound |
Stability of cefepime hydrochloride after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. |
|
1627 |
Int J Pharm Compound |
Chemical stability of methylprednisolone sodium succinate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes. |
|
1628 |
Int J Pharm Compound |
Stability of pentobarbital sodium after reconstitution in 0.9% sodium chloride injection and repackaging in glass and polypropylene syringes. |
|
1631 |
Int J Pharm Compound |
Chemical stability of perphenazine in two commercially available vehicles for oral liquid dosage forms |
|
1633 |
Can J Hosp Pharm |
Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions. |
|
1634 |
Can J Hosp Pharm |
Stability of ketorolac tromethamine in IV solutions and waste reduction. |
|
1635 |
Am J Health-Syst Pharm |
Stability of dacarbazine in amber glass vials and polyvinyl chloride bags. |
|
1637 |
Can J Hosp Pharm |
Concentration-dependant compatibility and stability of dexamethasone and midazolam. |
|
1638 |
Eur Hosp Pharm |
Stability of reconstituted ceftriaxone solution in polypropylene syringes. |
|
1639 |
Eur Hosp Pharm |
Stability of meropenem in elastomeric portable infusion devices. |
|
1643 |
Hosp Pharm |
Haldol-benztropine incompatibility. |
|
1645 |
EJHP |
Evaluation of a diltiazem hydrochloride gel for the treatment of anal fissure. |
|
1646 |
Anaesthesia |
Incompatibility of prochlorperazine and ketoprofen. |
|
1647 |
Anaesthesia |
Physical incompatibility between atracurium and intravenous diclofenac. |
|
1648 |
Int J Pharm Compound |
Effect of freezing, long-term storage, and microwave thawing on the stability of cefepime in 5% dextrose infusion polyvinyl chloride bags. |
|
1649 |
Aust J Hosp Pharm |
Ticarcillin-potassium clavulanate and vancomycin incompatibility. |
|
1651 |
J Clin Pharm Ther |
Comparison of ceftazidime degradation in glass bottles and plastic bags under various conditions. |
|
1655 |
Pharmacotherapy |
Stability of intravenous citalopram hydrochloride in either polyvinyl chloride bags or glass containers for infusion therapy, and compatibility with dipotassium clorazepate admixed. |
|
1656 |
Pharmazie |
Stability and compatibility studies of cefaloridine, cefuroxime and ceftazidime with PVC infusion bags. |
|
1658 |
J Am Pharm Assoc |
Compatibility and stability of linezolid injection admixed with aztreonam or piperacillin sodium. |
|
1659 |
J Am Pharm Assoc |
Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics. |
|
1660 |
Pharm World Sci |
Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers. |
|
1661 |
J Oncol Pharm Practice |
Physical and chemical stability of methotrexate, cytarabine, and hydrocortisone in Elliott’s B Solution for intrathecal use. |
|
1662 |
J Oncol Pharm Practice |
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. |
|
1663 |
EJHP |
The stability of (lyophilized) gemcitabine in 0.9% sodium chloride injection. |
|
1664 |
J Clin Pharm Ther |
Stability of cefmetazole-doxycycline mixtures in sodium chloride and dextrose injections. |
|
1665 |
J Clin Pharm Ther |
Compatibility of ropivacaine with morphine, sufentanil, fentanyl, or clonidine. |
|
1667 |
Int J Pharm |
Stability and compatibility study of a carboplatin solution in syringes for continuous ambulatory infusion. |
|
1668 |
Ann Pharmacotherapy |
Compatibility and stability of linezolid injection admixed with three quinolone antibiotics. |
|
1669 |
Can J Hosp Pharm |
The pharmaceutical stability of deferoxamine mesylate. |
|
1670 |
Pharmazie |
Compatibility of cefpirome and cephalotin with PVC bags during simulated infusion and storage. |
|
1671 |
Int J Pharm |
Compatibility and stability of vancomycin hydrochloride with PVC infusion material in various conditions using stability-indicating high-performance liquid chromatographic assay. |
|
1672 |
Anesthesiology |
Incompatibility of propofol emulsion with anesthesic drugs. |
|
1673 |
Int J Pharm |
Stability study of cefepime in different infusion solutions. |
|
1674 |
Hosp Pharm |
Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. |
|
1675 |
Int J Pharm Compound |
Stability of 4-Aminopyridine and 3,4-Diaminopyridine oral capsules |
|
1676 |
Int J Pharm |
Compatibility of granisetron towards glass and plastics and its stability under various storage conditions. |
|
1678 |
Int J Pharm |
Stability and compatibility of intrathecal admixtures containing baclofen and high concentrations of morphine. |
|
1679 |
Int J Pharm |
Stability and sterility of meglumine gadoterate injection repackaged in plastic syringes. |
|
1680 |
Int J Pharm Compound |
Chemical stability of furosemide in minibags and polypropylene syringes. |
|
1682 |
Int J Pharm Compound |
Stability of neostigmine methylsulfate injection at ambient temperature and 4°C in polypropylene syringes. |
|
1685 |
Krankenhauspharmazie |
Stabilitätsstudie zu metamizol-natrium im PVC-infusionbeutel. |
|
1688 |
Krankenhauspharmazie |
Stabilitätsstudie zu alizaprid im PVC-infusionbeutel. |
|
1690 |
Krankenhauspharmazie |
Stabilitätsstudie zu tramadolhydrochlorid im PVC-infusionbeutel. |
|
1692 |
Krankenhauspharmazie |
Pharmazeutische kompatibilität von piperacillin mit metronidazol. |
|
1694 |
Krankenhauspharmazie |
Stabilitätsstudie zu fosfomycin-dinatrium (Fosfocin° p.i. 5.0) in applikationsfertigen perfusorspritzen. |
|
1696 |
J Pharm Biomed Anal |
Photodegradation studies on Atenolol by liquid chromatography. |
|
1697 |
Krankenhauspharmazie |
Stabilitätsuntersuchung von Dipidolor°-zubereitungen. |
|
1698 |
Krankenhauspharmazie |
Stabilität von dopaminhydrochlorid (Dopamine Solvay°) in mischungen mit infusionlösungen. |
|
1699 |
Krankenhauspharmazie |
Mischbarkeit von serotonin-antagonisten mit dexamethason und heparin. |
|
1701 |
Int J Pharm Compound |
Chemical stability of dexamethasone sodium phosphate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes. |
|
1703 |
Krankenhauspharmazie |
Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln. |
|
1704 |
Int J Pharm Compound |
Stability of gentamicin sulfate and tobramycin sulfate in autodose infusion system bags. |
|
1705 |
Int J Pharm Compound |
Stability of ampicillin sodium, nafcillin sodium, and oxacillin sodium in autodose system bags. |
|
1706 |
Int J Pharm Compound |
Physical and chemical stability of hydromorphone hydrochloride 1.5 and 80 mg/ml packaged in plastic syringes. |
|
1707 |
Int J Pharm Compound |
Physical and chemical stability of low and high concentrations of morphine sulfate with bupivacaine hydrochloride packaged in plastic syringes. |
|
1708 |
Int J Pharm Compound |
Physical and chemical stability of low and high concentrations of morphine sulfate with clonidine hydrochloride packaged in plastic syringes. |
|
1709 |
Int J Pharm Compound |
Physical and chemical stability of morphine sulfate 5 mg/ml and 50 mg/ml packaged in plastic syringes. |
|
1711 |
Int J Pharm Compound |
Stability of cefotaxime sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. |
|
1712 |
Int J Pharm Compound |
Compatibility screening of Precedex during simulated Y-site administration with other drugs. |
|
1713 |
Int J Pharm Compound |
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. |
|
1714 |
Int J Pharm Compound |
Stability of ketamine hydrochloride injection after reconstitution in water for injection and storage in 1-ml tuberculin polypropylene syringes for pediatric use. |
|
1715 |
Int J Pharm Compound |
Stability of lidocaine hydrochloride injection at ambient temperature and 4°C in polypropylene syringes. |
|
1716 |
Int J Pharm Compound |
Stability of ethacrynate sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. |
|
1717 |
Int J Pharm Compound |
Stability of acyclovir sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. |
|
1718 |
Int J Pharm Compound |
Stability of piperacillin sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. |
|
1720 |
Int J Pharm Compound |
Stability of ephedrine sulfate at ambient temperature and 4°C in polypropylene syringes. |
|
1721 |
Int J Pharm Compound |
Compatibility screening of Hextend during simulated Y-site administration with other drugs. |
|
1722 |
EJHP |
Compatibility of etoposide solution with polyvinyl chloride and low density polyethylene containers and its stability in different storage conditions. |
|
1723 |
Pharmazie |
Physico-chemical stability of infusion solutions for epidural administration containing fentanyl and bupivacaine or lidocaine. |
|
1724 |
Can J Hosp Pharm |
Visual compatibility of various injectable neuroleptic agents with benztropine and lorazepam in polypropylene syringes. |
|
1725 |
Can J Hosp Pharm |
Compatibility of oxytocin, zidovudine, and penicillin G. |
|
1726 |
Can J Hosp Pharm |
Stability of oxycodone hydrochloride for injection in dextrose and saline solutions. |
|
1727 |
Pharmazie |
Stability of vinblastine sulphate containing infusions. |
|
1728 |
Pharmazie |
Stability of cyclophosphamide containing infusions. |
|
1729 |
Pharmazie |
Stability of cisplatin containing infusion. |
|
1730 |
Act Pharm Nord |
Chemical compatibility of mitoxantrone and etoposide (VP-16). |
|
1733 |
Pharmazie |
HPTLC-based stability assay for determination of amiodarone in intravenous admixtures. |
|
1734 |
J Pharm Biomed Anal |
The suitability of carboplatin solutions for 14-day continuous infusion by ambulatory pump : an HPLC-dynamic FAB study. |
|
1735 |
J Pharm Biomed Anal |
Stability of mepiridine in an implantable infusion pump using capillary gas chromatography-mass spectrometry and a deuterated internal standard. |
|
1736 |
J Clin Pharm Ther |
Effects of sucrose, citric buffer and glucose oxidase on the stability of captopril in liquid formulations. |
|
1739 |
Am J Health-Syst Pharm |
Incompatibility of cefperazone and promethazine. |
|
1740 |
Int J Pharm Compound |
Stability of ciprofloxacin in an extemporaneous oral liquid dosage form. |
|
1741 |
Am J Hosp Pharm |
Precipitation of paclitaxel during infusion by pump. |
|
1744 |
Am J Health-Syst Pharm |
Incompatibility of ceftriaxone sodium with lactated Ringer’s injection. |
|
1745 |
Am J Health-Syst Pharm |
Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate. |
|
1746 |
EJHP |
Stability studies of amoxicillin/clavulanic acid combinaison in polyolefin infusion bags. |
|
1748 |
Int J Pharm Compound |
Compatibility of vancomycin hydrochloride and famotidine in 5% dextrose injection. |
|
1750 |
Int J Pharm Compound |
Chemical stability of meperidine hydrochloride in polypropylene syringes. |
|
1752 |
Int J Pharm Compound |
Stability of sufentanil in a syringe pump under simulated epidural infusion. |
|
1753 |
Int J Pharm Compound |
Stability of dobutamine hydrochloride 4 mg/ml in 5% dextrose injection at 5 and 23°C. |
|
1754 |
Int J Pharm Compound |
Compatibility of docetaxel with selected drugs during simulated Y-site administration. |
|
1755 |
Int J Pharm Compound |
Stability of succinylcholine chloride injection at ambient temperature and 4°C in polypropylene syringes. |
|
1756 |
Int J Pharm Compound |
Stability of glycopyrrolate injection at ambient temperature and 4°C in polypropylene syringes. |
|
1757 |
J Clin Pharm Ther |
Determination of compatibility and stability of drugs used in palliative care. |
|
1758 |
Can J Hosp Pharm |
Ampicillin and ciprofloxacin incompatibility. |
|
1759 |
Antimicrob Agents Chemother |
Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. |
|
1762 |
J Pharm Biomed Anal |
Stability study of fotemustine in PVC infusion bags and sets under various conditions using a stability-indicating high-performance liquid chromatographic assay. |
|
1800 |
Am J Health-Syst Pharm |
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. |
|
1801 |
Am J Health-Syst Pharm |
Physical compatibility of vasopressin with medications commonly used in cardiac arrest. |
|
1802 |
Am J Health-Syst Pharm |
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. |
|
1803 |
Am J Health-Syst Pharm |
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. |
|
1804 |
Am J Health-Syst Pharm |
Stability of multidose, preserved formulation epoetin alfa in syringes for three and six weeks. |
|
1805 |
Am J Health-Syst Pharm |
Stability of cefazolin sodium in icodextrin-containing peritoneal dialysis solution. |
|
1806 |
Can J Hosp Pharm |
Chemical stability of dimenhydrinate in minibags and polypropylene syringes. |
|
1807 |
Can J Hosp Pharm |
Stability of dolasetron mesylate in 0.9% sodium chloride and 5% dextrose in water. |
|
1809 |
EJHP |
Diluted solution of sodium ioxitalamate in paediatrics: A stability and cost effectiveness study. |
|
1810 |
EJHP |
Stability of morphine sulphate in P.C.A.s. |
|
1811 |
Hosp Pharm |
Stability of imipenem-cilastatin sodium in autodose infusion system bags. |
|
1812 |
Int J Pharm Compound |
Stability of 5-fluorouracil in an extemporaneously compounded ophtalmic solution. |
|
1813 |
Int J Pharm Compound |
Chemical stability of cefuroxime sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. |
|
1814 |
Int J Pharm Compound |
Chemical stability of cefazolin sodium after reconstituting in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. |
|
1815 |
Int J Pharm Compound |
Stability of clindamycin phosphate in autodose infusion system bags. |
|
1816 |
Int J Pharm Compound |
Stability of amikacin sulfate in autodose infusion system bags. |
|
1817 |
J Oncol Pharm Practice |
Stability and compatibility of 5-fluorouracil infusions in the Braun Easypump®. |
|
1819 |
J Clin Pharm Ther |
Leaching of diethyl hexyl phtalate from polyvinyl chloride bags into intravenous etoposide solution. |
|
1820 |
J Clin Pharm Ther |
Stability of dopamine hydrochloride 0.5 mg/ml in polypropylene syringes. |
|
1822 |
Am J Health-Syst Pharm |
Physical compatibility of antithymocyte globulin (rabbit) with heparin sodium and hydrocortisone sodium succinate. |
|
1823 |
J Clin Pharm Ther |
Stability of intravesical epirubicin infusion: a sequential temperature study. |
|
1824 |
J Clin Pharm Ther |
Stability of reconstituted parecoxib for injection with commonly used diluents. |
|
1826 |
Ann Pharmacotherapy |
Stability of piperacillin and ticarcillin in autodose infusion system bags. |
|
1827 |
J Parenter Sci Technol |
Chemical stability of the antitumor mitomycin C in solutions for intravesical instillation. |
|
1832 |
Pharmazie |
Stability of fentanyl/ropivacain preparations for epidural application. |
|
1833 |
Ann Pharmacotherapy |
Stability of cyclophosphamide and mesna admixtures in polyethylene infusion bags. |
|
1834 |
Ann Pharmacotherapy |
Stability of cefepime hydrochloride in autodose infusion system bags. |
|
1835 |
Eur J Pharm Sci |
Stability of sufentanil and levobupivacain solutions and a mixture in a 0.9% sodium chloride infusion stored in polypropylene syringes. |
|
1840 |
J Am Pharm Assoc |
Stability of three cephalosporin antibiotics in autodose infusion system bags. |
|
1842 |
Arzneimittel Forschung |
Compatibility of morphin, baclofen, floxuridine and fluorouracil in an implantable infusion pump. |
|
1845 |
EJHP |
The stability of amoxicillin, ampicillin, benzylpenicillin, flucloxacillin, mezlocillin and piperacillin in isotonic saline solutions when stored in an innovative infusion container (Freeflex container). |
|
1847 |
J Pharm Biomed Anal |
Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration. |
|
1851 |
J Pharm Biomed Anal |
Photostability and phototoxicity studies on diltiazem. |
|
1855 |
J Pharm Biomed Anal |
Furosemide assay in pharmaceuticals by Micellar liquid chromatography: study of the stability of the drug. |
|
1857 |
J Pharm Biomed Anal |
Stability of reconstituted solutions of ceftazidime for injections: an HPLC and CE approach. |
|
1858 |
Pharm Acta Helv |
Stability of L-asparaginase: an enzyme used in leukemia treatment. |
|
1859 |
Il Farmaco |
Physicochemical compatibility between thiocolchicoside injections (Miotens®) and pharmaceutical products frequently used for combined therapy. |
|
1860 |
Int J Pharm |
Compatibility of propofol diluted in 5% glucose with glass and plastics (polypropylene, molyvinylchloride) containers. |
|
1861 |
Int J Pharm |
Medical plastics: compatibility of alfentanil and propofol alone or mixed. Stability of the alfentanil-propofol mixture. |
|
1863 |
Journal of clinical anesthesia |
Compatibility of propofol, fentanyl,and vecuronium mixtures designed for potential use in anesthesia and patient transport. |
|
1864 |
Pain |
Compatibility of ketamine and morphin injections. |
|
1865 |
Int J Pharm |
Compatibility of paclitaxel in 5% glucose solution with ECOFLAC® low-density polyethylene containers - Stability under different storage conditions. |
|
1866 |
Int J Pharm |
Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone. |
|
1867 |
J Pain Symptom Manage |
Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system. |
|
1868 |
Nutr Clin Metab |
Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange. |
|
1869 |
J Pain Symptom Manage |
Stability and compatibility of morphine-clonidine admixtures in an implantable infusion system. |
|
1871 |
Int J Pharm |
Impact of deep freezing on the stability of 25 mg/ml vancomycin ophtalmic solutions. |
|
1873 |
Clin Ther |
Assessment of the stability of dalteparin sodium in prepared syringes for up to thirty days/ In vitro study. |
|
1875 |
Acta Anaesthesiol Scand |
Stability of an epidural analgesic solution containing adrenaline, bupivacaine and fentanyl. |
|
1877 |
Br Ophtalmol |
Vancomycin and ceftazidime incompatibility upon vitreal injection. |
|
1878 |
Int J Pharm Compound |
Stability of zidovudine and dobutamine hydrochloride injections in 0.9% sodium chloride and 5% dextrose injections stored at ambient temperature (23±2°C) and 4°C in 50 ml polyvinyl chloride bags up to 24 hours. |
|
1879 |
Clin J Pain |
Stability, compatibility, and safety of intrathecal bupivacaine administered via an implantable delivery system. |
|
1882 |
Ziekenhuisfarmacie |
Decrease of sufentanil citrate concentration during formulation and application of an epidural infusion solution. |
|
1885 |
Pharm World Sci |
Long-term stability of morphine and bupivacaine mixture for spinal use. |
|
1886 |
Palliative Med |
The stability of diamorphine alone and in combinaison with antiemetics in plastic syringes. |
|
1887 |
Int J Pharm |
Photochemical decomposition of midazolam. IV . Study of pH dependant stability by high-performance liquid chromatography. |
|
1888 |
Ziekenhuisfarmacie |
Compatibility study of midazolam. |
|
1889 |
Int J Pharm |
Stability of micafungin sodium solutions at different concentrations in glass bottles and syringes. |
|
1891 |
Int J Pharm Compound |
Chemical stability of phenylephrine hydrochloride after reconstitution in 0.9% sodium chloride injection for infusion. |
|
1892 |
Int J Pharm Compound |
Effect of freezing, long-term storage and microwave thawing on the stability of tramadol in 5% dextrose infusion in polyvinyl chloride bags. |
|
1893 |
Ann Pharmacotherapy |
Anti-Xa stability of diluted enoxaparin for use in pediatrics. |
|
1895 |
J Pharm Biomed Anal |
Analysis by liquid chromatography and infrared spectrometry of di(2-ethylhexyl)phtalate released by multilayer infusion tubing. |
|
1897 |
EJHP |
Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. |
|
1898 |
Int J Pharm Compound |
Physical and chemical stability of treprostinil sodium injection packaged in plastic syringe pump reservoirs. |
|
1899 |
Int J Pharm Compound |
Long-term stability of Trimix : a three drug injection used to treat rectile dysfunction. |
|
1900 |
Int J Pharm Compound |
Stability of zidovudine and ranitidine in 0.9% sodium chloride and 5% dextrose injections stored at ambient temperature (23°C±2°C) and 4°C in 50 ml polyvinylchloride bags up to 24 hours. |
|
1901 |
J Pain Symptom Manage |
The compatibility and stability of midazolam and dexamethasone in infusion solutions. |
|
1902 |
Can J Hosp Pharm |
Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. |
|
1903 |
Am J Obstet Gynecol |
Oxytocin preparation stability in several common obstetric intravenous solutions. |
|
1904 |
Am J Health-Syst Pharm |
Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents. |
|
1906 |
Am J Health-Syst Pharm |
Stability and compatibility of reconstituted ertapenem with commonly used iv infusion and coinfusion solutions. |
|
1907 |
Hosp Pharm |
Sustaining treatment of coccidioidal meningitidis by extending the stability of amphotericin B. |
|
1908 |
J Pain Symptom Manage |
Long-term stability of sufentanil citrate with levobupivacaine hydrochloride in 0.9% sodium chloride infusion PVC bags at 4°C. |
|
1909 |
J Pharm Clin |
Compatibilité et stabilité du mélange bupivacaïne-sufentanil en poche. |
|
1910 |
Baxter |
Compatibility of imiglucerase (personal communication) |
|
1911 |
Janssen-Cilag Ltd |
Bortezomib (Velcade®) - Summary of Product Characteristics |
|
1912 |
Merck Sharp Dohme |
Ertapenem (Invanz®) - Summary of Product Characteristics |
|
1913 |
Pfizer Europe |
Gemtuzumab ozogamicin (Mylotarg® - Summary of Product Characteristics) |
|
1914 |
Eli Lilly |
Pemetrexed (Alimta®) - Summary of Product Characteristics |
|
1915 |
Genzyme |
Imiglucerase (Cerezyme®) -Summary of product Characteristics |
|
1917 |
J Pharm Biomed Anal |
Analysis of gentamicin sulfate and a study of its degradation in dextrose solution. |
|
1918 |
J Pharm Sci |
Photodegradation of irinotecan (CPT-11) in aqueous solutions : identification of fluorescent products and influence of solution composition. |
|
1920 |
Drug Stability |
Photodegradation reactions of CPT-11, a derivative of campothecion, part i: chemical structure of main degradation products in aqueous solution. |
|
1921 |
Drug Stability |
Photodegradation reactions of CPT-11, a derivative of campothecion, part ii: photodegradation behaviour of CPT-11 in aqueous solution. |
|
1922 |
J Am Pharm Assoc |
Stability of methylprednisolone sodium succinate in autodose infusion system bags. |
|
1925 |
J Am Pharm Assoc |
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. |
|
1926 |
Am J Health-Syst Pharm |
Stability of zidovudine with oxytocin in a simulated Y-site injection. |
|
1927 |
EJHP |
Stability of ranitidine hydrochloride in different aqueous solutions. |
|
1928 |
J Pain Symptom Manage |
Drug stability testing to support clinical feasibility investigations for intrathecal baclofen-clonidine admixture. |
|
1929 |
J Pharm Biomed Anal |
Shelf lives of aseptically prepared medicines - stability of netilmicin injection in polypropylene syringes. |
|
1931 |
Can J Hosp Pharm |
Physical compatibility and chemical stability of bupivacaine and hydromorphone in polypropylene syringes. |
|
1932 |
Int J Pharm Compound |
Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate. |
|
1933 |
Int J Pharm Compound |
Chemical stability of terbutaline sulfate injection after diluting with 0.9% sodium chloride injection when stored at room temperature in polyvinyl chloride bags. |
|
1934 |
Am J Health-Syst Pharm |
Compatibility of ketamine hydrochloride and fentanyl citrate in polypropylene syringes. |
|
1935 |
Am J Health-Syst Pharm |
Stability of lorazepam in 0.9% sodium chloride stored in polyolefin bags. |
|
1936 |
Ann Pharmacotherapy |
Physical and chemical stability of palonosetron HCl in 4 infusion solusions. |
|
1937 |
Ann Pharmacotherapy |
Physical and chemical stability of daptomycin with nine medications. |
|
1938 |
Ann Pharmacotherapy |
Stability of sufentanil citrate with levobupivacaine hydrochloride in NaCl 0.9% after microwave freeze-thaw treatment. |
|
1940 |
Am J Health-Syst Pharm |
Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. |
|
1941 |
Am J Health-Syst Pharm |
Potency and stability of frozen urokinase solutions in syringes. |
|
1942 |
Am J Health-Syst Pharm |
Stability of meropenem in polyvinyl chloride bags and an elastomeric infusion device. |
|
1943 |
Am J Health-Syst Pharm |
Compatibility and stability of ceftazidime sodium and tenoxicam in 5% dextrose injection. |
|
1944 |
Am J Health-Syst Pharm |
Visual compatibility of bivalirudin with selected drugs. |
|
1945 |
Ann Pharmacotherapy |
Stability of cefepime in icodextrin peritoneal dialysis solution. |
|
1946 |
Can J Hosp Pharm |
Effects of freezing, long-term storage, and microwave thawing on the stability of piperacillin plus tazobactam in 5% dextrose for infusion. |
|
1948 |
J Pain Symptom Manage |
Stability of admixtures containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system. |
|
1949 |
Clinical Cancer Research |
Phase I trial of 96 hour continuous infusion of dexrazoxane in patients with advanced malignancies. |
|
1950 |
J Oncol Pharm Practice |
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. |
|
1951 |
Chin Pharm J |
Stability of sodium cefazolin and tenoxicam in 5% dextrose. |
|
1953 |
Am J Health-Syst Pharm |
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. |
|
1955 |
Ann Pharmacotherapy |
Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. |
|
1956 |
Hospira UK Limited |
Paclitaxel - Summary of Product Characteristics |
|
1957 |
Int J Pharm Compound |
Chemical stability of metoclopramide hydrochloride injection diluted with 0.9% sodium chloride injection in polypropylene syringes at room temperature. |
|
1958 |
EJHP Science |
Effect of freezing, long-term storage and microwave thawing on the stability of cefuroxime sodium in 5% dextrose infusion polyvinyl chloride bags. |
|
1959 |
Hosp Pharm |
Precipitate formation after subconjonctival administration of ceftazidime and vancomycin. |
|
1960 |
J Pharm Biomed Anal |
Compatibility of nitroglycerin, diazepam and chlorpromazine with a new multilayer material for infusion containers. |
|
1961 |
Int J Pharm |
Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles. |
|
1962 |
Pharmakon |
Long term stability of sufentanyl citrate with levobupivacaine hydrochloride in 0.9% sodium chloride infusion P.V.C bags at 4°C. |
|
1963 |
Am J Health-Syst Pharm |
Compatibility of argatroban with selected cardiovascular agents. |
|
1964 |
Am J Health-Syst Pharm |
Visual compatibility of argatroban with selected drugs. |
|
1965 |
PDA J Pharm Sci Technol |
Photostability of sympatomimetic agents in commonly used infusion media in the absence and presence of bisulfite. |
|
1966 |
Support Care Cancer |
Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide. |
|
1968 |
Hosp Pharm Pract |
Stability of morphine and droperidol separately and combined, for use as an infusion. |
|
1970 |
Support Care Cancer |
Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. |
|
1971 |
Support Care Cancer |
Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care. |
|
1972 |
Drug Dev Ind Pharm |
Stability of 10 mg/mL cefuroxime solution for intracameral injection in commonly used polypropylene syringes and new ready-to-use cyclic olefin copolymer sterile vials using the LC–UV stability-indicating method. |
|
1974 |
J Pain Symptom Manage |
Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. |
|
1975 |
Int J Pharm Compound |
Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration. |
|
1976 |
Int J Pharm Compound |
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. |
|
1978 |
Clin Ther |
Comparative sorption of clomipramine, viloxazine and maprotiline hydrochlorides in polyvinylchloride bags and glass vials. |
|
1979 |
Am J Health-Syst Pharm |
Stability of cefazolin in heparinized and nonheparinized peritoneal dialysis solutions. |
|
1980 |
Act Pharm Nord |
Loss of nitroglycerin during passage through two different infusion sets. |
|
1981 |
Am J Health-Syst Pharm |
Stability of i.v. mycophenolate mofetil in 5% dextrose injection in polyvinyl chloride infusion bags. |
|
1982 |
Am J Health-Syst Pharm |
Compatibility of anidulafungin with other drugs during simulated Y-site administration. |
|
1984 |
Am J Health-Syst Pharm |
Leaching of diethylhexyl phtalate from multilayer tubing into etoposide infusion solutions. |
|
1985 |
Am J Health-Syst Pharm |
Stability of ibuprofen in injection solutions. |
|
1986 |
Am J Health-Syst Pharm |
Stability and sterility of dolasetron mesylate in syringes stored at room temperature. |
|
1987 |
Am J Health-Syst Pharm |
Stability of roxatidine acetate in parenteral nutrient solutions containing different amino acid formulations. |
|
1988 |
Am J Health-Syst Pharm |
Stability and compatibility of levofloxacin and metronidazole during simulated and actual Y-site administration. |
|
1989 |
Am J Health-Syst Pharm |
Stability of cidofovir in extemporaneously prepared syringes. |
|
1990 |
Krankenhauspharmazie |
Treosulfan : chemisch-physikalische stabilität, Hinweise für die pharmazeutisch-onkologische praxis. |
|
1992 |
J Pharm Clin |
Traitement par étoposide oral : présentation adaptée à une meilleure observance pédiatrique hospitalière. |
|
1993 |
Am J Health-Syst Pharm |
Compatibility of fentanyl citrate, ketamine hydrochloride, and droperidol in 0.9% sodium chloride injection stored in polyvinyl chloride bags. |
|
1995 |
Am J Health-Syst Pharm |
Extended stability of ascorbic acid in 5% dextrose injection and 0.9% sodium chloride injection. |
|
1998 |
Am J Health-Syst Pharm |
Fluorouracil precipitate. |
|
2000 |
J Pharm Biomed Anal |
Quality control and stability study using HPTLC: applications to cyclophosphamide in various pharmaceutical products. |
|
2001 |
J Pharm Biomed Anal |
Shelf lives of aseptically prepared medicines - stability of hydrocortisone sodium succinate in PVC and non-PVC bags and in polypropylene syringes. |
|
2002 |
Am J Health-Syst Pharm |
Compatibility of tramadol hydrochloride injection with selected drugs and solutions. |
|
2003 |
EJHP Science |
Stability of prostaglandin E1 (PGE1) in aqueous solutions. |
|
2004 |
Am J Health-Syst Pharm |
Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration. |
|
2005 |
Am J Health-Syst Pharm |
Influence of temperature and drug concentration on nafcillin precipitation. |
|
2006 |
Hosp Pharm |
Stability of Reconstituted Telavancin Drug Product in Frozen Intravenous Bags. |
|
2007 |
J Pharm Biomed Anal |
Migration of diethylhexyl phtalate from PVC into intravenous cyclosporine solutions. |
|
2008 |
Ann Pharmacotherapy |
Effect of the freezing conditions and microwave thawing power on the stability of cefuroxime in dextrose 5% infusion polyolefin bags at 4°C. |
|
2009 |
Int J Pharm Compound |
Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. |
|
2010 |
Ann Pharmacotherapy |
Stability of bortezomib 1 mg/ml solution in plastic syringe and glass vial. |
|
2011 |
Krankenhauspharmazie |
HPLC-stabilitätuntersuchungen zu rekonstituierten Bortezomib-Lösungen. |
|
2012 |
Am J Health-Syst Pharm |
Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers. |
|
2014 |
J Clin Pharm Ther |
Seventy-two-hour stability of Taxol® in 5% dextrose or 0.9% sodium chloride in Viaflo®, Freeflex®, Ecoflac® and Macoflex N® non PVC bags. |
|
2015 |
Ann Pharmacotherapy |
Effect of freezing, long term storage, and microwave thawing on the stability of ketorolac tromathamine. |
|
2016 |
Am J Health-Syst Pharm |
Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration. |
|
2017 |
Am J Health-Syst Pharm |
Visual compatibility of vasopressin with other injectable drugs. |
|
2018 |
Am J Health-Syst Pharm |
Visual compatibility of clonidine with selected drugs. |
|
2019 |
Am J Health-Syst Pharm |
Visual compatibility of gentamicin sulfate and 4% sodium citrate solutions. |
|
2020 |
Can J Hosp Pharm |
Effect of freezing on stability of a fortified 5 mg/ml ticarcillin ophtalmic solution. |
|
2022 |
J Pain Symptom Manage |
Compatibility and stability of dexamethasone sodium phosphate and ketamine hydrochloride subcutaneous infusions in polypropylene syringes. |
|
2024 |
J Pain Symptom Manage |
Stability of tramadol and haloperidol for continuous infusion at home. |
|
2026 |
J Pharm Biomed Anal |
Shelf lives of aseptically prepared medicines - stability of piperacillin/tazobactam in PVC and non-PVC bags. |
|
2027 |
Can J Hosp Pharm |
Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. |
|
2028 |
EJHP Science |
Sodium nitroprusside stability at 1 µg/ml in aqueous solutions. |
|
2030 |
Am J Health-Syst Pharm |
Stability of pantoprazole in 0.9% sodium chloride injection in polypropylene syringes. |
|
2031 |
Int J Pharm Compound |
Chemical stability of fentanyl in polypropylene syringes and polyvinylchloride bags. |
|
2034 |
EJHP Science |
Effect of freezing, long-term storage and microwave thawing on the stability of vancomycin hydrochloride in 5% dextrose infusions. |
|
2035 |
EJHP Science |
The stability of ready-to-use (RTU) ephedrine hydrochloride in polypropylene syringes for use in maternal hypotension. |
|
2036 |
Ann Pharmacotherapy |
Physical and chemical stability of pemetrexed solutions in plastic syringes. |
|
2037 |
J Antimicrob Chemother |
Stability of heparin and physical compatibility of heparin/antibiotic solutions ... |
|
2042 |
Antimicrob Agents Chemother |
Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). |
|
2043 |
Antimicrob Agents Chemother |
Amphotericin B in lipid emulsion : stability, compatibility, and in vitro antifungal activity. |
|
2046 |
Antimicrob Agents Chemother |
Stability and antibacterial activity of cefepime during continuous infusion. |
|
2050 |
Current Ther Res |
Stability of reconstituted urokinase solutions. |
|
2051 |
Br J Anaesth |
Premixed solutions of diamorphine in ropivacaine for epidural anaesthesia: a study on long-term stability. |
|
2053 |
Anesth Analg |
Physicochemical compatibility of propofol-lidocaine mixture. |
|
2054 |
Int J Pharm Compound |
Stability of Prednisone in Oral Mix Suspending Vehicle. |
|
2055 |
Int J Pharm |
Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients. |
|
2056 |
J Antimicrob Chemother |
Stability of benzylpenicillin during continuous home intravenous therapy. |
|
2057 |
J Antimicrob Chemother |
Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. |
|
2064 |
Int J Pharm Compound |
Stability of morphine sulfate in polypropylene infusion bags for use in patient-controlled analgesia pumps for postoperative pain management. |
|
2071 |
Anesth Analg |
Precipitation of protamine by cefazolin. |
|
2073 |
Can J Anesth |
Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. |
|
2074 |
Ann Intern Med |
Dissolving phenytoin precipitate in central venous access device. |
|
2076 |
Ann Emerg Med |
Stability and microbiology of inhalant N-acetylcysteine used as an intravenous solution for the treatment of acetaminophen poisoning. |
|
2077 |
Ann Emerg Med |
Stability of epinephrine in alkalinized solutions. |
|
2078 |
J Ped Surg |
Polyvinylchloride infusion lines expose infants to large amounts of toxic plasticizers. |
|
2079 |
Can J Anesth |
The effect of pancuronium on the solubility of aqueous thiopentone. |
|
2083 |
J Pharm Pract and Res |
Stability and compatibility of morphine, midazolam and bupivacaine combinaisons for iontravenous infusion. |
|
2086 |
J Pharm Pract and Res |
Stability and compatibility of alfentanil hydrochloride and morphine sulfate in poypropylene syringes. |
|
2087 |
Pharmactuel |
Compatibility of dimenhydrinate injectable by Y administration. |
|
2089 |
Pharmazie |
Photostability of epinephrine - the influence of bisulfite and degradation products. |
|
2090 |
Pharmactuel |
Compatibility of injectable pantoprazole in Y-site administration. |
|
2091 |
J Pharm Pract and Res |
Stability of insulin aspart in normal saline infusion. |
|
2093 |
Shionogi B.V. |
Cefiderocol (Fetcroja®)- Summary of Product Characteristics |
|
2094 |
EJHP Science |
Stability of intravenous admixtures of doxorubicin and vincristine confirmed by LC-MS. |
|
2095 |
EJHP Science |
Stability of cefuroxime infusion: the brand-name drug versus a generic product. |
|
2097 |
Int J Pharm Compound |
Extended stability of oxytocin in common infusion solutions. |
|
2100 |
Farm Hosp |
Estabilidad fisica y quimica del sulfato magnesico combinado con heparina sodica en solucion salina al 0,9 por 100. |
|
2103 |
Farm Hosp |
Estabilidad y compatibilidad del metamizol en jeringa y en mezclas intravenosas. |
|
2104 |
Farm Hosp |
Estudio de la estabilidad de mezclas ciclofosfamida/mesna e ifosfamida/mesna en soluciones intravenosas de gran volumen. |
|
2105 |
Farm Hosp |
Estabilidad de una mezcla de etomidato y pentotal para administracion intravenosa en bolo. |
|
2107 |
Int J Pharm Compound |
Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration. |
|
2108 |
Int J Pharm Compound |
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. |
|
2109 |
Pharmactuel |
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. |
|
2110 |
EJHP Science |
Effect of freezing, long term storage and microwave thawing on the stability of ceftriaxone sodium in 5% dextrose infusion polyolefin bags at 2-8°C. |
|
2111 |
EJHP Science |
Long-term stability of voriconazole 4 mg/ml in dextrose 5% polyvinyl chloride bags at 4°C. |
|
2113 |
Pharm World Sci |
Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. |
|
2114 |
Ann Pharmacotherapy |
Physical and chemical stability of pemetrexed in infusion solutions. |
|
2115 |
J Pain Symptom Manage |
Effect of tubing on loss of clonazepam administered by continuous subcutaneous infusion. |
|
2116 |
Am J Health-Syst Pharm |
Visual compatibility of furosemide with phenylephrine and vasopressine. |
|
2117 |
Ann Pharmacotherapy |
Physical instability of frozen pemetrexed solutions in PVC bags. |
|
2118 |
J Pain Symptom Manage |
Microbiological and physicochemical stability of fentanyl and sufentanil solutions for patient-controlled delivery-systems. |
|
2119 |
Eur J Anaesthesiol |
Adsorption of sufentanil to epidural filters and catheters. |
|
2120 |
J Pharm Biomed Anal |
Stability and degradation kinetics of meropenem in powder for injection and reconstituted sample. |
|
2122 |
EJHP Science |
Stability and compatibility of paracetamol injection admixed with ketoprofen. |
|
2123 |
EJHP Science |
Stability of morphine sulphate in ANAPA Plus ambulatory infusion device and PEGA infusion sets. |
|
2124 |
EJHP Science |
Freeze thaw treatment of ketorolac tromethamine in 5% dextrose infusion polyolein bags: effect of drug concentration and microwave power on the long-term stability at 4°C. |
|
2125 |
Hospital Pharmacist |
Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. |
|
2128 |
Pharmazie |
Untersuchungen zur Stabilität der Busulfan-Stammlösung (Busilvex®, Busulfex TM) in B/Braun Injekt® Einmalspritzen. |
|
2130 |
Bull Cancer |
Stabilité du mélange 5-fluoro-uracil-acide fonique : influence des concentrations, du contenant et de la forme de l’acide folinique. |
|
2131 |
Am J Health-Syst Pharm |
Stability of voriconazole injection in 0.9% sodium chloride and 5% dextrose injections. |
|
2132 |
Int J Pharm Compound |
Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes. |
|
2134 |
J Pharm Sci |
Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions. |
|
2138 |
Eur J Anaesthesiol |
Stability of a sufentanil-ropivacaine mixture in a glass and a PVC reservoir. |
|
2139 |
EJHP Science |
Assessment of injectable drug’s administration in two intensive care units and determination of potential physico-chemical incompatibilities. |
|
2140 |
EJHP Science |
Stability and compatibility of the ready-to-use solution of paracetamol admixted with phloroglucinol for intravenous infusion. |
|
2141 |
J Antimicrob Chemother |
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. |
|
2143 |
J Pharm Biomed Anal |
The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry. |
|
2145 |
J Clin Pharm Ther |
Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1.36%® and Dianeal PD1 3.86%®). |
|
2146 |
Am J Health-Syst Pharm |
Drug compatibility with new polyolefin infusion solution containers. |
|
2147 |
Ann Pharmacotherapy |
Stability of vancomycin in icodextrin peritoneal dialysis solution. |
|
2148 |
Anal Biochem |
Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. |
|
2150 |
J Urology |
Vasoactive cocktails for erectile dysfunction: chemical stability of PGE1, papaverine and phentolamine. |
|
2151 |
Int J Pharm |
Stability study of prostaglandin E1 (PGE1) in physiological solutions by liquid chromatography (HPLC). |
|
2155 |
Perit Dial Int |
Stability of ofloxacin in peritoneal dialysis solutions. |
|
2156 |
Perit Dial Int |
Stability of deferoxamine peritoneal dialysate solutions. |
|
2162 |
Perit Dial Int |
Stability of cotrimoxazole in peritoneal dialysis fluid. |
|
2163 |
Perit Dial Int |
Linezolid stability in peritoneal dialysis solutions. |
|
2164 |
Perit Dial Int |
Compatibility of insulin over 24 hours in standard and bicarbonate-based peritoneal dialysis solutions contained in bags made of different materials. |
|
2165 |
J Liquid Chrom Rel Technol |
Development and validation of an HPLC method for oxytocin in Ringer’s lactate and its application in stability analysis. |
|
2166 |
J Liquid Chrom Rel Technol |
HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate and scopolamine. |
|
2167 |
Cancer Chemother Pharmacol |
Stability of the iv and oral formulations of etoposide in solution. |
|
2168 |
Cancer Chemother Pharmacol |
Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. |
|
2172 |
J Oncol Pharm Practice |
Physical and chemical stability of paclitaxel infusions in different container types. |
|
2173 |
EJHP Science |
Chemical stability and microbiological potency of intravenous vancomycin hydrochloride syringes for use in the neonatal intensive care. |
|
2174 |
EJHP Science |
Long-term physical and chemical stability of a generic paclitaxel infusion under simulated storage and clinical-use conditions. |
|
2175 |
J Pharm Clin |
Peut-on conditionner les solutions de docétaxel dans des poches en PVC ? |
|
2176 |
Support Care Cancer |
Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability. |
|
2178 |
J Pharm Biomed Anal |
Stability of ertapenem in aqueous solutions. |
|
2179 |
Int J Pharm Compound |
Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration. |
|
2181 |
Bull Cancer |
Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique. |
|
2183 |
EJHP Science |
Stability of pemetrexed 25 mg/ml in a glass vial and 5 mg/ml stored in a PVC container after storage for one month at 2-8°C. |
|
2184 |
J Pain Symptom Manage |
Stability and compatibility of a meperidine-clonidine mixture in portable pump reservoirs for the management of cancer pain syndromes. |
|
2185 |
J Pharm Biomed Anal |
Study on the compatibility of cefotaxime with tinidazole in glucose injection. |
|
2188 |
EJHP Science |
Chemical and physical stability of diluted busulfan infusion solutions. |
|
2191 |
J Oncol Pharm Practice |
Stability of a heparin-free 50% ethanol lock solution for central venous catheters. |
|
2192 |
Am J Health-Syst Pharm |
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs. |
|
2194 |
Am J Health-Syst Pharm |
Stability of phenylephrine hydrochloride injection in polypropylene syringes. |
|
2196 |
Am J Health-Syst Pharm |
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration. |
|
2197 |
Medac |
Treosulfan injection : details about handling and stability. |
|
2199 |
Mundipharma |
Chlorhydrate d'oxycodone (Oxynorm®)– Résumé des caractéristiques du produits |
|
2201 |
EJHP Science |
Chemical and physical stability of dexrazoxane, diluted with Ringer's lactate solution, in polyvinyl and polyethylene containers. |
|
2202 |
Investig Clin Farm |
Estabilidad de parecoxib en dilucion con ostros farmacos y administrado en perfusion continua IV para el control del dolor postoperatorio. |
|
2203 |
J Oncol Pharm Practice |
A sequential temperature cycling study for the investigation of carboplatin infusion stability to facilitate 'dose-banding'. |
|
2204 |
J Oncol Pharm Practice |
Long-term stability of sodium folinate in dextrose 5% polyolefin bags at 4°C. |
|
2205 |
Arzneimittel Forschung |
Compatibility and stability of furosemide and dexamethasone combined in infusion solutions. |
|
2206 |
Am J Health-Syst Pharm |
Stability of chlorothiazide sodium in polypropylene syringes |
|
2207 |
Am J Health-Syst Pharm |
Stability of oxaliplatin in infusion bags containing 5% dextrose injection.
|
|
2209 |
Am J Health-Syst Pharm |
Stability of vecuronium in sterile water for injection stored in polypropylene syringes for 21 days. |
|
2210 |
Can J Hosp Pharm |
Stability of Docetaxel Solution after Dilution in Ethanol and Storage in Vials and after Dilution in Normal Saline and Storage in Bags. |
|
2211 |
J Clin Pharm Ther |
Compatibility and stability of tramadol and dexamethasone in solution and its use in terminally ill patients. |
|
2212 |
Actavis UK Ltd |
Reteplase (Rapilysin®) - Summary of Product Characteristics |
|
2214 |
Int J Pharm Compound |
Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration. |
|
2215 |
Chem Pharm Bull |
Hydrolysis of succinylcholine chloride in pH range 3.0 to 4.5. |
|
2216 |
J Pharm Biomed Anal |
Stability of adenosin infusion. |
|
2217 |
Ziekenhuisfarmacie |
De stabiliteit van clonazepaminjectievloeistof. |
|
2220 |
Merck Serono |
Cétuximab (Erbitux®) - Dossier scientifique |
|
2221 |
Am J Health-Syst Pharm |
Stability of 70% alcohol solutions in polypropylene syringes for use in ethanol-lock therapy. |
|
2224 |
Bolletino SIFO |
Dexrazoxane: Stabilià in soluzione. |
|
2225 |
Bolletino SIFO |
Studio di stabilità chimico-fisica di una formulazione per la terapia antalgica a base di levobupivacaina e fentanyl.
|
|
2226 |
Pfizer Ltd |
Temsirolimus (Torisel®) - Summary of Product Characteristics |
|
2227 |
Int J Pharm Compound |
Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration. |
|
2228 |
Int J Pharm Compound |
Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration. |
|
2231 |
J Antimicrob Chemother |
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. |
|
2232 |
Can J Hosp Pharm |
Stability of Bortezomib Reconstituted with 0.9% Sodium Chloride at 4°C and Room Temperature (23°C) |
|
2233 |
Am J Health-Syst Pharm |
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery |
|
2238 |
Baxter |
Clinomel - Résumé des caractéristiques du produit |
|
2239 |
Chinese J New Drugs |
Determination of the stability of oxaliplatin for injection by dual wavelength spectrophotometry. |
|
2240 |
Janssen Pharmaceuticals |
Décitabine (Dacogen®) - Summary of Product caracteristics |
|
2241 |
J Oncol Pharm Practice |
Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags. |
|
2242 |
Int J Pharm |
A note on the solution chemistry of carboplatin in aqueous solutions. |
|
2243 |
Int J Pharm |
Degradation pathway of carboplatin in aqueous solution. |
|
2244 |
J Pharm Biomed Anal |
Stability of carboplatin in 5% glucose solution in glass, polyethylene and polypropylene containers. |
|
2245 |
Int J Pharm |
Stability of carboplatin in 5% glucose solution exposed to light. |
|
2247 |
Int J Pharm Compound |
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. |
|
2248 |
Neuromodulation |
Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. |
|
2249 |
Neuromodulation |
Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. |
|
2250 |
Int J Pharm Compound |
Stability of Metronidazole Benzoate in SyrSpend SF One-Step Suspension System. |
|
2251 |
Neuromodulation |
Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. |
|
2252 |
Neuromodulation |
Chemical stability of admixture combining ziconotide and bupivacaine during simulated intrathecal administration. |
|
2253 |
J Synchrotron Rad |
Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS. |
|
2254 |
New J Chem |
Carboplatin decomposition in aqueous solution with chloride ions monitored by X-ray absorption spectroscopy. |
|
2255 |
Ebewe Pharma |
Stability of Alexan "Ebewe" infusion solutions. |
|
2256 |
Ebewe Pharma |
Stability of doxorubicin "Ebewe" infusion solutions. |
|
2257 |
Ebewe Pharma |
Stability of epirubicin "Ebewe" infusion solutions. |
|
2258 |
Ebewe Pharma |
Stability of oxaliplatin "Ebewe" lyophilisate after reconstitution. |
|
2259 |
Ebewe Pharma |
Stability of oxaliplatin "Ebewe" lyophilisate infusion solutions. |
|
2260 |
Ebewe Pharma |
Stability of vinorelbin "Ebewe" infusion solutions. |
|
2261 |
Can J Hosp Pharm |
Stabilité et compatibilité de l'association ondansétron-méthylprednisolone en solution. |
|
2262 |
Am J Health-Syst Pharm |
Compatibility of doripenem with other drugs during simulated Y-site administratioN |
|
2263 |
Il Farmaco |
Stability of aztreonam in AZACTAM. |
|
2265 |
J Pharm Sci |
Nefopam hydrochloride degradation kinetics in solution. |
|
2267 |
Am J Health-Syst Pharm |
Stability of metoprolol tartrate injection 1 mg/ml undiluted and 0.5 mg/ml in 0.9% sodium chloride injection and 5% dextrose injection. |
|
2268 |
Ann Pharmacotherapy |
AntiXa stability of diluted dalteparin for pediatric use. |
|
2269 |
Am J Health-Syst Pharm |
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. |
|
2270 |
Ann Pharmacotherapy |
Physical and chemical stability of esomeprazole sodium solutions. |
|
2271 |
Novartis |
Daptomycine (Cubicin®) Résumé des caractéristiques du produits |
|
2272 |
Genzyme |
Clofarabine (Evoltra®) – Résumé des caractéristiques du produits |
|
2275 |
Int J Pharm |
Hydrolysis kinetics and stability predictions for a mixture of R and S temocillin isomers. |
|
2276 |
Pharma Mar SA |
Trabectedine (Yondelis®) - Summary of Product Characteristics |
|
2277 |
GlaxoSmithKline |
Argatroban - Summary of Product Characteristics |
|
2279 |
Am J Health-Syst Pharm |
Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. |
|
2280 |
Int J Pharm Compound |
Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration. |
|
2281 |
Int J Pharm Compound |
Compatibility and stability of palonosetron hydrochloride with lactated Ringer's, Hetastarch in lactated electrolyte, an mannitol injections during simulated Y-site administration. |
|
2284 |
Astra Zenaca |
Esomeprazole sodium (Nexium IV®) – Summary of Product Characteristics |
|
2285 |
Antimicrob Agents Chemother |
Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. |
|
2286 |
Int J Pharm Compound |
Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration. |
|
2287 |
EJHP Science |
Development of ready-to-use ketamine hydrochloride syringes for safe use in post-operative pain. |
|
2288 |
Cephalon |
Bendamustine hydrochloride (Treanda®) – Summary of Product Characteristics |
|
2289 |
Pharmazie |
Stabilität von bendamustinhydrochloride in infusion lösungen. |
|
2291 |
Drug Dev Ind Pharm |
Degradation kinetics of neostigmine in solution. |
|
2292 |
EJHP |
Diluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w/v) in polypropylene bottles and bags: effects on chemical stability |
|
2294 |
Can J Hosp Pharm |
Stability of magnesium sulfate 20% in Viaflex bags. |
|
2295 |
Merck Sharp Dohme |
Fosaprepitant (Emend®) - Summary of Product Characteristics |
|
2296 |
Eumedica |
Témocilline (Negaban®) - Résumé des caractéristiques du produit |
|
2297 |
Int J Pharm Compound |
Physical compatibility and chemical stability of a concentrated solution of atropine sulfate (2 mg/ml) for use as an antidote in nerve agent casualties. |
|
2298 |
Int J Pharm Compound |
Chemical stability of admixtures containing ziconotide 25 mcg/ml and morphine sulfate 10 mg/ml or 20 mg/ml during simulated intrathecal administration. |
|
2302 |
Lettre AFFSAPS 30 November 2008 |
Ceftriaxone et incompatibilités physico-chimiques, particulièrement avec les solutions contenant des sels de calcium. |
|
2304 |
Int J Pharm |
The development and stability assessment of extemporaneous pediatric formulations of Accupril. |
|
2305 |
Anaesthesia |
Stability and compatibility of drug mixtures in an implantable infusion system. |
|
2306 |
Anaesthesia |
Stability of an epidural analgesic admixture containing epinephrine, fentanyl and bupivacaine. |
|
2307 |
Palliative Med |
Epidural diamorphine and bupivacaine stability study. |
|
2308 |
Int J Obstet Anesth |
Stability of premixed syringes of diamorphine and hyperbaric bupivacaine. |
|
2310 |
EJHP Science |
Stability of diluted nadroparin for the treatment of paediatric thrombosis. |
|
2311 |
J Clin Pharm Ther |
Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion. |
|
2312 |
Int J Pharm Compound |
Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration. |
|
2316 |
Clin Ther |
Stability of doripenem in vitro in representative infusion solutions and infusion bags. |
|
2317 |
EJHP Science |
Development and stability testing of a concentrated injectable clonidine solution for intrathecal analgesia. |
|
2319 |
EJHP Science |
Chemical stability of a solution of bupivacaine hydrochloride 0.125% and sufentanil citrate 0.5 µg/ml for filling syringes using a repeater pump. |
|
2320 |
EJHP Science |
Effect of freezing, long-term storage and microwave thawing on the stability of sodium folinate. |
|
2321 |
Ann Pharmacotherapy |
Stability of Oxaliplatin Solution. |
|
2322 |
Can J Hosp Pharm |
Physical Compatibility and Chemical Stability of Ketamine–Morphine Mixtures in Polypropylene Syringes. |
|
2323 |
Can J Hosp Pharm |
Long-Term Stability of 5-Fluorouracil in 0.9% Sodium Chloride after Freezing, Microwave Thawing, and Refrigeration |
|
2324 |
Int J Pharm |
Investigation into the sorption of nitroglycerin and diazepam into PVC tubes and alternative tube materials during application |
|
2325 |
Pharmazie |
The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions. |
|
2328 |
Organon |
Sugammadex (Bridion®) – Résumé des caractéristiques du produits |
|
2329 |
Can J Hosp Pharm |
Stability of Ketamine-Propofol mixtures for procedural sedation and analgesia in the emergency department. |
|
2331 |
Hospital Pharmacy Europe |
Stability of 5-fluorouracil and sodium folinate admixture. |
|
2332 |
Janssen-Cilag |
Doripenem (Doribax®) - Laboratoire informations |
|
2334 |
Am J Health-Syst Pharm |
Stability of fentanyl 5 µg/mL diluted with 0.9% sodium chloride injection and stored in polypropylene syringes |
|
2335 |
Am J Health-Syst Pharm |
Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients |
|
2336 |
Can J Hosp Pharm |
Stability of Hydromorphone–Ketamine Solutions in Glass Bottles, Plastic Syringes, and IV Bags for Pediatric Use |
|
2337 |
Can J Hosp Pharm |
Extended Stability of Pantoprazole for Injection in 0.9% Sodium Chloride or 5% Dextrose at 4°C and 23°C |
|
2339 |
Can J Hosp Pharm |
Stability of Trimethoprim in Admixtures of Trimethoprim–Sulfamethoxazole Prepared in Polyvinylchloride Bags and Glass Bottles |
|
2340 |
Can J Hosp Pharm |
Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers |
|
2341 |
Poster ESCP Stockholm May 2005 |
Release of di(2-ethylhexyl)phtalate from polyvinylchloride bags during docetaxel infusions |
|
2343 |
Fresenius Biotech |
Catumaxomab (Removab®) |
|
2345 |
Can J Hosp Pharm |
Stability of aseptically prepared Tazocin solutions in polyvinyl chloride bags. |
|
2346 |
Am J Health-Syst Pharm |
Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents |
|
2348 |
Alexion Europe SAS |
Eculizumab (Soliris®) – Summary of Product Characteristics |
|
2349 |
Am J Health-Syst Pharm |
Incompatibility of imipenem–cilastatin and amoxicillin |
|
2350 |
Int J Pharm Compound |
Stability of morphine-ketamine in 0.9% sodium chloride injection packaged in syringes, plastic bags and MEDICATION CASSETTE Reservoirs. |
|
2352 |
Int J Pharm Compound |
Stability of nafcillin sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. |
|
2353 |
Int J Pharm Compound |
Compatibility and stability of linezolid injection admixted with gentamicin sulfate and tobramycin sulfate. |
|
2354 |
Int J Pharm Compound |
Stability of hydrocortisone sodium succinate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. |
|
2355 |
Int J Pharm Compound |
Stability of ranitidine hydrochloride with cefazolin sodium, cefbuperazone sodium, cefoxitin sodium nd cephalotin sodium during simulated Y-site administration. |
|
2356 |
Int J Pharm Compound |
Stability of magnesium sulfate in 0.9% sodium chloride and lactated Ringers solutions. |
|
2358 |
Int J Pharm Compound |
Stability of levothyroxine sodium injection in polypropylene syringes. |
|
2360 |
Int J Pharm Compound |
Room temperature stability of injectable succinylcholine dichloride. |
|
2361 |
J Clin Pharm Ther |
Effect of freeze-thawing on the long-term stability of calcium levofolinate in 5% dextrose stored on polyolefin infusion bags. |
|
2362 |
ADKA Congress 2009 |
Morphin-Haloperidol mischungen in PCA Pumpen : Kompatibel? |
|
2363 |
ADKA Congress |
Morphin-Metamizol mischungen zur kontinuierlichen parenteralen applikation : Sind sie immer inkompatibel? |
|
2364 |
PharmSciFair |
Hydromorphone and dipyrone in PCA devices: Is still a therapy with hydromorphone? |
|
2366 |
ADKA Congress |
Oxycodon-Metamizol in PCA pumpen : Kompatibel? |
|
2367 |
Int J Pharm Compound |
Chemical stability of hydralazine hydrochloride after reconstitution in 0.9% sodium chloride injection or 5% dextrose injection for infusion. |
|
2368 |
Am J Hosp Pharm |
Stability of ciprofloxacin in peritoneal dialysis solution |
|
2369 |
Am J Hosp Pharm |
Stability of ceftazidime and tobramycin sulfate in peritoneal dialysis solution |
|
2370 |
Am J Hosp Pharm |
Stability of vancomycin hydrochloride in peritoneal dialysis solution |
|
2371 |
Am J Hosp Pharm |
Stability of dobutamine hydrochloride in peritoneal dialysis solutions |
|
2372 |
Am J Hosp Pharm |
Stability of cefazolin sodium in peritoneal dialysis solutions |
|
2374 |
Am J Hosp Pharm |
Stability of cefotaxime in two peritoneal dialysis solutions |
|
2375 |
Am J Hosp Pharm |
Visual compatibility of vancomycin and heparin in peritoneal dialysis solutions |
|
2376 |
J Sep Sci |
Chemical stability of midazolam injection by high performance liquid chromatography. |
|
2381 |
Ann Pharmacotherapy |
Stability of Extemporaneously Prepared Rufinamide Oral Suspensions .
|
|
2382 |
Am J Health-Syst Pharm |
Stability of fumagillin in an extemporaneously prepared ophthalmic solution |
|
2383 |
Am J Health-Syst Pharm |
Stability of zonisamide in extemporaneously compounded oral suspensions |
|
2384 |
Am J Health-Syst Pharm |
Stability of valganciclovir in an extemporaneously compounded oral liquid |
|
2385 |
Am J Health-Syst Pharm |
Stability of pantoprazole in an extemporaneously compounded oral liquid |
|
2386 |
Am J Health-Syst Pharm |
Stability of valganciclovir in extemporaneously compounded liquid formulations |
|
2387 |
Am J Health-Syst Pharm |
Stability of oral liquid preparations of tramadol in strawberry syrup and a sugar-free vehicle |
|
2388 |
Am J Health-Syst Pharm |
Stability of tiagabine in two oral liquid vehicles |
|
2389 |
Am J Health-Syst Pharm |
Characterization of an extemporaneous liquid formulation of lisinopril |
|
2392 |
Am J Health-Syst Pharm |
Stability of famotidine in an extemporaneously compounded oral liquid |
|
2394 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared moxifloxacin oral suspensions |
|
2395 |
Am J Health-Syst Pharm |
Stability of a flavored formulation of acetylcysteine for oral administration |
|
2396 |
Am J Health-Syst Pharm |
Effect of buffer and antioxidant on stability of a mercaptopurine suspension |
|
2397 |
Am J Health-Syst Pharm |
Stability of codeine phosphate in an extemporaneously compounded syrup |
|
2399 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions |
|
2400 |
Am J Health-Syst Pharm |
Stability of acetylcysteine solution repackaged in oral syringes and associated cost savings |
|
2401 |
Am J Health-Syst Pharm |
Stability of an extemporaneously prepared alcohol-free phenobarbital suspension |
|
2402 |
Am J Health-Syst Pharm |
Stability and viscosity of a flavored omeprazole oral suspension for pediatric use |
|
2403 |
Am J Health-Syst Pharm |
Stability of nimodipine solution in oral syringes |
|
2404 |
Palliative Med |
The compatibility and stability of octreotide acetate in the presence of diamorphine hydrochloride in polypropylene syringes |
|
2405 |
Am J Health-Syst Pharm |
Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations |
|
2406 |
Am J Health-Syst Pharm |
Stability of oral liquid preparations of tramadol in strawberry syrup and a sugar-free vehicle |
|
2407 |
Am J Health-Syst Pharm |
Stability of tramadol hydrochloride--acetaminophen (Ultracet) in strawberry syrup and in a sugar-free vehicle |
|
2408 |
Am J Health-Syst Pharm |
Stability of nifedipine in an extemporaneously compounded oral solution |
|
2409 |
Am J Health-Syst Pharm |
Stability of levofloxacin in an extemporaneously compounded oral liquid |
|
2410 |
Am J Health-Syst Pharm |
Stability of oral suspensions of ursodiol made from tablets |
|
2412 |
Am J Health-Syst Pharm |
Stability of norfloxacin in an extemporaneously prepared oral liquid |
|
2413 |
Am J Health-Syst Pharm |
Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids |
|
2414 |
Am J Health-Syst Pharm |
Stability of mycophenolate mofetil in an extemporaneously compounded sugar-free oral liquid |
|
2415 |
Am J Health-Syst Pharm |
Stability of propylthiouracil in extemporaneously prepared oral suspensions at 4 and 25 degrees C |
|
2416 |
Am J Health-Syst Pharm |
Stability of lamotrigine in two extemporaneously prepared oral suspensions at 4 and 25 degrees C |
|
2417 |
Am J Health-Syst Pharm |
Stability of terbinafine hydrochloride in an extemporaneously prepared oral suspension at 25 and 4 degrees C |
|
2419 |
Am J Health-Syst Pharm |
Stability of rifabutin in two extemporaneously compounded oral liquids |
|
2420 |
Am J Health-Syst Pharm |
Stability of vancomycin in an extemporaneously compounded ophthalmic solution |
|
2421 |
Am J Health-Syst Pharm |
Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids |
|
2422 |
Am J Health-Syst Pharm |
Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids |
|
2423 |
Am J Health-Syst Pharm |
Stability of granisetron hydrochloride in two oral suspensions |
|
2425 |
Am J Health-Syst Pharm |
Stability of enalapril maleate in three extemporaneously prepared oral liquids |
|
2426 |
Am J Health-Syst Pharm |
Stability of acetylcysteine in an extemporaneously compounded ophthalmic solution |
|
2427 |
Am J Health-Syst Pharm |
Stability of granisetron hydrochloride in an extemporaneously prepared oral liquid |
|
2428 |
Am J Health-Syst Pharm |
Stability of sumatriptan succinate in extemporaneously prepared oral liquids |
|
2429 |
Am J Health-Syst Pharm |
Stability of granisetron hydrochloride in an extemporaneously prepared oral liquid |
|
2430 |
Am J Health-Syst Pharm |
Stability of omeprazole in an extemporaneously prepared oral liquid |
|
2431 |
Am J Health-Syst Pharm |
Stability of phenoxybenzamine hydrochloride in various vehicles |
|
2432 |
Am J Health-Syst Pharm |
Effects of ingredients on stability of captopril in extemporaneously prepared oral liquids |
|
2433 |
Am J Health-Syst Pharm |
Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids |
|
2434 |
Am J Health-Syst Pharm |
Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids |
|
2435 |
Am J Health-Syst Pharm |
Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids |
|
2436 |
Am J Health-Syst Pharm |
Stability of tacrolimus in an extemporaneously compounded oral liquid |
|
2437 |
Am J Health-Syst Pharm |
Stability of epinephrine hydrochloride in an extemporaneously compounded topical anesthetic solution of lidocaine, racepinephrine, and tetracaine |
|
2440 |
Am J Health-Syst Pharm |
Stability of flucytosine in an extemporaneously compounded oral liquid |
|
2441 |
Am J Health-Syst Pharm |
Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids |
|
2442 |
Am J Health-Syst Pharm |
Stability of itraconazole in an extemporaneously compounded oral liquid |
|
2443 |
Am J Health-Syst Pharm |
Stability of ramipril in water, apple juice, and applesauce |
|
2444 |
Am J Health-Syst Pharm |
Stability of cyclosporine in an extemporaneously compounded paste |
|
2445 |
Am J Health-Syst Pharm |
Stability of ondansetron hydrochloride injection in various beverages |
|
2446 |
Am J Health-Syst Pharm |
Content uniformity and stability of nifedipine in extemporaneously compounded oral powders |
|
2447 |
Am J Health-Syst Pharm |
Stability of pyrimethamine in a liquid dosage formulation stored for three months |
|
2448 |
Am J Health-Syst Pharm |
Stability of mycophenolate mofetil in an extemporaneously compounded oral liquid |
|
2449 |
Am J Health-Syst Pharm |
Stability of ursodiol in an extemporaneously compounded oral liquid |
|
2450 |
Am J Health-Syst Pharm |
Stability of ceftazidime sodium and teicoplanin sodium in a peritoneal dialysis solution |
|
2451 |
Am J Health-Syst Pharm |
Stability of piperacillin sodium-tazobactam sodium in peritoneal dialysis solutions |
|
2453 |
Am J Health-Syst Pharm |
Stability of pentoxifylline in an extemporaneously prepared oral suspension |
|
2454 |
Am J Health-Syst Pharm |
Stability of pyrazinamide in two suspensions |
|
2455 |
Am J Health-Syst Pharm |
Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations |
|
2463 |
Am J Hosp Pharm |
Instability of aqueous captopril solutions |
|
2466 |
Am J Hosp Pharm |
Compatibility of lithium citrate syrup with 10 neuroleptic solutions |
|
2468 |
J Pharm Sci |
In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin Pumps. |
|
2469 |
Am J Hosp Pharm |
Stability of aqueous suspensions of disulfiram |
|
2471 |
Am J Hosp Pharm |
Stability of disopyramide phosphate in cherry syrup |
|
2475 |
Hosp Pharm |
Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam |
|
2476 |
Am J Hosp Pharm |
Formulation and stability of diazepam suspension compounded from tablets |
|
2477 |
Am J Hosp Pharm |
Stability of propranolol hydrochloride suspension compounded from tablets |
|
2478 |
Am J Hosp Pharm |
Stability of an extemporaneously compounded baclofen oral liquid |
|
2481 |
Am J Hosp Pharm |
Stability of ondansetron hydrochloride injection in extemporaneously prepared oral solutions |
|
2482 |
Am J Hosp Pharm |
Stability of etoposide solution for oral use |
|
2486 |
Am J Hosp Pharm |
Stability of cefadroxil in reconstituted suspension under refrigeration and at room temperature |
|
2487 |
Am J Hosp Pharm |
Stability of gentamicin sulfate and tobramycin sulfate in extemporaneously prepared ophthalmic solutions at 8 degrees C |
|
2488 |
Am J Hosp Pharm |
Stability of captopril in powder papers under three storage conditions |
|
2489 |
Am J Hosp Pharm |
Stability of extemporaneously compounded spironolactone suspensions |
|
2490 |
Am J Hosp Pharm |
Concentration uniformity of extemporaneously prepared ranitidine suspension |
|
2491 |
Am J Hosp Pharm |
Stability of cefuroxime axetil in beverages |
|
2494 |
Am J Hosp Pharm |
Stability of 1% rifampin suspensions prepared in five syrups |
|
2495 |
Am J Hosp Pharm |
Long-term stability study of histamine in sterile bronchoprovocation solutions |
|
2496 |
Am J Hosp Pharm |
Stability of 5-aminosalicylic acid suspension |
|
2499 |
Am J Hosp Pharm |
Stability of midazolam hydrochloride in a flavored, dye-free oral solution |
|
2500 |
Am J Hosp Pharm |
Stability of nizatidine in extemporaneous oral liquid preparations |
|
2501 |
Am J Hosp Pharm |
Stability of procainamide hydrochloride in an extemporaneously compounded oral liquid |
|
2502 |
Am J Hosp Pharm |
Stability of an extemporaneously compounded clonidine hydrochloride oral liquid |
|
2503 |
Am J Hosp Pharm |
Stability of an extemporaneously compounded terbutaline sulfate oral liquid |
|
2504 |
Am J Hosp Pharm |
Stability of propranolol hydrochloride suspension and solution |
|
2505 |
Am J Hosp Pharm |
Stability of cefazolin sodium in various artificial tear solutions and aqueous vehicles |
|
2508 |
Am J Hosp Pharm |
Stability of amoxicillin trihydrate-potassium clavulanate in original containers and unit dose oral syringes |
|
2511 |
Am J Hosp Pharm |
Stability of oxybutynin chloride syrup after repackaging in unit doses |
|
2513 |
Am J Hosp Pharm |
Stability of propranolol hydrochloride suspension and solution compounded from injection or tablets |
|
2516 |
Am J Hosp Pharm |
Stability of famotidine in an extemporaneously prepared oral liquid. |
|
2517 |
Am J Hosp Pharm |
Stability of ondansetron hydrochloride in syrups compounded from tablets |
|
2522 |
Am J Hosp Pharm |
Stability of captopril in liquid containing ascorbic acid or sodium ascorbate |
|
2523 |
Am J Hosp Pharm |
Stability of isradipine in an extemporaneously compounded oral liquid |
|
2524 |
Am J Hosp Pharm |
Stability of mesalamine in rectal suspension diluted with distilled water |
|
2527 |
Am J Hosp Pharm |
Stability of fluconazole in an extemporaneously prepared oral liquid |
|
2530 |
Int J Pharm Compound |
Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes. |
|
2531 |
J Oncol Pharm Practice |
Stability of calcium levofolinate reconstituted in syringes and diluted in NaCl 0.9% and glucose 5% polyolefin/ polyamide infusion bags. |
|
2534 |
Ann Pharmacotherapy |
Stability of spironolactone in an extemporaneously prepared suspension at two temperatures
|
|
2538 |
Ann Pharmacotherapy |
Stability of hydrocortisone oral suspensions prepared from tablets and powder.
|
|
2541 |
Ann Pharmacotherapy |
Stability of amiodarone in an oral suspension stored under refrigeration and at room temperature.
|
|
2542 |
Ann Pharmacotherapy |
Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone.
|
|
2543 |
Ann Pharmacotherapy |
Stability of mycophenolate mofetil as an extemporaneous suspension.
|
|
2545 |
Ann Pharmacotherapy |
Stability of dapsone in two oral liquid dosage forms.
|
|
2546 |
Ann Pharmacotherapy |
Stability of suspension formulations of lansoprazole and omeprazole stored in amber-colored plastic oral syringes.
|
|
2547 |
Ann Pharmacotherapy |
Stability of extemporaneously prepared gentamicin ophthalmic solutions.
|
|
2548 |
Ann Pharmacotherapy |
Stability of Sotalol in Two Liquid Formulations at Two Temperatures
|
|
2549 |
Ann Pharmacotherapy |
Stability of Lisinopril in Two Liquid Dosage Forms
|
|
2550 |
Aust J Hosp Pharm |
Compatibility of nebulizer solutions |
|
2556 |
Aust J Hosp Pharm |
Stability of extemporaneously prepared mixtures of metoprolol and spironolactone. |
|
2557 |
Aust J Hosp Pharm |
Prednisolone stability in a hydroalcoholic prednisolone mixture. |
|
2558 |
Aust J Hosp Pharm |
The stability of acetylcysteine eyedrops. |
|
2559 |
Aust J Hosp Pharm |
The formulation of spironolactone solution for paediatric use. |
|
2560 |
Aust J Hosp Pharm |
A short-term stability study of an oral solution of dexamethasone. |
|
2561 |
Aust J Hosp Pharm |
The stability of an enalapril maleate oral solution prepared from tablets. |
|
2567 |
Pakistan J Biol Sci |
Preparation and stability study of diclofenac sodium suppositories. |
|
2570 |
Am J Hosp Pharm |
Degradation of captopril in solutions compounded from tablets and standard powder. |
|
2575 |
Anest Prog |
Stability of parenteral midazolam in an oral formulation. |
|
2586 |
Br Assoc Dermatol |
Chemical stability of adepalene and tretinoin when combined with benzoyl peroxyde in presence and in absence of visible light and ultraviolet radiation. |
|
2591 |
Can J Hosp Pharm |
Stability of a sotalol hydrochloride oral liquid formulation. |
|
2592 |
Can J Hosp Pharm |
Stability of clozapine stored in oral suspension vehicles at room temperature. |
|
2593 |
Can J Hosp Pharm |
Stability of sulfasalazine oral suspension. |
|
2594 |
Can J Hosp Pharm |
Stability of lansoprazole in extemporaneously compounded suspensions for nasogastric or oral administration. |
|
2621 |
Eur J Pharm Biopharm |
Stability of fludrocortisone acetate solutions prepared from tablets and powder. |
|
2630 |
Hosp Pharm |
Incompatibilities with orally administered liquid neuroleptic medication combinations. |
|
2634 |
Hosp Pharm |
Stability of metolazone in a liquid dosage form. |
|
2635 |
Hosp Pharm |
Stability of levalbuterol in a mixture of levalbuterol and ipratropium nebulizer solution. |
|
2642 |
Int J Pharm |
Factors affecting captopril stability in aqueous solution |
|
2647 |
Int J Pharm |
Stability of loperamide hydrochloride in aqueous solutions as determined by high performance liquid chromatography |
|
2648 |
Int J Pharm |
Stability and compatibility of an aerosol mixture including N-acetylcysteine, netilmicin and betamethasone |
|
2649 |
Int J Pharm |
Impact of deep freezing on the stability of 25 mg/ml vancomycin ophtalmic solutions. |
|
2654 |
Int J Pharm |
Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability. |
|
2655 |
Int J Pharm |
Invitro release and stability of an artesunate rectal gel suitable for pediatric use. |
|
2657 |
Int J Pharm Compound |
Stability of an extemporaneously formulated levothyroxine sodium syrup compounded from commercial tablets. |
|
2659 |
Int J Pharm Compound |
Chemical stability of hydromorphone hydrochloride in patient-controlled analgesia injector. |
|
2661 |
Eye |
Storage stability of bevacizumab in polycarbonate and polypropylene syringes |
|
2663 |
Int J Pharm Compound |
The formulation development and stability of metronidazole suspension. |
|
2665 |
Int J Pharm Compound |
The stability of lisinopril as an extemporaneous syrup. |
|
2668 |
Int J Pharm Compound |
Stability of mechlorethamine hydrochloride 0.01% ointment in Aquafor Base. |
|
2670 |
Int J Pharm Compound |
Stability of albuterol in continuous nebulization. |
|
2671 |
J Oncol Pharm Practice |
Stability of irinotecan-loaded eluting beads (DC Bead) used for transarterial chemoembolization. |
|
2676 |
Int J Pharm Compound |
Stability of ciprofloxacin in an extemporaneous oral liquid dosage form. |
|
2678 |
Int J Pharm Compound |
Naratriptan hydrochloride in extemporaneously compounded oral suspensions. |
|
2680 |
Int J Pharm Compound |
Stability of lisinopril syrup (2 mg/ml) extemporaneously compounded from tablets. |
|
2682 |
Int J Pharm Pract |
Formulation and stability of cefuroxime eye-drops. |
|
2683 |
Int J Pharm Pract |
Shelf life of cefuroxime eye-drops when dispensed in artificial tear preparations. |
|
2685 |
Int J Pharm Pract |
Stability of ipratropium bromide and salbutamol nebuliser admixtures. |
|
2686 |
J Am Acad Dermatol |
Topical corticosteroid compounding: effects on physicochemical stability and skin penetration rate. |
|
2689 |
J Am Pharm Assoc |
Stability of amlodipine besylate in two liquid dosage form. |
|
2690 |
J Am Pharm Assoc |
Stability of mexiletine in two extemporaneously liquid formulations stored under refrigeration and et room temperature |
|
2691 |
J Am Pharm Assoc |
Stability of nifedipine in two oral suspensions stored at two temperatures. |
|
2692 |
J Am Pharm Assoc |
Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules. |
|
2695 |
Int J Pharm Compound |
Stability of Metronidazole Suspensions. |
|
2697 |
J Clin Pharm Ther |
The formulation and stability of a unit-dose oral vitamin K1 preparation. |
|
2699 |
J Clin Pharm Ther |
Stability of cefuroxime axetil in suspensions. |
|
2702 |
J Clin Pharm Ther |
Stability of metronidazole benzoate in suspensions |
|
2704 |
J Clin Pharm Ther |
Stability of rifampin in two suspensions at room temperature |
|
2705 |
J Clin Pharm Ther |
Stability of caffeine oral formulations for neonatal use. |
|
2707 |
J Clin Pharm Ther |
Stability of cefazolin sodium eye drops |
|
2708 |
J Clin Pharm Ther |
Stability of ceftazidime in a viscous eye drop formulation |
|
2717 |
J Liquid Chrom |
Determination of ceftazidime and pyridine by HPLC: application to a viscous eye drop formulation. |
|
2720 |
J Ocular Pharm Ther |
Formulation of sirolimus eye drops corneal permeation studies. |
|
2721 |
J Pad Ophtalmol Strabismus |
Development of Two Stable Oral Suspensions of Levodopa-Carbidopa for Children With Amblyopia |
|
2723 |
J Ped Hematol Oncol |
Chemical and functional analysis of hydroxyurea oral solutions. |
|
2729 |
J Pharm Clin |
Bains de bouche antifongiques: études de stabilité. |
|
2730 |
J Pharm Pract and Res |
Evaluation of the physicochemical compatibility of cyclosporin infusion and parenteral nutrition when intravenously administered via the same central line lumen. |
|
2732 |
J Pharm Clin |
Stability of vancomycin eye drops. |
|
2733 |
J Pharm Clin |
Impact of deep-freezing on pefloxacin eye drops stability. |
|
2737 |
J Pharm Pharmacol |
Chemical stability of artesunate injection and proposal for its administration by intravenous infusion. |
|
2759 |
Pediatr Neurol |
Development of two stable oral suspensions of gabapentin. |
|
2760 |
Pharm Hosp et Clin |
Etude de stabilité d’un collyre à ,6 mg/ml de ticarciline. |
|
2765 |
Pharm World Sci |
Stability of dithranol in creams. |
|
2770 |
Pharmazie |
Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol. |
|
2771 |
Skin Pharm Appl Skin Physiol |
Long-term stability of 8-methoxypsoralen in ointments for topical PUVA therapy (Cream PUVA). |
|
2772 |
South Med J |
Stability of midazolam prepared for oral administration |
|
2773 |
Support Care Cancer |
Stability of an extemporaneous oral liquid aprepitant formulation. |
|
2774 |
Ann Pharmacotherapy |
Compatibility of Budesonide Inhalation Suspension with Four Nebulizing Solutions. |
|
2783 |
Int J Pharm |
Stability of colistimethate sodium in a disposable elastomeric infusion device. |
|
2785 |
Am J Health-Syst Pharm |
Stability of misoprostol in suppositories. |
|
2786 |
Am J Health-Syst Pharm |
Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus. |
|
2787 |
Am J Health-Syst Pharm |
Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium. |
|
2789 |
Bone Marrow Transplantation |
Long-term stability of a patient-convenient 1mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. |
|
2790 |
Int J COPD |
Physicochemical compatibility of fluconasone-17-propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions. |
|
2791 |
Int J Pharm |
Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. |
|
2793 |
Hosp Pharm |
In Vitro Stability Evaluation of Different Pharmaceutical Products Containing Meropenem. |
|
2795 |
J Pharm Pharm Sci |
Stability of sulfadiazine oral liquids prepared from tablets and powder. |
|
2803 |
Respiratory Care |
Chemical and physical compatibility of levalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium or acetylcysteine sodium. |
|
2808 |
Int J Pharm Compound |
Long-term Stability of Cocaine Hydrochloride Aqueous Solution 50 mg/mL (5%) at Room Temperature and at 5°C ± 3°C in Glass Bottles. |
|
2810 |
Antimicrob Agents Chemother |
Preparation and stability of voriconazole eye drop solution. |
|
2814 |
Ann Pharm Fr |
Long-term stability of tramadol hydrochloride and droperidol mixture in 5% dextrose infusion polyolefin bags at 5 +/- 3°C. |
|
2815 |
EJHP |
Assessment of stability in extemporaneously prepared venlafaxine solutions. |
|
2816 |
J Pharm Biomed Anal |
Photodegradation of folic acid in aqueous solution |
|
2818 |
J Pharm Biomed Anal |
Stability of isoniazid in isoniazid syrup: formation of hydrazine |
|
2820 |
J Pharm Biomed Anal |
Stability of amphotericin B and nystatin in antifungal mouthrinses containing sodium hydrogen carbonate |
|
2824 |
J Clin Pharm Ther |
Stability of extemporaneously prepared saquinavir formulations |
|
2825 |
Int J Pharm Compound |
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials. |
|
2827 |
Am J Health-Syst Pharm |
Long-term stability of extemporaneously prepared captopril oral liquids in glass bottles |
|
2828 |
J Clin Pharm Ther |
Evaluation of the stability of morphine sulphate in combination with Instillagel®. |
|
2833 |
Int J Pharm Compound |
Stability of an Oral Liquid Dosage Form of Glycopyrrolate Prepared from Tablets |
|
2834 |
Int J Pharm Compound |
Stability of Oral Liquid Dosage Forms of Glycopyrrolate Prepared With the Use of Powder |
|
2835 |
Int J Pharm Compound |
Chemical Stability of Hydrocortisone in an Oral Liquid Dosage Form without Suspending Agents |
|
2836 |
Int J Pharm Compound |
Stability of Hydralazine Hydrochloride in Both Flavored and Nonflavored Extemporaneous Preparations |
|
2837 |
Int J Pharm Compound |
Chemical Stability of Isoniazid in an Oral Liquid Dosage Form |
|
2838 |
Pierre Fabre |
Vinflunine (Javlor®) – Résumé des caractéristiques du produits |
|
2840 |
Can J Hosp Pharm |
Stability of Diclofenac Sodium Oral suspensions Packaged in Amber Polyvinyl Chloride Bottles. |
|
2841 |
Atencion Pharmaceutica |
Estudio de estabilidad de la mezcla ondansetron-dexametasona en cloruro sodico 0,9%. |
|
2842 |
Int J Pharm Compound |
Stability of Memantine in an Extemporaneously Prepared Oral Liquid |
|
2843 |
Int J Pharm Compound |
Chemical Stability of Methadone Concentrate and Powder Diluted in Orange-Flavored Drink |
|
2849 |
Int J Pharm Compound |
Chemical Stability of Perphenazine in Oral Liquid Dosage Forms |
|
2851 |
Int J Pharm Compound |
Stability of An Extemporaneously Compounded Propylthiouracil Suspension |
|
2852 |
Int J Pharm Compound |
Stability of Extemporaneous Oral Ribavirin Liquid Preparation |
|
2854 |
Int J Pharm Compound |
The Formulation Development and Stability of Spironolactone Suspension |
|
2855 |
Int J Pharm Compound |
Temozolomide Stability in Extemporaneously Compounded Oral Suspensions |
|
2857 |
Can J Hosp Pharm |
Stability of Mycophenolate Mofetil in a 1:1 Mixture of Ora-Sweet and Ora-Plus. |
|
2858 |
Int J Pharm Compound |
Stability of Two Concentrations of Tiagabine in an Extemporaneously Compounded Suspension. |
|
2864 |
Astellas Pharma |
Isavuconazonium (Cresemba®) - Summary of Product Characteristics |
|
2865 |
Int J Pharm |
Stability indicating HPLC method for the estimation of oxycodone and lidocaine in rectal gel |
|
2867 |
Int J Pharm Compound |
Stability of Amphotericin B in 5% Dextrose Ophthalmic Solution. |
|
2868 |
Int J Pharm Compound |
Some Studies of the Stability of Compounded Cefazolin Ophthalmic Solution. |
|
2872 |
Int J Pharm Compound |
Stability of Melatonin in an Extemporaneously Compounded Sublingual Solution and Hard Gelatin Capsule. |
|
2875 |
Can J Hosp Pharm |
Chemical Stability of 4-Aminopyridine Capsules. |
|
2876 |
Int J Pharm Compound |
Chemical Stability of Scopolamine Hydrobromide Nasal Solution. |
|
2877 |
Int J Pharm Compound |
Chemical Stability of Amitriptyline Hydrochloride in Oral Liquid Dosage Forms. |
|
2878 |
Can J Hosp Pharm |
Buffered Lidocaine Hydrochloride Solution With and Without Epinephrine: Stability in Polypropylene Syringes. |
|
2879 |
GSASA Congress - Lucerne - Switzerland |
Compatibilité entre amiodarone, catecholamines et/ou nitroprussiate de sodium, administré en continu par voie veineuse aux soins intensifs adultes. |
|
2881 |
SFPO Congress |
Stabilité d'un anticorps monoclonal d'intérêt thérapeutique après reconstitution: le rituximab. |
|
2882 |
SFPO Congress |
Stabilité de solutions diluées de bévacizumab en fonction de la température. |
|
2883 |
Am J Health-Syst Pharm |
Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags. |
|
2884 |
Int J Pharm |
Design and stability study of a paediatric oral solution of methotrexate 2 mg/ml |
|
2886 |
Int J Pharm Compound |
Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A methods of compounding. |
|
2890 |
Acta Pharm |
Stability and compatibility of thiamine hydrochloride in liquid dosage forms et various temperatures. |
|
2894 |
J Dermatolog Treat |
A topical azythromycin preparation for the treatment of acne vulgaris and rosacea. |
|
2900 |
EJHP |
Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration. |
|
2902 |
Forrest Pharmaceuticals |
Ceftazidime - avibactam (Avycaz®) - Summary of Product Characteristics |
|
2904 |
Ann Pharm Fr |
Development of an oxybutynin chloride solution: from formulation to quality control. |
|
2906 |
Farm Hosp |
Stability study of an aqueous formulation of captopril at 1 mg/ml. |
|
2914 |
Palliative Med |
Stability of morphine sulphate and diamorphine hydrochloride in Intrasite gel. |
|
2925 |
Am J Health-Syst Pharm |
Stability of anhydrous theophylline in extemporaneously prepared alcohol-free oral suspensions. |
|
2926 |
Am J Health-Syst Pharm |
Extemporaneous sildefanil citrate oral suspensions for the treatment of pulmonary hypertension in children. |
|
2928 |
EJHP Science |
Stability of spironolactone in an extemporaneously prepared aqueous suspension: the importance of microbiological quality of compounded paediatric formulations. |
|
2931 |
Hosp Pharm |
Stability of two extemporaneously prepared oral metoprolol and carvedilol liquids. |
|
2932 |
J Pharm Pract and Res |
Extemporaneous isoniazid mixture: stability implications. |
|
2940 |
Am J Health-Syst Pharm |
Stability of amphotericin B in an extemporaneously compounded oral suspension. |
|
2949 |
Pharmazie |
Development validation and stability study of pediatric atenolol syrup. |
|
2951 |
J Clin Pharm Ther |
Stability of amoxicillin and potassium clavulanate in co-amoxiclav oral suspension. |
|
2953 |
J Pharm Sci |
Effect of some formulation adjuncts o the stability of benzoyl peroxide. |
|
2960 |
Respiratory Care |
Stability of albuterol and tobramycin when mixed for aerosol administration. |
|
2961 |
Can J Hosp Pharm |
Stability of dexamethasone in extemporaneously prepared oral suspensions. |
|
2970 |
J Pharm Pharm Sci |
Stability of levamisole oral solutions prepared from tablets and powder. |
|
2975 |
ESCP 2014 |
In-Use stability of herceptin for subcutaneous injection with different administration materials. |
|
2980 |
Ann Pharmacotherapy |
Stability of partial doses of omeprazole-sodium bicarbonate oral suspension. |
|
2982 |
J Ped Pharm Pract |
Stability of itraconazole in an extemporaneously suspension. |
|
2984 |
EJHP Science |
The development of a stable oral solution of captopril for paediatric patients. |
|
2986 |
J Clin Pharm Ther |
Chemical stabilities of isoetharine hydrochloride, metaproterenol sulphate and terbutaline sulphate after mixing with normal saline for respiratory therapy. |
|
2988 |
J Clin Pharm Ther |
Compounding of vitamin A, D3, E, and K3 supplements for cystic fibrosis patients: formulation and stability study. |
|
2990 |
Roche |
Trastuzumab Emtansine (Kadcyla®) - Summary of Product Characteristics. |
|
2991 |
Drug Dev Ind Pharm |
Evaluation of oil/water-type cyclosporine gel ointment with commercially available oral solution. |
|
2998 |
J Pharm Technol |
Preparation and stability of an oral suspension of dipyridamole. |
|
3001 |
Ann Pharm Fr |
Long-term stability of aciclovir in 0.9% NaCl infusion polyolefin bags at 2-8°C after freeze-thaw treatment: A generic product versus the brand name. |
|
3002 |
J Ped Pharm Pract |
Stability of trimethoprim in an extemporaneous liquid dosage form. |
|
3006 |
J Am Acad Dermatol |
Anthralin stability in various vehicles. |
|
3008 |
Pharm J |
Stability of retinoic acid eye-drops. |
|
3012 |
Hosp Pharm |
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration |
|
3017 |
Eur Hosp Pharm |
Formulation of a stable calcium gluconate gel for topical treatment of hydrofluoric acid burns. |
|
3019 |
Curr Med Res Opin |
Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs. |
|
3033 |
Eur Respir J |
Stability of metacholine chloride solutions under different storage conditions over a 9 months period. |
|
3041 |
Acta Pol Pharm |
Physicochemical and microbiological properties of eye drops containing cefuroxime. |
|
3052 |
J Pharm Pract and Res |
Stability of mixtures formulated from warfarin tablets or powder. |
|
3069 |
Eur Hosp Pharm |
Stability of amphotericin B in water solution for inhalation. |
|
3074 |
Int J Pharm |
Stability of the nitrogen mustard mechlorethamine in novel formulations for dermatological use. |
|
3075 |
EJHP Science |
Compatibility and stability of parenteral analgesic admixtures for multimodal analgesia |
|
3076 |
Ann Pharm Fr |
Effect of freezing, long-term storage and microwave thawing on the stability of a mixture of diclofenac and sodium bicarbonate in glucose 5% polyolefin bags. |
|
3077 |
Roche |
Trastuzumab (Herceptin®) – Summary of Product Characteristics |
|
3078 |
Can J Hosp Pharm |
Stability of celecoxib oral suspensions. |
|
3082 |
J Oncol Pharm Practice |
Long-term stability of tramadol chlorhydrate and metoclopramide hydrochloride in dextrose 5% polyolefin bag at 4°C. |
|
3083 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared voriconazole ophthalmic solution |
|
3084 |
Bristol Myers Squibb |
Ixabepilone (Ixempra®) – Summary of Product Characteristics |
|
3086 |
Anaesthesia |
Chemical stability of bupivacaine, lidocaine and epinephrine in pH-adjusted solutions. |
|
3087 |
BJID |
Treatment of invasive fungal infections: Stability of voriconazole infusion solutions in PVC bags. |
|
3090 |
Int J Pharm Compound |
Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup, and SyrSpend SF (For Reconstitution). |
|
3091 |
Wien Med Wochenschr |
Prüfung von Stabilität und Kompatibilität von Flucloxacillin (Floxapen®) und Ceftazidim (Fortum®) in zwei Infusionslösungen:Relevanz für die klinische Praxis. |
|
3093 |
J Pharm Sci |
Degradation of paclitaxel and related compounds in aqueous solutions III: Degradation under acidic pH conditions and overall kinetics |
|
3095 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared rifaximin oral suspensions. |
|
3096 |
Ann Pharmacotherapy |
Stability of Cyclophosphamide in Extemporaneous Oral Suspensions. |
|
3101 |
Perit Dial Int |
Incompatibility of Vancomycin and Ceftazidime for Intraperitoneal Use. |
|
3109 |
Bayer Schering Pharma |
Moxifloxacine (Izilox®) -Notice information |
|
3110 |
Poster ADKA Congress May 2010 |
Physikalisch-chemische Stabilität von Clofarabin-Zubereitungen. |
|
3111 |
Can J Hosp Pharm |
Stability of Norepinephrine Solutions in Normal Saline and 5% Dextrose in Water. |
|
3112 |
J Antimicrob Chemother |
Stability of meropenem and doripenem solutions for administration by continuous infusion |
|
3113 |
Compendium Suisse des m?dicaments |
Herceptin |
|
3115 |
Ann Pharm Fr |
Long term stability of the hydrochloride of tramadol and alizapride in dextrose 5% polyolefin bags at 5 +/- 3°C. |
|
3116 |
Am J Health-Syst Pharm |
Stability of sodium bicarbonate solutions in polyolefin bags. |
|
3117 |
Merck Sharp Dohme |
Temozolomide (Temodal ®) - Summary of Product Characteristics |
|
3119 |
Congrès HOPIPHARM |
Stabilité de la vincristine sans conservateurs. |
|
3120 |
Congrès HOPIPHARM |
Etude de stabilité de solutions intravitréennes de vancomycine à 10 mg/ml. |
|
3121 |
Am J Health-Syst Pharm |
Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 °C |
|
3122 |
Am J Health-Syst Pharm |
Physical compatibility of 4% sodium citrate with selected antimicrobial agents. |
|
3124 |
EJHP Science |
Physicochemical stability of a 1mg/ml dexamethasone acetate oral suspension. |
|
3125 |
Int J Pharm Compound |
Compatibility and Stability of Cefotaxine, Vancomycin, and Ciprofloxacin in Antibiotic Lock Solutions Containing Heparin. |
|
3126 |
J Pain Symptom Manage |
Microbiological and Physicochemical Stability of Oxycodone Hydrochloride Solutions for Patient-Controlled Delivery Systems. |
|
3128 |
Prostrakan |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit |
|
3129 |
Pfizer |
Irinotécan (Campto®) – Résumé des caractéristiques du produits |
|
3130 |
Sanofi Avantis France |
Docétaxel (Taxotere®) – Résumé des caractéristiques du produits |
|
3131 |
Can J Hosp Pharm |
Physical compatibility of high-concentration bupivacaine with hydromorphone, morphine and fentanyl. |
|
3132 |
J Palliat Med |
Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine. |
|
3134 |
Enferm Intensiva |
Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. |
|
3135 |
Am J Health-Syst Pharm |
Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags. |
|
3137 |
Retina |
Infliximab stability after reconstitution, dilution, and storage under refrigeration. |
|
3138 |
GlaxoSmithKline |
Ofatumumab (Arzerra®) - Summary of Product Characteristics |
|
3140 |
Int J Pharm Compound |
Stability and Compatibility of Reconstituted Caspofungin in Select Elastomeric Infusion Device. |
|
3141 |
Can J Hosp Pharm |
Stability of Trisodium Citrate and Gentamicin Solution for Catheter Locks after Storage in Plastic Syringes at Room Temperature. |
|
3142 |
SP Europe |
Doxorubicin hydrochloride liposome (Caelyx®) - Summary of Product Characteristics |
|
3143 |
Teva Laboratoire |
Doxorubicin hydrochloride liposome (Myocet®) - Summary of Product Characteristics |
|
3144 |
Ortho Biotech |
Doxorubicin liposome (Doxil®) - Product Information |
|
3145 |
Am J Health-Syst Pharm |
Stability of doripenem in polyvinyl chloride bags and elastomeric pumps. |
|
3149 |
Diabetes Tech and Ther |
In Vitro Stability of Insulin Lispro in Continuous Subcutaneous Insulin Infusion. |
|
3152 |
Am J Health-Syst Pharm |
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. |
|
3153 |
Can J Hosp Pharm |
Stability of Vancomycin 25 mg/mL in Ora-Sweet and Water in Unit-Dose Cups and Plastic Bottles at 4°C and 25°C. |
|
3154 |
J Antimicrob Chemother |
Long-term stability of temocillin in elastomeric pumps for outpatient antibiotic therapy in cystic fibrosis patients. |
|
3155 |
J Ocular Pharm Ther |
Stability of Fortified Cefazolin Ophthalmic Solutions Prepared in Artificial Tears Containing Surfactant-Based Versus Oxidant-Based Preservatives. |
|
3157 |
Celgene Europe Limited |
Paclitaxel albumin (Abraxane®) - Summary of Product Characteristics |
|
3158 |
Astellas Pharma GmbH |
Bendamustine (Levact®) - Summary of Product Characteristics |
|
3159 |
Acta Anaesthesiol Taiwan |
Compatibility and stability of binary mixtures of ketorolac tromethamine and tramadol hydrochloride injection concentrate and diluted infusion solution. |
|
3162 |
Bayer HealthCare |
Moxifloxacine (Izilox®) - Résumé des caractéristiques du produits |
|
3163 |
EJHP |
Physical and chemical stability of Taxotere 1-vial 20mg/mL infusion solution following refrigerated storage. |
|
3165 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared acetylcysteine 1% and 10% solutions for treatment of meconium ileus |
|
3166 |
Can J Hosp Pharm |
Stability of Levothyroxine in Sodium Chloride for IV Administration. |
|
3167 |
Farm Hosp |
Carvedilol stability in paediatric oral liquid formulations. |
|
3168 |
Am J Hosp Pharm |
Stability of hydralazine hydrochloride syrup compounded from tablets. |
|
3169 |
Pain Clinic |
Experimentation about precipitation of pharmacological association: morphine and ketorolac. |
|
3172 |
J Clin Pharm Ther |
Stability and compatibility of doxofylline with phentolamine mesilate in 0·9% sodium chloride or 5% dextrose injection for intravenous infusion.
|
|
3173 |
SNPHPU Congress France |
Stability of tetracaine eye-drops |
|
3174 |
Ann Pharmacotherapy |
Stability of Ondansetron and Dexamethasone Infusion upon Refrigeration. |
|
3176 |
16èmes JFSPH, Sion, 18-19 novembre |
Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté. |
|
3177 |
16èmes JFSPH, Sion, 18-19 novembre 2010 |
Compatibilités physico-chimique entre catécholamines, amiodarone, et/ou nitroprussiate de sodium intraveineux. |
|
3180 |
Int J Pharm Compound |
Chemical stability of brompheniramine maleate in an oral liquid dosage form. |
|
3181 |
Int J Pharm Compound |
Stability of venlafaxine immediate-release suspension. |
|
3182 |
Pharmazie |
Stability of cefepime in eye drops. |
|
3183 |
EJOP |
Physical and chemical stability of cisplatin infusions in PVC containers. |
|
3184 |
CP Pharmaceuticals |
Hyaluronidase (Hyalase®) - Summary of Product characteristics. |
|
3185 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared oxandrolone oral suspensions. |
|
3186 |
Am J Health-Syst Pharm |
Physical compatibility of 4% sodium citrate with 23.4% sodium chloride, fluconazole, and micafungin. |
|
3187 |
Am J Health-Syst Pharm |
Stability of an extemporaneous alcohol-free melatonin suspension. |
|
3188 |
J Clin Pharm Ther |
Stability indicating HPLC assay for the determination of piritramide and droperidol in PCA solutions. |
|
3189 |
J Pharm Pract and Res |
Stability of intravenous flucloxacillin solutions used for hospital-in-the-home. |
|
3190 |
Advance in Haematology |
An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. |
|
3195 |
EJHP |
Physical and chemical stability of docetaxel infusions. |
|
3198 |
Farm Hosp |
Estabilidad en suero fisiológico del busulfán intravenoso en un envase de poliolefinas. |
|
3201 |
J Pediatr Pharmacol Ther |
Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. |
|
3202 |
Am J Health-Syst Pharm |
Stability of compounded thioguanine oral suspensions |
|
3203 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared glycopyrrolate oral suspensions. |
|
3204 |
Ann Pharmacotherapy |
Stability of Azacitidine Suspensions. |
|
3205 |
AAPS Pharm Sci |
in vitro stability and compatibility of tenecteplase in central venous access devices. |
|
3206 |
Int J Pharm Compound |
Nifedpine in Compounded Oral and Topical Preparations. |
|
3207 |
Int J Pharm Compound |
Stability of Droperidol 0.625 mg/mL Diluted with 0.9% Sodium Chloride Injection and Stored in Polypropylene Syringes. |
|
3208 |
Int J Pharm Compound |
Stability of Ertapenem in an Elastomeric Infusion Device. |
|
3209 |
Int J Pharm Compound |
Stability of Verapamil Hydrochloride in SyrSpend SF Compared to Sorbitol Containing Syrup and Suspending Vehicles. |
|
3210 |
Int J Pharm Compound |
Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. |
|
3212 |
Enferm Intensiva |
Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos. |
|
3214 |
EJOP |
Stability of vincristine (TEVA) in original vials after re-use in dilute infusions in polyolefin bags and in polypropylene syringes. |
|
3215 |
EJOP |
Taxotere 1-vial (docetaxel 20 mg/ml) physical and chemical stability over 28 days in infusion bags containing 0.9% saline solution and 5% glucose solution. |
|
3216 |
Pharmactuel |
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. |
|
3218 |
Perit Dial Int |
Daptomycin Compatibility in Peritoneal Dialysis Solutions |
|
3220 |
Can J Hosp Pharm |
Stability of Pantoprazole Sodium in Glass Vials, Polyvinyl Chloride Minibags, and Polypropylene Syringes. |
|
3221 |
Can J Hosp Pharm |
Stability of Levetiracetam in Extemporaneously Compounded Suspensions. |
|
3222 |
Am J Health-Syst Pharm |
Stability of midazolam hydrochloride injection 1-mg/mL solutions in polyvinyl chloride and polyolefin bags |
|
3223 |
Am J Health-Syst Pharm |
Stability of diluted adenosine solutions in polyvinyl chloride infusion bags |
|
3224 |
EJHP Science |
The stability of soluble insulin in plastic syringes |
|
3225 |
EJHP Science |
Physico-chemical stability of nelarabine infusion solutions in EVA infusion bags. |
|
3227 |
Braz J Pharm Sci |
Application of capillary electrophoresis to the simultaneous determination and stability study of four extensively used penicillin derivatives |
|
3228 |
Am J Health-Syst Pharm |
Stability of levothyroxine injection in glass, polyvinyl chloride, and polyolefin containers |
|
3229 |
Am J Health-Syst Pharm |
Stability of cyclosporine solutions stored in polypropylene–polyolefin bags and polypropylene syringes. |
|
3230 |
Can J Hosp Pharm |
Stability of Cefazolin Sodium in Polypropylene Syringes and Polyvinylchloride Minibags |
|
3231 |
Can J Hosp Pharm |
Stability of Ciprofloxacin in Polyvinylchloride Minibags. |
|
3235 |
ADKA Congress 2011 |
Stabilität von Argatroban-Dauerinjektionslösungen in applikationsfertigen Konzentrationen. |
|
3236 |
Celgene |
Azacitidine (Vidaza®) - Résumé des caractéristiques du produit |
|
3237 |
Sanofi Aventis France |
Cabazitaxel (Jevtana®) - Résumé des caractéristiques du produit. |
|
3240 |
Congrès SFPO |
Etude de la stabilité d'une solution de bortézomib à 1 mg/mL conditionnée en seringue de polypropylène. |
|
3243 |
ECCO Congress Stockholm |
Stability of diluted L-asparaginase in normal saline solution. |
|
3244 |
SFPO Congress Mandelieu, France |
Stabilité chimique et microbiologique d'une suspension de mercaptopurine à 5 mg/mL. |
|
3246 |
SFPO Congress Mandelieu, France |
Stabilité physico-chimique de la suspension d'azacitidine (25 mg/mL) conservée à 4°C. |
|
3249 |
Am J Health-Syst Pharm |
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. |
|
3250 |
Eisai Ltd |
Eribulin (Halaven®) - Summary of Product Characteristics. |
|
3254 |
Am J Health-Syst Pharm |
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration |
|
3255 |
Ann Pharm Fr |
Long-term stability of temocillin in dextrose 5% and in sodium chloride 0.9% polyolefin bags at 5±3°C after freeze-thaw treatment |
|
3256 |
EJHP |
Stability of Hospira filgrastim following changes to thermal and photic storage conditions. |
|
3258 |
Int J Pharm Compound |
Physicochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags. |
|
3260 |
Astellas Pharma Europe |
Telavancin (Vibativ®) - Summary of Products characteristics |
|
3261 |
Bristol Myers Squibb |
Belatacept (Nulojix®) – Résumé des caractéristiques du produit |
|
3262 |
J Oncol Pharm Practice |
Conditions causing gemcitabine crystallization. |
|
3263 |
Can J Hosp Pharm |
Stability of buffered lidocaine in glass vials. |
|
3264 |
AAPS Congress - Washington, October 2011 |
Nalbuphine stability at 1 mg/mL concentration. |
|
3265 |
SFPO Congress, France |
Stabilité physico-chimique du bévacizumab à 25 mg/mL conservée à 4°C en seringue polypropylène. |
|
3266 |
Lipomed |
Dacarbazine solutions: In Use stability of dacarbazine lipomed® |
|
3267 |
Lipomed |
Dacarbazine Lipomed - Summary of Product Characteristics |
|
3268 |
Am J Health-Syst Pharm |
Physical compatibility of calcium gluconate and magnesium sulfate injections. |
|
3269 |
Am J Health-Syst Pharm |
Stability of an extemporaneously prepared thalidomide suspension. |
|
3274 |
Intensice Care Medecine |
Stability of sildenafil (Revatio®) dolutions in dextrose 5%. |
|
3275 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared cytarabine, methotrexate sodium, and methylprednisolone sodium succinate |
|
3277 |
Int J Pharm Compound |
Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration. |
|
3278 |
Int J Pharm Compound |
Chemical Stability of Pentoxifylline in a Topical Cream. |
|
3279 |
J Clin Pharm Ther |
A stability indicating assay for a combination of morphine sulphate with levomepromazine hydrochloride used in palliative care. |
|
3284 |
Yakugaku Zasshi |
Effect of the Admixture of Tetracycline and Nadifloxacin Ointments on Their Stability and Their Antibacterial Activity. |
|
3285 |
Yakugaku Zasshi |
Development of New Mixing Method of Busulfex® Injecton for the Purpose of Improvement of Medical Safety Method; The Prefilled Syringe Method. |
|
3286 |
Yakugaku Zasshi |
Light-induced Deterioration Test of Carboplatin under Clinical Settings. |
|
3289 |
Acta Pol Pharm |
Stability of ceftazidime in 1% and 5% buffered eye drops determined by HPLC method. |
|
3290 |
Acta Pol Pharm |
Stability of cefuroxime in 1% and 5% buffered eye drops determined with HPLC method. |
|
3291 |
Acta Pol Pharm |
Physical and chemical properties and stability of sodium cefazolin in buffered eye drops determined with HPLC method. |
|
3293 |
EJHP |
Stability of dobutamine 500 mg in 50 ml syringes prepared using a Central Intravenous Additive Service |
|
3294 |
EJHP |
In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs |
|
3295 |
LFB Biom?dicaments |
Argatroban - Résumé Caractéristiques du Produit |
|
3296 |
J Chromatographic Sci |
Determination of Tramadol, Metamizole, Ropivacaine, and Bupivacaine in Analgesic Mixture Samples by HPLC with DAD Detection. |
|
3297 |
Chromatographia |
Development of an LC–DAD Method for Analysis of Dexketoprofen, Tramadol, and Haloperidol. Study of the Stability of Mixtures Used for Patient-Controlled Analgesia. |
|
3298 |
Am J Health-Syst Pharm |
Stability of an extemporaneously prepared tadalafil suspension |
|
3299 |
Am J Health-Syst Pharm |
Stability of dexmedetomidine 4 µg/mL in polypropylene syringes. |
|
3300 |
Ann Pharm Fr |
Stability study of amiodarone hydrochloride in capsules for paediatric patients using a high-performance liquid chromatography method. |
|
3301 |
Hosp Pharm |
Extended Stability of Magnesium Sulfate Infusions Prepared in Polyolefin Bags. |
|
3302 |
Int J Pharm Compound |
Stability of Omeprazole in SyrSpend SF Alka (Reconstituted). |
|
3303 |
Int J Pharm Compound |
Stability of Vancomycin in SyrSpend SF. |
|
3306 |
EJOP |
New stability studies for fludarabine according to the European Pharmacopoeia 7.0 |
|
3307 |
Hosp Pharm |
Managing the intravenous calcium shortage: Evaluation of calcium chloride stability in 0.9% sodium chloride and dextrose 5% water polyvinyl chloride bags.
|
|
3308 |
Antimicrob Agents Chemother |
Stability of Extemporaneously Prepared 0.5-Percent Caspofungin Eye Drops: a Potential Cost-Savings Exercise. |
|
3309 |
EJHP |
Stability of diluted epinephrine in prefilled syringes for use in neonatology.
|
|
3310 |
Hosp Pharm |
Stability of Regular Human Insulin Extemporaneously Prepared in 0.9% Sodium Chloride in a Polyvinyl Chloride Bag. |
|
3312 |
Ann Pharm Fr |
Long-term stability of bevacizumab repackaged in 1 mL polypropylene syringes for intravitreal administration. |
|
3313 |
J Oncol Pharm Practice |
Long-term stability study of clofarabine injection concentrate and diluted clofarabine infusion solutions. |
|
3314 |
Bristol Myers Squibb |
Carmustine (Bicnu®) – Résumé des caractéristiques du produits |
|
3315 |
Communication orale Hopipharm |
Mise en évidence d'une incompatibilité physico-chimique entre la phénytoïne sodique et le paracétamol injectable en flacon. |
|
3316 |
Chem Pharm Bull |
A 5% Glucose Infusion Fluid Provokes Significant Precipitation of Phenytoin Sodium Injection via Interruption of the Cosolvent Effect of Propylene Glycol.
|
|
3317 |
APHIF Congress |
Stabilité de l'infliximab en solutions diluées. |
|
3318 |
Ann Pharm Fr |
Stability of ready-to-use temsirolimus infusion solution (100 mg/L) in polypropylene containers under different storage conditions. |
|
3319 |
Int J Pharm |
Development and validation of a paediatric oral formulation of clonidine hydrochloride |
|
3320 |
CTI Life Sciences Limited |
Pixantrone (Pixuvri®) - Summary of Product Characteristics |
|
3321 |
Int J Pharm Compound |
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets. |
|
3322 |
Int J Pharm Compound |
Stability of Gabapentin in SyrSpend SF. |
|
3323 |
Int J Pharm |
Long-term stability of diluted solutions of the monoclonal antibody rituximab. |
|
3324 |
J Pharm Pract and Res |
Stability study of a thalidomide suspension. |
|
3326 |
J Pharm Pract and Res |
Chiral stability study of oral liquid clopidrogel formulations for infants. |
|
3327 |
Am J Health-Syst Pharm |
Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions. |
|
3329 |
Hosp Pharm |
Extended Stability of Sodium Bicarbonate Infusions Prepared in Polyolefin Bags. |
|
3331 |
Ann Pharm Fr |
Stability of the ready-to-use solutions of eribulin for intravenous infusion. |
|
3332 |
Pfizer |
Tigecycline (Tigacyl®) - Summary of Product characteristics |
|
3333 |
Am J Health-Syst Pharm |
Stability of infliximab in polyvinyl chloride bags. |
|
3334 |
EJHP |
Physicochemical compatibility of nebuliser solution admixtures containing colistimethate and hypertonic saline or colistimethate, fluticasone-17-propionate, ipratropium bromide and salbutamol sulfate. |
|
3336 |
EJHP |
Stability of an oral ranitidine suspension (15 mg/ml). |
|
3337 |
EJHP |
Stability of bortezomib reconstituted under clinical use conditions in original vials and polypropylene syringes at 4 °C and room temperature. |
|
3341 |
Krankenhauspharmazie |
Ist teurer immer auch besser? Analytiklabor der Apotheke unterstütz Einkauf sentcheidungen bei Carboplatin-Präparaten. |
|
3342 |
Pharmaceutical Technology in Hospital Pharmacy |
Stability of Bendamustine Solutions: Influence of Sodium Chloride Concentration, Temperature and Container. |
|
3343 |
ECOP Congress, Budapest, Hungary |
Physicochemical stability of diluted trastuzumab solutions stored 6 months at 4°C. |
|
3344 |
ECOP Congress, Budapest, Hungary |
Stabilité physicochimique du bevacizumab 5 mg/mL dilué dans le chlorure de benzalkonium 0.1 mg/mL. |
|
3345 |
Int J Pharm Compound |
Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date. |
|
3346 |
Krankenhauspharmazie |
Stabilität, Qualität und Analytik individueller Noradrenalin-Zubereitungen. |
|
3347 |
Drug Discov Ther |
Stability-indicating HPLC method for the determination of the stability of oxytocin parenteral solutions prepared in polyolefin bags. |
|
3348 |
Amgen |
Carfilzomib (Kyprolis®) - Résumé des caractéristiques du produit |
|
3349 |
Int J Pharm Bio Sci |
Chemical stability of bortezomib solutions in original manufacturer vials. |
|
3350 |
Am J Health-Syst Pharm |
Extended stability of intravenous acetaminophen in syringes and opened vials. |
|
3351 |
Can J Hosp Pharm |
Stability of Azacitidine in Sterile Water for Injection. |
|
3352 |
Bristol Myers Squibb |
Ipilimumab (Yervoy®) - Summary of Product Characteristics |
|
3356 |
Int J Pharm Compound |
Stability of Propranolol Hydrochloride in SyrSpend SF. |
|
3360 |
Antimicrob Agents Chemother |
Stability of Colistimethate Sodium in Aqueous Solution. |
|
3361 |
Int J Pharm |
Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide. |
|
3363 |
J Pharm Pract and Res |
Stability of Oral Cholecalciferol (Vitamin D3) Liquid Formulations in Olive Oil. |
|
3364 |
Am J Health-Syst Pharm |
Visual compatibility of micafungin sodium and levofloxacin injections. |
|
3365 |
Hosp Pharm |
Y-Site Compatibility of Vancomycin and Piperacillin/Tazobactam at Commonly Utilized Pediatric Concentrations. |
|
3366 |
J Pharm Sci |
Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration. |
|
3369 |
MEDAC France |
Levofolinate de sodium Medac - Résumé des caractéristiques du produits |
|
3372 |
Rev Bras Anestesiol |
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. |
|
3373 |
J R Soc Med Sh Rep |
Precipitation of thiopental with muscle relaxants: a potential hazard. |
|
3374 |
Anaesthesia |
Precipitation in Manchester: ketorolac/cyclizine |
|
3377 |
Anaesthesia |
Precipitation betwen meptazinol and thiopentone. |
|
3378 |
Am J Health-Syst Pharm |
Compatibility of butorphanol and droperidol in 0.9% sodium chloride injection |
|
3379 |
Am J Health-Syst Pharm |
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. |
|
3380 |
Ann Pharmacotherapy |
Incompatibility of Piritramide with Cephalosporins. |
|
3381 |
EJHP |
In vitro compatibility of various cardioactive drugs during simulated Y-site administration. |
|
3383 |
Farm Hosp |
Evaluación de la estabilidad de un jarabe de hidrato de cloral al 7% en envases mono y multidosis bajo condiciones ambiente y de refrigeración. |
|
3384 |
Farm Hosp |
Estudio de estabilidad de tiaprida en disolución para administración en perfusión intravenosa continua. |
|
3385 |
J Antimicrob Chemother |
Stability and compatibility of vancomycin for administration by continuous infusion. |
|
3386 |
Int J Pharm |
Long-term physico-chemical stability of diluted trastuzumab. |
|
3390 |
Int J Pharm |
Degradation kinetics of the antitumor drug nimustin (ACNU) in aqueous solution. |
|
3397 |
EAHP Congress Paris |
Physicochemical stability of ready-to-administer epinephrine injection solutions 20 µg/mL, 50 mL. |
|
3398 |
Gilead Science (France) |
Amphotéricine B (Ambisome®) - Résumé des caractéristiques du produit |
|
3399 |
EAHP Congress Paris |
Development of a hydrochlorothiazide 0.5 mg/mL oral solution for children. |
|
3401 |
J Clin Pharm Ther |
Stability of an epidural analgesic admixture of levobupivacaine, fentanyl and epinephrine. |
|
3402 |
J Oncol Pharm Practice |
Doxorubicin-loaded drug-eluting beads (DC Bead®) for use in transarterial chemoembolization: A stability assessment. |
|
3403 |
Int J Pharm Compound |
Stability of Minoxidil in Espumil Foam Base |
|
3404 |
Int J Pharm Compound |
Stability of Rifampin in SyrSpend SF |
|
3407 |
Farm Hosp |
Suspensiones extratemporáneas de clobazam para uso pediátrico preparadas a partir de tabletas disponibles comercialmente y fármaco puro. |
|
3408 |
Pharmactuel |
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. |
|
3409 |
Am J Health-Syst Pharm |
Stability of extemporaneously compounded diltiazem hydrochloride infusions stored in polyolefin bags |
|
3410 |
Can J Hosp Pharm |
Stability of Propranolol in Extemporaneously Compounded Suspensions |
|
3413 |
Pharm Res |
Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex. |
|
3415 |
Pharmaceut Anal Acta |
Stability-Indicating HPLC Assay and Stability Study Over Two Years of Morphine Hydrochloride Diluted Solutions in Polypropylene Syringes |
|
3416 |
Am J Health-Syst Pharm |
Physical compatibility of sodium citrate with alcohol and cefepime. |
|
3417 |
ADKA Congress, Dresden, Germany |
Aliquotierte Levosimendanlösungen - stabil ? |
|
3418 |
Int J Pharm Bio Sci |
Chemical stability of bortezomib solutions in original manufacturer vial at room temperature and in syringe at 4°C. |
|
3420 |
J Oncol Pharm Practice |
Stability of an extemporaneously prepared bleomycin-lidocaine-epinephrine intradermal admixture used in dermatology |
|
3421 |
Am J Health-Syst Pharm |
Physical compatibility of vancomycin and piperacillin sodium–tazobactam at concentrations typically used during prolonged infusions. |
|
3422 |
Hosp Pharm |
Stability of Diluted Adenosine Solutions in Polyolefin Infusion Bags. |
|
3426 |
Journal of Addiction Medicine |
Stability of Dilute Oral Morphine Solution for Neonatal Abstinence Syndrome. |
|
3428 |
Hosp Pharm |
Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations. |
|
3429 |
Am J Health-Syst Pharm |
Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration |
|
3431 |
Can J Hosp Pharm |
Stability of preservative-free tobramycin in half-normal saline. |
|
3432 |
Celgene Corporation |
Romidepsin (Istodax®) - Summary of Product Characteristics |
|
3433 |
Am J Health-Syst Pharm |
Stability of dexmedetomidine in polyvinyl chloride bags containing 0.9% sodium chloride injection. |
|
3434 |
Can J Hosp Pharm |
Compatibility and Stability of Morphine Sulphate and Naloxone Hydrochloride in 0.9% Sodium Chloride for Injection. |
|
3435 |
Can J Hosp Pharm |
Stability of Diluted Ketamine Packaged in Glass Vials. |
|
3436 |
Int J Pharm Compound |
Stability of Captopril in SyrSPend SF. |
|
3437 |
Int J Pharm Compound |
Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry. |
|
3438 |
J Pharm Biomed Anal |
A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids. |
|
3439 |
Perit Dial Int |
Effect of Glucose Concentration on the Stability of Daptomycin in Peritoneal Solutions. |
|
3440 |
Pharmazie |
Physicochemical compatibility of nebulizable drug admixtures containing colistimethate and tobramycin. |
|
3443 |
J Pharm Pract and Res |
Stability of Diluted Iron Polymaltose in PVC Infusion Bags. |
|
3445 |
Krankenhauspharmazie |
Aseptische Herstellung applikationsfertiger Adrenalin-Dauerinjektionen 20 µg/ml. |
|
3446 |
SFPO Congress, Mandelieu, France |
Stabilité physicochimique de solutions diluées d'ipilimumab : résultats préliminaires à 1 mois. |
|
3447 |
SFPO Congress, Mandelieu, France |
Etude de la stabilité d’une solution de bortézomib à 2,5 mg/mL par chromatographie liquide à haute performance couplée à un détecteur à barrettes de diodes et à un détecteur évaporatif à diffusion de lumière. |
|
3448 |
Ann Pharm Fr |
Physicochemical stability study of a new Trimix formulation for treatment of erectile dysfunction. |
|
3449 |
Ann Pharmacotherapy |
Stability of Betaxolol Suspensions in Oral Syringes and Glass Bottles. |
|
3455 |
J Drug Deliv Sci Tecnol |
Novel formulation and clinical evaluation of nalidixic acid ointment in impetigo. |
|
3456 |
Curr Med Res Opin |
Short-term stability of a new generic sodium ferric gluconate in complex with sucrose. |
|
3459 |
Cancer Chemother Pharmacol |
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. |
|
3463 |
Nursing |
Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad. |
|
3464 |
Enferm Clin |
Compatibilidad física de la amiodarona en perfusión continua |
|
3465 |
Enferm Intensiva |
Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. |
|
3466 |
Enferm Intensiva |
Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos |
|
3470 |
Support Care Cancer |
Physical compatibility of binary and tertiary mixtures of morphine and methadone with other drugs for parenteral administration in palliative care. |
|
3472 |
Krankenhauspharmazie |
Physikalisch-chemische kompatilibität von Mischinhalationslösungen und suspensionen zur simultanen feuchtinhalationstherapie bei Mukoviszidose Patienten. |
|
3473 |
Int J Pharm |
Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization. |
|
3474 |
Accord Healthcare Limited |
Fluorouracil - Summary of Product Characteristics |
|
3475 |
Am J Health-Syst Pharm |
Incompatibility of ciprofloxacin and meropenem injections. |
|
3476 |
Am J Health-Syst Pharm |
Stability of cyclosporine diluted with 0.9% sodium chloride injection or 5% dextrose injection and stored in ethylene-vinyl acetate containers. |
|
3485 |
Anaesthesia |
Vancomycin causes dangerous precipitation when infused with gelatin fluid. |
|
3486 |
Cardiovasc Intervent Radiol |
Incompatibility of contrast medium and trisodium citrate. |
|
3488 |
Farm Hosp |
Jarabe de midazolam: Estudio de estabilidad de una solucion oral para uso hospitaliaro. |
|
3489 |
Farm Hosp |
Estabilidad de las soluciones orales de clohidrato de metadona al 0,1% y 0,5% en suero fisiologico. |
|
3490 |
Ann Pharmacotherapy |
Stability of furosemide in human albumin solution. |
|
3495 |
Takeda |
Brentuximab (Adcetris®) - Summary of Product Characteristics |
|
3496 |
Actavis |
Gemcitabin Actavis solution - Stability Study |
|
3498 |
Ann Pharmacotherapy |
Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions. |
|
3501 |
Pfizer |
Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics |
|
3502 |
Astra Zeneca |
Propofol (Diprivan®) - Summary of Products Characteristics |
|
3503 |
Hameln Pharmaceuticals |
Fentanyl - Summary of product Characteristics |
|
3504 |
Pfizer |
Parecoxib (Dynastat®) - Summary of Product Characteristics |
|
3507 |
AbbVie |
Chirocaine - Summary of Product Characteristics |
|
3508 |
Sanofi Aventis Group |
Aflibercept (Zaltrap®) - Summary of Product characteristics |
|
3516 |
SFPO Congress, Mandelieu, France. |
Stabilité du melphalan à 2 mg/ml dans le chlorure de sodium 0,9% dans des conditions pratiques d'utilisation. |
|
3519 |
Glaxo Smith Kline |
Remifentanil hydrochloride(Ultiva®) - Summary of Product Characteristics |
|
3520 |
Sanofi |
Cidomycin - Summary of product Chracteristics. |
|
3521 |
Beacon Pharmaceuticals |
Tramadol® - Summary of Product Characteristics. |
|
3522 |
Actavis |
Flucloxacillin - Summary of Product Characteristics. |
|
3523 |
Roche |
Ceftriaxone (Rocephin®) - Summary of Product Characteristics. |
|
3524 |
Sanofi |
Amiodarone hydrochloride (Cordarone®) - Summary of Product Characteristics. |
|
3525 |
AMCO Amdipharm Mercury |
Pethidine hydrochloride - Summary of product Characteristics |
|
3526 |
Pharmacia |
Clindamycin (Dalacin®) - Summary of Product Characteristics |
|
3527 |
Glaxo Smith Kline |
Amoxicillin (Amoxil®) – Summary of Product Characteristics |
|
3528 |
Essential generics |
Ampicillin sodium – Summary of Product Characteristics |
|
3529 |
Hospira |
Ciprofloxacin – Summary of Product Characteristics |
|
3530 |
Hospira |
Imipenem/Cilastatin – Summary of Product Characteristics |
|
3531 |
Wockhardt |
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics |
|
3534 |
Am J Health-Syst Pharm |
Chemical stability of azacitidine suspensions for injection after cold-chain reconstitution of powder and storage |
|
3535 |
Int J Pharm Compound |
Stability of Non-aqueous Topical Tetracaine and Clotrimazole Solutions in Polypropylene Droptainer Bottles |
|
3536 |
Int J Pharm Compound |
Stability of Nitroglycerin 100 mcg/mL Stored in Polypropylene Syringes |
|
3537 |
Krankenhauspharmazie |
Bortezomib zur subkutanen Applikation. |
|
3538 |
Krankenhauspharmazie |
Physikalisch-chemische Stabilität einer Metoprolol-Injektionslösung 1 mg/ml, 50 ml. |
|
3539 |
The Medecines Company |
Bivalirudin (Angiox®) - Summary of Product Characteristics. |
|
3540 |
Wockhardt |
Heparin sodium - Summary of Product Characteristics. |
|
3541 |
Sanofi |
Rifampicin (Rifadin®) – Summary of Product Characteristics |
|
3542 |
Am J Health-Syst Pharm |
Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion |
|
3543 |
Wockhardt |
Ceftazidime – Summary of Product Characteristics |
|
3544 |
Pfizer |
Cefoperazone (Cefobid®) - Summary of Product Characteristics |
|
3545 |
Mylan SAS |
Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit |
|
3546 |
Panpharma SA |
Cefamandole Flavelab - Résumé des caractéristiques du produit |
|
3547 |
Sanofi-Aventis France |
Aztréonam (Azactam®) - Résumé des caractéristiques du produit |
|
3548 |
Bristol Myers Squibb |
Cefepime (Maxipime®) - Summary of Product caracteristics. |
|
3549 |
B Braun |
Amikacine B Braun - Résumé des caractéristiques du produit. |
|
3557 |
Can J Hosp Pharm |
Physical Incompatibility between Parenteral Cloxacillin and Vancomycin. |
|
3558 |
Can J Hosp Pharm |
Physical Compatibility of Ranitidine and Metoclopramide in 50-mL Minibags of Normal Saline. |
|
3559 |
Sanofi Aventis France |
Pentamidine diiséthionate (Pentacarinat®) - Résumé des caractéristiques du produit |
|
3560 |
Pharmacia |
Linezolid (Zyvox®) - Summary of Product Characteristics |
|
3561 |
Am J Health-Syst Pharm |
Stability of frozen 1% voriconazole ophthalmic solution. |
|
3562 |
Sanofi |
Ofloxacin (Tarivid®) - Summary of Product Characteristics |
|
3563 |
Sanofi Aventis France |
Spiramycine adipate (Rovamycine®) - Résumé des caractéristiques du produit |
|
3564 |
B Braun |
Rocuronium B Braun - Résumé des caractéristiques du produit. |
|
3565 |
Aguettant |
Flumazenil Aguettant - Résumé des caractéristiques du produit. |
|
3566 |
Pfizer |
Voriconazole (Vfend®) - Summary of Product characteristics. |
|
3567 |
Pfizer |
Anidulafungin (Ecalta®) - Summary of Product Characteristics. |
|
3568 |
Am J Health-Syst Pharm |
Stability of levetiracetam oral solution repackaged in oral plastic syringes. |
|
3569 |
EJHP |
Development of ready-to-use cefuroxime syringes for use in ophthalmology. |
|
3571 |
Hosp Pharm |
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. |
|
3572 |
Int J Pharm Compound |
Long-term Stability of Morphine Hydrochloride in 0.9% NaCl Infusion Polyolefin Bags After Freeze-thaw Treatment and in Polypropylene Syringes at 5°C ± 3°C. |
|
3573 |
Astellas |
Micafungin (Mycamine®) – Summary of Product Characteristics |
|
3574 |
Accord Healthcare France SAS |
Ondansetron - Résumé des caractéristiques du produit |
|
3575 |
Prostrakan |
Mitomycine (Ametycine®) - Résumé des caractéristiques du produit |
|
3576 |
Prostrakan |
Amsacrine (Amsalyo®) - Résumé des caractéristiques du produit |
|
3577 |
Galen Limited |
Daunorubicine (Daunoxome®) - Résumé des caractéristiques du produit |
|
3578 |
Accord Healthcare |
Cisplatin - Summary of Product Characteristics |
|
3579 |
Janssen Cilag |
Cladribine Janssen Cilag - Résumé des caractéristiques du produit |
|
3580 |
Accord Healthcare France |
Cytarabine Accord - Résumé des caractéristiques du produit |
|
3581 |
Clinigen Healthcare |
Dexrazoxane (Cardioxane®) - Résumé des caractéristiques du produit |
|
3583 |
Roche |
Sulfaméthoxazole triméthoprime (Bactrim®) - Résumé des caractéristiques du produit |
|
3584 |
Aspen Pharma |
Melphalan (Alkéran®) - Résumé des caractéristiques du produit |
|
3585 |
Genus Pharmaceuticals |
Benzylpenicillin sodium - Summary of Product Characteristics |
|
3586 |
Actavis France |
Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit |
|
3587 |
GlaxoSmithKline |
Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics |
|
3588 |
Sandoz |
Vancomycine (Vancocin®) - Résumé des caractéristiques du produit |
|
3589 |
PanPharma |
Oxacilline PanPharma – Résumé des caractéristiques du produits |
|
3590 |
Dakota Pharm |
Piperacilline - Résumé des caractéristiques du produit |
|
3591 |
Bristol Myers Squibb |
Amphotericine B (Fungizone®) - Résumé des caractéristiques du produit |
|
3592 |
Sandoz |
Cimetidine - Résumé des caractéristiques du produit |
|
3593 |
Beacon Pharmaceuticals |
Ketorolac trometamol (Ketorolac®) - Summary of Product Characteristics |
|
3594 |
Zentiva |
Metronidazole (Flagyl®) - Summary of Product Characteristics |
|
3595 |
Hospira |
Aciclovir - Summary of Product Characteristics |
|
3596 |
Sanofi |
Chlorpromazine (Largactil®) - Summary of Product Characteristics |
|
3597 |
AstraZeneca |
Terbutaline sulfate (Bricanil®) - Summary of Product Characteristics |
|
3598 |
Clinigen Healthcare Ltd |
Amifostine (Ethyol®) - Résumé des caractéristiques du produit |
|
3599 |
Amco Amdipharm Mercry |
Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics |
|
3600 |
UCB Pharma SA |
Hydroxyzine (Atarax®) - Résumé des caractéristiques du produit |
|
3601 |
Actavis |
Cisatracurium Actavis - Résumé des Caractéristiques du Produit |
|
3602 |
Baxter SAS |
Mesna (Uromitexan®)- Summary of Product Characteristics |
|
3603 |
Adienne Pharma Biotech |
Thiotepa (Tepadina®) - Summary of Product Characteristics |
|
3604 |
Sanofi Aventis France |
Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit |
|
3605 |
Lipomed |
Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit |
|
3606 |
Wokhardt |
Dobutamine - Summary of Product Characteristics |
|
3607 |
AOP Orphan Pharmaceuticals AG |
Esmolol hydrochloride for injection - Summary of Product Characteristics |
|
3609 |
Aspen Pharma |
Labetalol (Trandate®) - Summary of Product Characteristics |
|
3610 |
J Oncol Pharm Practice |
Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion. |
|
3611 |
J Oncol Pharm Practice |
Physical and chemical stability of reconstituted and diluted dexrazoxane infusion solutions. |
|
3612 |
Amdipharm Mercury Company |
Doxapram (Dopram) - Summary of Product Characteristics |
|
3613 |
Primius Lab |
Dihydralazine (Nepressol®) - Résumé des caractéristiques du produit |
|
3614 |
American Regent Inc |
Nicardipine Injection - Summary of Product Characteristics |
|
3616 |
Boehringer Ingelheim |
Altéplase (Actilyse®) - Résumé des caractéristiques du produit |
|
3617 |
Wockhardt |
Hyaluronidase (Hyalase®) - Summary of Product Characteristics |
|
3618 |
Amgen |
Filgrastim (Neupogen®) - Summary of Product Characteristics |
|
3619 |
Wockhardt |
Pamidronate (Pamidronate Actavis®) - Summary of Product Characteristics |
|
3620 |
Beacon Pharmaceuticals |
Phenylephrine - Summary of Product Characteristics |
|
3621 |
Renaudin |
Phosphate dipotassique - Résumé des caractéristiques du produit |
|
3622 |
Int J Pharm Compound |
Chemical and Physical Compatibility of an Intravenous Solution of Epinephrine with Calcium Chloride. |
|
3624 |
Int J Pharm Compound |
Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets. |
|
3625 |
CSL Behring |
Streptokinase (Streptase®) - Summary of Product Characteristics |
|
3626 |
Astellas Pharma |
Tacrolimus (Prograf®) - Résumé des Caractéristiques du Produit |
|
3627 |
Boeringer Ingelheim |
Tenecteplase (Metalyse®) - Summary of Product Characteristics |
|
3629 |
Actavis UK |
Atracurium (Atracurium solution for injection/infusion®) - Summary of Product Characteristics |
|
3630 |
Merck Sharp Dohme |
Vecuronium (Norcuron®) - Summary of Product Characteristics |
|
3631 |
Aguettant |
Suxamethonium (Suxamethonium Aguettant®) - Résumé des caractéristiques du produit |
|
3632 |
Hospira |
Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics |
|
3634 |
Accord Healthcare |
Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit |
|
3635 |
Novartis Pharmaceuticals UK Ltd |
Aldesleukine (Proleukin®) - Summary of Product Characteristics |
|
3637 |
Hameln Pharmaceuticals |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics |
|
3638 |
Hospira |
Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics |
|
3639 |
Wockhardt |
Furosemide - Summary of Product Characteristics |
|
3640 |
Hospira |
Mitoxantrone - Summary of Product Characteristics |
|
3641 |
Pierre Fabre |
Vinorelbine (Navelbine®) - Summary of Product Characteristics |
|
3642 |
International Medication System (UK) |
Epinephrine - Résumé des Caractéristiques du Produit |
|
3643 |
Sanofi |
Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics |
|
3644 |
Hameln Pharmaceuticals |
Calcium gluconate® - Summary of Product Characteristics |
|
3645 |
Accord Healthcare |
Doxorubicin - Summary of Product Characteristics |
|
3646 |
Sanofi Aventis France |
Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produit |
|
3647 |
Roche |
Trastuzumab (Herceptin® 600 mg for subcutaneous injection) - Summary of Product Characteristics |
|
3648 |
Am J Health-Syst Pharm |
Stability of penicillin G sodium diluted with 0.9% sodium chloride injection or 5% dextrose injection and stored in polyvinyl chloride bag containers and elastomeric pump containers. |
|
3649 |
Am J Health-Syst Pharm |
Stability of clonidine suspension in oral plastic syringes. |
|
3651 |
Perit Dial Int |
Stability of the Combination of Ceftazidime and Cephazolin in Icodextrin or pH Neutral Peritoneal Dialysis Solution. |
|
3653 |
Laboratoire Léo |
Bumétanide (Burinex®) - Résumé des caractéristiques du produit |
|
3654 |
Keocyt |
Streptozocine (Zanosar®) - Résumé des caractéristiques du produit |
|
3655 |
Bristol Myers Squibb |
Etoposide phosphate (Etopophos®) - Résumé des caractéristiques du produit |
|
3656 |
Sanofi Aventis France |
Teicoplanine (Targocid®) - Résumé des caractéristiques du produit |
|
3658 |
Sandoz |
Omeprazole - Summary of Product Characteristics.
|
|
3659 |
AstraZeneca |
Propofol (Diprivan®) - Résumé des caractéristiques du produit |
|
3660 |
Hospira |
Isoprenaline (Isuprel®) - Résumé des caractéristiques du produit |
|
3661 |
Laboratoire Léo |
Fusidate de sodium (Fucidine®) - Résumé des caractéristiques du produit |
|
3662 |
Clinigen |
Foscavir (Foscarnet®) - Summary of Product Characteristics |
|
3663 |
Panpharma |
Fosfomycine (Fosfomycine Panpharma®) - Résumé des caractéristiques du produit |
|
3664 |
Am J Health-Syst Pharm |
Incompatibility of esmolol hydrochloride and furosemide in a central venous access port |
|
3665 |
Am J Health-Syst Pharm |
Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer’s injection and stored in polypropylene syringes at 4 and -20°C. |
|
3666 |
Int J Pharm Compound |
Investigation of Physical and Chemical Stability of an Ointment with Herbals |
|
3667 |
Int J Pharm Compound |
Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date |
|
3668 |
Hospira |
Dexamethasone - Summary of Product Characteristics |
|
3669 |
Ann Pharm Fr |
Formulation and stability study of a pediatric 2% phenylephrine hydrochloride eye drop solution |
|
3670 |
EJOP |
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. |
|
3671 |
Teva UK Ltd |
Deferoxamine - Résumé des caractéristiques du produit |
|
3672 |
Mylan SAS |
Nalbuphine Mylan - Résumé des caractéristiques du produit |
|
3674 |
PanPharma |
Erythromycin lactobionate - Summary of Product Characteristics |
|
3675 |
Archimedes Pharma UK Ltd |
Thiopental sodium - Summary of Product Characteristics |
|
3676 |
Hospira |
Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit |
|
3677 |
Sanofi Aventis France |
Cefpirome (Cefrom®) - Résumé des caractéristiques du produit |
|
3682 |
EJHP |
Extemporaneous sotalol hydrochloride oral solutions for use in paediatric cardiology: formulation and stability study. |
|
3683 |
Aguettant |
Baclofen - Résumé des caractéristiques du produit |
|
3684 |
Laboratoire Léo |
Bumétanide (Burinex®) - Résumé des caractéristiques du produit |
|
3685 |
EJHP |
A stability study of amphotericin B, colistin and tobramycin in a hydrophilic suspension commonly used for selective decontamination of the digestive tract by HPLC and in vitro potency measurements. |
|
3686 |
Eusapharma |
L asparaginase (Kidrolase®) - Résumé des caractéristiques du produit |
|
3687 |
Stravencon |
Cefuroxime sodium - Summary of Product Characteristics |
|
3688 |
Can J Hosp Pharm |
Stability of bortezomib 2.5 mg/mL in vials and syringes stored at 4°C and room temperature (23°C). |
|
3691 |
J Oncol Pharm Practice |
Physical and chemical stability of proflavine contrast agent solutions for early detection of oral cancer |
|
3694 |
Am J Hosp Pharm |
Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration. |
|
3696 |
Braz J Pharm Sci |
Biological and physicochemical stability of ceftazidime and aminophylline on glucose parenteral solution. |
|
3700 |
Braz J Pharm Sci |
Development, stability and in vitro permeation studies of gels containing mometasone furoate for the treatment of dermatitis of the scalp. |
|
3701 |
Gentium SPa |
Defibrotide (Defitelio®) - Summary of Product Characteristics |
|
3702 |
J Pharm Pract and Res |
Stability of buffered benzylpenicillin solutions for outpatient parenteral antimicrobial therapy. |
|
3704 |
Can J Hosp Pharm |
Stability of Epinephrine at Standard Concentrations |
|
3705 |
EJHP |
Physicochemical compatibility of commonly used analgesics and sedatives in the intensive care medicine. |
|
3706 |
Farm Hosp |
Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia. |
|
3707 |
J Oncol Pharm Practice |
Physico-chemical stability of eribulin mesylate containing concentrate and ready-to-administer solutions. |
|
3708 |
ECOP 2 Krakow |
Compatibility of epirubicin-loaded DC Beads with different contrast media. |
|
3711 |
Takeda |
Vedolizumab (Entyvio®) - Summary of Product Characteristics |
|
3712 |
Pediatr Crit Care Med |
Stability of dopamine and epinephrine solutions up to 84 hours. |
|
3713 |
Can J Hosp Pharm |
Stability of Extemporaneously Compounded Dexamethasone in Glass and Plastic Bottles and Plastic Syringes. |
|
3714 |
Can J Hosp Pharm |
Stability of Extemporaneously Compounded Clonidine in Glass and Plastic Bottles and Plastic Syringes. |
|
3715 |
Am J Health-Syst Pharm |
Compatibility of conivaptan injection with select cardiovascular medications. |
|
3717 |
Am J Health-Syst Pharm |
Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and -20 °C. |
|
3718 |
Bayer Healthcare Corporation |
Conivaptan (Vaprisol®) - Summary of Product Characteristics |
|
3721 |
Spectrum Pharmaceuticals |
Belinostat (Beleodaq®) - Summary of Product Characteristics |
|
3722 |
Acta Pol Pharm |
Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms. |
|
3723 |
Archives de Pédiatrie |
Stabilité des préparations extemporanées de doxapram (Doprams®) à usage néonatal. |
|
3725 |
Dysphagia |
An investigation into the stability and sterility of citric acid solutions used for cough reflex testing. |
|
3728 |
Am J Health-Syst Pharm |
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. |
|
3731 |
J Pharm Sci |
Thermal and photolytic decomposition of methotrexate in aqueous solutions. |
|
3743 |
Int J Pharm |
The degradation of carboplatin in aqueous solutions containing chloride or other selected nucleophiles. |
|
3745 |
Am J Hosp Pharm |
Sodium chloride residue provides potential for drug incompatibiities. |
|
3752 |
Durata Therapeutics Holding |
Dalbavancin (Dalvance®) - Summary of Product Characteristics |
|
3753 |
Cubist Pharmaceuticals |
Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics |
|
3754 |
Int J Pharm Compound |
Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation. |
|
3755 |
Int J Pharm Compound |
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition. |
|
3756 |
Int J Pharm Compound |
Stability of Tranexamic Acid in 0.9% Sodium Chloride, Stored in Type 1 Glass Vials and Ethylene/Propylene Copolymer Plastic Containers. |
|
3757 |
Antimicrob Agents Chemother |
How To Minimize Toxic Exposure to Pyridine during Continuous Infusion of Ceftazidime in Patients with Cystic Fibrosis? |
|
3758 |
J Pharm Pract and Res |
Feasibility and stability of metaraminol in pre-filled syringes. |
|
3759 |
Yakugaku Zasshi |
Examination of the cause of changing solution color by mixing aminophylline and dopamine, the compatibility of which was indicated by the supplier. |
|
3760 |
J Oncol Pharm Practice |
An evaluation of the stability of granulocyte colony stimulating factor on the short-term storage and delivery from an elastomeric infusion system. |
|
3761 |
Master en pharmacie - University of Geneva |
Etude de la stabilité de solutions de prostaglandine E1 à 48 et 72 heures en vue d'une administration parentérale en continu à des patients de néonatalogie. |
|
3763 |
Can J Hosp Pharm |
Stability of Extemporaneously Compounded Pyridoxine in Glass and Plastic Bottles and Plastic Syringes. |
|
3764 |
Am J Health-Syst Pharm |
Compatibility of argatroban injection with select antiarrhythmic drugs |
|
3766 |
Pharmactuel |
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels |
|
3767 |
Pharmactuel |
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. |
|
3768 |
Roche Products Limited |
Obinutuzumab (Gazyvaro®) - Summary of Product Characteristics |
|
3769 |
B Braun laboratoire |
Paracatamol (Paracetamol B Braun®) - Résumé des caractéristiques du produit |
|
3770 |
Eclat Pharmaceuticals |
Phenylephrine hydrochloride (Vazculep®) - Summary of Product Characteristics |
|
3772 |
Janssen Biotech |
Siltuximab (Sylvant®) - Summary of Product Characteristics |
|
3773 |
Eli Lilly |
Ramicirumab (Cyramza®) - Summary of Product Characteristics |
|
3774 |
Amgen |
Blinatumomab - (Blincyto®) - Summary of Product Characteristics |
|
3775 |
Talon Therapeutics |
Vincristine sulfate liposome (Marqibo®) - Summary of Product Characteristics |
|
3776 |
Teva Pharmaceuticals |
Omecetaxine (Synribo®) - Summary of Product Characteristics |
|
3777 |
Am J Health-Syst Pharm |
Stability of ampicillin and amoxicillin in peritoneal dialysis solutions |
|
3779 |
Am J Health-Syst Pharm |
Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection |
|
3780 |
EJHP |
Stability of an epidural analgesic admixture containing butorphanol tartrate and ropivacaine hydrochloride |
|
3781 |
EJHP |
Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. |
|
3782 |
Int J Pharm |
Study of quality and stability of ursodeoxycholic acid formulations for oral pediatric administration |
|
3785 |
J Pain Palliat Care Pharm |
Formulation and Stability of an Extemporaneously Compounded Oral Solution of Chlorpromazine HCl |
|
3786 |
JAMA Ophtalmology |
Stability of Melphalan Solution for Intravitreal Injection for Retinoblastoma |
|
3787 |
The Medicines Company |
Oritavancin diphosphate (Orbactiv®) - Summary of Product Characteristics |
|
3789 |
Int J Pharm Compound |
Physicochemical and Microbiological Stability of Azathioprine in InOrpha Suspending Agent Studied Under Various Conditions. |
|
3791 |
Apifh Congress, Paris November 2014 |
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. |
|
3792 |
J Ped Pharm Pract |
Stability of amiodarone in extemporaneous oral suspension prepared from commercially available vehicles. |
|
3793 |
Drug Intell Clin Pharm |
Stability of labetalol hydrochloride in distilled water, simple syrup, and three fruit juices. |
|
3794 |
Can J Hosp Pharm |
Vancomycin 50 mg/mL Suspension in Oral Syrup: Stability in Plastic Bottles and Syringes at 2 Temperatures. |
|
3796 |
Br Ophtalmol |
High dose intravitreal ganciclovir for CMV retinitis: a shelf life and cost comparison study. |
|
3798 |
Analytical Letter |
Stability indicating HPLC assay of zidovudine in extemporaneously syrup. |
|
3800 |
Iranian J Pharm Res |
Formulation and Clinical Evaluation of Povidone-Iodine Ophthalmic Drop. |
|
3802 |
J Clin Pharm Ther |
Stability of captopril in invert sugar solution |
|
3803 |
Laboratoires Merck Sharp & Dohme Chibret |
Ceftolozane / tazobactam (Zerbaxa®) - Summary of Product Characteristics |
|
3804 |
EJHP |
Physicochemical stability of cabazitaxel and docetaxel solutions. |
|
3805 |
Am J Health-Syst Pharm |
Compatibility of butorphanol with granisetron in 0.9% sodium chloride injection packaged in glass bottles or polyolefin bags. |
|
3810 |
Int J Pharm Compound |
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF. |
|
3811 |
Int J Pharm Compound |
Stability of Levothyroxine, Doxycycline, Hydrocortisone, and Pravastatin in Liquid Dosage Forms Stored at Two Temperatures. |
|
3812 |
Int J Pharm Compound |
In-use Stability of Ceftaroline Fosamil in Elastomeric Home Infusion Systems and MINI-BAG Plus Containers. |
|
3813 |
Hosp Pharm |
Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery. |
|
3816 |
SFPO Congress, Nantes, France |
Stabilité des poches d'azacitidine pour injection intraveineuse (1- 4 et 2,4 mg/mL) conservées à 4°C. |
|
3817 |
Gerpac Congress, Giens, France |
A stability study of 25 mg/mL phenylephrine hydrochloride and 5 mg/mL tropicamide eye drops. |
|
3818 |
Pharmaceutical Technology in Hospital Pharmacy |
Stability of 25 mg/mL 5-azacitidine suspension kept in fridge after freezing. |
|
3819 |
J Pharm Biomed Anal |
Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. |
|
3821 |
Am J Health-Syst Pharm |
Stability of furosemide and chlorothiazide stored in syringes. |
|
3823 |
Pharmactuel |
Compatibilité physique de médicaments administrés dans l’unité de soins intensifs
|
|
3824 |
Pharmactuel |
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. |
|
3825 |
J Pharm Pract and Res |
Evaluation of the physicochemical and functional stability of diluted REMSIMA(R) upon extended storage—A study compliant with NHS (UK) guidance. |
|
3826 |
Can J Hosp Pharm |
Stability of Extemporaneously Compounded Naproxen 25 mg/mL Suspension in Glass and Plastic Bottles and Plastic Syringes. |
|
3827 |
ASHP Midyear |
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. |
|
3828 |
ASHP Midyear |
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. |
|
3829 |
ASHP Midyear |
Compatibility of isavunazonium sulfate during simulated Y-site administration. |
|
3830 |
J Oncol Pharm Practice |
Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags. |
|
3832 |
Ann Pharmacotherapy |
Stability Studies of Extemporaneously Compounded Clobazam Oral Suspension. |
|
3835 |
Current Ther Res |
Chemical Stability of Telavancin in Elastomeric Pumps. |
|
3837 |
South Asian J Trop Med Pub Health |
Stability of meropenem in normal saline solution after storage at room temperature. |
|
3838 |
Martindale Pharmaceuticals Ltd |
Magnesium Sulphate - Summary of Product Characteristics |
|
3839 |
Current Ther Res |
Post-reconstitution Stability of Telavancin with Commonly Used Diluents and Intravenous Infusion Solutions. |
|
3840 |
Acta Pol Pharm |
Stability of cefpirome sulfate in aqueous solutions. |
|
3841 |
Am J Health-Syst Pharm |
Visual and absorbance analyses of admixtures containing vancomycin and piperacillin–tazobactam at commonly used concentrations. |
|
3842 |
Am J Health-Syst Pharm |
Stability of tacrolimus solutions in polyolefin containers. |
|
3843 |
Int J Pharm Compound |
Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date. |
|
3844 |
Ann Pharmacotherapy |
Stability and Osmolality of Extemporaneously Prepared Clonidine Oral Liquid for Neonates. |
|
3845 |
Ann Pharmacotherapy |
Stability of Pentobarbital in Water and Oral Pediatric Suspensions. |
|
3846 |
Pharmazie |
Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. |
|
3847 |
J Pain Palliat Care Pharm |
A Pilot Chemical and Physical Stability Study of Extemporaneously Compounded Levetiracetam Intravenous Solution. |
|
3848 |
Thèse de doctorat en pharmacie |
Etude de stabilité d'un collyre à l'amphotéricine B 0,5%. |
|
3849 |
Curr Pharm Biotech |
Physical and structural stability of the monoclonal antibody, trastuzumab (Herceptin®), intravenous solutions. |
|
3850 |
Eur J Cancer |
Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues. |
|
3851 |
Can J Hosp Pharm |
Dexamethasone 1 mg/mL Suspension Prepared from Crushed Tablets: Stability in Glass and Plastic Bottles and Plastic Syringes. |
|
3854 |
Can J Hosp Pharm |
Stability of extemporaneously compounded trimethioprim in glass and plastic bottles and plastic syringes. |
|
3856 |
Int J Pharm Compound |
Long-term Stability of Zonisamide, Amitriptyline, and Glycopyrrolate in Extemporaneously Prepared Liquid-dosage Forms at Two Temperatures |
|
3857 |
Int J Pharm Compound |
Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions |
|
3859 |
RRJHCP |
Microbiological and Physico-Chemical Stability of Ketamine Solution for Patient-Controlled Analgesia Systems. |
|
3860 |
J Pharm Pract and Res |
Stability of trimethoprim in newly formulated liquid dosage form. |
|
3861 |
J Pharm Pract and Res |
Evaluation of stability of melatonin in extemporaneously compounded oral suspensions. |
|
3862 |
Hosp Pharm |
Enzymatic Stability of Alteplase Solution for Injection: Effect of Various Methods of Thawing Frozen Solutions. |
|
3865 |
Int J Pharm Compound |
Compatibility of Norepinephrine Bitartrate with Levofloxacin and Moxifloxacin During Simulated Y-site Administration. |
|
3866 |
Int J Pharm Compound |
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children. |
|
3868 |
J Oncol Pharm Practice |
Incompatibility of busulfan with 1 ml Luer-Lock syringes. |
|
3869 |
J Pharm Pharmacol |
Influence of 5% dextrose volume on amphotericin B deoxycholate preparation |
|
3871 |
Synprefh Congress Clermont Ferrand, France |
Peut-on administrer le céfotaxime en Y avec d'autres médicaments injectables ? |
|
3872 |
Hosp Pharm |
Stability of an Extemporaneously Compounded Oral Suspension of Bosentan. |
|
3873 |
Am J Health-Syst Pharm |
Incompatibility between irinotecan and fluorouracil injections |
|
3874 |
Ann Pharm Fr |
Long-term stability of ketamine hydrochloride 50 mg/ml injection in 3 ml syringes |
|
3875 |
EJHP |
Development and stability study of glibenclamide oral liquid paediatric formulations for the treatment of permanent neonatal diabetes mellitus. |
|
3879 |
Int J Pharm Compound |
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. |
|
3880 |
Int J Pharm Compound |
Stability of Ampicillin in Normal Saline and Buffered Normal Saline. |
|
3881 |
Int J Pharm Compound |
Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump. |
|
3883 |
Arrow |
Ceftazidime - Résumé des caractéristiques du produit |
|
3885 |
Int J Pharm |
Diazepam sorption to PVC- and non-PVC-based tubes in administration sets with quantitative determination using a high-performance liquid chromatographic method. |
|
3886 |
Eur J Pharm Sci |
Design and stability study of an oral solution of amlodipine besylate for pediatric patients. |
|
3887 |
Perit Dial Int |
Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. |
|
3888 |
Perit Dial Int |
Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study). |
|
3891 |
Can J Hosp Pharm |
Stability of Ertapenem 100 mg/mL in Manufacturer’s Glass Vials or Syringes at 4°C and 23°C |
|
3892 |
Can J Hosp Pharm |
Stability of Hydrocortisone, Nifedipine, and Nitroglycerine Compounded Preparations for the Treatment of Anorectal Conditions |
|
3893 |
Can J Hosp Pharm |
Stability of Extemporaneously Compounded Amlodipine Besylate Oral Suspensions |
|
3895 |
Ann Pharmacotherapy |
Physicochemical Stability Study of Polymyxin B in Various Infusion Solutions for Administration to Critically Ill Patients |
|
3896 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical Stability of Mozobil® (Plerixafor) Solution for Injection in Glass Vials and Plastic Syringes over a Three-Month Storage Period |
|
3897 |
Pharmaceutical Technology in Hospital Pharmacy |
Stability of Reconstituted and Diluted Mitomycin C Solutions in Polypropylene Syringes and Glass Vials. |
|
3898 |
EJHP |
Chemical and microbiological stability studies of an aqueous solution of pravastatin sodium salt for drug therapy of the dysphagic patients |
|
3901 |
Int J Pharm Compound |
Stability of Clindamycin Hydrochloride in PCCA Base SuspendIt |
|
3902 |
Int J Pharm Compound |
Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions. |
|
3903 |
Int J Pharm Compound |
Stability of Sodium Nitroprusside in 5% Dextrose Stored at 4°C in Polypropylene Syringes Protected from Light. |
|
3910 |
EJHP |
Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. |
|
3911 |
EJHP |
Does an interaction exist between ketamine hydrochloride and Becton Dickinson syringes? |
|
3913 |
EJHP |
Compatibility of proton pump inhibitors in a preservative-free suspending vehicle. |
|
3915 |
Am J Health-Syst Pharm |
Stability of tacrolimus injection diluted in 0.9% sodium chloride injection and stored in Excel bags |
|
3916 |
Int J Pharm Compound |
Stability of Fentanyl Citrate in Polyolefin Bags. |
|
3917 |
Int J Pharm Compound |
Stability of Ribavirin for Inhalation Packaged in Syringes or Glass Vials when Stored Frozen, Refrigerated, and at Room Temperature. |
|
3918 |
J Oncol Pharm Practice |
Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media. |
|
3919 |
Eur J Pharm Sci |
Physicochemical stability and compatibility testing of levetiracetam in all-in-one parenteral nutrition admixtures in daily practice. |
|
3920 |
Fresenius Kabi |
Levofloxacine - Résumé Caractéristique du Produit |
|
3921 |
Can J Hosp Pharm |
Stability of extemporaneously prepared enalapril maleate suspensions in glass bottles and plastic syringes. |
|
3922 |
Perit Dial Int |
Compatibility of meropenem with different commercial dialysis solutions. |
|
3923 |
Am J Health-Syst Pharm |
Stability of sildenafil in combination with heparin and dopamine. |
|
3924 |
Ann Pharm Fr |
One-month stability study of a biosimilar of infliximab (Remsima®) after dilution and storage at 4 C and 25 C. |
|
3925 |
Ann Pharm Fr |
Long-term stability of dexamethasone and alizapride or ondansetron in sodium chloride 0.9% polyolefin bag at 5±3 C. |
|
3926 |
Hosp Pharm |
Stability of Levodopa/Carbidopa Rectal Suspensions. |
|
3927 |
Int J Pharm Compound |
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate. |
|
3928 |
Int J Pharm Compound |
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride. |
|
3930 |
Serb laboratoire |
Indocyanine (Infracyanine®) - Résumé des caractéristiques du produit |
|
3931 |
Pfizer Laboratoire |
Trimébutine (Débridat®) - Résumé des caractéristiques du produit |
|
3932 |
Serb Laboratoire |
Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit |
|
3933 |
Teva Laboratoire |
Acide zolédronique - (Acide zoledronique Teva Pharma) - Résumé des caractéristiques du produit |
|
3934 |
GlaxoSmithKline Laboratoire |
Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit |
|
3935 |
Sanofi Laboratoire |
Insuline glulisine (Insulines Sanofi Apidra®) - Résumé des caractéristiques du produit |
|
3936 |
GlaxoSmithKline Laboratoire |
Bélimumab (Benlysta®) – Résumé des caractéristiques du produits |
|
3937 |
Biomat Res |
Stability study of docetaxel solution (0.9% saline) using Non-PVC and PVC tubes for intravenous administration. |
|
3938 |
Lilly S.A |
Necitumumab (Portrazza®) – Résumé des caractéristiques du produits |
|
3941 |
Concordia International |
Nicardipine - Summary of Product Characteristics |
|
3942 |
Am J Health-Syst Pharm |
Physical compatibility of valproate sodium injection with dobutamine and dopamine. |
|
3945 |
Can J Hosp Pharm |
Extended Stability of Sodium Phosphate Solutions in Polyvinyl Chloride Bags. |
|
3946 |
Can J Hosp Pharm |
Stability of Extemporaneously Compounded Tacrolimus in Glass Bottles and Plastic Syringes |
|
3948 |
JPEN |
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. |
|
3949 |
JFSPH Congress, Bern, Switzerland. |
Optimisation du processus de préparation des solutions de melphalan destinées à l’administration intra-vitréenne dans le traitement du rétinoblastome et étude de leur stabilité |
|
3951 |
Hemodial Int |
Antibiotic lock: In vitro stability of vancomycin and four percent sodium citrate stored in dialysis catheters at 37°C |
|
3952 |
Hemodial Int |
Antibiotic lock: In vitro stability of gentamicin and sodium citrate stored in dialysis catheters at 37°C. |
|
3953 |
Hemodial Int |
In vitro stability and compatibility of tenecteplase in central venous access devices. |
|
3956 |
ASAIO Journal |
Prolonged Stability of Stored Vancomycin, Gentamicin, and Heparin for Use in the Antibiotic-Lock Technique. |
|
3958 |
J Infect Dis |
A Dilute Solution of Vancomycin and Heparin Retains Antibacterial and Anticoagulant Activities . |
|
3960 |
Hosp Pharm |
Y-site Incompatibility Between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story? |
|
3961 |
Int J Pharm Compound |
Stability of Alprostadil in 0.9% Sodium Chloride Stored in Polyvinyl Chloride Containers. |
|
3963 |
Int J Pharm Compound |
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions. |
|
3964 |
Pharmactuel |
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. |
|
3967 |
J Pharm Pharmacol |
Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. |
|
3968 |
Fresenius Kabi |
Ringer lactate - Résumé des Caractéristiques du Produit |
|
3969 |
Neuromodulation |
Solubility and stability of Baclofen 3 mg/mL intrathecal formulation and its compatibility with implantable programmable intrathecal infusion systems. |
|
3971 |
Int J Pharm Compound |
Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs. |
|
3974 |
Eur J Pharm Sci |
Stability of frozen 1% voriconazole eye drops in glass and in innovative containers. |
|
3975 |
EAHP congress - Cannes |
Stability of 50 and 100 µg/0,1mL intraocular solutions of voriconazole at 2-8°C. |
|
3976 |
Am J Health-Syst Pharm |
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. |
|
3977 |
Drugs R D |
Stability of Melphalan in 0,9% Sodium Chloride Solutions Prepared in Polyvinyl Chloride Bags for Intravenous Injection. |
|
3978 |
Am J Health-Syst Pharm |
Beyond-use dating of lidocaine alone and in two “magic mouthwash” preparations. |
|
3980 |
Am J Health-Syst Pharm |
Stability study of methotrexate in 0.9% sodium chloride injection and 5% dextrose injection with limit tests for impurities. |
|
3981 |
EJHP |
Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study |
|
3983 |
EJHP |
Compounding and stability evaluation of atorvastatin extemporaneous oral suspension using tablets or pure powder. |
|
3984 |
Hosp Pharm |
Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. |
|
3985 |
Hopipharm Congress 2017 - Nancy |
Compatibilité physique entre médicaments injectables et nutrition parentérale pédiatrique : Evaluation in-vitro. |
|
3986 |
Krankenhauspharmazie |
Physikalisch-chemische Stabilität von Carfilzomib (Kyprolis®) im Originalbehältnis nach Erstanbruch und in applikationsfertigen Zubereitungen. |
|
3988 |
Am J Health-Syst Pharm |
Stability of tacrolimus ophthalmic solution. |
|
3989 |
Pharmaceutical Technology in Hospital Pharmacy |
Stability of midazolam and noradrenaline stored in cyclic olefin copolymer AT-Closed Vials® and polypropylene syringes during 365 days. |
|
3992 |
Int J Pharm |
Formulation and charaterization of 0,1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas. |
|
3993 |
Int J Pharm Compound |
Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes. |
|
3994 |
Int J Pharm Compound |
Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions. |
|
3996 |
Int J Pharm Compound |
Updated Stability Data of Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSprend SF and Minoxidil in Espumil. |
|
3997 |
Am J Health-Syst Pharm |
Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. |
|
3998 |
Int J Pharm Compound |
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia. |
|
3999 |
Int J Pharm Compound |
Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4. |
|
4000 |
Int J Pharm Compound |
Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt. |
|
4001 |
Int J Pharm Compound |
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox). |
|
4003 |
EJHP |
Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab). |
|
4004 |
Krankenhauspharmazie |
Physikalisch-chemische Stabilität von Oxaliplatin-beta-Infusionslösungskonzentrat und Infusionslösungen in 5 % Glucose in Polyolefin-Infusionsbeuteln. |
|
4007 |
Hopipharm Congress 2017-Nancy |
Etude de la stabilité de la vancomycine à 40 mg/ml au cours d'une perfusion de 24 heures. |
|
4008 |
Hopipharm Congress 2017-Nancy |
Formulation et étude de stabilité de crèmes au sirolimus dosées à 0,1, à 0,25 ou à 0,5% m/m. |
|
4009 |
Panpharma |
Droperidol - Résumé des Caractéristiques du Produit |
|
4011 |
EJHP |
Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit. |
|
4012 |
EJHP |
Investigations into the physical and chemical stability of concentrated co-trimoxazole intravenous infusions. |
|
4013 |
EJHP |
Stability of warfarin sodium flavoured preservative-free oral liquid formulations. |
|
4016 |
Ann Pharm Fr |
Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bag. |
|
4018 |
Krankenhauspharmazie |
Physikalisch-chemische Stabilität von rekonstituierten Trabectedin-haltigen Lösungen. |
|
4020 |
Hosp Pharm |
Stability of Sodium Nitroprusside and Sodium Thiosulfate 1:10 Intravenous Admixture. |
|
4021 |
J Oncol Pharm Practice |
Long-term stability of ganciclovir in polypropylene containers at room temperature. |
|
4022 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared rosuvastatin oral suspension. |
|
4023 |
Hosp Pharm |
Compounded Apixaban Suspensions for Enteral Feeding Tubes. |
|
4024 |
SFPO Congress 2017 - Nantes |
Pénurie mondiale d'Etopophos et conséquences pratiques : Intérêt des études de stabilité dans le choix d'un générique. |
|
4025 |
SFPO Congress 2017 - Nantes |
Stabilité physico-chimique de solutions de Nivolumab à 1 mois. |
|
4026 |
Hosp Pharm |
Extended Stability of Epinephrine Hydrochloride Injection in Polyvinyl Chloride Bags Stored in Amber Ultraviolet Light-Blocking Bags. |
|
4027 |
Hosp Pharm |
Compatibility, Stability, and Efficacy of Vancomycin Combined With Gentamicin or Ethanol in Sodium Citrate as a Catheter Lock Solution. |
|
4028 |
Hosp Pharm |
Stability of Procainamide Injection in Clear Glass Vials and Polyvinyl Chloride Bags. |
|
4029 |
Int J Pharm Compound |
Stability of Dexmedetomidine in 0.9% Sodium Chloride in Two Types of Intravenous Infusion Bags. |
|
4030 |
Int J Pharm Compound |
Physicochemical Stability of an Oral Suspension of Trimethoprim 20 mg/mL in Combination with Sulfadiazine 200 mg/mL in PCCA Base SuspendIt. |
|
4031 |
Int J Pharm Compound |
Stability of Dalteparin 1,000 Unit/mL in 0.9% Sodium Chloride for Injection in Polypropylene Syringes. |
|
4032 |
EAHP Congress - Paris |
Stability of frozen ceftazidime in polypropylene syringes for intravitreal injection. |
|
4033 |
Am J Health-Syst Pharm |
Stability of busulfan solutions in polypropylene syringes and infusion bags as determined with an original assay. |
|
4034 |
Afr J Pharm Pharmacol |
Compatibility and stability of lornoxicam with morphine, tramadol or fentanyl in infusion solutions. |
|
4035 |
EJHP |
Physicochemical stability of voriconazole in elastomeric devices. |
|
4036 |
EJHP |
Stability and compatibility of ondansetron with haloperidol in parenteral admixtures. |
|
4040 |
J Oncol Pharm Practice |
The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion. |
|
4041 |
SNPHPU Congress 12th |
Etude de stabilité d'un collyre de ceftazidime à 50mg/ml conditionné en flacon de polyéthylène basse densité. |
|
4043 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical Stability of Reconstituted Decitabine (Dacogen®) Solutions and Ready-to-Administer Infusion Bags when Stored Refrigerated or Frozen. |
|
4044 |
Pharm Sci Communications |
Quality assessment and stability study of compounded furosemide syrup. |
|
4045 |
J Pharm Biomed Anal |
A UHPLC-UV-QTOF study on the stability of carfilzomib, a novel proteasome inhibitor. |
|
4047 |
J Oncol Pharm Practice |
Physicochemical stability of carfilzomib (Kyprolis®) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over a 28-day storage period. |
|
4048 |
Hosp Pharm |
In vitro evaluation of eslicarbazepine delivery via enteral feeding tubes. |
|
4049 |
J Pharm Biomed Anal |
Stability of infliximab solutions in different temperature and dilution conditions. |
|
4050 |
Pharmaceutical Technology in Hospital Pharmacy |
Preparation and physico-chemical stability of dexamethasone oral suspension. |
|
4051 |
Pharmaceutical Technology in Hospital Pharmacy |
Stability study of morphine and baclofen solution in polypropylene syringes. |
|
4052 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical and microbiological stability of a new paediatric oral solution of clonidine. |
|
4053 |
Am J Health-Syst Pharm |
Stability of a pyrimethamine suspension compounded from bulk powder. |
|
4054 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared preservative-free prochlorperazine nasal spray. |
|
4055 |
Am J Health-Syst Pharm |
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. |
|
4056 |
Perit Dial Int |
Stability of ceftazidime and heparine in four different types of peritoneal dialysis solutions. |
|
4057 |
Hosp Pharm |
Physical Compatibility of Micafungin With Sodium Bicarbonate Hydratation Fluids Commonly Used With High-Dose Methotrexate Chemotherapy. |
|
4059 |
EJHP |
Physical and chemical stability of ceftaroline in an elastomeric infusion device. |
|
4060 |
EJHP |
Furosemide ethanol-free oral solutions for paediatric use : formulation, HPLC method and stability study. |
|
4061 |
Int J Pharm Compound |
Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous granisetron hydrochloride. |
|
4062 |
Int J Pharm Compound |
Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous palonosetron hydrochloride injection and dexamethasone sodium phosphate injection. |
|
4063 |
Int J Pharm Compound |
Stability of an Alcohol-free, Dye-free Hydrocortisone (2mg/mL) Compounded Oral Suspension. |
|
4065 |
Mylan |
Urapidil (Eupressyl® - résumé des caractéristiques du produit) |
|
4066 |
APHIF 2017 - Congress 2017 |
Etude de stabilité physico-chimique et microbiologique des collyres de ciclosporine à 0.5 ; 5 et 20 mg/mL conditionnés en flacons de polyéthylène basse densité. |
|
4067 |
Pharmazie |
Caspofungin infusion solutions (50 mg/mL): chemical stability and antifungal activity against Candida spp. |
|
4068 |
|
Natalizumab (Tysabri®) - Summary of Product Characteristics |
|
4069 |
EJHP |
Stability of prostaglandin E1 solutions stored in polypropylene syringes for continuous intravenous administration to newborns. |
|
4070 |
Hosp Pharm |
Stability of 2 mg/mL Adenosine Solution in Polyvinyl Chloride and Polyolefin Infusion Bags. |
|
4074 |
EJHP |
Stability of daptomycin reconstituted vials and infusion solutions. |
|
4075 |
Am J Health-Syst Pharm |
Stability of an extemporaneously compounded minoxidil oral suspension. |
|
4077 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical Stability of 5 mg/mL Pediatric Prednisone Oral Suspensions in Syrspend® SF PH4. |
|
4079 |
J Pharm Anal |
Formulation, stability testing, and analytical characterization of melatonin-based preparation for clinical trial. |
|
4080 |
Anaesthesia |
Physical Compatibility of Propofol-Sufentanil Mixtures. |
|
4082 |
EJHP |
Stability of mixtures of ondansetron and haloperidol stored in infusors at different temperatures. |
|
4084 |
Accord Health Care |
Cisplatine - Résumé des caractéristiques du produits |
|
4085 |
Can J Hosp Pharm |
Stability of Thiamine in Extemporaneously Compounded Suspensions. |
|
4086 |
Novartis Pharma |
Octréotide - (Sandostatine®)- Résumé des caractéristiques du produit |
|
4087 |
Pharmaceutical Technology in Hospital Pharmacy |
Stability of 5 mg/mL Nitrendipine Oral Suspension in SyrSpend® SF PH4. |
|
4089 |
Pharmaceutical Technology in Hospital Pharmacy |
Stability of Concentrated Solution of Vancomycin Hydrochloride in Syringes for Intensive Care Units. |
|
4090 |
Pharm Dev Technol |
Stability study of a clonidine oral solution in a novel vehicle designed for pediatric patients. |
|
4092 |
Pharm Dev Technol |
Stability study of oral paediatric idebenone suspensions. |
|
4096 |
Pharm Dev Technol |
Physicochemical stability of a new topical timolol 0.5% gel formulation for the treatment of infant hemangioma. |
|
4097 |
Pharm Dev Technol |
Physicochemical stability of captopril and enalapril extemporaneous formulations for pediatric patients. |
|
4101 |
Pharmaceutical Technology in Hospital Pharmacy |
Paediatric formulation: budesonide 0.1 mg/mL viscous oral solution for eosinophilic esophagitis using cyclodextrins. |
|
4102 |
J Oncol Pharm Practice |
Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastromeric pump supporting transition of the EPOCH regimen to oupatient care. |
|
4103 |
Pharmaceutical Technology in Hospital Pharmacy |
Safe use of Dexamethasone in pediatrics: design and evaluation of a novel stable oral suspension. |
|
4104 |
Pharmaceutical Technology in Hospital Pharmacy |
Formulation of a 3-months Stability Oral Viscous Budesonide Gel and Development of an Indicating Stability HPLC Method. |
|
4105 |
Ann Pharmacotherapy |
Stability of Sunitinib in Oral Suspensions. |
|
4106 |
Can J Hosp Pharm |
Stability of Dapsone in Extemporaneously Compounded Oral Suspensions. |
|
4107 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical Stability of Extemporaneously Prepared Oral Suspension of Fluconazole 50 mg/mL in SuspendIt. |
|
4108 |
Am J Health-Syst Pharm |
Physical compatibility of levetiracetam injection with heparin, dobutamine, and dopamine. |
|
4109 |
Am J Health-Syst Pharm |
Stability of milrinone in continuous ambulatory delivery devices. |
|
4111 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared ophtalmic solutions for mydriasis. |
|
4112 |
Int J Pharm Compound |
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions. |
|
4113 |
Am J Health-Syst Pharm |
Stability of isoniazid injection in i.v. solutions. |
|
4115 |
Drug Design Dev Ther |
Physicochemical stability of ternary admixtures of butorphanol, ketamine, and droperidol in polyolefin bags for patient-controlled analgesia use. |
|
4116 |
Drug Design Dev Ther |
Stability of tramadol with three 5-HT3 receptor antagonists in polyolefin bags for patient-controlled delivery systems. |
|
4117 |
Drug Design Dev Ther |
Evaluation of the stability of linezolid in aqueous solution and commonly used intravnous fluids. |
|
4118 |
Drug Design Dev Ther |
Stability studies of lincomycin hydrochloride in aqueous solution and intravenous infusion fluids. |
|
4119 |
Hôpitaux Universitaire de Genève |
Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®) |
|
4120 |
J Oncol Pharm Practice |
Stability of carboplatin infusion solutions used in desensitization protocol. |
|
4121 |
Int J Pharm Compound |
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia. |
|
4122 |
Hosp Pharm |
Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion. |
|
4123 |
J Oncol Pharm Practice |
Storage and transport of reconstituted omacetaxine mepesuccinate: Considerations for home administration. |
|
4125 |
EJHP |
Physicochemical stability of etoposide diluted at range concentrations between 0.38 and 1.75 mg/mL in polyolefin bags. |
|
4126 |
Pharmaceutical Technology in Hospital Pharmacy |
Physico-Chemical Stability of Sodium Thiosulfate Infusion Solutions in Polyolefin Bags at Room Temperature over a Period of 24 Hours. |
|
4128 |
GRITA Symposium Perfusion 2017, Lille, France. |
Stabilité de la vancomycine à des doses méningées dans les seringues au cours d'une perfusion de 24 heures. |
|
4130 |
Pharmaceutics |
Untersuchungen zur Kompatibilität von Clonidin mit häufig eingesetzen Arzneimittel auf Intensivstationen. |
|
4131 |
Hosp Pharm |
Physical Compatibility and Chemical Stability of Injectable and Oral Ranitidine. |
|
4137 |
Newsletter Stabilis |
Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare). |
|
4139 |
Int J Pharm Compound |
Stability of Extemporaneously Prepared Sodium Benzoate Oral Suspensions. |
|
4140 |
Int J Pharm Compound |
Comparative Stability of Vitamin K1 Oral Liquids Prepared in Sterile Water for Injection and Stored in Amber Glass Bottles and Amber Plastic Syringes. |
|
4141 |
J Clin Pharm Ther |
Stability of dobutamine in continuous ambulatory delivery devices. |
|
4142 |
Can J Hosp Pharm |
Stability of Extemporaneously Compounded Domperidone 5 mg/mL Suspension in Oral Mix in Plastinc and Glass Bottles and Plastic Syringes. |
|
4143 |
EJHP |
Physicochemical stability of oxycodone-ketamine solutions in polypropylene syringe and polyvinyl chloride bag for patient-controlled analgesia use. |
|
4144 |
EJHP |
Physical compatibility of milrinone with levofloxacin and ceftriaxone injection. |
|
4145 |
Am J Health-Syst Pharm |
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. |
|
4147 |
Minerva Anestesiologica |
Stability of generic brands of meropenem reconstituted in isotonic saline. |
|
4148 |
Pharmaceutical Technology in Hospital Pharmacy |
Long-Term Stability Comparison between an Original and a Generic Version of Piperacillin/Tazobactam in Dextrose 5% Infusion Polyolefin Bags at 5+/-3°C after Microwave Freeze-Thaw Treatment. |
|
4153 |
Orphan Europe (UF) Limited |
Dactinomycin (Cosmegen Lyovac®) - Summary of Product Characteristics |
|
4154 |
Accord Health Care |
Bleomycin sulfate- Summary of Product Characteristics |
|
4157 |
Pediatric Anesthesia |
Evaluation of the stability and stratification of propofol and ketamine mixtures for pediatric anesthesia. |
|
4160 |
J Pharm Pharmacol |
The Stability of Noradrenaline Solutions. |
|
4162 |
Ann Pharm Fr |
Stability of sufentanil and baclofen mixtures for intrathecal analgesia at different concentrations in polypropylene syringes. |
|
4163 |
Int J Pharm Compound |
Prolonged In-Use Stability of Reconstituted Herceptin in Commercial Intravenous Bags. |
|
4164 |
Int J Pharm Compound |
Stability of Tranexamic Acid Mouth Rinse. |
|
4166 |
J Clin Pharm Ther |
Stability of heparin in sodium chloride solution. |
|
4170 |
Int J Pharm Compound |
Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding. |
|
4173 |
Baxalta Innovations GmbH |
Pegaspargase (Oncaspar®) - Résumé des Caractéristiques du Produit |
|
4174 |
Int J Pharm Compound |
Physical and Chemical Stability of Estriol 0.025% to 1% Vaginal Creams (VersaBase). |
|
4176 |
Am J Health-Syst Pharm |
Compatibility of linezolid with commercial peritoneal dialysis solutions |
|
4177 |
Int J Pharm Compound |
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide,
Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. |
|
4178 |
EJHP |
Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration. |
|
4179 |
Pharmaceutical Technology in Hospital Pharmacy |
Validation of an HPLC Assay Method for Routine QC Testing and Stability Study of Compounded Low-Dose Capsules of Acetylsalicylic Acid. |
|
4180 |
Perit Dial Int |
Stability of meropenem and piperacillin/tazobactam with heparin in various peritoneal dialysis solutions. |
|
4183 |
Professional Practice Conference - the Canadian So |
Stability if 4 and 10 mcg/mL Remifentanil Solutions Stored in Syringes at Room Temperature (23°C). |
|
4185 |
Hosp Pharm |
Stability and Compatibility of Diphenhydramine Hydrochloride in Intravenous Admixtures : A New Look at an Old Drug. |
|
4189 |
Am J Health-Syst Pharm |
Stability of Captisol-enabled versus propylene glycol–based melphalan at room temperature and after refrigeration. |
|
4190 |
Janssen |
Daratumumab (Darzalex®) - Summary of Product Characteristics. |
|
4191 |
GaBI Journal |
Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at varioustemperatures. |
|
4192 |
Pediatric Anesthesia |
Quality control and stability of ketamine, remifentanil and sufentanil syringes in a pediatric operating theater. |
|
4194 |
Bio Drugs |
In-Use Physichochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion. |
|
4197 |
Pharmaceutical Technology in Hospital Pharmacy |
Stability of a 50 mg/mL Ceftazidime Eye-Drops Formulation. |
|
4198 |
Pharmazie |
Stability of regularly prescribed oral liquids formulated with SyrSpend® SF. |
|
4199 |
EJHP |
Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas. |
|
4200 |
EJHP |
Stability study of hydromorphone and bupivacaine mixture by HPLC-UV. |
|
4201 |
Am J Health-Syst Pharm |
Long-term stability of ready-to-use 1-mg/mL midazolam solution. |
|
4205 |
J Kor Soc Hosp Pharm |
Stability of Carboplatin in normal saline : dependence on initial dilution concentration and storage time. |
|
4211 |
PlosOne |
Overcoming stability challenges during continuous intravenous administration of high-dose amoxicillin using portable elastomeric pumps. |
|
4214 |
Int J Pharm Compound |
Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt. |
|
4215 |
Int J Pharm Compound |
Stability Assessment of Topical Amitriptyline HCl Extemporaneously Compounded with Lipoderm Base and PLO Gel Mediflo 30. |
|
4216 |
Sunnybrook |
Stability of 1.0, 0.2 and 0.025 mg/mL Milrinone Solutions Stored in Syringes at 4ºC and at Room Temperature (25ºC). |
|
4218 |
EJHP |
Assessment of the stability of citrate-buffered flucloxacillin for injection when stored in two commercially available ambulatory elastomeric devices: INfusor LV (Baxter) and Accufuser (Woo Young Medical): a study compliant with the NHS Yellow Cover Document (YCD) requirements. |
|
4223 |
Prof Practice Conference - Canadian Society of PH |
Stability of 20,40 and 50 microg/mL Fentanyl Solutions Stored in Syringes at Room Temperature (23°C). |
|
4227 |
Prof Practice Conference - Canadian Society of PH |
Stability of Azacitidine Solutions In Sterile Water for Injection. |
|
4228 |
Prof Practice Conference - Canadian Society of PH |
Stability of 10 and 50 microg/mL Fentanyl Solutions in CADD Reservoirs, PVC containers and Ethylene/Propylene Co-Polymer (PAB) Bags at Refrigerated (4°C) and Room Temperature (23°C). |
|
4229 |
Int J Pharm Compound |
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure. |
|
4230 |
Prof Practice Conference - Canadian Society of PH |
Stability of 0.2 and 10 mg/mL Hydromorphone Solutions In CADD reservoirs, PVC and Ethylene/Propylene Co-Polymer (PAB) Bags at Room Temperature (23°C°). |
|
4231 |
Professional Practice Conference - Canadian Societ |
Stability of 4 and 10 mcg/mL Remifentanil Solutions Stored in Syringes at Room Temperature (23°C) |
|
4244 |
|
Chemical Stability of Cloxacillin in Sterile Water for Injection (SWFI) Stored in Polypropylene (PP) Syringes (50 and 100 mg/mL) and Glass Vials (250 mg/mL) at 4°C and 25°C. |
|
4245 |
|
Physical Compatibility and Stability of Ascorbic acid Injection in Polyvinyl Chloride Minibags at 4ºC and Room Temperature (25ºC). |
|
4246 |
|
Stability of 2.5mg/mL Indocyanine Green (ICG) Solutions Stored in Syringes at 25ºC, 4ºC, -20ºC and -67ºC. |
|
4247 |
Clin Ther |
Stability of Cefazolin in Polyisoprene Elastomeric Infusion Devices. |
|
4248 |
Hosp Pharm |
Long-Term Stability of Lorazepam in Sodium Chloride 0.9% Stored at Different Temperatures in Different Containers. |
|
4249 |
PeerJ |
Stability of an ophtalmic formulation of polyhexamethylene biguanide in gamma-sterilized and ethylene oxide sterilized low density polyethylene multi dose eyedroppers. |
|
4250 |
Ann Pharm Fr |
Physicochemical stability of norepinephrine bitartrate in polypropylene syringes at high concentrations for intensive care units. |
|
4251 |
Int J Pharm Compound |
Physicochemical Stability of Compounded Naltrexone Hydrochloride Solutions in PCCA Base, SuspendIt. |
|
4252 |
Int J Pharm Compound |
Evaluation of the Physicochemical Stability of Amiodarone Hydrochloride in Syringes for the Intensive Care Unit. |
|
4254 |
Pharmaceutical Technology in Hospital Pharmacy |
Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs |
|
4255 |
J Pharm Anal |
Rapid, simple and stability-indicating determination of polyhexamethylene biguanide in liquid and gel-like dosage forms by liquid chromatography with diode-array detection. |
|
4256 |
Pharmaceutics |
Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients. |
|
4263 |
Am J Hosp Pharm |
Stability of ciprofloxacin injection in peritoneal dialysis solutions. |
|
4264 |
Acta Ophtalmol |
Stability and antibacterial potency of ceftazidime and vancomycin eyedrops reconstituted in BSS against Pseudomonas aeruginosa and Staphylococcus aureus. |
|
4267 |
EJHP |
Physicochemical stability of nefopam and nefopam/droperidol solutions in polypropylene syringes for intensive care units. |
|
4268 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical Stability of Cefotaxime Sodium in Polypropylene Syringes at High Concentrations for Intensive Care Units. |
|
4271 |
Adv Ther |
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties |
|
4272 |
Pharm Dev Technol |
Physicochemical and microbiological stability of two news oral liquid formulations of clonidine hydrochloride for pediatric patients. |
|
4274 |
J Clin Anesth |
Stability of suxamethonium in pharmaceutical solution for injection by validated stability-indicating chromatographic method. |
|
4279 |
Bio Drugs |
Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA). |
|
4280 |
J Pediatr Pharmacol Ther |
Sterility and Stability Testing of Preservative-free Albuterol. |
|
4282 |
Drugs R D |
Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. |
|
4283 |
Eur J Pharm Sci |
Pharmaceutical preformulation studies and paediatric oral formulations of sodium dichloroacetate. |
|
4284 |
Journal of Chemotherapy |
Stability of 90 mg/mL cefuroxime sodium solution for administration by continuous infusion. |
|
4289 |
Photochemical & Photobiological Sciences |
Stability and degradation of indocyanine green in plasma, aqueous solution and whole blood. |
|
4290 |
Microbiology Insights |
Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion. |
|
4292 |
Drugs R D |
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion. |
|
4293 |
J Pharm Pract and Res |
Validation of the stability of paracetamol in extemporaneously compounded suppositories. |
|
4298 |
Biomed Chromatogr |
Stability and degradation products of imipenem applying High-Resolution Mass Spectrometry: an analytical study focused on solutions for infusion. |
|
4299 |
Biomed Chromatogr |
Stability of mycophenolate mofetil in polypropylene 5% dextrose infusion bags and chemical compatibility associated with the use of the EQUASHIELD® closed-system transfer device. |
|
4301 |
Oncotarget |
Stability of azasetron-dexamethasone mixture for chemotherapyinduced nausea and vomiting administration. |
|
4303 |
Pharmacy |
Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes. |
|
4304 |
Drugs R D |
Stability of Etoposide Solutions in Disposable Infusion Devices for Day Hospital Cancer Practices. |
|
4307 |
J Pediatr Pharmacol Ther |
Stability of Extemporaneously Prepared Lansoprazole Suspension at Two Temperatures. |
|
4308 |
PlosOne |
Stability of gabapentin in extemporaneously compounded oral suspensions. |
|
4309 |
J Am Pharm Assoc |
Stability of U-500 regular
insulin in prefilled syringes |
|
4310 |
Kaohsiung J Med Sci |
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs. |
|
4313 |
PlosOne |
Stability of Diazoxide in Extemporaneously Compounded Oral Suspensions. |
|
4314 |
J Am Pharm Assoc |
Effects of Time and Storage Conditions on the Chemical and Microbiologic Stability of Diluted Buprenorphine for Injection. |
|
4316 |
J Pharm Technol |
Stability of Omeprazole Sodium and Pantoprazole Sodium Diluted for Intravenous Infusion. |
|
4317 |
J Pharm Technol |
Comparative Stability of Oral Vitamin K Liquids Stored in Refrigerated Amber Plastic Syringes. |
|
4319 |
Hosp Pharm |
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. |
|
4323 |
ADKA Kongress |
Stabilitätsprüfung von applikationsfertigen Adrenalin- und Noradrenalinverdünningen. |
|
4326 |
Pharmazie |
Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion. |
|
4331 |
Pharmaceutical Technology in Hospital Pharmacy |
Emulsion Stability of Different Intravenous Propofol Formulations in Simulated Co-Administration with Remifentanil Hydrochloride. |
|
4332 |
JFSPH 2019 |
Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI). |
|
4334 |
J Oncol Pharm Practice |
Physicochemical stability of pembrolizumab admixture solution in normal saline intravenous infusion bag. |
|
4341 |
Int J Pharm Compound |
Stability of Furosemide 5 mg/mL in Polypropylene Syringes. |
|
4342 |
Int J Pharm Compound |
Long-term Physicochemical Stability of Concentrated Solutions of Salbutamol (Albuterol) in Polypropylene Syringes for Use in the Intensive Care Unit and in Obstetrics. |
|
4344 |
EJHP |
Management of diabetic foot ulcers: a 25% lidocaine topical cream formulation design, physicochemical and microbiological assessments. |
|
4345 |
Pharmaceutical Technology in Hospital Pharmacy |
Carbidopa Capsules for Insulinoma Diagnostic: Compounding and Stability Study. |
|
4348 |
Can J Hosp Pharm |
Physicochemical Stability of Vancomycin at High Concentrations in Polypropylene Syringes. |
|
4350 |
EJHP |
Physicochemical stability of an admixture of lidocaine and ketamine in polypropylene syringe used in opioid-free anaesthesia. |
|
4352 |
J Clin Pharm Ther |
In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. |
|
4353 |
J Clin Pharm Ther |
Physicochemical stability of extemporaneously prepared clonidine solutions for use in neonatal abstinence syndrome. |
|
4354 |
GERPAC Congress 2019 |
Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables. |
|
4355 |
Jazz Pharmaceuticals UK |
Daunorubicine/cytarabine liposomale (Vyxeos®) - Summary of Product Characteristics |
|
4357 |
Nutrition in clinical Practice |
Physicochemical Compatibility of Dexmedetomidine With Parenteral Nutrition. |
|
4358 |
Ann Fr Anesth Réanim |
Stabilité physico-chimique des solutions injectables de bésilate de cisatracurium dans les conditions cliniques d'utilisation |
|
4360 |
Hosp Pharm |
Formulation and Stability Study of Omeprazole Oral Liquid Suspension for Pediatric Patients. |
|
4362 |
EJHP |
Physicochemical stability of binary admixtures of paracetamol and dexketoprofen-trometamol for patient-controlled analgesia use. |
|
4366 |
Braz J Pharm Sci |
Midazolam and haloperidol for palliative sedation: physicochemical stability and compatibility of parenteral admixtures. |
|
4367 |
J Glaucoma |
The Degradation of Mitomycin C Under Various Storage Methods. |
|
4368 |
J Pharm Health Care Sci |
Physical, chemical, and microbiological stability study of diluted atropine eye drops. |
|
4369 |
J Pharm Biomed Anal |
Physical and chemical stability of a generic etoposide formulation as an alternative to etoposide phosphate |
|
4370 |
EJHP |
Physical stability of an all-in one parenteral nutrition admixture for preterm infants upon mixing with micronutrients and drugs |
|
4371 |
Journal of Parenteral and Enteral Nutrition |
Physicochemical Compatibility of Amiodarone with Parenteral Nutrition. |
|
4373 |
EJHP |
Evaluation of the stability of vancomycin solutions at concentrations used in clinical services. |
|
4374 |
Int J Pharm Compound |
Long-term Physicochemical Stability of Concentrated Solutions of Isosorbide Dinitrate in Polypropylene Syringes for Administration in the Intensive Care Unit. |
|
4375 |
Int J Pharm Compound |
Stability of Metronidazole Free-base Oral Suspensions Formulated with United States Pharmacopeia-grade Metronidazole Powder and Commercial Metronidazole Tablets. |
|
4376 |
Int J Pharm Compound |
Compatibility of Melphalan in Iodinated Contrast Media. |
|
4377 |
Radiology |
Ionic lodinated Contrast Medium and Amobarbital Sodium Mixtures: Potential for Precipitation. |
|
4378 |
Perit Dial Int |
Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. |
|
4380 |
Merck Sharp & Dohme Limited |
Posaconazole (Noxafil®) - Summary of Product Characteristics |
|
4383 |
Crit Care Resusc |
Stability of bicarbonate in normal saline: a technical report. |
|
4388 |
Int J Pharm Compound |
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment. |
|
4389 |
Pharmactuel |
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. |
|
4393 |
Sunnybrook Health Sciences Centre |
Chemical Stability of Epinephrine Diluted in 0.9% Sodium Chloride and Stored in Polypropylene (PP) Syringes at 4°C and 25°C. |
|
4395 |
Sunnybrook Health Sciences Centre |
Stability of Morphine Solutions of 20, 40, 100 , 200 and 1,000 µg/mL in Syringes Following Dilution with 0.9% Sodium Chloride or D5W at Room Temperature (25°C). |
|
4396 |
GaBI Journal |
c |
|
4397 |
J Oncol Pharm Practice |
Stability of extemporaneously compounded temozolomide 10 mg/mL suspensions in Oral Mix SF in glass and plastic syringes. |
|
4398 |
J Pharm Pract and Res |
Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush. |
|
4403 |
J Pharm Biomed Anal |
Stability in clinical use and stress testing of meropenem antibiotic by direct infusion ESI-Q-TOF: Quantitative method and identification of degradation products. |
|
4404 |
JFSPH 2019 |
Compatibility studies of seven commonly used drugs for parenteral administration in palliative care. |
|
4405 |
Pharmazie |
Stability of tedizolid phosphate-sodium rifampicin and tedizolid phosphate-meropenem admixtures in intravenous infusion bags stored at different temperatures |
|
4406 |
Can J Hosp Pharm |
Stability of Methadone Hydrochloride for Injection in Saline Solution |
|
4407 |
Am J Health-Syst Pharm |
Compatibility of treprostinil sodium and dopamine hydrochloride during simulated Y-site administration. |
|
4408 |
Int J Pharm Compound |
Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF PH4. |
|
4411 |
Int J Pharm Compound |
Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions. |
|
4412 |
J Pediatr Pharmacol Ther |
Chiral Stability of an Extemporaneously Prepared Clopidogrel Bisulfate Oral Suspension. |
|
4413 |
J Pediatr Pharmacol Ther |
Stability and Sterility of Enoxaparin 8 mg/mL Subcutaneous Injectable Solution. |
|
4416 |
J Pediatr Pharmacol Ther |
Stability of Hydrocortisone Preservative-Free Oral Solutions. |
|
4418 |
J Pediatr Pharmacol Ther |
Chemical Stability of Extemporaneously Prepared Lorazepam Suspension at Two Temperatures. |
|
4419 |
J Pediatr Pharmacol Ther |
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. |
|
4424 |
11ème Recontres Convergences Santé Hôpital |
Etude de stabilité d'une suspension buvable de cloxacilline à usage pédiatrique. |
|
4426 |
Medicine |
Evaluation of Y-site compatibility of home total parenteral nutrition and intravenous loop diuretics. |
|
4428 |
J Pediatr Pharmacol Ther |
Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. |
|
4429 |
Medicine |
Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration. |
|
4430 |
Medicine |
Stability study of dezocine in 0.9% sodium chloride solutions for patient-controlled analgesia administration. |
|
4431 |
Medicine |
Compatibility and stability of dezocine and tropisetron in 0.9% sodium chloride injection for patient-controlled analgesia administration. |
|
4433 |
Clin Ther |
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications |
|
4434 |
Clin Ther |
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. |
|
4435 |
Anaesthesiol Intensive Ther |
Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. |
|
4436 |
Anaesthesiol Intensive Ther |
Extended compatibility of fentanyl and ketamine in dextrose 5%. |
|
4438 |
Pharmaceutics |
Safe Practice of Y-Site Drug Administration: The Case of Colistin and Parenteral Nutrition |
|
4439 |
Nutrients |
Effect of Lipid Emulsion on Stability of Ampicillin in Total Parenteral Nutrition. |
|
4440 |
Ann Nutr Metab |
Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. |
|
4441 |
Pharmaceutics |
The Interactions between Ciprofloxacin and Parenteral Nutrition Admixtures. |
|
4444 |
Clinical Nutrition |
Stability and compatibility of Teicoplanin in parenteral nutrition solutions used in pediatrics. |
|
4445 |
Chemotherapy |
Antibiotic compatibility and stability in a parenteral nutrition solution. |
|
4449 |
J Pharm Pract and Res |
Stability assessment of levofloxacin in three different suspension vehicles. |
|
4452 |
Congrès Hopipharm |
Influence d'un ajout de L-carnitine dans les mélanges de nutrition parentérale destinés aux patients à domicile. |
|
4455 |
J Oncol Pharm Practice |
Physical and chemical stability of cytarabine in polypropylene syringes. |
|
4456 |
Scientific reports |
Compatibility of aztreonam in four commercial peritoneal dialysis fluids. |
|
4457 |
J Obstet Gynaecol Can |
Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes. |
|
4458 |
Eur J Clin Microbiol Infec Dis |
Compatibility of fosfomycin with different commercial peritoneal dialysis solutions. |
|
4460 |
Scientific reports |
Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. |
|
4461 |
Molecules |
Physicochemical Compatibility and Stability of Linezolid with Parenteral Nutrition. |
|
4464 |
PlosOne |
Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion. |
|
4465 |
Am J Health-Syst Pharm |
Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. |
|
4467 |
Roche Products Limited |
Avastin - Summary of Product Characteristics |
|
4470 |
Critical care |
Continuous versus intermittent infusion of temocillin in intensive care unit patient. |
|
4471 |
Kyowa Kirin Pharma |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 |
|
4472 |
Pharmaceutics |
Stability of Ophthalmic Atropine Solutions for Child Myopia Control. |
|
4473 |
Neuromodulation |
Study of Physicochemical Stability of Ziconotide in Medication Cassette Reservoir. |
|
4474 |
Merck |
Avelumab (Bavencio®) - Summary of Product Characteristics |
|
4477 |
GaBI Journal |
Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentration and stress conditions. |
|
4478 |
Int J Pharm Compound |
Physicochemical Stability of Compounded Allopurinol Suspensions in PCCA Base, SuspendIt. |
|
4479 |
J Oncol Pharm Practice |
Long term stability of an admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags stored at 5 +/- 3°C. |
|
4482 |
Cipla USA |
ZEMDRI (plazomicin) injection, Highlights of Prescribing Information, Cipla USA, Revised: 1/2020 |
|
4484 |
Drugs R D |
In Vitro Stability and Recovery Studies of Pimavanserin in Water and in Different Vehicles Orally Administered. |
|
4485 |
Can J Hosp Pharm |
Stability of Generic Formulations of Bortezomib 1.0 and 2.5 mg/mL in Vials and Syringes Stored 4°C and Room Temperature (23°C) |
|
4487 |
Pharmaceutics |
Do Ophthalmic Solutions of Amphotericin B Solubilised in 2-Hydroxypropyl- -Cyclodextrins Possess an Extended Physicochemical Stability? |
|
4488 |
Pharmaceutics |
Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care. |
|
4490 |
Sci Pharm |
Medication Safety in Intravenous Therapy: A Compatibility Study and Analysis of Reaction Products of Dihydralazine and Metamizole. |
|
4491 |
Eur J Pedia |
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. |
|
4492 |
Int J Antimicrob Agents |
Preparation and physicochemical stability of 50 mg/ml hydroxychloroquine oral suspension in Syrspend pH4 dry. |
|
4493 |
J Oncol Pharm Practice |
Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion. |
|
4496 |
Neuromodulation |
Stability Study of Admixtures Combining Ziconotide With Morphine or Sufentanil in Polypropylene Syringes. |
|
4498 |
Pharmaceutical Technology in Hospital Pharmacy |
Development and validation of a new HPLC method for the analysis of a novel oral suspension formulation of 50 mg/mL ursodesoxycholic acid for newborns. |
|
4499 |
J Pharm Pract and Res |
Stability evaluation of an extemporaneously compounded carbimazole oral suspension. |
|
4500 |
J Pediatr Pharmacol Ther |
Stability of Extemporaneously Prepared Acetazolamide Oral Suspensions at Two Temperatures. |
|
4501 |
BMC Anesthesiology |
The effect of concentration, reconstitution solution and pH on the stability of a remifentanil hydrochloride and propofol admixture for simultaneous co-infusion. |
|
4502 |
TH Open |
Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro. |
|
4503 |
RIEMSER Pharma GmbH |
Ziconotide (Prialt®) - Summary of Product Characteristics |
|
4505 |
Eur J Cancer |
Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion. |
|
4506 |
Am J Health-Syst Pharm |
Physical compatibility of milrinone 1 mg/mL with select cardiovascular medications during simulated Y-site administration. |
|
4507 |
Am J Health-Syst Pharm |
Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. |
|
4510 |
J Oncol Pharm Practice |
Stability studies of parenteral nutrition with a high dose of vitamin C. |
|
4512 |
EJHP |
Assessment of the stability of citrate- buffered piperacillin/tazobactam for continuous infusion when stored in two commercially available elastomeric devices for outpatient parenteral antimicrobial chemotherapy: a study compliant with the NHS Yellow Cover Document requirements |
|
4515 |
Pharmaceutics |
Co-Administration of Drugs and Parenteral Nutrition: In Vitro Compatibility Studies of Loop Diuretics for Safer Clinical Practice. |
|
4516 |
GaBI Journal |
Physicochemical stability of the bevacizumab biosimilar, ABP 215, after preparation and storage in intravenous bags. |
|
4517 |
EJHP |
Formulation, long-term physicochemical and microbiological stability of 15% topical resorcinol for hidradenitis suppurativa. |
|
4518 |
EJHP |
In-use stability of diluted thiamazole (methimazole) infusion solutions in prefilled 0.9% sodium chloride infusion bags for continuous infusion. |
|
4520 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical stability of compounded midazolam capsules over a one-year storage period. |
|
4521 |
Pharmaceutical Technology in Hospital Pharmacy |
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. |
|
4522 |
J Pharm Biomed Anal |
Six months stability investigation of sufentanil and ropivacaine/levobupivacaine admixtures in plastic container by LC-UV. |
|
4523 |
Pharm Dev Technol |
Formulation and stability study of hydroxychloroquine sulfate oral suspensions. |
|
4524 |
ESCP Symposium, Geneva, Switzerland |
Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology. |
|
4525 |
Adv Ther |
Evaluation of the Physico-Chemical and Biological
Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions. |
|
4526 |
EJOP |
Stability of mitomycin in polypropylene syringes for use in glaucoma surgery. |
|
4528 |
Int J Pharm Compound |
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. |
|
4530 |
Int J Pharm Compound |
Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt. |
|
4532 |
Roche Products Limited |
Atezolizumab (Tecentriq®) - Summary of Product Characteristics |
|
4533 |
Int J Pharm Compound |
Stability of Diazepam Enema Extemporaneous Formulation in Manzoni Base. |
|
4534 |
Int J Pharm Compound |
Compatibility of Gestrinone, Nimesulide, and Piroxican in Pentravan for Transdermal and Transmucosal Application. |
|
4538 |
Archives of Disease in Childhood |
Compatibility of pentoxifylline and parenteral medications. |
|
4543 |
Archives of Disease in Childhood |
Physical compatibility of pentoxifylline and intravenous medications. |
|
4544 |
Int J Pharm Compound |
Stability Evaluation of Minoxidil in FOAMIL Foam Base with Bracketing Study Design. |
|
4545 |
Journal of Nippon Medical school |
Physical compatibility of nafamostat with analgesics, sedatives, and muscle relaxants for coronavirus disease treatment. |
|
4546 |
EJHP |
Stability of pemetrexed diarginine concentrates for solution in vials and diluted in 0.9% sodium chloride and dextrose 5% polyolefin infusion bags. |
|
4547 |
EJHP |
Formulation and stability of an extemporaneously compounded propafenone hydrochloride oral suspension for children with arrhythmia. |
|
4548 |
Clin Ther |
Intravenous Compatibility of Ceftazidime/Avibactam and Aztreonam Using Simulated and Actual Y-site Administration. |
|
4550 |
Crit Care Resusc |
The compatibility of a low concentration of hydrocortisone sodium succinate with selected drugs during a simulated Y-site administration. |
|
4556 |
J Pharm Technol |
The Physical Compatibility of Clinically Used Concentrations of Diltiazem Hydrochloride With Heparin Sodium. |
|
4558 |
Milit Med |
Compatibility of Hydroxyethyl Starch and Tranexamic Acid for Battlefield Co-Administration. |
|
4559 |
Drug Design Dev Ther |
Physical Compatibility and Chemical Stability of Fentanyl and Naloxone Hydrochloride in 0.9% Sodium Chloride Injection Solution for Patient-Controlled Analgesia Administration. |
|
4560 |
J Pediatr Pharmacol Ther |
Stability Determination of an Extemporaneously Compounded Ambrisentan Suspension by High Performance Liquid Chromatography Analysis. |
|
4561 |
Pharmaceutical Technology in Hospital Pharmacy |
New liquid oral formulations of hydroxychloroquine: a physicochemical stability study. |
|
4563 |
Eur J Pharm Sci |
Stability study of a compounded oral solution of nicardipine for the treatment of hypertension in children. |
|
4567 |
Pharmaceutics |
Addition of Regular Insulin to Ternary Parenteral Nutrition: A Stability Study. |
|
4568 |
Journal of Chemotherapy |
Long-term physico-chemical stability of 5-fluorouracile at standardised rounded doses (SRD) in MyFuser® portable infusion pump. |
|
4569 |
Hosp Pharm |
Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications. |
|
4570 |
Pharmaceuticals |
Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients. |
|
4571 |
Orion Pharma |
Levosimendan (Simdax 2.5 mg/ml) - Summary of Product Characteristics |
|
4572 |
Antibiotics |
Toward Safe Pharmacotherapy: The Interplay between Meropenem and Parenteral Nutrition Admixtures. |
|
4573 |
Am J Health-Syst Pharm |
Long-term physicochemical stability of acyclovir 5 mg/mL solution stored in polypropylene bags as a simulated hospital stock preparation. |
|
4574 |
Am J Hosp Pharm |
Stability of 10-mg/mL and 50-mg/mL ketamine oral solutions. |
|
4575 |
Int J Pharm Compound |
Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt. |
|
4576 |
Int J Pharm Compound |
Stability of Extemporaneously-compounded Nadolol 10-mg/mL Suspension in Oral Mix in Glass and Plastic Bottles and Plastic Syringes. |
|
4577 |
Int J Pharm Compound |
Stability of Fagron's Phytobase Cream Compounded with Various Hormones. |
|
4578 |
|
Etude de stabilité de médicaments anticancéreux injectables : apports analytiques et pharmaceutiques |
|
4579 |
Processes |
Application of the HPLC Method in Parenteral Nutrition
Assessment: Stability Studies of Ondansetron |
|
4582 |
J Pharm Technol |
Beyond-Use Dates Assignment for Pharmaceutical Preparations: Example of Low-Dose Amiodarone Capsules. |
|
4583 |
Int J Pharm Compound |
Prolonged In-use Stability of Diluted Atezolizumab in Commercial Intravenous Bags |
|
4584 |
EJHP |
Long-term stability of 10 mg/mL dobutamine injectable solutions in 5% dextrose and normal saline solution stored in polypropylene syringes and cyclic-oleofin- copolymer vials. |
|
4587 |
J Pediatr Pharmacol Ther |
Stability-indicating LC-MS Method for Determination of Stability of Extemporaneously Compounded Buprenorphine Oral Syringes for Neonatal Abstinence Syndrome. |
|
4589 |
Viatris |
Pemetrexed Viatris- Résumé des caractéristiques du produit |
|
4590 |
J Pediatr Pharmacol Ther |
Stability of buffered benzylpenicillin and flucloxacillin for a paediatric outpatient parenteral antibiotic therapy service. |
|
4592 |
Antibiotics |
The Role of Non-Enzymatic Degradation of Meropenem—Insights from the Bottle to the Body. |
|
4593 |
Int J Pharm Compound |
Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases. |
|
4596 |
Am J Health-Syst Pharm |
Stability of 5% vancomycin ophthalmic solution prepared using balanced salt solution after freezing for 90 days. |
|
4598 |
Int J Pharm Compound |
Compatibility of Estradiol, Estriol; Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base. |
|
4600 |
EJOP |
Physicochemical stability of lurbinectedin reconstituted at 500 µg/mL and diluted at 15, 30, and 70 µg/mL in 0.9% sodium chloride and 5% dextrose. |
|
4602 |
Hosp Pharm |
Physical and Chemical Stability of Dexamethasone Sodium Phosphate in Intravenous Admixtures Used to Prevent Chemotherapy-Induced Nausea and Vomiting. |
|
4603 |
Hosp Pharm |
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. |
|
4605 |
Ann Allergy |
Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility. |
|
4606 |
Int J Pharm Compound |
Study on the Optimal Conditions for Long-term Storage of Melatonin Powder as an In-hospital Preparation. |
|
4607 |
Can J Hosp Pharm |
Stability of Compounded Clozapine 25 mg/mL and 50 mg/mL Suspensions in Plastic Bottles. |
|
4608 |
Astra Zeneca |
Durvalumab (Imfinzi - Summery of Product Characteristics, updated August 2021) |
|
4609 |
PlosOne |
The stability of quetiapine oral suspension compounded from commercially available tablets. |
|
4611 |
J Pharm Anal |
Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes. |
|
4612 |
OFIL |
Estabilidad de la solución de gentamicina y heparina para sellado de catéter. |
|
4616 |
Pharmaceutics |
Stability of Hydrocortisone in Oral Powder Form Compounded for Pediatric Patients in Japan. |
|
4617 |
Sanofi Genzyme |
Isatuximab - SARCLISA 20mg/mL concentrate for solution for infusion - Summary of Product Characteristics - updated 16 August 2021 |
|
4619 |
Quality Control North West, Stockport NHS Foundati |
Stability Study for Clindamycin 9.52mg/mL in 5.0% w/v Glucose 50mL Infusion Bags. |
|
4620 |
Quality Control North West, Stockport NHS Foundati |
Stability Study for Piperacillin/Tazobactam 56.9 mg/mL in Sodium Chloride 0.9% w/v in 50mL Infusion Bags. |
|
4621 |
Quality Control North West, Stockport NHS Foundati |
Stability Study for Piperacillin/Tazobactam 56.9 mg/mL in Glucose 5.0% w/v in 50mL Infusion Bags. |
|
4622 |
Quality Control North West, Stockport NHS Foundati |
Stability Study for Clindamycin 9.52mg/mL in 0.9% w/v Sodium Chloride 50mL Infusion Bags. |
|
4624 |
EJHP |
Stability of pemetrexed disodium in sodium chloride 0.9% w/v intravenous Viaflo infusion bags. |
|
4627 |
Adv Ther |
Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature. |
|
4628 |
Pharmaceuticals |
Development and Validation of a New Storage Procedure to Extend the In-Use Stability of Azacitidine in Pharmaceutical Formulations. |
|
4629 |
|
Pemetrexed Sandoz - Summary of Product Characteristics (SmPc) |
|
4630 |
J Pharm Health Care Sci |
Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan. |
|
4633 |
Pharmaceutics |
Physicochemical Stability and Compatibility Testing of Voriconazole in All-in-One Parenteral Nutrition Admixtures. |
|
4634 |
Antibiotics |
Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. |
|
4635 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical stability of human insulin 1 I.U./mL infusion solution in 50 mL polypropylene syringes. |
|
4636 |
J Oncol Pharm Practice |
Design and stability of pediatric oral formulation of imatinib |
|
4637 |
Braz J Pharm Sci |
Evaluation of physicochemical and microbiological stability of liquid preparation from tizanidine hydrochloride tablets - a Hospital concern. |
|
4638 |
Can J Hosp Pharm |
Stability of Extemporaneously Compounded Suspensions of Trimethoprim and Sulfamethoxazole in Amber Plastic Bottles and Amber Plastic Syringes. |
|
4639 |
Can J Hosp Pharm |
Stability of N-Acetylcysteine 60 mg/mL in Extemporaneously Compounded Injectable Solutions. |
|
4640 |
Hosp Pharm |
Stability of Ampicillin in Normal Saline Following Refrigerated Storage and 24-Hour Pump Recirculation. |
|
4641 |
Eur J Pharm Sci |
Stability of high concentrated triple intrathecal therapy for pediatrics and mitigation strategies. |
|
4642 |
SEFH Congress (Virtual) October 2021 |
Compatibilidad en Y de atosiban y farmacois habitualmente utilizados en obstetricia. |
|
4643 |
EJHP |
Evaluation of 30-day stability of morphine hydrochloride and clonidine at high and low concentrations in polypropylene syringes. |
|
4644 |
Adv Ther |
Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17. |
|
4645 |
JAC Antimicrob Resist |
Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy. |
|
4646 |
Int J Pharm Compound |
Stability Studies of Fludrocortisone Acetate Capsules and Fludrocortisone Acetate Titrated Powders (Powder Triturates). |
|
4648 |
PlosOne |
Stability evaluation of compounded clonidine hydrochloride oral liquids based on a solidphase extraction HPLC-UV method. |
|
4649 |
GaBI Journal |
Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices. |
|
4650 |
Advanz Pharma |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. |
|
4651 |
Eur J Pedia |
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. |
|
4652 |
Bristol Myers Squibb Pharmaceuticals |
Nivolumab (Opdivo®) - Summary of Product Characteristics |
|
4653 |
EJHP |
Development of a sterile morphine hydrogel for the local treatment of painful skin ulcers. |
|
4654 |
Communication personnelle |
Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. |
|
4655 |
Am J Health-Syst Pharm |
Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. |
|
4661 |
J Pharm Biomed Anal |
Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization |
|
4664 |
Biomed Chromatogr |
Stability evaluation of morphine, hydromorphone, metamizole and esketamine containing analgesic mixtures applied for patient-controlled analgesia in hospice and palliative care. |
|
4665 |
Sanofi Aventis |
LEMTRADA 12 mg concentrate for solution for infusion - Summary of Product Characteristics. Updated 24-Sep-2021 |
|
4666 |
J Anal Sci Tech |
Intravenous patient-controlled analgesia: in vitro stability profiles of mixtures containing fentanyl, hydromorphone, oxycodone, nefopam, ondansetron, and ramosetron. |
|
4667 |
Int J Pharm Pharm Sci |
Stability of Hydromorphone Hydrochloride and Morphine under Different Clinical Infusion Conditions. |
|
4669 |
Neuromodulation |
Physicochemical Stability Study of the Morphine-Ropivacaine-Ziconotide Association in Implantable Pumps for Intrathecal Administration. |
|
4670 |
Molecules |
Stability and Formulation of Erlotinib in Skin Creams. |
|
4671 |
Int J Antimicrob Agents |
Voriconazole topical cream formulation: evidence for stability and antifungal activity. |
|
4673 |
Pharmaceutics |
Physicochemical Stability of a Novel Tacrolimus Ophtalmic Formulation for the Treatment of Ophtalmic Inflammatory Diseases. |
|
4675 |
Pharmaceuticals |
Simple Approach to Enhance Green Tea Epigallocatechin Gallate Stability in Aqueous Solutions and Bioavailability: Experimental and Theoretical Characterizations. |
|
4676 |
EAHP Congress Vienna |
Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days. |
|
4677 |
EAHP Congress Vienna |
Physicochemical stability of diluted "Thiotepa Riemser" infusion solutions in prefilled 5% glucose infusion bags. |
|
4679 |
PlosOne |
Stability of extemporaneously prepared sitagliptin phosphate solution. |
|
4681 |
Hosp Pharm |
An Exploratory Study of a New Vancomycin Eye Drops Formulation for Extemporaneous Compounding. |
|
4683 |
J Pharm Pract and Res |
Stability of omeprazole in a commercial calcium carbonate based oral suspension at 2, 5 and 10 mg/mL stored under refrigeration (4°C) for 70 days |
|
4686 |
Roche Products Ltd. |
Pertuzumab (Perjeta®) - Summary of Product Characteristics. |
|
4689 |
Braz J Pharm Sci |
Captopril oral solution for pediatric use: formulation, stability study and palatability assessment in vivo. |
|
4690 |
Hosp Pharm |
Stability of Compounded Digoxin Solution 0.05mg/mL for Injection. |
|
4691 |
Int J Pharm Compound |
Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine. |
|
4692 |
The Scientific World Journal |
Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease. |
|
4693 |
Drug Design Dev Ther |
Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection. |
|
4694 |
PlosOne |
Stability evaluation of compounded hydroxyurea 100 mg/mL oral liquids using a novel analytical method involving chemical derivatization. |
|
4695 |
Int J Pharm Compound |
Physicochemical and Microbiological Stability of Amitriptyline Hydrochloride Oral Liquid Dosage Forms in PCCA Base, SuspendIt. |
|
4696 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical stability of 20 mg/mL amiodarone hydrochloride oral suspension in SyrSpend® SF PH4 (liquid) |
|
4697 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical stability of azacitidine suspensions at 25 mg/mL in polypropylene syringes stored under different conditions of storage. |
|
4698 |
Pharmaceutical Technology in Hospital Pharmacy |
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. |
|
4700 |
AS Kalceks |
Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics |
|
4701 |
Pharm Dev Technol |
Solution stability of Captisol-stabilized melphalan (Evomela) versus Propylene glycol-based melphalan hydrochloride injection.
|
|
4702 |
EJOP |
Physicochemical stability of pemetrexed diarginine at 25 mg/mL in partially-used vials and at 3 and 12 mg/mL diluted in dextrose 5% or in sodium chloride 0.9% in polyolefin bags. |
|
4705 |
Pharmaceutical Technology in Hospital Pharmacy |
Stability of voriconazole 10 mg/mL ophthalmic solution during 90 days |
|
4708 |
Drugs R D |
Study of the Stability of Sandoz Rituximab Biosimilar Rixathon®/Riximyo® When Subjected for up to 21 Days to Ambient Storage. |
|
4709 |
Tetraphase Pharmaceuticals. |
XERAVA® (eravacycline) for injection, for intravenous use. HIGHLIGHTS OF PRESCRIBING INFORMATION. |
|
4712 |
GERPAC Congrès - octobre 2022 |
Développement de formulations buvables de vinorelbine à usage pédiatrique. |
|
4714 |
GERPAC Congrès - octobre 2022 |
Etude de stabilité d'un biosimilaire du Bevacizumab dans les flacons et après dilution dans du NaCl 0.9% en poche de polyoléfine. |
|
4716 |
J Pediatr Pharmacol Ther |
Pre-formulation and Stability Study of 20 mcg Clonidine Hydrochloride Pediatric Capsules. |
|
4717 |
|
Enhertu®- Résumé des caractéristiques du produit |
|
4719 |
SAGE Open Medicine |
Prepared omadacycline for injection: Nine-day stability and sterility in an elastomeric pump. |
|
4720 |
Paratek Pharmaceuticals |
Nuzyra (omadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021. |
|
4723 |
Am J Health-Syst Pharm |
Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration. |
|
4724 |
Int J Pharm Compound |
Intravenous Physical Compatibility of Heparin Sodium and Furosemide. |
|
4725 |
J Pharm Biomed Anal |
Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers. |
|
4726 |
Mylan |
Arsenic trioxide Mylan - Résumé des caractéristiques du produit |
|
4727 |
Pharmaceuticals |
Stability Study of Parenteral N-Acetylcysteine, and Chemical Inhibition of Its Dimerization |
|
4728 |
J Pharm Biomed Anal |
Stability study over time of clinical solutions of ziv-aflibercept prepared in infusion bags using a proper combination of physicochemical and functional strategies. |
|
4729 |
Pharmaceutics |
Extemporaneous Preparation of 20 mg/mL Ganciclovir in Artificial Tears in Comparison with SterileWater for Ophthalmic Administration: Formulation and Stability Study. |
|
4730 |
Neuromodulation |
Stability of Morphine Sulfate-Clonidine and Sufentanil-Clonidine Mixtures. |
|
4732 |
Am J Health-Syst Pharm |
Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration. |
|
4735 |
J Oncol Pharm Practice |
Long-term physicochemical stability of 5-fluorouracil at selected standardised rounded doses in polyolefin bags. |
|
4736 |
J Pharm Biomed Anal |
An Ultra-High-Performance Chromatography method to study the long term stability of gemcitabine in dose banding conditions. |
|
4737 |
Hosp Pharm |
Extended Stability of Isoproterenol Hydrochloride Injection in Polyvinyl Chloride Bags Stored in Amber Ultraviolet Light Blocking Bags. |
|
4739 |
PlosOne |
Low-dose erythromycin in pediatrics: Formulation and stability of 20 mg hard gelatin capsules. |
|
4740 |
Roche Products Limited |
MabThera 500 mg concentrate for solution for infusion. Summary of Product Characteristics Updated 07-Oct-2021 |
|
4741 |
Int J Pharm Compound |
Physicochemical and Microbiological Stability of Pyrimethamine in Paraben-free PCCA Base,
SuspendIt. |
|
4742 |
Pharmactuel |
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. |
|
4744 |
Samsung laboratory |
Stability Report of Extended SB8 Opened Vial (400 mg) Stability (personal communication). |
|
4745 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical stability study of a biosimilar of Bevacizumab in vials and after dilution in 0.9% NaCl in polyolefin intravenous bags. |
|
4746 |
|
Stability and Compatibility of Bupivacaine and Hydromorphone in PVC and non-DEHP bags for 30 days at 4°C and 25°C. |
|
4747 |
Pharmaceutics |
Pharmaceutical Oral Formulation of Methionine as a Pediatric Treatment in Inherited Metabolic Disease. |
|
4748 |
Pharmaceutics |
Physicochemical Stability of Generic Thiotepa Concentrate and Ready-to-Administer Infusion Solutions for Conditioning Treatment. |
|
4750 |
Pharmaceutics |
Development and Stability of a New Formulation of Pentobarbital Suppositories for Paediatric Procedural Sedation. |
|
4751 |
Pharmaceutics |
Product Validation and Stability Testing of Pharmacy Compounded Cholic Acid Capsules for Dutch Patients with Rare Bile Acid Synthesis Defects. |
|
4754 |
J Oncol Pharm Practice |
Physicochemical stability of PF-05280014 (trastuzumab-qyyp; TrazimeraTM), a trastuzumab biosimilar, under extended in-use conditions. |
|
4755 |
J Oncol Pharm Practice |
Extended physicochemical stability of cetuximab in opened vials and infusion bags when stored at 4°C and 25°C. |
|
4756 |
J Oncol Pharm Practice |
Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev®), a bevacizumab biosimilar, under extended in-use conditions. |
|
4757 |
Hosp Pharm |
In Vitro Assessment of Compounded Lurasidone Suspensions for Enteral Feeding Tubes. |
|
4758 |
Curr Pharm Anal |
Stability Study and Simultaneous Determination of Norepinephrine, Moxifloxacin, and Piperacillin + Tazobactam Mixtures Applied in Intensive Care Medicine . |
|
4759 |
Sunnybrook Healt Science Centre |
Stability of 5-fluorouracil at 4°C, 25°C, and 33°C stored in NiproSureFuser+ Ambulatory Balloon Infusers. |
|
4761 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical stability of Cabazitaxel Zentiva® solution in vials after opening and diluted- solutions in three infusion bags. |
|
4762 |
EJHP |
Physicochemical stability of carmustine-containing medicinal products after reconstitution and after dilution to ready-to-administer infusion solutions stored refrigerated or at room temperature |
|
4763 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical stability of urea-containing Mitomycin C preparations in glass vials (1.0 mg/mL) and plastic syringes (2.0, 0.4, 0.2 mg/mL) |
|
4766 |
Int J Pharm Compound |
Stability of omeprazole extemporaneous oral solution in Chopin Base. |
|
4767 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical stability of durvalumab (Imfinzi® ) concentrate for solution in original vials after first opening. |
|
4768 |
Journal of Nippon Medical school |
Y-site injection physical compatibility of remdesivr with select intravenous drugs used in palliative care and for treating coronavirus disease 2019. |
|
4769 |
Pharmaceutics |
Cisatracurium Besylate 10 mg/mL Solution Compounded in a Hospital Pharmacy to Prevent Drug Shortages : A Stability Study Involving Four Degradation Products. |
|
4770 |
Pharmaceutical Technology in Hospital Pharmacy |
Use of a liquid chromatography-tandem mass spectrometry method to assess the concentration of epinephrine, norepinephrine, and phenylephrine stored in plastic syringes. |
|
4771 |
J Pharm Technol |
Stability of Olmesartan Medoxomil Extemporaneous Suspensions. |
|
4772 |
J Pharm Sci |
Stability of Opened Durvalumab (IMFINZI) Vials. The Beginning of the End of Costly Product Wastage? |
|
4773 |
Eur J Pharm Sci |
Predictive stability, novel HPLC-MS analysis and semi-automatic compounding process for the emergency implementation of a production line of pancuronium in injectable solution. |
|
4776 |
Pharmaceutics |
Antiemetic Drugs Compatibility Evaluation with Paediatric Parenteral Nutrition Admixtures. |
|
4777 |
Int J Pharm Compound |
Physicochemical and microbiological stability of azathioprine suspensions in PCCA base Suspendit. |
|
4778 |
Int J Pharm Compound |
Chemical stability of epinephrine 10 µg/mL doluted in 0.9% sodium chloride and stored in polypropylene syringes at 4°C and 25°C. |
|
4780 |
Int J Pharm Compound |
Extemporaneous Topical Minoxidil Solutions for the treatment of Alopecia : Stability Studies and Incorporation Tests of Active Ingredients in ALOPLUS FAST Base. |
|
4782 |
Drugs R D |
In‑Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period. |
|
4784 |
EJHP |
In-use stability of ready-to- administer daratumumab subcutaneous injection solution in plastic syringes. |
|
4785 |
Janssen-Cilag International NV |
Darzalex 1800 mg solution for injection - Summary of Product characteristics. |
|
4786 |
SFPO Congress |
Etude de stabilité de solutions de pembrolizumab à 1 et 4 mg/mL à 5 et 25°C dans des poches de NaCl 0,9% en polyoléfine . |
|
4789 |
Braz J Pharm Sci |
Stability of sulfadiazine sugar-free oral suspensions for the treatment of congenital toxoplasmosis. |
|
4790 |
Int J Retina Vitreous |
Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties. |
|
4792 |
EJHP |
Evaluation of the stability of aciclovir in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy. |
|
4798 |
Frontiers in Ophthalmology |
A silicone Oil-Free Syringe Tailored for Intravitreal Injection of Biologics. |
|
4799 |
|
Stability of Voriconazole 10 mg/mL in IsoptoTears 0.5% stored in Glass Vials And Low Density Polyethylene Droppers at 4°C and 25°C for 28 Days. |
|
4800 |
|
Stability of Dr.Reddy’s Cabazitaxel Following Reconstitution with Manufacturer’s Diluent & Dilution with Sodium Chloride and Dextrose 5% in non-PVC non-DEHP bags and Original Glass Vials at 25°C, 4°C and -20°C.
|
|
4801 |
Am J Health-Syst Pharm |
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. |
|
4802 |
Aguettant Laboratory |
Glucose-1-Phosphate disodique tétrahydraté (Phocytan®) - Résumé des caractéristiques du produit |
|
4807 |
Amgen Ltd |
Vectibix 20 mg/mL concentrate for solution for infusion. Summary of Product Characteristics Updated 13-Jul-2023 |
|
4808 |
Hosp Pharm |
Characterizing the Stability of Angiotensin II in 0.9% Sodium Chloride Using High Performance Liquid Chromatography and Liquid Chromatography Tandem Mass Spectrometry. |
|
4809 |
|
Recarbrio® - Résumé des caractéristiques du produit |
|
4810 |
|
Libtayo® - Résumé des caractéristiques du produit |
|
4812 |
J Pharm Pract and Res |
Stability of extemporaneously prepared clofazimine oral suspensions |
|
4813 |
Int J Pharm Compound |
Compatibility of Various Hormones in Phytobase and HRT Heavy Cream Bases |
|
4814 |
Int J Pharm Compound |
Compatiblity of Caffeine, Clobetasol Propionate, Dutasteride, Nicotinamide, and Progesterone in TrichoFoam, a Natural Vehicle for Hair Forms. |
|
4816 |
Int J Pharm Compound |
Stability Evaluation of Bracketed Diclofenac Sodium USP in VersaPro Cream Base, Versa Pro Gel Base and PLO Gel Mediflo30 Compound Kit. |
|
4818 |
PAION UK Ltd |
Giapreza 2.5mg per ml concentrate for solution for infusion - Summary of Product Characteristics Updated 30-Jun-2022 |
|
4819 |
Int J Pharm |
Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations. |
|
4820 |
EJHP |
Physicochemical and biological stability of diluted vedolizumab in intravenous infusion bags. |
|
4821 |
Pharmaceutics |
AmBisome® Formulations for Pediatrics: Stability, Cytotoxicity, and Cost-Effectiveness Studies. |
|
4822 |
JAC Antimicrob Resist |
Evaluation of the stability of ceftazidime/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilizing a national stability protocol framework. |
|
4824 |
EJHP |
Physicochemical stability of pevonedistat at 50, 100 and 200 µg/mL diluted in 0.9% sodium chloride and at 10 mg/mL in partially used vials. |
|
4825 |
Farm Hosp |
Physicochemical and microbiological stability study of two new preservative-free methylprednisolone eye drops. |
|
4828 |
Anesth Prog |
The Physical Compatibility of Glycopyrrolate and Rocuronium. |
|
4831 |
Acta Paediatr |
Frequently acquired drugs in neonatal intensive care and their physical compatibility. |
|
4832 |
Eur J Pedia |
Co‑administration of drugs with parenteral nutrition in the neonatal intensive care unit—physical compatibility between three components. |
|
4835 |
Intensive Care Medecine Experimental |
Plasma-Lyte 148 and Plasma-Lyte 148 + 5% glucose compatibility with commonly used critical care drugs. |
|
4837 |
Eur J Clin Pharmacol |
Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. |
|
4842 |
Drug Design Dev Ther |
Harmonising IV Oxycodone with Paediatric Perioperative Medications: A Compatibility Study Through Y-Type Connectors |
|
4843 |
Pharmaceutics |
Y-Site Compatibility Studies of Ketoprofen with Parenteral Nutrition Admixtures for Central and Peripheral Administration. |
|
4845 |
Pharmaceutics |
The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings. |
|
4846 |
Hosp Pharm |
Chemical Stability of Lorazepam Oral Solution Repackaged in Plastic Oral Syringes at Room and Refrigerated Temperature. |
|
4849 |
Pharmaceuticals |
Formulation and Stability of a 1% Clarithromycin-Based Topical Skin Cream: A New Option to Treat Buruli Ulcers? |
|
4850 |
Pharmaceuticals |
The Infusion of Piperacillin/Tazobactam with an Elastomeric Device: A Combined 24-H Stability Study and Drug Solution Flow Rate Analysis. |
|
4851 |
EJHP |
Long-term stability of esketamine in polypropylene syringes at 5 ± 3°C. |
|
4852 |
Merck Sharp & Dohme B.V. |
KEYTRUDA 25 mg/mL solution à diluer pour perfusion. Résumé des caractéristiques du produit. |
|
4855 |
Am J Hosp Pharm |
Physical compatibility of colistin with analgesics during simulated Y-site administration. |
|
4857 |
Int J Pharm Compound |
Physicochemical and Microbiological Stability of Compounded Clonidine Hydrochloride Oral iquid Dosage Forms in PCCA Base, SuspendIt®. |
|
4858 |
Int J Pharm Compound |
Physical Compatibility of Intravenous Ondansetron Hydrochloride and Nafcillin Sodium. |
|
4859 |
Int J Pharm Compound |
Physicochemical and Microbiological Stability of Compounded Bethanechol Chloride Oral Suspensions in PCCA Base, SuspendIt® |
|
4862 |
Porton Biopharma Limited |
Erwinase, 10,000 IU/vial, Powder for solution for injection/infusion - Summary of Product Characteristics Updated 04-Jul-2022. |
|
4863 |
Hosp Pharm |
Physical Compatibility Between Intravenous Magnesium Sulfate and Potassium or Sodium Phosphate in a Pediatric Intensive Care Unit. |
|
4865 |
Dr REDDY laboratoire |
Cyclophosphamide REDDY PHARMA 2000 mg/4 ML, solution à diluer pour solution injectable/perfusion. - Résumé des caractéristiques du produit. |
|
4867 |
CSH (SNPHPU) Congress sept 2024 |
Etude des compatibilités entre la nalbuphine et d'autres principes actifs pour optimiser leur administration en service de pédiatrie. |
|
4868 |
CSH (SNPHPU) Congress sept 2024 |
Etude de la stabilité physico-chimique de solutions de 5-fluorouracile diluées en poches polyoléfine a des concentrations comprises entre 9 et 15 mg/ml. |
|
4874 |
Antibiotics |
Enhancing Stability and Investigating Target Attainment of Benzylpenicillin in Outpatient Parenteral Antimicrobial Therapy: Insights from In Vitro and In Vivo Evaluations. |
|
4875 |
Am J Health-Syst Pharm |
Physicochemical and microbiological stability of 40 mg/mL amiodarone hydrochloride oral suspension. |
|
4878 |
Int J Pharm Compound |
Compatibility of Cetirizine Hydrochloride, Dutasteride, Hydrocortisone Acetate, Nicotinamide, Porgesterone, and Pyridoxine Hydrochloride in TrichoSol, A Natural Vehicle for Hair Solutions. |
|
4879 |
Int J Pharm Compound |
Compatibility of Active Pharmaceutical Ingredients in Cleoderm: A Comprehensive Study for Enhanced Topical Dermatological Treatments. |
|
4880 |
Int J Pharm Compound |
Stability of Allopurinol in Extemporaneously Compounded Oral Suspensions with Oral Mix and Oral Mix SF. |
|
4883 |
Pharmaceutics |
Physicochemical I.Stability of Nab-Paclitaxel (Pazenir) Infusion Dispersions in Original Glass Vials and EVA Infusion Bags. |
|
4884 |
Int J Pharm Compound |
Stability of Diluted Desmopressin Acetate Intranasal Solution at 0.01 mg/mL. |
|
4886 |
J Pediatr Pharmacol Ther |
Physicochemical and Microbiological Stability of Ursodiol Oral Compounded Suspensions. |
|
4887 |
Astra Zenaca AB |
IMJUDO (tremelimumab) 20 mg/mL concentrate for solution for infusion. Summary of Product Characteristics. |
|
4888 |
Pharmactuel |
Stabilité du propofol, du rocuronium, du phénobarbital et du magnésium injectables reconditionnés en seringue pour les trousses d’aide médicale à mourir. |
|
4891 |
Ophtalmol Ther |
Physicochemical and Biological Stability Assessment of SB11 (Ranibizumab Biosimilar) Under Ambient and In-Use Storage for Intravitreal Administration. |
|
4892 |
Arch Pharm |
Combined physicochemical and functional assessment of pertuzumab integrity supports extended in‐use stability. |
|
4893 |
Siriraj Medical Journal |
Stability and Sterility of Extemporaneously Prepared .01% Atropine Ophthalmic Solution in Artificial Tears and Balanced Salt Solution. |
|
4894 |
Pharm Chem J |
Chemical stability of pharmacy-compounded cefazolin sodium eye drops. |
|
4895 |
JCO Oncology Practice |
Real-World Nivolumab Wastage and Leftover Drug Stability Assessment to Facilitate Drug Vial for Cost Savings. |
|
4904 |
EJHP |
Y-site simulation compatibility study of 10% calcium salts with various injectable solutions during toxicological resuscitation. |
|
4905 |
Pharmaceuticals |
Characterization of Liquid Dosage Forms of Atenolol and Enalapril Maleate for Oral and Enteral Feeding Administration |
|
4911 |
|
Glofitamab (Columvi®) - Résumé des caractéristiques du produit |
|
4912 |
Incyte Biosciences |
Tafasitamab (Minjuvi®) - Résumé des caractéristiques du produit |
|
4913 |
Janssen-Cilag International NV |
Teclistamab (Tecvayli®) - Résumé des caractéristiques du produit |
|
4914 |
Drugs R D |
In‐Use Physicochemical Stability of Sandoz Rituximab Biosimilar in 0.9% Sodium Chloride Solution After Prolonged Storage at Room Temperature Conditions. |
|
4916 |
J Investig Allergol Clin Immunol |
Stability Over Time of In-Hospital-Compounded Amoxicillin Capsules and Ceftriaxone Patch Tests for Drug Allergy Testing. |
|
4917 |
Pharmacy |
A Physicochemical Stability Study of Pembrolizumab Vial Leftovers: Let Us Stop Pouring Good Money Down the Drain. |
|
4919 |
|
Dostarlimab (Jemperli®) – Résumé des caractéristiques du produits |
|
4920 |
Pharmaceuticals |
Formulation, Quality Control and Stability Study of Pediatric Oral Dextrose Gel. |
|
4921 |
Int J Pharm Compound |
Compatibility of 17-a-estradiol, Caffeine, Clobetasol Propionate, Finasteride, Melatonin, Metronidazole, Spironolactone, Tretinoin, and Triamcinolone in Trichosol, a Natural Vehicle for Hair Solutions. |
|
4922 |
J Allergy Clin Immunol Pract |
Stability of Antibiotics for Use in the Testing of Immediate Drug Allergy Reactions. |
|
4924 |
EJHP |
Physical compatibility of lipid emulsions and intravenous medications used in neonatal intensive care settings |
|
4927 |
GERPAC Congress |
Préparation d'étoposide injectable concentrée à 10 mg/mL : intérêts et stabilité physicochimique. |
|
4928 |
Newsletter INFOSTAB 68 - march 2025 |
Compatibility tests - march 2025. |
|
4929 |
Int J Pharm Compound |
Long-term Physicochemical Stability of a Pharmaceutical Preparation of Morphine Hydrochloride and Droperidol in Polypropylene Syringes. |
|
4931 |
Int J Pharm Compound |
Compatibility of Active Pharmaceutical Ingredients Combinations Compounded in Cleoderm, a Cream Base for Personalized Dermatological Treatments. |
|
4932 |
Pharmaceuticals |
Physical stability of bevacizumab solutions for intravitreal injections: Influence of conditioning material and storage conditions. |
|
4935 |
Korean J Pain |
Physicochemical stability of mixtures of nonsteroidal anti-inflammatory drugs such as ketorolac and diclofenac and antiemetics such as ondansetron and ramosetron: an in vitro study. |
|
4936 |
Can J Anesth |
Stability of Daptomycin in Dextrose and Icodextrin-Based Peritoneal Dialysis Solutions. |
|
4942 |
Pfizer |
Elranatamab (ELREXFIO) - Information Médicale PFIZER |
|
4943 |
Antibiotics |
Stability of Nine Time-Dependent Antibiotics for Outpatient Parenteral Antimicrobial Therapy (OPAT) Use |
|
4944 |
JAC Antimicrob Resist |
Evaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy. |
|
4945 |
Colonis Pharma Ltd |
Iloprost 100 micrograms/ml concentrate for solution for infusion - Summary of Product Characteristics Updated 12-Oct-2023. |
|
4950 |
Pfizer Europe MA EEIG |
Emblaveo 1,5 g/0,5 g, poudre pour solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
4951 |
PANMEDICA |
ACIDE ACETYLSALICYLIQUE PANPHARMA 1 g, poudre et solvant pour solution injectable - Résumé des caractéristiques du produit - Mise à jour 19/09/2024. |
|
4952 |
Hameln pharma ltd |
Alfentanil 5 mg/ml solution for injection - Summary of Product Characteristics Updated 19-Oct-2022 | hameln pharma ltd |
|
4953 |
SANOFI WINTHROP |
PLITICAN, solution injectable - Résumé des caractéristiques du produit |
|
4954 |
INTSEL CHIMOS |
ALPROSTADIL INTSEL CHIMOS 0,5 mg/ml, solution injectable - Résumé des caractéristiques du produit |
|
4956 |
Newsletter Stabilis |
Stability of Isatuximab in NaCl Dilutions and Opened Vials Under Controlled and Excursion Conditions. |
|
4957 |
Newsletter Stabilis |
Send your ideas of compatibility studies to Stabilis®. |
|
4958 |
SANOFI B.V. |
THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion - Résumé des caractéristiques du produit. |
|
4959 |
EVER VALINJECT GMBH |
ATOSIBAN EVER PHARMA 75 mg/10 mL, solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
4960 |
ASPEN PHARMA TRADING LIMITED |
IMUREL 50 mg, poudre pour solution injectable (IV) - Résumé des caractéristiques du produit. |
|
4961 |
Baxter Healthcare Ltd |
Bupivacaine 2.5mg/ml Solution for Injection - Summary of Product Characteristics Updated 21-Mar-2024. |
|
4963 |
ACCORD HEALTHCARE FRANCE |
BUSULFAN ACCORD 6 mg/mL, solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
4964 |
B BRAUN MELSUNGEN AG |
GLUCONATE DE CALCIUM 10 % B.BRAUN, solution pour perfusion - Résumé des caractéristiques du produit. |
|
4965 |
ACCORD HEALTHCARE FRANCE SAS |
CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion - Résumé des caractéristiques du produit. |
|
4966 |
PANPHARMA |
CEFAZOLINE PANPHARMA 1 g, poudre pour solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
4967 |
Renascience Pharma Ltd |
Renoxitin 1g Powder for solution for injection or Infusion - Summary of Product Characteristics Updated 21-Mar-2025. |
|
4968 |
Pfizer Limited |
Zinforo 600 mg powder for concentrate for solution for infusion - Summary of Product Characteristics Updated 06-Jun-2024. |
|
4969 |
Essential Pharma Ltd |
Chloramphenicol 1 g Powder for Injection - Summary of Product Characteristics Updated 21-Jan-2025. |
|
4970 |
TILLOMED PHARMA GMBH |
CIDOFOVIR TILLOMED 75 mg/mL solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
4971 |
J Pharm Biomed Anal |
Stability of the antibiotic ceftaroline fosamil with focus on degradation products and decomposition pathways – Integrative analysis by LC-DAD, ESI-QTOF and in silico prediction |
|
4972 |
CHEPLAPHARM ARZNEIMITTEL GMBH |
RIVOTRIL 1 mg/1 ml, solution à diluer injectable en ampoules - Résumé des caractéristiques du produit. |
|
4973 |
GLENWOOD GMBH |
CATAPRESSAN 0,15 mg/ml, solution injectable - Résumé des caractéristiques du produit. |
|
4974 |
PANPHARMA |
CLOXACILLINE PANPHARMA 1 g, poudre pour solution injectable (I.V.) - Résumé des caractéristiques du produit. |
|
4975 |
Teva UK Limited |
Colomycin 1 million International Units (IU) Powder for solution for injection, infusion orinhalation
Summary of Product Characteristics Updated 12-Jul-2023. |
|
4976 |
PFIZER HOLDING FRANCE |
FRAGMINE 10 000 U.I. anti-Xa/0,4 mL, solution injectable en seringue pré-remplie - Résumé des caractéristiques du produit. |
|
4981 |
MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. |
KETESSE 50 mg/2 ml, solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
4982 |
Wockhardt UK Ltd |
Diamorphine Hydrochloride 100mg for Injection - Summary of Product Characteristics Updated 06-May-2020. |
|
4983 |
|
DIAZEPAM RENAUDIN 10 mg/2 ml, solution injectable - Résumé des caractéristiques du produit. |
|
4984 |
GLENWOOD GMBH |
PERSANTINE 10 mg/2 mL, solution injectable en ampoule - Résumé des caractéristiques du produit. |
|
4985 |
ARROW GENERIQUES |
ENOXAPARINE ARROW 10 000 UI (100 mg)/1 mL, solution injectable en seringue préremplie - Résumé des caractéristiques du produit. |
|
4986 |
Fresenius Kabi France SA |
FLUCONAZOLE KABI 2 mg/ml, solution pour perfusion - Résumé des caractéristiques du produit. |
|
4987 |
TILLOMED PHARMA GMBH |
MILRINONE TILLOMED 1 mg/mL, solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
4989 |
Dr REDDY |
Extended dilution stability study report of cyclophosphamide concentrate for solution for infusion at room temperature and refrigerated condition ( 2-8°C) - Personal communication - July 2025 |
|
4990 |
LABORATOIRE AGUETTANT |
NORADRENALINE (TARTRATE) AGUETTANT 2 mg/ml (SANS SULFITES), solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
4991 |
B BRAUN MELSUNGEN |
GRANISETRON B BRAUN 3 mg/3 ml, solution à diluer injectable ou pour perfusion - Résumé des caractéristiques du produit. |
|
4992 |
MACURE HEALTHCARE LTD. |
LORAZEPAM XILMAC 4 mg/mL, solution injectable - Résumé des caractéristiques du produit. |
|
4993 |
ASPEN PHARMA TRADING LIMITED |
MIVACRON 20 mg/10 ml, solution injectable (IV) - Résumé des caractéristiques du produit. |
|
4994 |
LABORATOIRE AGUETTANT |
KETOPROFENE AGUETTANT 100 mg, solution pour perfusion - Résumé des caractéristiques du produit. |
|
4995 |
EUGIA PHARMA (MALTA) LTD |
PANTOPRAZOLE ARROW 40 mg, poudre pour solution injectable (IV) - Résumé des caractéristiques du produit. |
|
4996 |
ALTAN PHARMA LTD |
NIMODIPINE ALTAN 10 mg/50 mL, solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
4997 |
VIATRIS SANTÉ |
NALOXONE VIATRIS 0,4 mg/1 ml, solution injectable en ampoule - Résumé des caractéristiques du produit. |
|
4998 |
MITEM PHARMA |
PROPRANOLOL ACETLAB 5 mg/5 mL, solution injectable - Résumé des caractéristiques du produit. |
|
4999 |
PFIZER HOLDING FRANCE |
NIPENT 10 mg, poudre pour solution pour injection, poudre pour solution pour perfusion - Résumé des caractéristiques du produit. |
|
5000 |
PANPHARMA |
OXYTOCINE PANPHARMA 5 UI/1 ml, solution injectable - Résumé des caractéristiques du produit. |
|
5002 |
Int J Pharm Compound |
Personalized compounded hair loss treatments: A compatibility assessment of the Trichoconcept vehicle line. |
|
5004 |
TEVA B.V. |
NEFOPAM TEVA 20 mg/2 mL, solution injectable - Résumé des caractéristiques du produit. |
|
5005 |
LABORATOIRE RENAUDIN |
QUININE RENAUDIN 245 mg/ml, solution injectable pour perfusion IV - Résumé des caractéristiques du produit. |
|
5006 |
TEVA SANTE |
SPASFON, solution injectable en ampoule - Résumé des caractéristiques du produit. |
|
5007 |
EUGIA PHARMA (MALTA) LTD |
LEVETIRACETAM ARROW LAB 100 mg/mL, solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5008 |
CHEPLAPHARM ARZNEIMITTEL GMBH |
CYMEVAN 500 mg, poudre pour solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5009 |
SUBSTIPHARM |
HYDROCORTISONE SUBSTIPHARM 100 mg, lyophilisat (flacon) et solution pour usage parentéral - Résumé des caractéristiques du produit. |
|
5010 |
CHUGAI PHARMA FRANCE |
GRANOCYTE 34 Millions UI/ml, poudre et solvant pour solution injectable / perfusion en seringue préremplie - Résumé des caractéristiques du produit. |
|
5011 |
Piramal Critical Care Limited |
Hypnomidate 2 mg/ml Injection - Summary of Product Characteristics Updated 02-Apr-2024. |
|
5012 |
LABORATOIRES CHAIX ET DU MARAIS |
CHLORURE DE MAGNESIUM 10 POUR CENT (1 g/10 ml) LAVOISIER, solution injectable (I.V.) en ampoule - Résumé des caractéristiques du produit. |
|
5013 |
VIFOR FRANCE |
FERINJECT 50 mg/mL, dispersion injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
5014 |
TILLOMED PHARMA GMBH |
TREPROSTINIL TILLOMED 5 mg/mL, solution pour perfusion - Résumé des caractéristiques du produit. |
|
5015 |
LABORATOIRE RENAUDIN |
SUFENTANIL RENAUDIN 50 microgrammes/mL, solution injectable (IV ou péridurale) - Résumé des caractéristiques du produit. |
|
5016 |
Tillomed Laboratories Ltd |
Tranexamic Acid 100 mg/ml Solution for Injection - Summary of Product Characteristics Updated 25-Mar-2025. |
|
5017 |
A. Menarini Farmaceutica Internazionale SRL |
Vaborem 1 g/1 g powder for concentrate for solution for infusion - Summary of Product Characteristics Updated 22-Aug-2024. |
|
5018 |
AS KALCEKS |
SCOPOLAMINE BUTYLBROMURE KALCEKS 20 mg/mL, solution injectable - Résumé des caractéristiques du produit. |
|
5020 |
SERB Laboratory |
TIBERAL 1 g, solution injectable pour perfusion - Résumé des caractéristiques du produit. |
|
5021 |
SERB Laboratory |
L-THYROXINE SERB 200 microgrammes/mL, solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
5022 |
Pharmacosmos A/S |
CosmoFer 50mg/ml solution for infusion and injection - Summary of Product Characteristics. |
|
5024 |
PFIZER |
LINCOCINE 600 mg, solution injectable, B/1/2ml - Résumé des caractéristiques du produit. |
|
5026 |
Gilead Sciences Ireland UC |
Veklury 100 mg poudre pour solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5027 |
Almirall, S.A. |
Meptid 100 mg/ml Solution for Injection - Summary of Product Characteristics. |
|
5028 |
TAKEDA PHARMA A/S |
XEFO 8 mg, poudre et solvant pour solution injectable - Résumé des caractéristiques du produit. |
|
5029 |
Teva Pharma Belgium S.A. |
VoriNa 25 mg/ml solution injectable - Résumé des caractéristiques du produit. |
|
5030 |
Viatris |
FLECAINE 10 mg/ml, solution injectable - Résumé des caractéristiques du produit. |
|
5031 |
Akorn Operating Company |
IntravenousSodium Diuril® ) - Summary of Product Characteristics. |
|
5032 |
SERB |
VIBRAVEINEUSE, solution injectable pour voie IV et perfusion - Résumé des caractéristiques du produit. |
|
5034 |
|
Methohexital Monograph for Professionals - Drugs.com |
|
5035 |
Xellia Pharmaceuticals |
POLYMYXIN B for INJECTION, USP500,000 Units/vial - Summary of Product Characteristics. |
|
5037 |
EG LABO - LABORATOIRES EUROGENERICS |
VELBE 10 mg, poudre pour solution injectable I.V. - Résumé des caractéristiques du produit. |
|
5038 |
Tillomed Laboratories Limited |
Treosulfan 5g Powder for Solution for Infusion - Summary of Product Characteristics Updated 06-Dec-2024. |
|
5039 |
Novo Nordisk A/S |
Esperoct powder and solvent for solution for injection - Summary of Product Characteristics. |
|
5040 |
B BRAUN MELSUNGEN AG |
CHLORURE DE POTASSIUM B. BRAUN 10 % (0,10 g/ml), solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5041 |
Partner Therapeutics |
LEUKINE® (sargramostim) for injection, for subcutaneous or intravenous use - Highlights of prescribing information. |
|
5042 |
Orion Corporation |
Dexdor 100 micrograms/ml concentrate for solution for infusion - Summary of Product Characteristics. |
|
5043 |
Genta Incorporated |
GANITE- gallium nitrate injection, s olution, concentrate - Summary of Product Characteristics. |
|
5044 |
Novo Nordisk A/S |
Actrapid 100 unités internationales/ml, solution injectable en flacon. - Résumé des caractéristiques du produit. |
|
5045 |
Eli Lilly |
Humalog 100 UI/ml, solution injectable en flacon - Résumé des caractéristiques du produit. |
|
5046 |
Global Harvest Pharmaceuticals |
Metaraminol 10 mg/ml Solution for Injection or Infusion - Package leaflet: Information for the user. |
|
5047 |
Roche |
CellCept 500 mg poudre pour solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5048 |
|
NATRECOR® (nesiritide) lyophilized powder for intravenous use - Highlights of prescribing information. |
|
5049 |
Namigen |
Sodium Nitroprusside Injection - Summary of Product Characteristics. |
|
5050 |
Drugs.com |
Phentolamine - Drugs.com monograph |
|
5053 |
LABORATOIRE RENAUDIN |
PHOSPHATE MONOPOTASSIQUE RENAUDIN 136,10 mg/ml, solution pour perfusion - Résumé des caractéristiques du produit. |
|
5054 |
POLİFARMA İLAÇ SAN. VE TİC. A.Ş. |
POLTEOFİLİN 400 MG/500 ML INJECTABLE SOLUTION FOR I.V. INFUSION - Summary of Product Characteristics. |
|
5055 |
Roche |
RoActemra 20 mg/mL concentrate for solution for infusion - Résumé des caractéristiques du produit. |
|
5057 |
EUMEDICA PHARMACEUTICALS GMBH |
ACTOSOLV 600 000 UI, poudre pour solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
5058 |
Melinta Therapeutics, |
MINOCIN®, Minocycline For Injection - Summary of Product Characteristics. |
|
5059 |
Acrotech Biopharma LLC |
EVOMELA (melphalan) for injection, for intravenous use. - Highlights of prescribing information. |
|
5060 |
ADVANZ Pharma |
Lidocaine Hydrochloride Injection B.P. 1.0% w/v - Summary of Product Characteristics Updated 09-Nov-2023 |
|
5062 |
ADVANZ Pharma |
Hydralazine 20mg Powder for Concentrate for Solution for Injection/Infusion - Summary of Product Characteristics Updated 09-Sep-2024 |
|
5064 |
SteriMax Inc. |
Monographie de produit ETHACRYNATE SODIUM. |
|
5065 |
Mylan Institutional LLC |
ALOPRIM- allopurinol injection, powder, lyophilized, for solution. |
|
5066 |
Bowmed Ibisqus Limited |
Meropenem 500mg powder for solution for injection/ infusion - Summary of Product Characteristics Updated 21-Aug-2024. |
|
5067 |
PFIZER HOLDING FRANCE |
UNACIM INJECTABLE 0,5 g/1 g, poudre pour usage parentéral - Résumé des caractéristiques du produit. |
|
5068 |
ACINO FRANCE SAS |
ABELCET 5 mg/ml, suspension à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5069 |
LABORATOIRE AGUETTANT |
MORPHINE (CHLORHYDRATE) AGUETTANT 10 mg/mL, solution injectable - Résumé des caractéristiques du produit. |
|
5071 |
LABORATOIRE AGUETTANT |
FOLINATE DE CALCIUM AGUETTANT 100 mg, poudre pour solution injectable - Résumé des caractéristiques du produit. |
|
5072 |
Fresenius Kabi |
Floxuridine: Package Insert / Prescribing Info |
|
5073 |
Napp Pharmaceuticals Limited |
Palladone 10 mg/ml solution for injection or infusion - Summary of Product Characteristics Updated 28-Apr-2025. |
|
5074 |
EUGIA PHARMA (MALTA) LTD |
FOSPHENYTOINE ARROW 75 mg/mL, solution à diluer pour solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
5075 |
ACCORD HEALTHCARE FRANCE SAS |
IDARUBICINE ACCORD 5 mg/5 ml, solution pour perfusion - Résumé des caractéristiques du produit. |
|
5076 |
Panmedica |
AMIKACINE PANPHARMA 250 mg/mL, solution injectable - Résumé des caractéristiques du produit. |
|
5077 |
VIATRIS SANTE |
ETOPOSIDE VIATRIS 20 mg/ml, solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5084 |
Int J Pharm Compound |
Stability Study of Pediatric Oral Suspensions Formulated with PCCA SuspendIt Vehicle Used for the Treatment of Cardiovascular Disease. |
|
5085 |
Pfizer |
Pfizerpen - Prescribing information |
|
5086 |
Hospira UK Limited |
Tobramycin 40mg/ml Solution for Injection - Summary of Product Characteristics Updated 29-Feb-2024 | Hospira UK Ltd |
|
5087 |
ALFASIGMA FRANCE |
ANAFRANIL 25 mg/2 ml, solution injectable - Résumé des caractéristiques du produit. |
|
5088 |
Chemidex Pharma Limited |
Ampicillin 500 mg powder for solution for injection - Summary of Product Characteristics Updated 04-Feb-2025 | Chemidex Pharma Ltd |
|
5089 |
Phoenix Labs |
Ascorbic Acid Injection 500mg/5ml - Summary of Product Characteristics Updated 04-Jan-2024 | Phoenix Labs |
|
5090 |
Sanofi |
TILDIEM 25 mg, poudre et solution pour préparation injectable I.V. - Résumé des caractéristiques du produit. |
|
5091 |
PHARMHOLDING SA |
RIMIFON 500 mg/5 ml, solution injectable / pour perfusion - Résumé des caractéristiques du produit. |
|
5092 |
ZENTIVA FRANCE |
LEVOFOLINATE DE CALCIUM ZENTIVA 25 mg/2,5ml, solution injectable (IM/IV) - Résumé des caractéristiques du produit. |
|
5093 |
ACCORD HEALTHCARE FRANCE SAS |
FUROSEMIDE ACCORD 20 mg/2 ml, solution injectable - Résumé des caractéristiques du produit. |
|
5094 |
LUNDBECK SAS |
SEROPRAM 20 mg/0,5 ml, solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5095 |
Drug Design Dev Ther |
Compatibility and Physico-Chemical Stability of Six Intravenous Mixtures for Postoperative Multimodal Analgesia. |
|
5096 |
Current Ther Res |
Compatibility and Stability of Cipepofol (Ciprofol) and Etomidate Mixture for Intravenous Anesthesia. |
|
5097 |
PlosOne |
Stability and physical compatibility of parenteral nalbuphine hydrochloride during continuous infusion in pediatrics. |
|
5098 |
Infect Dis Ther |
Stability of Ceftobiprole Medocaril in Portable Elastomeric Infusion Devices. |
|
5110 |
J Pediatr Pharmacol Ther |
Stability Study of Lorazepam Oral Solution Repackaged in Amber Colored ENFit Oral Syringes. |
|
5134 |
Sunnybrook Health care Center. 2025. |
Stability of vancomycin 10, 25 and 50 mg/mL ophtalmic drops in tears naturale II stored in low density polyethylene dropper bottles at 4 and 25°C for 30 days |
Buscar
